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Abstract 
Changing lifestyle and dietary habits, for example using herbal medicines, can 
influence the management and progression of some diseases, such as cardiovascular 
disease (CVD), diabetes and obesity. This thesis describes a series of in vitro 
experiments and human studies; the aims were to investigate the potential health 
benefits of Cinnamomum cassia (C. cassia) and Cinnamomum zeylanicum (C. 
zeylanicum) extracts in vitro, and C. cassia supplements on biomarkers of glucose, 
lipid profiles, weight, blood pressure, insulin and inflammatory markers.  
Both extracts were found to be rich in polyphenols and proanthocyanidins which can 
act as effective free radical scavenging compounds in vitro. Both cinnamon types dose-
dependently reduced the rapidly available glucose (RAG) and increased the slowly 
available glucose (SAG) values of cornflakes, possibly due to their polyphenolic 
compounds which have the capacity to inhibit carbohydrate digesting enzymes, 
particularly α-glucosidase and α-amylase. The preliminary randomised cross-over 
control human study investigated the effect of ingesting capsules of 1 g C. cassia prior 
to consuming cornflakes (a high starch food) on the glycaemic response in healthy 
participants. The results showed there were no significant differences in glucose 
response, nor in the incremental area under the curve for the cinnamon supplement or 
the placebo. In an 8-week randomised controlled human study, 5 g of C. cassia 
supplementation in overweight individuals reduced body weight (P=0.01), plasma non-
esterified fatty acid levels (P=0.017), systolic (P=0.01) and diastolic blood pressure 
(P=0.02), without significantly affecting LDL, CHO and HDL levels as well as fasting 
insulin and glucose levels. There were no significant effects of cinnamon 
supplementation on cytokine and adhesion molecule levels. However, IL-6, IL-8, TNF-
α, IL-1-α, MCP-1, sPSEL levels were significantly altered due to time in both cinnamon 
and control groups.      
In conclusion, cinnamon supplementation (5 g/d for eight weeks) produced important 
health benefits in vitro and in vivo, therefore it may be useful as a natural herbal remedy 
for obesity and CVD. 
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Chapter 1 
Introduction 
1.1 General introduction 
The improvement of diet and lifestyle is a key strategy to help prevent chronic diseases 
such as cardiovascular disease (CVD), diabetes, cancer and obesity (Buttar et al., 
2005). Changes in lifestyle could include: pursuing physical activity, reducing sugar 
intake, replacing refined grains with whole grains, eating plenty of fruit and vegetables, 
and limiting calorie intake (Lichtenstein et al., 2006). Fruits and vegetables are a good 
source of vitamins, fibre and phytochemicals; phytochemicals are bioactive non-
nutrient compounds, such as polyphenols, alkaloids, tannins and flavonoids, which are 
found in fruits, vegetables, herbs and spices, which may provide health benefits as well 
as playing an important role in the prevention of chronic diseases such as 
atherosclerosis (Liu, 2003; Lichtenstein et al., 2006). In Asia, with assistance from the 
World Health Organisation (WHO), they are introducing and developing the use of 
herbs into primary health care (de Boer and Cotingting, 2014).  
Herbs are defined as any part of the plant, including the leaves, stems, flowers, roots, 
barks and seeds, and herbal products may contain a single herb or a combination of 
several different herbs, which are believed to have complementary effects (Bent and 
Ko, 2004). Spices are dried herbs and are primarily used to enhance the flavour of 
foods (Dragland et al., 2003; Opara and Chohan, 2014). Herbs and spices have been 
identified as sources of various phytochemicals (Dragland et al., 2003), and when 
herbs and spices are used as a medicinal treatment, they are called medicinal herbs 
(Opara and Chohan, 2014). Herbal medicines can play an important role in the 
management and prevention of some disease such as diabetes, obesity, inflammation 
and CVD, and the use of herbal remedies in developed countries, such as the USA, 
has increased dramatically from 2.9 % in 1990, to 18 % in 2007 (Eisenberg et al., 
2011). Moreover, a significant number of patients used herbal remedies for over a one-
year period, for example 23 % in Denmark and 49 % in France. These data were 
compiled from public opinion surveys between 1985 and 1992 (Fisher and Word, 
1994). In Saudi Arabia, 24 % of diabetic patients who were attending a primary care 
facility in Arar City used herbal medicines during the previous six months (Al-Ajaji et 
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al., 1998), and further studies in Saudi Arabia showed that 17.4 % of diabetic patients 
who were attending the outpatient clinics in hospitals used some form of herbs, 
indicating how wide spread herbal use is (Al-Rowais, 2002). 
1.2 History of herbal medicine use 
The use of herbal medicines has a long history, more than 50 % of clinical drugs come 
from herbal products or their derivatives (Kadir et al., 2012). For example, metformin, 
which is a drug that lowers blood glucose by increasing the body’s cell sensitivity to 
insulin in type 2 diabetes, is derived from French lilac, and was a herbal remedy used 
to treat diabetes in the Middle Ages (Ryan et al., 2001). Similarly, ginger was used to 
treat sore throats, which is still used currently (Jungbauer and Medjakovic, 2012).   
The use of herbal supplements has also been proved effective, for example in a double 
blind crossover study it was shown that consuming 1200 mg/day of curcumin as a 
supplement, plus the patient’s medication (phenyibutazone 300 mg/day), for two 
weeks improved morning stiffness, walking time, and joint swelling in people with 
rheumatoid arthritis, while there was no changed in control (Deodhar et al., 1980). 
Moreover, herbs and spices such as cinnamon, cloves, tea, oregano, and nutmeg, 
have been shown to possess insulin-like biological activity (Broadhurst et al., 2000). 
Cinnamon has been used since ancient times and is the inner bark of the 
Cinnamomum tree, which belongs to Lauraceae family. The main types of cinnamon 
are C. zeylanicum (also known as C. verum, C. cylone) which is produced in Sri Lanka, 
and C. cassia which is mainly grown in China. The term ‘Cinnamomum’ is derived from 
Greek and means ‘sweet wood’ (Ravindran et al., 2004; Hamidpour et al., 2015).  
Current research, both in vitro and in animals in vivo, suggests that cinnamon has anti-
inflammatory, anti-microbial, antibacterial, anti-oxidant, anti-diabetic, anti-obesity and 
immunomodulatory effects (Anderson et al., 2004; Wang et al., 2009; Dudonné et al., 
2009; Lee et al., 2005).  
1.2.1 The major bioactive components of cinnamon 
Cinnamon has been shown to consist of phenolic compounds, tannins, sugars, 
mucilage, resins and volatile oils, all of which have different properties. The main 
volatile oil is cinnamaldehyde which contributes 80-90 % of the volatile oil content of 
Cinnamomum cassia, and 60-80 % of the volatile oil of Cinnamomum zeylanicum 
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(Hamidpour et al., 2015). The composition of cinnamon bark oil has been further 
investigated by Kim et al., (2015) who identified the main components using GC-MS 
analysis and they found 17 different components (Table 1.1). As with the previous 
studies, cinnamaldehyde was the predominant component and accounted for 64.49 % 
of cinnamon bark oil. In addition, eugenol (16.57 %) and linalool (4.82 %) were also 
important constituents of cinnamon bark oil, which suggests these are also likely to 
cause the medicinal properties seen in previous studies. 
Table 1.1 GC-MS analysis of cinnamon bark oil composition (source Kim et al., 2015). 
Compounds Composition (%) 
α-Pinene                              3.02 
β-Pinene                              1.23 
ρ-Cymene                         0.81 
Limonene                           2.53 
Linalool                             4.82 
α-Terpineol                         0.26 
Benzaldehyde                     1.80 
Cinnamaldehyde                 64.49 
Safrole                                     0.73 
Eugenol                                 16.57 
α-Copaene  0.12 
trans-Caryophyllene  1.10 
Cinnamyl acetate  1.15 
α-Humulene  0.20 
Acetyleugenol  0.48 
O-mentha-1(7),8-dien-3-ol 0.20 
Benzylbenzoate  0.49 
 
The composition of cinnamon has also been investigated by other groups who found 
that cinnamon bark contained high levels of condensed tannins which were comprised 
of 23.2 % proanthocyanidins, and 3.6 % epi-catechins (Shan et al., 2007). All of which 
may be involved in producing the medicinal effects previously observed. 
The current in vitro (Table 1.2) and in vivo studies involving cinnamon suggest that it 
could be used to treat and prevent chronic diseases, such as obesity and diabetes 
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mellitus, which have a high prevalence in the developed world (Ranasinghe et al., 
2013) but the actual mechanism of action needs to be determined in humans.  
Table 1.2 The benefit effects of cinnamon from in vitro studies. 
References Cinnamon impact 
 Jarvill-Taylor et al., 2001 Cinnamon activated insulin receptors and enhance 
glucose uptake in 3T3-L1 pre-adipocytes 
Peng et al., 2008 Cinnamon inhibited advance glycation end 
products (AGEs) in bovine serum albumin glucose 
model 
Hong et al., 2002 Cinnamon inhibited cyclooxygenase (COX-2) 
activity in mouse macrophage RAW 264.7 cells 
Lu et al., 2011 Cinnamon significantly increased the consumption 
of extracellular glucose in insulin-resistant HepG2 
cells 
Friedman et al., 2002 Cinnamon had a potent anti-microbial activity 
against Escherichia coli (E. coli)  
Mastura et al., 1999 Cinnamon had anti-fungal properties against 
Candida albicans 
Premanathan et al., 2000 Cinnamon inhibited the virus-induced 
cytopathogenicity in MT-4 cells infected with HIV 
 
1.3 Overweight and obesity  
One of the most prevalent health conditions in the world is obesity, which is associated 
with various metabolic abnormalities including insulin resistance and dyslipidaemia 
(Klop et al., 2013). Furthermore, obesity can increase the risk of developing diabetes, 
hypertension and cardiovascular disease (CVD), therefore, there is a great deal of 
interest in preventing and treating this condition (Klop et al., 2013). 
1.3.1 Definition and prevalence 
Obesity is defined as the excess accumulation of body fat (Hawkesworth, 2013), and 
the most common method used to classify whether an individual is overweight or obese 
is based on their Body Mass Index (BMI). This is calculated by dividing the body weight 
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of an individual in kg by their height in meters squared (kg/m2). According to the World 
Health Organisation (WHO, 2004) individuals with a BMI of 25-29.9 kg/m2 are classified 
as overweight, whereas individuals with a BMI of over 30 kg/m2 are classified as obese.  
Research shows that obesity increases the risk of developing type 2 diabetes, 
dyslipidaemia, hypertension and CVD (Mokdad et al., 2003; Parikh et al., 2015). The 
prevalence of individuals who are overweight exceeds 37 % of the population in most 
developing countries (Tully et al., 2015), and globally, more than 1.4 billion adults were 
overweight in 2008 (WHO, 2013). This is further exemplified by the fact that in the USA 
there were 154.7 million overweight or obese individuals recorded in 2011 (American 
Heart Association, 2013), and in the UK, the prevalence of obesity in adults rose from 
15 % in 1993 to 25 % in 2013 (National Obesity Observatory, 2013). A recent study in 
Saudi Arabia confirmed that the prevalence of obesity was 28.7 %, which was 
determined from a large household survey in 2013 (Memish et al., 2014). The results 
of a recent systematic study of the global prevalence of adults who are overweight or 
obese in various countries between 1980 and 2013 (Table 1.3) shows the prevalence 
of this condition is worldwide (Ng et al., 2014).  
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Table 1.3 National estimates of the prevalence of individuals who are overweight or 
obese in 2013* 
Country Overweight and obese Overweight and obese 
Men % (95 % uncertainty 
intervals, UIs) 
Women % (95 % uncertainty 
intervals, UIs) 
New Zealand 71·4 (69·6–73·3) 60·0 (57·8–62·2) 
Mexico 66·8 (64·9–68·6) 71·4 (69·5–73·2) 
Russia 54·3 (51·5–57·1) 58·9 (56·3–61·4) 
USA 70·9 (69·2–72·5) 61·9 (59·8–63·8) 
Bahrain 67·7 (65·3–70·2) 75·2 (72·8–77·5) 
Egypt 71·2 (68·9–73·7) 75·2 (72·8–77·5) 
Kuwait 74·5 (72·4–76·6) 84·3 (82·6–86·1) 
Libya 70·6 (68·1–73·1) 77·0 (74·6–79·3) 
Qatar 75·7 (73·8–77·4) 78·5 (77·0–80·1) 
Saudi Arabia 69·0 (67·1–70·7) 74·2 (72·3–76·0) 
United Arab 
Emirates 
66·1 (63·6–68·8) 60·6 (57·4–63·4) 
Germany 64·3 (61·9–66·8) 49·0 (46·5–51·4) 
Ireland 66·4 (63·9–68·8) 50·9 (48·3–53·6) 
UK 66·6 (65·3–68·0) 57·2 (55·7–58·6) 
*The participants in this study were adults over the age of 20 who were located in 188 countries and 21 GBD 
regions, source (Ng et al., 2014). 
 
As a result of the increasing rate of obesity, there has been a significant increase in 
interest in using of complementary and herbal medicines for treating obesity, together 
with suitable diet and exercise programs for losing and maintaining weight (Westerterp-
Plantenga et al., 2006; Auvichayapat et al., 2008). 
1.3.2 Abdominal obesity 
Waist circumference provides an indication of the distribution of body fat, and 
compared to BMI, it is a better predictor of the health risks associated with an excess 
of weight, whereas BMI can be used as an indicator of overall body fat content (Zhu et 
al., 2002; Janssen et al., 2004).  
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There are studies that show abdominal obesity is linked with hyperinsulinaemia, insulin 
resistance, diabetic dyslipidaemia, hypertension, CVD, and inflammation (Sowers, 
2003; Aoki et al., 2015). An overall reduction in weight has health benefits such as 
reducing blood pressure and inflammatory markers, and improving lipid concentrations 
(Klein et al., 2004), and in addition, weight loss, and more specifically loss of abdominal 
obesity, can improve insulin sensitivity (Norris et al., 2005). 
1.3.3 Health consequences of obesity 
There is strong evidence for the association between obesity and other diseases, for 
example, obesity increases the risk of developing type 2 diabetes 12-fold compared 
with individuals with BMI within the normal range (Kumanyika et al., 2008). Also, 
obesity increases the risk of developing CVD by 20 %, type 2 diabetes by more than 
30 % (McQuigg et al., 2008), and central (abdominal) obesity contributes to the 
development of insulin resistance (Rader, 2007). 
Insulin resistance has been shown to increase the development of hypertension and 
CVD (Grundy, 1998; McFarlane et al., 2001). Insulin resistance is considered as a pro-
inflammation state via elevated inflammatory marker levels (Meigs et al., 1997; 
McFarlane et al., 2001). Obesity, type 2 diabetes mellitus, and metabolic syndrome 
have increased dramatically in the past decades (Mokdad et al., 2001). The increasing 
health effects related to obesity result in higher costs to the world’s health care systems 
(Huang et al, 2009), and there are also implications for the workforce and reducing 
absenteeism through ill-health. Therefore, it is important that diet and lifestyle 
interventions are identified to reduce obesity and their associated diseases. 
1.3.3.1 Insulin resistance 
Insulin resistance (IR) is a biological reduction in the response to insulin; it is 
associated with metabolic syndrome, which includes central obesity, low levels of high-
density lipoprotein (HDL) cholesterol, high triglyceride levels, high low-density 
lipoprotein (LDL) cholesterol levels, glucose intolerance, type 2 diabetes mellitus, and 
hypertension (Greenfield and Campbell, 2004). Currently, there is no single method 
that can be used directly to determine IR, however the homeostasis model assessment 
[HOMA] index is widely used as a validated way to determine IR [HOMA-IR] index and 
insulin sensitivity, and is based on the values of fasting blood glucose and insulin 
(Romualdo et al., 2014).  
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1.3.3.1.1 The role of weight loss in improving IR 
One of the most important complications related to obesity is IR, which is correlated to 
the pathogenesis of chronic diseases, such as type 2 diabetes and CVD (Facchini et 
al., 2001). Schenk et al. (2009) have reported that insulin sensitivity was improved by 
weight loss, either by diet-only or a diet and exercise program in obese women. This 
study randomly divided obese women into lifestyle intervention groups of either weight 
loss without exercise (WL) (n = 7), or a weight loss + exercise program (WL+EX) (n = 
10). Insulin sensitivity (IS) and rates of systemic fatty acid appearance and 
disappearance were measured at the baseline, and after losing 12 % of their body 
weight. They concluded that losing weight reduced fatty acid mobilization and uptake 
and improved insulin sensitivity. Overall these studies suggest that weight loss is very 
important for IS and obesity. 
1.3.3.2 Metabolic syndrome 
Metabolic syndrome (MetS) is a metabolic abnormality associated with an increased 
risk of developing CVD and type 2 diabetes (Figure 1.1). Indicators of MetS include 
abdominal obesity with a waist circumference >102 cm for men and >88 cm for women, 
hypertension (systolic blood pressure >130 mm Hg or diastolic blood pressure >85 mm 
Hg), dyslipidaemia, IR, a pro-inflammatory state, and hyperglycaemia (Kaur, 2014). 
The prevalence of MetS was reported to be approximately 17.8–34.0 % of the 
population in Europe and 12.8–41.1 % in Asia, and it has been shown to be increasing 
over time, suggesting this is a large and increasing problem (Athyros et al., 2005; 
Grundy, 2008). IR and MetS have been shown to be associated with disease 
progression in non-alcoholic fatty liver disease (NAFLD) (Pais et al., 2015), and also 
with increased non-esterified fatty acid (NEFA) levels (Maison et al., 2000). A 
systematic study has shown that NAFLD and fatty livers have increased in the general 
population, which in turn can lead to chronic liver disease (Argo et al., 2009). NAFLD 
is present in 70-80 % of diabetic and obese patients, therefore efforts to reduce obesity 
should also help to reduce the incidence of NAFLD (Soffientini et al., 2014). 
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Figure 1.1: Representation of the correlation between obesity and other aspects of 
metabolic syndrome (adapted form the following sources: Taube et al., 2009; Hebbard 
and George, 2011; Jungbauer and Medjakovic, 2012). Excessive energy intake over 
expenditure leads to an enlargement of adipose tissue. These tissues release pro-
inflammatory cytokines such as IL-6 and TNF-α, as well as NEFA. Hypertrophic 
adipocytes are infiltrated by macrophages and activated by monocytes. These cause 
a chronic inflammation, leading to metabolic syndrome, insulin resistance, type 2 
diabetes, and arteriosclerosis. 
 
1.3.3.3 The effect of inflammatory status 
Inflammation is a reactive response of the immune system to infection and tissue 
damage; it is a protective action which increases the movement of defence cells from 
the bloodstream into an infected area (Pomin, 2015). Acute inflammatory responses 
generally progress over several days, whereas chronic inflammatory responses 
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progress over a much longer time period, from months to years, to a lifetime, such as 
in atherosclerosis, obesity, and autoimmune diseases (Nayak et al., 2013; Fleit, 2014). 
During an inflammatory response neutrophil cells are activated, these release pro-
inflammatory cytokines such as interleukins (IL-1, IL-6, IL-12 and IL-18) and tumour 
necrosis factor (TNF-α) (Jungbauer and Medjakovic, 2012). This leads to the activation 
of nitric oxide synthase (NOS) and cyclooxygenase-2 (COX-2). The activated 
neutrophils travel into the tissues and recruit macrophages, which release factors to 
heal the effected site and clear any pathogens (Jungbauer and Medjakovic, 2012). 
Continual low-grade inflammation and persistent infections cause chronic 
inflammation, which can be detected by increased levels of inflammatory markers such 
as C-reactive protein (CRP) and TNF-α (Libby et al., 2002). Immune problems can be 
further exacerbated by a disorder in the immune system, which leads to an 
accumulation of leukocytes that induce DNA damage in proliferating cells through their 
generation of reactive oxygen (ROS) and nitrogen species that are normally produced 
by these cells to fight infection (Coussens and Werb, 2002).  
Increasing adiposity in obesity is associated with recruitment of inflammatory cells, 
such as macrophages and monocytes, into the adipose tissue. These cells can release 
cytokines, such as IL-6, IL-1β, and TNF-α, that are capable of impeding insulin 
signalling and therefore their action is related to the development of IR (Figure 1.1) 
(Fain, 2010; Deer et al., 2015). Obesity, diabetes and CVD are associated with 
elevated markers of chronic inflammation, such as CRP, IL-6 and TNF-α (Berg and 
Scherer, 2005), which suggests the inflammatory state might be responsible for IR and 
the other disorders associated with obesity, such as hyperlipidaemia and MetS 
(Calabrò et al., 2010). By reducing the extent of obesity, the levels of these markers 
should also be reduced, which could have beneficial effects on patient health.  
1.3.3.4 Dyslipidaemia 
Lipoproteins are a complex of lipid and protein that are synthesised in the liver and the 
intestines, and they are responsible for transporting lipids in the blood (Jain et al., 
2007). There are four classes of lipoproteins: low density lipoproteins (LDL), high 
density lipoproteins (HDL), very low density lipoproteins (VLDL), and triglycerides 
(TAG) (Jain et al., 2007).  
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Dyslipidaemia is a common complication of obesity and consists of an increase in both 
fasting and postprandial TAG levels, an increase in LDL, VLDL, NEFA (for adipose 
tissue), and low HDL concentration in the body. (Klop et al., 2013; Soffientini et al., 
2014). Dyslipidaemia is a major risk factor in the development of coronary heart 
disease and has become one of the most common public health problems as it of 
associated with IR, MetS, obesity and diabetes (Garvey et al., 2003). A review of the 
area has shown that a reduction of 10 % of the weight in healthy men by diet alone, 
can decrease the non-fasting TAG by between 26 - 46 % which suggests a reduction 
in dyslipidaemia (Klop et al., 2013). However, a meta-analysis of anti-obesity drugs 
reported that weight was significantly reduced by 3.13 kg (95 % CI: 24.00 to 22.26) 
compared with placebo but the treatment did not improve TAG, LDL and CHO levels 
(Zhou et al., 2012). Overall this suggests that more research is needed to determine 
the effect of weight loss on dyslipidaemia. 
1.4 Diabetes mellitus 
1.4.1 Definition and classification 
Diabetes mellitus (DM) is a serious metabolic disorder characterised by chronic 
hyperglycaemia and additional disturbances of carbohydrate, fat and protein 
metabolism. (WHO, 1999; American Diabetes Association (ADA), 2015. It results from 
either too little production of the hormone insulin, which is released by β-cells located 
in the pancreas, or the failure of insulin to function appropriately (WHO, 1999; 
American Diabetes Association (ADA), 2015). 
The number of people with diabetes in the world is expected to reach 366 million by 
2030, with increases worldwide, for example, in the Middle Eastern Crescent region 
the estimated number of people with DM was 20.05 million in 2000 and this is expected 
to rise to 52.79 million by 2030 (Wild et al., 2004). In Saudi Arabia, the prevalence of 
DM in adults was 23.7 % between 1995 and 2000 (Al-Nozha et al., 2004), which has 
been shown to have risen significantly by a recent study by Al-Rubeaan et al. (2014) 
which highlighted that more than 50 % of the Saudi population was either diabetic or 
pre-diabetic between 2007 and 2009.  
This increase in diabetes is thought to be due to population growth and urbanization, 
but also due to an ageing population and the increased prevalence of obesity combined 
with reduced physical activity (Wild et al., 2004). According to ADA (2015), DM is 
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classified into four clinical groups; the first group is type 1 diabetes, which is also known 
as Insulin-Dependent Diabetes Mellitus (IDDM). Type 1 diabetes can occur at any age, 
but it is most often diagnosed in children, adolescents or young adults. This type of 
diabetes results from β-cell destruction, usually leading to absolute insulin deficiency. 
The second group is type 2 diabetes, which is also called Non-Insulin-Dependent 
Diabetes Mellitus (NIDDM). Type 2 is the most common form of diabetes and usually 
occurs progressively among the adult population. Type 2 diabetes results from a 
progressive insulin secretory defect and leads to IR.  
Other types of diabetes exist due to other causes, such as genetic defects in β-cell 
function or insulin action, diseases of the exocrine pancreas (such as pancreatic 
fibrosis), and drug- or chemical-induced diabetes (such as in the treatment of AIDS or 
after organ transplantation). The final class is gestational diabetes mellitus (GDM) 
which is diagnosed during pregnancy.  
IR is classified as a reduced sensitivity of a target cell or a whole organism to insulin, 
and is also linked to hyperinsulinaemia (Shanik et al., 2008). IR has been assigned a 
key role in the metabolic disturbances associated with obesity and type 2 diabetes 
(Shanik et al., 2008). Furthermore, IR in the brain is suggested to be a factor that 
relates to Alzheimer’s disease among type 2 diabetic patients, which could be 
considered as a new type of diabetes (de la Monte et al., 2008). 
1.4.2 Diagnosis of DM 
The common symptoms of diabetes include fatigue, increased appetite, excessive 
thirst, increased urination and increased frequency of infections. The ADA (2015) 
suggests that three blood tests are required for an accurate diagnosis of diabetes, and 
a fasting plasma glucose test (FPGT) is the easiest to use. A fasting level of blood 
glucose of 100 to 125 mg/dl is considered pre-diabetic, and one higher than 126 mg/dl 
(>7.0 mmol/l) on two occasions indicates the patient has diabetes. An oral glucose 
tolerance test (OGTT) is the second procedure that can be used to detect diabetes; 
this also involves a blood test and is more sensitive and specific than the FPGT to 
diagnose diabetes. The OGTT measures the blood glucose level after a fast and then 
two hours after drinking a glucose rich drink containing 75 g of anhydrous glucose 
dissolved in 250 ml of water. A glucose reading of more than 200 mg/dl (>11.1 mmol/l) 
indicates the presence of diabetes in the individual. Haemoglobin A1c (HbA1c) testing 
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is the third test used to diagnose diabetes; in this case a level higher than 6.4 % of 
haemoglobin A1c confirms a diabetes diagnosis. 
There are many factors that may increase the prevalence of DM in the population such 
as age, gender, and lifestyle (Wild et al., 2004). The patterns of eating in some 
countries have changed dramatically in recent years, in particular in the quantity and 
quality of dietary carbohydrates. As such it is useful to consider sources of dietary 
carbohydrates and the way in which they can be defined.  
1.5 Dietary carbohydrates  
1.5.1 Definition 
Carbohydrates are the most abundant organic components in most fruits, vegetables 
and cereal grains, and they are constructed from the atoms of carbon, oxygen and 
hydrogen (Garrett and Grisham, 2012). Carbohydrates are carbon-based molecules 
with an empirical formula for of (CH2O) n, where n = 3 or more, and they are rich in 
hydroxyl groups. Carbohydrates are comprised of two major classes; the simple 
carbohydrate class includes monosaccharides and disaccharides, the latter of which 
consists of two-monosaccharide units joined by a covalent bond. The complex 
carbohydrate class includes oligosaccharides, which contain short chains of 
monosaccharides between 3-10 units joined by covalent bonds, and the 
polysaccharides which contain a long chain of monosaccharides of more than 10 units 
(Gropper et al., 2009; Garrett and Grisham, 2012; Berg et al., 2012).  
1.5.2 Chemical structures  
1.5.2.1 Monosaccharides 
Monosaccharides consist typically of three to seven carbon atoms and are described 
either as aldoses (when they contain an aldehyde group) or ketoses (when they contain 
a keto group) (Gropper et al., 2009). They are classified by the number of carbon atoms 
in their structures (trioses, tetroses, pentoses, hexoses and heptoses), by their 
stereochemistry (D or L), and by the degree to which they are polymerized 
(disaccharides, oligosaccharides and polysaccharides) (Stipanuk, 2000; Berg et al., 
2012). In the Fisher projection, when the hydroxyl group is on the right of C4, these 
sugars have the D-sugar designation, whereas L-sugars are the mirror images of D-
sugars (Stipanuk, 2000). 
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The common monosaccharides are hexoses, such as glucose and fructose, which 
come in two isomeric forms; the D configuration is much more important nutritionally 
than the L configuration as the D isomers exist more frequently in nature and they are 
key in carbohydrate digestion and their subsequent metabolism (Figure 1.2). 
 
Figure 1.2: The ring forms of L-glucose, D-glucose and fructose. (Source Berg et al., 
2012). 
 
1.5.2.2 Disaccharides  
The simplest oligosaccharides are the disaccharides, which consist of two 
monosaccharide units linked by an acetal bond, which is also called a glycosidic bond 
(Gropper et al., 2009; Garrett and Grisham, 2012). Glycosidic bonds are formed 
between a hydroxyl group of one monosaccharide unit and a hydroxyl group of the 
next unit in the polymer chain (Gropper et al., 2009; Garrett and Grisham, 2012). The 
glycosidic bond can be in an α or β in orientation depending on the form of the anomeric 
hydroxyl group, which can be either α or β, before the glycosidic bond was formed. For 
instance, the glycosidic bond may be designated α 1-4, β 1-4, or α 1-6 (Gropper et al., 
2009). The most common disaccharides, which are the largest energy providing 
nutrient in the diet, are maltose, lactose and sucrose; maltose consists of two glucose 
units linked by an α 1-4 glycosidic bond, lactose is the main carbohydrate in milk and 
consists of D-galactose and D-glucose linked through a β 1-4 glycosidic bond, and 
sucrose is the most common disaccharide used as a sweetener, and is commonly 
known as table sugar, and is composed of glucose and fructose (Gropper et al., 2008; 
Berg et al., 2012; Garrett and Grisham, 2012). 
                                           
D-Glucose    L- Glucose Fructose 
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1.5.2.3 Polysaccharides  
Polysaccharides are formed from high molecular weight polymers. There are two kinds 
of polysaccharides, homopolysaccharides which contain only one type of 
monosaccharide, and heteropolysaccharides which contain different types of 
monosaccharide. Homopolysaccharides are more important than 
heteropolysaccharides nutritionally due to their abundance in many natural foods 
(Gropper et al., 2009; Garrett and Grisham, 2012). Starch is the most common storage 
polysaccharide in plants such as cereal grains, potatoes and legumes, which are the 
most common carbohydrate containing foods consumed in the human diet (Englyst et 
al., 1996; Cummings et al., 1997; Gropper et al., 2008; Garrett and Grisham, 2012). In 
addition, carbohydrates, either as starch or as simple sugars, account for 40-50 % of 
the calories consumed in the Western diet, which shows their overall importance 
(Caspary, 1992). Starch can exist in two forms: amylose and amylopectin; amylose is 
a straight-chain polymer of D-glucose linked through α 1-4 glycosidic bonds, whereas 
amylopectin is a branched chain polymer linked via α 1-6 and α 1-4 glycosidic bonds 
(Figure 1.3). Amylopectin has a larger molecular weight compared to amylose, and 
therefore has a larger surface area per molecule, this results in amylopectin being more 
accessible to enzymatic digestion as it is easier to hydrolyze (Thorn et al., 1983). 
Amylose typically contributes approximately 15-20 % of the total starch content of 
foods and amylopectin 80-85 % (Cummings and Englyst, 1995; Englyst and Hudson, 
1996; Cummings et al., 1997; Whitcomb and Lowe, 2007; Gropper et al., 2008; Garrett 
and Grisham, 2012). Barley and rice are examples of starch rich foods that are high in 
amylose (Zhou and Kaplan, 1997, Hu et al., 2004). The amylose: amylopectin ratio is 
a factor affecting starch digestibility and its physiological response, high amounts of 
amylose in starch products are sources of resistant starch (RS) that digests slowly, 
which might have potential health benefits. For example, they could slow the rise of 
postprandial blood glucose levels, and sustain blood glucose levels over time. Slow 
digestible starch foods produce a low glycaemic Index (GI) (Lehmann and Robin, 
2007).  
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 Figure 1.3: The structure of the common starch molecules amylose and amylopectin. 
(Source Garrett and Grisham, 2012). 
 
1.5.3 The digestion of carbohydrates 
Polysaccharides and disaccharides are the most important dietary carbohydrates, and 
starch is the most common digestible polysaccharide in the human diet (Gropper et al., 
2009). Both polysaccharides and disaccharides are hydrolysed by intestinal enzymes 
to their constituent monosaccharide units; this is the only form of carbohydrate that can 
be absorbed by the intestinal epithelium (Gropper et al., 2009). The digestion of 
polysaccharide starts in the mouth; the salivary glands release salivary α-amylase, 
which hydrolyses the α 1-4 glycosidic bonds in amylose and amylopectin, whereas the 
α 1-6 glycosidic bonds in amylopectin are resistant to α-amylase (Whitcomb and Lowe, 
2007; Gropper et al., 2009). The enzymatic activity of salivary α-amylase is destroyed 
by the acidity of gastric juices (pH 2.0) in the stomach, consequently, there is no 
enzymatic digestion of starch in the stomach and the dextrins (low-molecular-weight 
carbohydrates produced by the hydrolysis of starch or glycogen) pass through without 
any further change into the small intestine (Gropper et al., 2009). The pancreas 
releases pancreatic α-amylase into the small intestine which hydrolyses α 1-4 
glycosidic bonds in both amylose and amylopectin, and breaks down the dextrins into 
maltose (Gropper et al., 2009; Garrett and Grisham, 2012). On the brush border of the 
small intestine maltose is hydrolysed by maltase to produce glucose, and the α 1-4 
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glycosidic bonds in limit dextrins are hydrolysed by α-dextrinase to produce glucose 
(Gropper et al., 2009). 
Some disaccharides and oligosaccharides are not digested in the mouth or stomach, 
such as lactose, sucrose, maltose and isomaltose; they can be digested in the microvilli 
of the intestinal mucosal cells of the upper small intestine (Gropper et al., 2009). 
Lactose is broken down by lactase into galactose and glucose, sucrose is hydrolysed 
by sucrase into glucose and fructose, and finally, isomaltose, which is the remaining 
disaccharide from the incomplete breakdown of amylopectin, is separated by 
isomaltase (α-dextrinase) to yield two molecules of glucose (Gropper et al., 2009). 
1.5.4 The absorption of carbohydrates 
Carbohydrates in the diet occur as monosaccharaides, disaccharides, 
oligosaccharides and polysaccharides, however, in the human intestinal tract, only the 
monosaccharides can be absorbed (Wright et al., 2003). Approximately 70-85 % of the 
carbohydrates in the diet are absorbed as glucose, with the remainder being a mixture 
of fructose and galactose (Dikeman et al., 2004). The absorption of most of these 
monosaccharides occurs through the lumenal surface of microvilli cells (the brush 
border); glucose and galactose absorption depends on the activity of the sodium 
glucose transporter 1 (SGLT1), which is a protein complex dependent on Na+, K+, and 
ATP as energy (Kellett et al., 2008). Glucose enters the absorptive cell byGLUT4 and 
SGLT1 in the brush border membrane and exits into the blood by Glucose Transporter 
2 (GLUT2), which is a member of the facilitative glucose transporter family (Hediger 
and Rhoads, 1994; Kellett et al., 2008). However, fructose absorption is dependent on 
GLUT5, which is specific for fructose, it enters the cell by GLUT5 and exits the cell by 
GLUT2, which is the same member of the transporter family that moves glucose out of 
the cell (Kellett and Helliwell, 2000; Kellett, 2001). 
The hormone involved in glucose absorption regulation is insulin, it is released by the 
β-cells of the pancreas when the blood glucose levels are elevated (Wright et al., 2003; 
Baumgard et al., 2016). Insulin plays many roles in glucose absorption; it increases 
the activity of enzymes that catalyze the synthesis of glycogen in the liver to produce 
glucose, and it stimulates the glucose transport protein GLUT4 in skeletal muscle and 
adipose tissue (Baumgard et al., 2016). Skeletal muscle both stores glucose as 
glycogen and oxidizes it to produce energy (Gropper et al., 2009). Studies have shown 
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that GLUT4 plays an essential role in regulating whole body glucose homeostasis, and 
is therefore vital for the correct functioning of glucose uptake and metabolism (Huang 
and Czech, 2007; Baumgard et al., 2016). 
As highlighted above, carbohydrate is the main source of energy in the human diet. 
There are many methods to measure the quantity of the carbohydrates in food, as well 
as determining the release of glucose from starch-rich foods which will allow the 
amount of energy released to be determined. One of the most common methods for 
determining the speed of release of glucose from starchy foods is by using specific 
enzymes that break down the starch in vitro.  
1.5.5 The measurement of carbohydrate availability in vitro  
There are many different methods available that can be used to determine the total 
carbohydrate in foods, there are also many methods that use enzymes to determine 
the speed of glucose released from carbohydrate foods in vitro, for example enzyme 
based hydrolysis of starch (Englyst and Englyst, 2005). This approach uses pancreatic 
and brush border membrane enzymes to determine and measure the glucose released 
from a starch-rich food. The amount of glucose released is measured at specific times 
during hydrolysis to provide an indication of carbohydrate availability and speed of 
release (Englyst and Englyst, 2005). The two useful measurements obtained are the 
rapidly available glucose (RAG) and the slowly available glucose (SAG); these terms 
provide values for glucose that is released from starch, and other glucose yielding 
carbohydrates, that are available for absorption in the small intestine (Englyst and 
Englyst, 2005). These measurements can be used as a guide for the GI in vivo and 
provide a clear indicator of the effect of a starchy food on blood glucose levels (Englyst 
et al., 1999; Englyst et al., 2000; Englyst et al., 2003). Indeed, a significant correlation 
(P < 0.001) has been shown between the release of RAG, SAG, and GI (Englyst et al., 
1992; Englyst et al., 1999). This shows that a food or beverage with a high RAG value 
would probably have a high GI, while a food or beverage with a low RAG value would 
have a low GI. It is important to know the GI of a food to allow an accurate 
measurement of energy intake to create a balanced diet.  
1.6 Glycaemic index  
Carbohydrates can be classified according to their physiological effect in the human 
body, and not just by their chemical structure (section 1.5.2); they can be classified by 
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their ease of digestion and absorption, and their effect on the elevation of blood glucose 
levels (Asp, 1996; Englyst et al., 2007). The GI is a method that was introduced by 
Jenkins and colleagues in 1981 to classify carbohydrate containing foods according to 
their impact on the postprandial glycaemic response (Jenkins et al., 1981). GI is 
defined as the incremental area under the two-hour blood glucose response curve, 
after consumption of a test food containing 50 g or 25 g of available carbohydrates, 
expressed as the percentage of the response to the same amount of carbohydrates 
from a standard food (e.g. white bread or glucose) taken by the same participants 
(Wolever, 1990; Wolever et al., 1991; FAO/WHO, 1997). The GI has been reported to 
be a more useful nutritional concept than the chemical classification of carbohydrates, 
especially as low GI foods are slowly digested and absorbed, and produce a gradual 
rise in the blood glucose level (Wolever, 1990; Jenkins et al., 2002). Therefore, low GI 
foods are generally considered to be favourable in the dietary management of type 2 
diabetes, and are also considered important in reducing CVD and obesity (Granfeldt 
et al., 2006). 
1.6.1 Measuring the GI of starch rich foods  
According to the FAO/WHO guidelines (1997) the sample size required for a GI study 
is between 10 and 12 participants. Participants must refrain from consuming alcohol 
and caffeine-containing drinks for at least 24 hours prior to the test day. To measure 
fasting glucose and changes in glucose levels, capillary finger prick blood samples 
must be taken from the participants in the fasted state and then every 15 minutes 
during the first hour, and every 30 minutes throughout the second hour after the start 
of consumption of the test food or reference food, in random order, as this allows the 
changes over time to be observed. The amount of available carbohydrate in the test 
food, or reference food, should be 25 g or 50 g. The reference food, which is often a 
glucose drink, should be given to the participants three times on separate occasions 
to reduce the variability between experiments. Blood glucose is measured with an 
automatic analyser and plotted on a graph against the blood sampling time, as this will 
allow the incremental area under the curve (IAUC) of each blood glucose response to 
be calculated geometrically (Figure 1.4). The GI value is calculated as: (IAUC 
sample/IAUC standard) x 100 (Figure 1.5) (Wolever et al., 1991; Brouns et al., 2005). 
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Figure 1.4: The incremental area under the curve (IAUC) equals the sum of the area 
A, B, C, D and F (Wolever et al., 1991; Brouns et al., 2005). 
The area under the curve can be calculated from the following equation: 
Area = At/2+ At + (B-t)/2 + Bt + (C-B)t/2 + Ct + (D-C)t/2 + Dt + (E-D)t/2….etc.  
Where A, B, C, D, E and F represent the blood glucose increments, t represents the 
different time intervals between the blood samples, (Figure1.4). (Wolever et al., 1991; 
Brouns et al., 2005).  
 
 
 
Figure 1.5: Equation for the calculation of GI value for test foods. (Source Wolever et 
al., 1991). 
1.6.2 The classification of the GI of foods 
The GI value is a ranking system that indicates how quickly foods raise blood glucose 
levels; high GI foods are rapidly digested and absorbed by the small intestine and show 
a high glycaemic response, with their index between 70 and 100, when using a glucose 
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drink as a reference (index of 100) (Brouns et al., 2005). Conversely, low GI foods are 
digested and absorbed more slowly and show a low glycaemic response, with their 
index being less than 55 when compared to glucose as a reference. The index of 
medium GI foods is between 55 and 69 (Brand-Miller et al., 2003; Brouns et al., 2005; 
Kirpitch and Maryniuk, 2011). Overall this system is very useful for classifying different 
foods as it allows the releasable energy content of a diet to be calculated, and foods 
that release energy slowly can be selected to help maintain a feeling of fullness. 
1.6.3 Factors influencing GI value of food  
There are a number of factors that can affect the GI value obtained from a food, such 
as the combination of macronutrients used, the proportion of amylose and amylopectin, 
how the food is processed, and the starch type, the fibre in the food, the organic acids 
present, and the presence of simple sugars. 
1.6.3.1 The combination of macronutrients  
The presence of fat and protein in a carbohydrate meal can result in a different and 
variable glucose response, compared to carbohydrate alone, depending on the 
proportion of each nutrient in the meal (Pi-Sunyer, 2002). Ercan et al. (1994) 
investigated the effect of adding 50 g of fat, as butter, to a carbohydrate meal (which 
contained 50 g of available carbohydrate), on the glucose response, and found that 
the glucose response was significantly lower for the combination compared to the 
carbohydrate dose alone. Similarly, adding protein to a carbohydrate meal reduces the 
glycaemic response, possibly due to the protein having an effect on delaying gastric 
emptying and enhancing insulin secretion, which stimulates the peptide gut hormone 
release (Pi-Sunyer, 2002). Overall these results show that the carbohydrate content of 
a meal cannot be considered in isolation, the other components need to be considered 
in conjunction as they can affect its uptake. 
1.6.3.2 Proportion of amylose to amylopectin  
The nature of the starch in the carbohydrate meal is also important to consider in the 
calculation of the GI of foods. For most carbohydrate containing foods, the total starch 
can be divided up into 15-20 % amylose and 80-85 % amylopectin (Garrett and 
Grisham, 2012) (see section 1.5.2.2 and 1.5.2.3). The amount of amylose and 
amylopectin in the starch fraction is responsible for differences in rate of digestion, 
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which can be related to the difference in glycaemic response observed (Murray et al., 
1998). This can be due to the differences in structure allowing glucose units of amylose 
to participate more in hydrogen bonding and the presence of less branched chains of 
glucose than amylopectin, making them less accessible to enzymatic digestion 
(Thorne et al., 1983; Murray et al., 1998). Furthermore, amylose has a lower molecular 
weight than amylopectin and a smaller surface area for enzymatic attack for amylose 
(O’Dea et al., 1980; Murray et al., 1998). Therefore, foods which are higher in amylose 
produce a lower GI (Pi-Sunyer, 2002); for example, Doongara rice, which has 28 % 
amylose, gave a lower GI (GI = 63), (P < 0.01) than normal rice (GI = 88), which has 
20 % amylose (Miller et al., 1992). This shows that altering diets to contain higher 
quantities of amylose may help to maintain a sustained glucose release, reducing large 
spikes in blood glucose that can be detrimental. 
1.6.3.3 Processing, preparation and cooking methods  
The processing, preparation and cooking of foods can change the GI; grinding, rolling, 
and pressing can disrupt the granules of starch, which would allow more of the amylose 
and amylopectin macromolecules to be available for hydrolysis, and thus increase the 
GI of the food (Pi-Sunyer, 2002). Moreover, the cooking of starchy foods can produce 
a greater GI compared to the raw/uncooked foods, because cooking can increase the 
break-up of the starch granules, making them more readily available for hydrolysis. 
Studies have shown that starch granules can swell and burst when cooked, which also 
increases the availability of the starch to amylase (Thorne et al., 1983). These changes 
need to be taken into account when calculating GI and planning a diet to help weight 
loss or a controlled glucose release. 
1.6.3.4 The physical form of the starch foods 
Different physical forms of a single food, and particle size, can change the glycaemic 
response; for example, the GI of cooked ground rice was higher than cooked whole 
rice, when fed to both healthy people and diabetic patients. This is due to the fact that 
ground rice has a higher surface area than whole rice, and as such the rate of starch 
hydrolysis is increased (Thorne et al., 1983; Pi-Sunyer, 2002). A similar comparison 
can be drawn for fruit; for example, the GI for an orange is 42 ± 3, while that for orange 
juice is 52 ± 3, (Foster-Powell et al., 2002). This difference is due to the processing of 
the orange releasing the juice and the starches from the fruit. 
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1.6.3.5 Fibre type  
Fibre includes dietary fibre and functional fibre; dietary fibre consists of non-digestible 
carbohydrate and lignin that are naturally occurring in foods, such as non-starch 
polysaccharides (NSP) which include cellulose, pectin and gum (Slavin, 2005). 
Functional fibre contains isolated non-digestible carbohydrates (Slavin, 2013). Dietary 
fibre can be further divided into soluble (viscous) and insoluble (non-viscous) fibre such 
as oat bran and guar gum (Slavin, 2005). Resistant starch (RS) is a constituent of fibre 
and occurs naturally in plant cell walls, it is resistant to enzymatic digestion, passing 
through the small intestine and reaching the large bowel (Bravo et al., 1998, Bagchi et 
al., 2000). RS can be separated into four classes: RS1 is a starch that is inaccessible 
to amylase digestion, RS2 is a starch that is accessible to the amylase by 
gelatinization, RS3 is an isolated fibre form that is created during cooking and cooling 
of starch rich foods, and RS4 is chemically modified starch not found in nature (Englyst 
et al., 1992; Cummings et al., 1996). 
Soluble fibre reduces the glycaemic response by decreasing the absorption of 
macronutrients in the small intestine, as well as decreasing the availability of the starch 
for digestion (Wolever and Miller, 1995; Foster-Powell et al., 2002; Slavin, 2005). This 
occurs because the soluble fibre (especially non-starch polysaccharides) increases the 
viscosity of the food, which delays gastric emptying and intestinal absorption (Hallfrisch 
and Behall, 2000, Sasaki and Kohyama, 2012). 
1.6.3.6 Organic acids 
An organic acid is an organic compound with acidic properties, the most common are 
the carboxylic acids, such as citric acid found in fruit (Guevarra and Panlasigui, 2000). 
A high organic acid content in foods can lower the GI, for example, mango has a low 
GI because it contains malic, citric and tartaric acids, which could delay gastric 
emptying (Guevarra and Panlasigui, 2000). Moreover, increasing the amount of acidity 
of a meal has also been shown to reduce the GI of a meal (Pi-Sunyer, 2002). A study 
by Liljeberg and Björck (1998) showed that the presence of acetic acid (18 mmol per 
test meal) as vinegar reduced the postprandial blood glucose (GI = 64) and insulin 
indices (II = 65) significantly for a starchy meal, such as white wheat bread. This effect 
could be due to a delay in the gastric emptying rate (Liljeberg and Björck, 1998). This 
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suggests that adding these acidic fruits or acids such as vinegar, can make diets more 
effective by reducing the GI. 
1.6.3.7 Anti-nutrients  
Anti-nutrients are components that are present in some grains and legumes and can 
affect fasting glucose levels. These components include lectins, tannins and phytic 
acid, which is also known as myo-inositol hexaphosphate (Yoon et al., 1983; Greiner 
and Konietzny, 2006). Studies have shown that phytic acid added as a supplement in 
the diet can significantly reduce fasting glucose levels and haemoglobin A1c in diabetic 
KK mice (Lee et al., 2006). In addition, adding phytic acid to navy bean flour has been 
shown to decrease starch digestion in vitro and GI in vivo (Thompson et al., 1987). The 
mechanism responsible for this relationship is possibly that phytic acid may inhibit 
gastric emptying or inhibit starch digestion by altering the pH of the intestine (Yoon et 
al., 1983; Thompson et al., 1987). Another source of anti-nutrients are the polyphenols, 
such as tannins, which are widely present in foods such as legumes (Thompson et al., 
1984). Polyphenols in legumes may have been shown to have the ability to reduce the 
glycaemic response to a carbohydrate food in healthy and diabetic people (Thompson 
et al., 1984). This effect may be due to the polyphenolic compounds inhibiting some 
enzymes, such as amylase, leading to reduced starch digestibility (Section 1.6) 
(Thompson et al., 1984; Siddhuraju et al., 2005; Williamson, 2013). 
1.6.3.8 The presence of sugars 
The common simple sugars present in foods are lactose, glucose and sucrose; they 
have different GIs, the GI of fructose is 19, glucose is 99, lactose is 46 and sucrose is 
68, which shows how varied their response is (Foster-Powell et al., 2002). This shows 
that the GI value of foods is dependent on the type of sugar present, as fructose in a 
drink or meal produces a significantly lower glucose and insulin response compared 
with glucose and sucrose in a drink or meal (Wolever and Miller, 1995). For example, 
cake and ice-cream sweetened with fructose produces a lower glycaemic response 
than cake and ice-cream sweetened with sucrose (Wolever and Miller, 1995). This 
suggests that diets could be modified to include more fructose as this would help to 
reduce the GI.  
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1.6.4 GI and disease  
Recently, many studies have suggested that low-GI foods may be beneficial for the 
prevention or treatment of a number of chronic diseases, including diabetes, CVD and 
cancer (Jenkins et al., 2002; Brand-Miller et al., 2003). 
Low GI foods have a smaller 2 hour area under the glucose curve than white bread or 
glucose, which are used as controls, and this can lead to a reduced glycaemic and 
insulinaemic response; whereas high GI foods have a higher area under the glucose 
curve than the controls and lead to an increased insulin response (Bornet et al., 1987). 
Hodge et al. (2004) report that dietary high GI is positively associated with diabetes in 
a study of 31,641 type 2 diabetes participants completed at follow up. They suggest 
that a low GI diet may reduce the risk of type 2 diabetes. Another study examined the 
association between GI and dietary fibre in 91,249 women, who completed a frequency 
dietary intake questionnaire, and were followed for 8 years for the development of 
incident type 2 diabetes. This study found that high GI was significantly associated with 
an increased risk of diabetes (Schulze et al., 2004). McKeown et al. (2004) examined 
the association of insulin resistance, the prevalence of metabolic syndrome with dietary 
glycaemic index in 2,834 subjects. The outcome of their study showed that dietary high 
GI was positively associated with insulin resistance and the prevalence of metabolic 
syndrome. Several studies have shown that a high GI diet stimulates a greater level of 
insulin secretion than a low GI diet, which leads to hyperinsulinaemia, IR and increased 
beta cell demand (Jenkins et al., 1987, Miller, 1994, Ludwig, 2002). In addition, a high 
GI diet elevates blood glucose and free fatty acid levels that may impair beta cell 
function (Jenkins et al., 1987, Miller, 1994, Ludwig, 2002). However, there is evidence 
to suggest that low GI diets improve insulin sensitivity, and reduce the peak rise of 
blood glucose (Jenkins et al., 1987, Miller, 1994, Ludwig, 2002). Furthermore, they 
reduce blood glucose fluctuations during the day and this is one of the main benefits 
of consuming low GI foods, in particular for diabetic and pre-diabetic people who need 
to control their glucose levels (Jenkins et al., 1992, Ceriello, 1998). Studies have shown 
that a low GI diet can improve metabolic control in diabetes, and lower total plasma 
cholesterol and LDL cholesterol in type 2 diabetics, compared with a high GI diet, 
however, a low GI diet has no significant impact on HDL and triglyceride levels which 
is considered beneficial (Opperman et al., 2004, Kelly et al., 2004). On the other hand, 
a high GI diet has been shown to be strongly associated with an increased risk of 
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coronary heart disease (Liu et al., 2000). It is clear that there are several health benefits 
in using GI as an indicator for daily diets, as it as can help to reduce the risk of disease.    
1.7 Polyphenols  
Polyphenols are a group of phytochemicals widespread in plants; they are present in 
foods such as fruits, vegetables, herbs, and cereals and they are essential to the 
physiology of plant function, structure and growth (Haslam, 1998). There are more than 
8000 phenolic structures currently known, which can be simple molecules such as 
phenols, or more complex and variable in their composition, such as tannins 
(Harborne, 1993; Bravo, 1998; Urquiaga and Leighton, 2000). Simple phenols (Figure 
1.6 A), polyphenols (Figure 1.6 B) and tannins that are present naturally in food have 
been used for many years to give foods and beverages specific colours, odours and 
flavours (Shahidi and Naczk, 1995). Polyphenol structures consist of several hydroxyl 
groups on two or more six-carbon aromatic rings (D’Archivio et al., 2007; Stevenson 
and Hurst, 2007; Lindsay and Clifford, 2000). Therefore, molecules with only one ring, 
such as phenolic acids and phenolic alcohols, are strictly not polyphenols, however 
they share many properties and characteristics of polyphenols and so are usually 
grouped together when considering the properties of the components of plants, foods 
and beverages (Stevenson and Hurst, 2007). 
                                            
Figure 1.6: A) Basic structure of phenol        B) Basic structure of polyphenols 
1.7.1 Classification of polyphenols  
Polyphenols can be divided into different classes depending on their structure and 
function (Clifford, 2004; Weichselbaum and Buttriss, 2010). The main groups of 
polyphenols are flavonoids, phenolic acids and tannins (Figure 1.7); flavonoids can be 
further divided into several subclasses which are: flavones, flavanones, flavonols, 
flavanols (also called flavan-3-ols), anthocyanidins and isoflavones (D’Archivio et al., 
2007; Opara and Chohan., 2014).  
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Tannins can also be further divided in two groups, which are the condensed 
(proanthocyanidins) and hydrolysable tannins. Moreover, any polyphenols that have 
higher molecular weight structures (molecular weights ≥ 500) are usually classified as 
tannins (Khandelwal et al., 2010).   
 
Figure 1.7: The classification of polyphenols (source Opara and Chohan., 2014). 
 
1.7.2 Proanthocyanidins 
Proanthocyanidins (PAs) are oligomeric and polymeric flavan-3-ols, a type of tannin; 
they are present in fruits and vegetables, and the bark, leaves and seeds of many 
plants. They play an important role in plants as they provide protection against 
predation, and they also can give flavour to beverages such as teas (Dixon et al., 
2005). They share some common structural features with phenols such as procyanidin. 
Little is known about their dietary intakes, although they are likely to contribute to a 
large part of the daily polyphenol consumption due to their abundance in commonly 
consumed plants (Santos-Buelga and Scalbert, 2000). There are two main types of 
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PAs in fruits, vegetables, and herbs, A-type procyanidin contains (+) – catechin and/or 
(-) epicatechin units that are doubly link through carbon C2→C7 and C4→C8 bonds 
(Figure 1.8 A), whereas B-type procyanidin contains a single link through C4→C8 bond 
(Figure 1.8 B) (Passos et al., 2007). A-type trimers and tetramers have molecular 
masses of 864 and 1152 Da, respectively, whereas, B-types have trimers and 
tetramers with molecular masses of 866 and 1154 Da, respectively (Lu et al., 2011).  
The absorption, distribution, metabolism and excretion of proanthocyanidins is based 
on their chemical structures (Bravo, 1998). The absorption of proanthocyanidins is 
minor (Holt et al., 2002). Proanthocyanidins with a degree of polymerisation (DP) less 
than 3 are depolymerised into mixtures of epi-catechin or catechin monomers and 
dimers are absorbed by the small intestinal. While proanthocyanidins DP more than 
10, move from the small intestine to the large intestine and are degraded by micro-flora 
(Kruger et al., 2014). Although proanthocyanidins show impaired absorption in the 
small intestine, they still have health benefits (Teixeira, 2002). Proanthocyanidins such 
as procyanidin B2 and procyanidin A are metabolized by gut flora to produce phenolic 
acids, which can be detected in urine, and other metabolites are also formed. These 
may be important in terms of health effects in the gut (Forester and Waterhouse, 2009). 
There are a variety of gut flora that could participate in the metabolism of polyphenols, 
in particular the flavonoids, these are Bacteroides spp. and Eubacterium spp. (Blaut 
and Clavel, 2007). 
 
              A                                                                                      B 
                                                                               
Figure 1.8: A-type procyanidin (A) and B-type procyanidin structure (B), (Passos et 
al., 2007). 
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1.7.3 The health properties of polyphenols   
Studies have suggested that polyphenols might be important for health as they have a 
higher antioxidant activity than vitamin E and also carotenoids in vitro (Rice-Evans et 
al., 1997). They have been shown to inactivate free radicals, such as lipid peroxides, 
and they can reduce the oxidative effects of metal ions in vitro (Rice-Evans et al., 
1997). Furthermore, there is evidence that they are able to inhibit pro-oxidant enzymes 
and enhance antioxidant enzymes in vitro, and also protect other antioxidants, such as 
ascorbic acid, against oxidation in vitro (Aron and Kennedy, 2008; Heinonen, 2007; 
Stevenson and Hurst, 2007; Saura-Calixto et al., 2007; Lopez-Lazaro, 2009). 
However, the impact of polyphenols on antioxidant capacity in vivo has been shown to 
be different to that in vitro; D’Archivio et al. (2007), Stevenson and Hurst (2007) and 
Ghosh and Scheepens (2009) have stated that polyphenols do not appear to be 
circulating in the blood at high enough concentrations to contribute significantly to the 
antioxidant capacity of the body. Studies have also shown that approximately 90-95 % 
of the polyphenols ingested undergo molecular changes in their structure, and as such 
changes in their biological activities, compared to polyphenols investigated in vitro 
studies (Lotito and Frei, 2006; Stevenson and Hurst, 2007). Most polyphenols that are 
present in plants in the form of esters, glycosides or polymers are not absorbed, 
therefore these compounds, once ingested, travel to the large intestine where they are 
broken down by intestinal enzymes or microflora in the colon, which would modify the 
polyphenols allowing them to be absorbed (D’Archivio et al., 2007; Saura-Calixto et al., 
2007; Aron & Kennedy, 2008). A study by Visioli et al. (2009) claimed that the 
polyphenol forms reaching the blood and tissues were different from those present in 
food which concurs with other research in this area. The rate of polyphenol absorption 
is determined by the structure of the polyphenols, not by their concentration, and in 
addition, some of the variation observed for polyphenol absorption and metabolism 
may be due to the differences in the composition of the gut microflora between patients 
(D’Archivio et al., 2007; Weichselbaum and Buttriss, 2010). Overall this suggests 
further research is required to determine which factors play an important role in their 
uptake. 
There are many health benefits associated with the consumption of polyphenols, for 
example the consumption of plants which are high in polyphenol content, such as fruits 
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and vegetables, is associated with a reduced risk of CVD and an improvement in 
vascular endothelial function (Barona et al., 2012; Hodgson et al., 2006). Furthermore, 
studies have suggested that there can be a beneficial modification of the hormonal 
profile, modification of the lipid profile, a decrease in serum cholesterol and an increase 
in insulin sensitivity, after consumption of a polyphenol-rich diet, which may be due to 
more than just the polyphenols in the diet (Goldberg, 2003; Stanner, 2005; Kar et al., 
2006; Stevenson and Hurst, 2007; Aron and Kennedy, 2008; Ghosh and Scheepens, 
2009). Polyphenols are considered as non-nutrients; however, they have been shown 
to have antioxidant and anti-inflammatory effects in vitro (Bravo, 1998; Harborne, 
1993). 
Consuming fruits, vegetables and herbs, which are rich in polyphenols, might also 
contribute to reducing the risk of some forms of cancer, such as mouth, oesophagus, 
stomach and lung (WCRF/AICR, 2007). Herbal medicines such as cinnamon are 
considered as a good source of polyphenols (Anderson et al., 2004). These 
compounds are of interest as research has shown they are one group of the 
active compounds in cinnamon, and may be responsible for the medicinal 
properties observed. 
1.7.4 Polyphenols in cinnamon  
Studies on the composition of cinnamon using LC-MS have shown that about 26.8 % 
of crude cinnamon extract is condensed tannins, 23.2 % is proanthocyanidins, and 3.6 
% epi-catechins, which shows that cinnamon has a high polyphenol content (Shan et 
al., 2007). There are two major types of proanthocyanidins present in cinnamon which 
are A-type procyanidin and B-type procyanidin (section 1.6.1.1) (Jarvill-Taylor et al., 
2001; Lu et al., 2011).    
A study by Anderson et al. (2007) has indicated that A-type procyanidins perform an 
insulin like activity in vitro, which suggests they could be used to help patients with 
diabetes. Furthermore, a study by Lu et al. (2011) confirmed that A- and B-type 
procyanidins analysed by LC-MS methods exist in cinnamon, which might have 
hypoglycaemic activities and may improve insulin sensitivity.  The effect of co-
administration of C. cassia extracts at doses of 200 and 300 mg/kg body weight with a 
high-fat diet to male KM mice for 14 days has been studied. The results showed that 
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blood glucose concentrations were significantly decreased in animals fed cinnamon 
extract compared with the control group (Lu et al., 2011). 
Another study has shown that cinnamon extracted with acetone has antioxidant activity 
as shown in the linoleate oxidation assay and the 1,1-diphenyl-2-picryl hydrazyl 
(DPPH) assay in vitro (Jayaprakasha et al., 2007). In a recent review of bioactive 
properties of herbs and spices, cinnamon was demonstrated to have a significant 
inhibitory action on the pro-inflammatory enzyme cyclo-oxygenase-2 (COX-2), which 
is probably related to the polyphenolic content of cinnamon, as these type of 
polyphenols have previously been shown to inhibit this enzyme (Opara and Chohan, 
2014). Cinnamon also decreases lipopolysaccharide (LPS) TNF-α stimulation in mice 
serum, and it inhibits the generation of TNF-α and IL-6 in male BALB/c mice, which 
shows that cinnamon can cause immune modulation. This anti-inflammatory activity of 
cinnamon is related to the presence of polyphenols in cinnamon (Hong et al., 2012).  
Furthermore, catechin, epicatechin and procyanidin B2, which have been identified in 
cinnamon extract, have been shown to inhibit the formation of advanced glycation end-
products (AGEs) in vitro (Peng et al., 2008). Accumulation of AGEs are seen in the 
pathogenic process, and are associated with many disease states such as diabetes, 
Alzheimer’s disease and CVD (Peng et al., 2008). Further evidence of the benefits of 
cinnamon have come from a study by Kannappan, et al. (2006) which found that an 
aqueous cinnamon extract (100 mg/ml) improved glucose metabolism and prevented 
hyperlipidaemia in fructose-fed male albino rats. A study by Cao et al. (2007) 
summarised the potential effect of cinnamon polyphenols (CP) in the insulin signalling 
pathway in type 2 diabetics (Figure 1.9); CP activated insulin receptors by increasing 
their tyrosine phosphorylation activity and by decreasing phosphatase activity that 
inactivates them, moreover, CP increased the concentration of the insulin receptor β, 
GLUT4 protein, glycogen synthase activity and glycogen accumulation (Cao et al., 
2007). Overall this study showed that CP have many effects on the insulin signalling 
pathway, suggesting it may be helpful for people with diabetes. 
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Figure 1.9: A model of the pathways contributing to the beneficial effects of cinnamon 
polyphenols in insulin signalling (Cao et al., 2007). Cinnamon polyphenols (CP) 
enhance insulin receptors by increasing their tyrosine phosphorylation activity. CP 
increased the concentration of the insulin receptor β, GLUT4 protein, glycogen 
synthase activity and glycogen accumulation. CP reduced COX-2 and cytokines such 
as TNF-α.  
1.7.5 Cinnamaldehyde in cinnamon 
Cinnamaldehyde (cinnamic aldehyde) is one of the principal volatile oil components in 
cinnamon that gives the cinnamon its particular flavour (Rao and Gan, 2014) (Figure 
1.10). The properties of this oil have been investigated in a study by Subash Babu et 
al. (2007) who reported that the cinnamaldehyde in cinnamon had hypoglycaemic and 
hypolipidaemic effects in male diabetic Wistar rats. The doses administered in the 
study were 5, 10 and 20 mg/kg body weight (BW) for 45 days. The highest dose of 20 
mg/kg BW, significantly decreased glycosylated hemoglobin (HbA1c), serum total 
cholesterol and triglyceride levels. This study shows the potential effects that could be 
achieved in humans and the doses that would be useful in future studies.       
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Figure 1.10: Basic structure of cinnamaldehyde, (Rao and Gan, 2014) 
 
There are many studies that show cinnamon is an effective herbal medicine with many 
health benefits in vitro and in animal studies, however, only a few randomised human 
studies have highlighted the effect of cinnamon on glycaemia, which limits the 
conclusions that can be drawn about the potential health benefits of cinnamon in 
diabetic and pre-diabetic subjects (Gruenwald et al., 2010). Also, the anti-inflammatory 
property of cinnamon has been confirmed in vitro (Lee et al., 2005; Opara and Chohan, 
2014) but no human studies have been conducted, therefore it is worth examining the 
anti-inflammatory, anti-diabetic and lipid reducing properties in humans through 
studying the effect on biomarkers, inflammatory markers such as cytokines, adhesion 
molecule markers, glycaemic control, and lipid profiles.  
1.8 Cytokines  
Cytokines are very low molecular weight compounds, and they are involved in the 
regulation of the immune system and in the intercellular signalling response (Bown et 
al., 2001). Many different cell types produce cytokines and regulate the proliferation 
and differentiation, and other activities of cells (Scheller et al., 2011). Cytokines can be 
divided into those that are primarily pro-inflammatory and those that are anti-
inflammatory; pro-inflammatory cytokines promote the production of further cytokines 
and cause inflammation; these include interleukin 1 (IL-1), interleukin 2 (IL-2), 
interleukin 6 (IL-6) and interleukin 8 (IL-8), tumour necrosis factor alpha (TNF-α) and 
Interferon gamma (IFN-γ) (Souza et al., 2008). Anti-inflammatory cytokines are able to 
inhibit macrophage function and can act indirectly on T cells, for example IL-4, IL-10, 
and IL-13, and they lead to a reduction in pro-inflammatory cytokine production (Souza 
et al., 2008; Bown et al., 2001). All cytokines have multiple biological activities in 
multiple cell types, they can show stimulatory or inhibitory activities of other cytokines 
and hormones (Matsumoto and Kanmatsuse, 2000). Cytokines play important roles in 
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repairing damaged tissue, controlling cell replication and apoptosis, and also in the 
modulation of immune reactions (Foster, 2001). In acute and chronic inflammatory 
diseases in humans, such as arthritis, a large concentration of cytokines are released 
into plasma (Arvidson et al., 1994; Vindenes et al., 1998). Furthermore, monitoring the 
change in cytokine levels can be used as an indirect measurement of the progression 
of the disease in response to therapy, such as antibiotics, for example CRP levels can 
be monitored over time (Zissel et al., 1999; Simpson et al., 2000). Research by 
Dinarello (2000) has suggested that the susceptibility to disease is genetically 
determined by the balance or expression of either pro-inflammatory or anti-
inflammatory cytokines. Pro-inflammatory cytokines promote inflammation and 
infection such as IFN-γ that augments TNF-α activity and induces nitric oxide (NO), 
whereas anti-inflammatory cytokines suppress the intensity of the cascade of pro-
inflammatory cytokines or block this process (Dinarello., 2000). The balance between 
pro-inflammatory and anti-inflammatory cytokines can determine the outcome of 
disease, whether in the short term or long term (Dinarello., 2000). 
A study by Hatanaka et al. (2006) found that there was an excessive release of pro-
inflammatory cytokines (namely IL-8, IL-1β and TNF-α) produced by neutrophils and 
monocytes associated with type 2 diabetic patients, which suggests that there is an 
immune role in the progression of diabetes that could be treated to reduce symptoms. 
Obesity is also associated with a state of chronic inflammation, the detection of an 
elevated release of pro-inflammatory cytokines from obese adipose tissue was the first 
evidence of a direct connection between obesity and systemic inflammation (Berg and 
Scherer, 2005). This study showed that CRP concentration, which is considered as a 
systemic inflammation marker, was increased in obese patients (Berg and Scherer, 
2005). Further evidence of an immune role comes from the fact that adipose tissue of 
obese patients increases the expression of pro-inflammatory proteins such as ICAM 
and MCP-1 (Terra et al., 2009).  
1.8.1 The cytokine families   
There are six families of cytokines:  
1- The IL-1 family are soluble cytokines that are secreted very early in the immune 
response by dendritic and endothelial cells, as well as monocytes and macrophages, 
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and include IL-1α and IL-1β. They are considered to be pro-inflammatory (Hamblin, 
1993; Thomson and Lotze, 2003). 
2- The hematopoietin Class I cytokine family are soluble cytokines that communicate 
between immune cells and are secreted by T cells, B cells, mast cells, endothelial cells, 
monocytes, and macrophages. Their name is derived from the function of some of 
these cytokines, which are involved in the formation of blood cells. IL-2, IL-4, IL-6 and 
IL-12 are examples of this family (Hamblin,1993; Thomson and Lotze, 2003). 
3-The TNF family are soluble cytokines that regulate the development, function and 
homeostasis of skeletal cells, for example TNF-α and TNF-β. They are secreted from 
macrophages, T cells, B cells and natural killer cells (Hamblin, 1993; Thomson and 
Lotze, 2003). 
4- The IL-17 family, for example IL-17A and IL-17B, have been recently discovered 
and are considered to be pro-inflammatory. They play important roles in protective 
mechanisms against fungal and bacterial infections, and development of autoimmunity 
and inflammation. They are regulated by the innate and adaptive immune system 
(Hamblin, 1993; Thomson and Lotze, 2003; Iwakura et al., 2011). 
5- The IFN Class II cytokine family are regulated and modulated by the immune 
response, they are released from leucocytes, fibroblasts, natural killer cells, T cells and 
endothelial cells. This family includes IFN-α, IFN-β, IFN-γ, and IL-10. The interferon 
family play an important role in controlling virus infection (Hamblin, 1993; Thomson 
and Lotze, 2003; Randal and Goodbourn, 2008). 
6- Chemokines are a type of cytokine which produce a chemical that attracts and 
directs other immune cells to migrate to the site of inflammation, or tissue damage, and 
these regulate the immune cell function. They are released from monocytes, 
endothelial cells, epithelial cells, and fibroblasts. This family includes IL-8 and 
monocyte chemoattractant protein-1 (MCP-1) (Hamblin, 1993; Thomson and Lotze, 
2003). 
The cytokines are potent mediators of inflammatory processes and the maintenance 
of a homeostatic balance; they can work together in an inflammatory cascade (Figure 
1.11) and could potentially be used as predictors of the prevalence or incidence of 
some diseases, such as CVD (Pearson et al., 2003). 
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Figure 1.11: The relationship of inflammatory markers and some diseases, such as 
CVD (adapted from Pearson et al., 2003). 
1.9 Adhesion molecules 
There is evidence to suggest that within diseases cell adhesion molecules (CAMs) can 
play a vital role in inflammation. CAMs are a group of glycoproteins; they are expressed 
by several cell types including leukocytes and endothelial cells (Lawson and Wolf, 
2009). Endothelial cells are the inter cell line of the circulation system, which are 
specialise to different cell types, such as arterial and venous systems (Marcelo et al., 
2013). CAMs are constitutively present on endothelial cells and they include three 
families which are the selectins, integrins, and the immunoglobulin (Ig) superfamily 
(Furie, 2014). The expression of CAMs are increased by pro-inflammatory cytokines, 
and CVD (Lawson and Wolf, 2009). Adhesion molecules have also been shown to be 
involved in the recruitment and migration of leukocytes and neutrophils to sites of 
inflammation (Lawson and Wolf, 2009; Furie, 2014). The migration of neutrophils 
involves multiple steps and in each step a different family of adhesion molecules takes 
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part; for example, the rolling phase is mediated by the selectin family, and activation 
of neutrophil migration to the endothelium is regulated by integrins and the Ig 
superfamily (Etzioni, 1996). 
1.9.1 Immunoglobulin (Ig) superfamily 
Intercellular adhesion molecule-1 (ICAM-1) is a member of the Ig family and is 
expressed by several cell types including leukocytes and endothelial cells. Studies 
have shown that its expression is increased in CVD, autoimmune disorders, cancer, 
and other diseases (Lawson and Wolf, 2009; Furie, 2014). These results show this is 
an important marker to measure when determining disease progression, and also for 
the effectiveness of any treatments used. 
Vascular cell adhesion molecule-1 (VCAM-1) is a member of the Ig family and is 
expressed by endothelial cells. There is evidence to suggest that it is induced during 
inflammation (Furie, 2014). This suggests it would be a good marker to measure to 
determine the level of inflammation in diseases and how this changes during treatment. 
Studies have shown that the adipose tissue of obese people can increased the 
expression of pro-inflammatory proteins, such as ICAM and VCAM (Terra et al., 2009). 
It has been suggested that the elevated concentrations of adhesion molecules play a 
role in the formation and progression of atherosclerosis (Turan et al., 2014). Therefore, 
losing weight may prevent the progression of atherosclerosis in the overweight and 
obese population as they will have less adipose tissue producing the detrimental 
factors (Poirier, 2002). 
1.9.2 Selectins  
Selectins are transmembrane molecules that bind with carbohydrate ligands. There 
are three members of this family: E-selectin, P-selectin and L-selectin; E-selectin is 
expressed by endothelial, whereas P-selectin is produced by platelets, and L-selectin 
is formed on leukocytes and lymphocytes. They mediate the cell interaction of 
recruitment of leukocytes into endothelium (Furie, 2014). These molecules can play an 
important role in the progression of disease as a reduction or an increase in the number 
of leukocytes can cause different outcome. 
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1.10 C-reactive protein (CRP) 
One of the key systemic inflammation markers is CRP, which is synthesised by the 
liver and regulated by IL-6 (Otsuka et al., 2014). An increased CRP level is associated 
with many diseases such as CVD, obesity and IR (Yudkin, et al., 1999). In healthy and 
lean people the concentration of CRP increases 2000-fold during the first 24–48 h after 
tissue injury and inflammation (Gaysina et al., 2011). The approximate levels of CRP 
in a normal adult population is (< 1 mg/l), average low risk (1.0-3.0 mg/l) and high risk 
at (> 3.0 mg/l) (Ridker, 2003). Higher CRP levels, which are above 3 mg/l, have been 
shown to be associated with metabolic syndrome, cardiovascular disease, diabetes 
and obesity (Kritchevsky et al., 2005; Calabrò et al., 2010; Gaysina et al., 2011; Otsuka 
et al., 2014). The higher levels of CRP show that in these diseases there is an increase 
in inflammation which can cause some of the symptoms associated with this disease 
states. 
1.11 Inflammatory markers 
Inflammatory marker levels play a role in predicting the incidence of some diseases 
such as cardiovascular disease. Inflammatory markers are used to detect acute 
inflammation, which might reveal a specific disease, and to give a marker of treatment 
response (Watson, 2012).  In 2002 a workshop was organised by the American Heart 
Association and the Centers for Disease Control, title “CDC/AHA Workshop on 
Inflammatory Markers and Cardiovascular Disease: Applications to Clinical and Public 
Health Practice”, to make recommendations on how inflammatory markers should be 
used with other assessments of cardiovascular risk (Pearson et al., 2003). This 
workshop highlighted that determination of CRP could add value in predicting coronary 
events, and recommended in general population screening that CRP might be useful 
in predicting risk of coronary heart disease. Kritchevsky et al., (2005) stated that other 
inflammatory markers such as IL-6 and TNF-α may be useful markers for indicating 
elevated risk of cardiovascular disease. In addition, the concentration of inflammatory 
markers may indicate both the acute inflammatory state and long-term risk of many 
diseases, however, more work is needed to understand the ability of markers to predict 
over a longer periods of time in older populations (Kritchevsky et al., 2005). 
The normal serum levels of soluble cytokines, adhesion molecules and CRP in the 
healthy population have been studied by several groups including the Randox 
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laboratory (Table 1.4, Table 1.5, and Table 1.6), and show how much variation there 
is between different age groups and using different detection methods (Kim et al., 
2011; Kleiner et al., 2013). These values provide a starting point for evaluating how 
different diseases affect the expression of these markers, and also how effective the 
treatments for the diseases are. 
Table 1.4 The serum levels of soluble cytokines in healthy subjects as measured by 
the Randox laboratory, Kim et al. (2011) and Kleiner et al. (2013) when investigating.  
References  Randox  
laboratory a  
Kim et al., 2011 b Kleiner et al., 2013 b 
Group Age 20-45 45 > Age ≥ 65 Age ≥18  
Cytokines    
IL-2 (pg/ml) 0.00 - 2.42 5.58±4.17(3.06-32.1) 14 (9.4–15.9) 
IL-4 (pg/ml) 0.88 - 2.63 ND ND 
IL-6 (pg/ml) 0.00 - 2.13 2.57±5.22 (0.16-31.5) ND 
IL-8 (pg/ml) 0.95 - 14.11 27.6±43.9(4.76-217.0) 29.3 (24.4–35.9) 
IL-10 (pg/ml) 0.04 - 1.05 1.58± 6.17(0.01-41.7) 12.6 (8.5–16.7) 
VEGF (pg/ml) 0.00 - 211.65 100.5±75.4(6.9-329.3) 61.6 (32–118.9) 
IFN γ (pg/ml) 0.00 - 1.24 10.3±18.4(1.09-117.7) ND 
TNF-α (pg/ml) 2.28 - 7.81 4.94±4.79(0.86-20.8) ND 
IL-1β (pg/ml) 0.00 - 2.34 2.52±7.41(0.17-39.0) ND 
IL-1α (pg/ml) 0.00 - 0.27 ND ND 
MCP-1 (pg/ml) 44.62- 395.52 168.0±73.0(39.3-355.9) 41.5 (20.1–78.9) 
EGF (pg/ml) 54.06 - 196.88 61.0±65.1(3.20-251.6) ND 
aThe levels of the cytokines, chemokines, and growth factors were analysed using The Evidence 
Investigator™ Cytokine & Growth Factors High-Sensitivity immunoassays based on biochip. 
bThe levels of the cytokines, chemokines, and growth factors were analysed using multiplexed bead-based 
immunoassays. Data present as mean range or mean± standard deviation. ND=not determined 
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Table 1.5 The serum levels of CRP in healthy subjects as measured by the Randox 
laboratory and Ponthieux et al. (2004).  
References  Randox laboratory a  Ponthieux et al., 2004 b 
Group Age 20-45 Age 20-45 
CRP (mg/l) 0-1 1.64 ± 2.32  
a The levels of CRP was determined by Immunoturbidimetric assay ILAB 600. 
b Immunonephelometry on a Behring Nephelometer Analyser. Data present as mean range or mean± 
standard deviation 
 
Table 1.6 The serum levels of soluble adhesion molecules in healthy participants 
according to, Nash et al. (1996), Zonneveld et al. (2014), and Randox laboratory.  
References  Randox laboratory a Nash et al., 1996 b Zonneveld 
et al., 2014 
Group Age 20-45 Age 20-45 Age 20-71 
Adhesion 
molecules  
   
VCAM-1(ng/ml) 260.07 - 632.54 450-800 569±98 
ICAM-1(ng/ml) 147.14 - 299.55 150-300 208± 20.5 
E-selectin(ng/ml) 4.92 - 27.68 20- 60 42± 19.4 
P-selectin(ng/ml) 92.64 - 261.43 ND 116.9 ± 33.4 
L-selectin(ng/ml) 876.78 - 1811.87 ND 1600± 800 
aThe levels of adhesion molecules were analysed using Evidence Investigator™ Biochip Array Technology 
that based on immunoassays 
bThe levels of adhesion molecules were analysed using sandwich ELISA system 
Data present as mean range or mean± standard deviation.  ND=not determined 
 
1.12 Aims of the thesis 
This PhD research aims to investigate the hypothesis that consuming cinnamon 
supplements may improve glycaemia, lipid profiles, weight, blood pressure, insulin 
resistance and inflammatory markers in an overweight population. To test this 
hypothesis and to achieve this overall aim, a series of in vitro and human studies were 
conducted:  
Objective 1: In vitro studies  
The in vitro work consisted of two studies, which aimed to: 
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1. To optimise the extraction of polyphenols from cinnamon. 
2. To determine the total phenol and tannin content of a variety of cinnamon 
supplements. 
3. To determine the phenolic composition of C. cassia and C. zeylanicum using 
LC-MS.  
4. To test the antioxidant properties of C. cassia and C. zeylanicum supplements 
and the free-radical scavenging capacity of cinnamon types.  
5. To test the effect of C. cassia and C. zeylanicum supplements on RAG and SAG 
values. 
Objective 2: In vivo human studies  
The human studies involved the assessment of the acute effects of C. cassia 
supplementation in a healthy population and a longer term (8 week) evaluation of 
consuming C. cassia supplementation in overweight healthy women 45-70 years with 
the following aims:  
Acute effects  
1- To examine the effect of C. cassia supplementation (1 g) on glycaemic 
response. 
Long term effects 
1- To examine the effect of 4 and 8-week C. cassia supplementation (5 g) on 
weight, BMI, waist circumstance, hip circumference and heart rate. 
2- To examine the effect of C. cassia supplementation (5 g) on fasting     insulin 
and glucose levels. 
3- To examine the effect of C. cassia supplementation (5 g) on oral glucose and 
insulin tolerance tests. 
4- To examine the effect of C. cassia supplementation (5 g) on insulin resistance 
and HOMA.  
5- To examine the effect of C. cassia supplementation (5 g) on CRP levels.  
6- To examine the effect of C. cassia supplementation (5 g) on the levels of specific 
cytokines: IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, EGF, IFN-γ, MCP-1, TNF-α, and 
VEGF. 
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7- To examine the effect of cinnamon cassia supplementation (5 g) on the levels 
of adhesion molecules: VCAM, ICAM, E-selectin, P- selectin, and L-selectin. 
8- To examine the correlation between the inflammatory markers and bone density 
in overweight healthy women aged 45-70 years. 
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Chapter 2 
2 Materials and methods 
 
The following chapter will describe the materials and methods used to carry out the 
experimental work in this thesis. Individual protocols for each experiment or study will 
be described in detail at the beginning of each chapter. 
2.1 Materials  
2.1.1 Equipment 
1. Abbott Laboratories Ltd., Witney, Oxfordshire, UK: 
Freestyle Optium. 
2. Alpha Laboratories Ltd., Eastleigh, UK:  
Apex Plus Flat Screw Cap Rad; Apex Plus Flat Screw Cap Blue; Micro-centrifuge tube, 
Skirted (1.5 ml). 
3. Becton Dickinson (BD) and company, Oxford, UK:  
Vacutainer blood collection tubes: sodium fluoride tubes (2 ml); EDTA tubes (4 ml); 
serum tubes (6 ml); Lithium Heparin tubes (4 ml); BD Vacutainer single use holder; BD 
Vacutainer safety-lok blood collection set 21G 18 cm (green). 
4. CapsulCN International Co. Ltd., USA. Halal Capsules size 000 dark green (bovine 
gelatin), CapsulCN International Co. Ltd., USA. 
5. CapsulCN International Co. Ltd., USA. Manual capsule filling machine CN-400/CN-
400CL, CapsulCN International Co. Ltd., USA. 
6. Fisher Scientific Ltd., Loughborough, Leicestershire, UK:  
Pipette; pipette tips; plastic tubes; Falcon™ tubes (50 ml), conical flask (250 ml); 
Pyrex™ beakers (10-2000 ml); 1.5 ml plastic cuvettes; filtering flask; filter disk. 
7. Fisons Ltd., Leicestershire, UK: 
Vortex-mixer (WhirliMixer). 
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8. Grant Instruments Ltd., Cambridge, UK:  
Water bath with temperature range 35-90 ˚C (Grant Y22); shaking water-bath, with 
maximum shaking capacity of not less than 160 strokes per minute and a stroke length 
of 35 cm, temperature range 35-70 ˚C (Grant SS40-D).  
9. Idass, Kettering, Northamptonshire, Ltd., UK:  
Tape to measure the waist and hip circumferences of the participants. 
10. Instrumentation Laboratory, Birchwood Science Park, Warrington, UK:  
ILab 650 Clinical Chemistry System. 
11. KNF Neuberger Inc., Trenton, USA: 
Vacuum pump, LABOPRT. 
12. Kontron Ltd., UK:  
Uvikon 860 Spectrophotometer.  
13. Mettler Toledo Ltd., Leicestershire, UK: 
Digital scale, sensitivity ± 0.1 mg (AL 204); pH meter (SevenEasy).  
14. OMRON Healthcare Europe BV, Hoofddorp, Netherlands:  
Automatic blood pressure device (Omron MX3 Plus). 
15. Owen Mumford Ltd., Oxford, UK: 
Unistik 3 extra single use lancets. 
16. Randox Laboratories Ltd., Crumlin, UK: 
Evidence Investigator. 
17. Sarstedt Ltd., Leicester, UK: 
300 µl fluoride oxalate microvette tubes, 300 µl plasma plain microvette tubes.  
18. Seca Ltd., Birmingham, UK:  
A standard stadiometer to measure the participant’s height in centimetres. 
19. Sigma Chemical Company Ltd., Poole, UK:  
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Centrifuge 6K10. 
20. Stratec Medizintechnik GmbH, Pforzheim, Germany:  
Peripheral Quantitative Computed Tomography (pQCT) scanner. 
21. Stuart Scientific Ltd., Staffordshire, UK:  
Magnetic stirrer (SMS). 
22. Tanita TBF-300, Tanita UK Ltd., Middx, UK:  
Tanita scales to measure the weight and BMI of the participants. 
23. Wallac Wizard, Wallac International, Finland: 
Wallac 1470 wizard automatic gamma counter; Wallac 1410 liquid scintillation counter. 
24. Whatman International, Maidstone, Kent: 
Whatman No.1 filter paper. 
25. YSI Life Sciences, Hampshire, UK:  
YSI 2300 STAT Plus glucose analyser; YSI analyser printer paper.  
2.1.2 Cinnamon supplements 
This study focused only on the cinnamon supplements that were available to buy in 
health shops and were consumed as capsules. 
- Cinnamon bark (Bio-Health® Cinnamomum zeylanicum), 350 mg, Bio-Health Limited, 
Rochester, Kent, UK. Ingredients for each capsule: pure Cinnamomum zeylanicum 
powdered bark, vegetable hydroxypropyl methylcellulose (HPMC). (C. zeylanicum). 
- Cinnamon bark (Health Aid® Cinnamomum zeylanicum) 850 mg, Health Aid Limited, 
Middlesex, England, UK. (C. zeylanicum. E). Ingredients for each capsule: cinnamon 
powder (Cinnamomum zeylanicum), vegetable hydroxypropyl methylcellulose 
(HPMC), di-calcium phosphate, cinnamon extract, silicon dioxide, vegetable 
magnesium stearate. (C. zeylanicum. H). 
- Cinnamon bark (Puritan's Pride's® Cinnamomum cassia) 500 mg, Holbrook, USA. 
Ingredients for each capsule: pure Cinnamomum cassia powdered bark, vegetable 
hydroxypropyl methylcellulose (HPMC). (C. cassia). 
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- Cinnamon bark (Solgar® Cinnamomum cassia) 500 mg, Solgar Vitamin and Herb, 
USA. (C. cassia. E). Ingredients for each capsule: cinnamon powdered bark, cinnamon 
bark extract, silicon dioxide, vegetable magnesium stearate, vegetable hydroxypropyl 
methyl cellulose (HPMC), cellulose gum. (C. cassia. S). 
2.1.3 Chemical and reagents  
All chemicals were of analytical grade unless otherwise stated. 
1. Englyst Carbohydrate Services Ltd., Southampton, UK:  
Amyloglucosidase (from Aspergillus niger, 10000 U/ml in glycerol; 1 unit releases 1 
µmol glucose pH4.5, 55 ˚C), Englyst Cornflakes reference. 
2. Fisher Scientific Ltd., Loughborough, Leicestershire, UK: 
Calcium chloride dihydrate (CaCl2.2H2O); ethanol; methanol; potassium chloride (KCl); 
potassium hydroxide (KOH); invertase (general purpose grade, from yeast); sodium 
chloride (NaCl); sodium hydroxide (NaOH); sodium acetate (trihydrate); trichloroacetic 
acid.  
3. Merck Millipore Gmbh, Darmstadt, Germany: 
Immuno-chemiluminometric insulin assay (Millipore Insulin kit, HI-14K). 
4. Randox Laboratories Ltd., Crumlin, UK: 
Glucose GOD/PAP (glucose oxidase/phenol and 4 amino-antipyrine) test kit; non-
esterified fatty acid (NEFA) kit; triacylglycerides (TAG) kit; chemistry control level 1 and 
2; cytokine high sensitivity array, Biochips (cytokine); adhesion molecule array, 
Biochips (adhesion molecule); high sensitivity C reactive protein (hs-CRP); total 
cholesterol, high-density lipoproteins (HDL). Reagent signal EV805 for cytokine and 
adhesion molecules, Luminol EV805 and peroxide were mixed (1:1 v/v); cytokine high 
sensitivity diluent assay (20 mM, pH 7.2); cytokine high sensitivity conjugate (20 mM, 
pH 7.5); cytokine high sensitivity calibration: 2 ml of deionised water was added to each 
of the nine calibration bottles and rolled on a machine for 30 minutes; adhesion 
molecule calibration: 1 ml of deionised water was added to each of the nine calibration 
vials and rolled on a machine for 30 minutes; adhesion molecule diluent assay (19 mM, 
pH 7.2); adhesion molecule conjugate, 20 mM, pH 7.5.  
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5. Sigma Chemical Company Ltd., Poole, UK: 
D-glucose; benzoic acid; o-dianisidine reagent; guar gum powder; hydrochloric acid; 
pancreatin (from porcine pancreatase); pepsin powder (from porcine gastric mucosa, 
800-2500 U/mg); glucose oxidase diagnostic kit; anhydrous sodium acetate (≥ 99 %); 
calcium chloride (CaCl2.6H2O); Folin-Ciocalteu’s reagent; acetone (≥ 99.5 %); tannic 
acid; acarbose (˃ 95 %); poly-vinylpolypyrrolidone (PVPP); potassium ferricyanide; 
ferric chloride; ascorbic acid; trolox; 2,2-diphenyl-1-picrylhydrazyl (DPPH); 
ethylenediaminetetraacetic acid (EDTA); butylated hydroxytoluene (BHT); ferrozine 
ascorbate; H2O2; phosphate buffer; gallic acid; rutin; sodium nitrate; aluminium 
chloride; potato starch. 
2.1.4 Buffers and solutions  
1. Buffer concentrate kit (phosphate buffer) used in YSI 2357. It was made by 
dissolving the package contents into 500 ml of distilled water. 
2. Buffer wash concentrate, 20 mM, pH 7.4, used in Evidence Investigator. 32 ml of 
buffer wash concentration was diluted with 968 ml of distilled water. 
3. Enzyme preparation mixture (prepared immediately before use). Three g of 
pancreatin was added into each of six centrifuge tubes and suspended in 20 ml of 
water using a vortex-mixer. A magnetic stirring bar was added and the mixture was 
stirred for 10 min. The suspension was centrifuged at 1500 g for 10 min and 15 ml of 
the cloudy supernatant was removed from each tube and combined to give a total of 
90 ml. Four ml of amyloglucosidase and 6 ml of invertase solutions were added, and 
the solutions mixed well by inversion. 
4. Glucose standard solution. 5 g of glucose was weighed to the nearest 0.1 mg. The 
solution was then made up to 200 ml with sodium acetate buffer to give a concentration 
of 25 mg/ml glucose. 
5. Pepsin Guar Gum solution. 1 g of pepsin powder was added to 200 ml of 0.05 mol/l 
hydrochloric acid and mixed with a magnetic stirring bar. Just before use, 1 g of guar 
gum was added and the solution was mixed well. This solution was prepared 
immediately prior to use. 
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6. Sodium acetate buffer, 0.1 mol/l, pH 5.2. 13.6 g of sodium acetate trihydrate was 
weighed and dissolved in 500 ml of water. Then, 250 ml of saturated benzoic acid 
solution was added and the solution was made up to 1 l with water after the solution 
was adjusted to pH 5.2 with 0.1 mol/l acetic acid. Four ml of 1 mol/l calcium chloride 
was added to 1 l of buffer to stabilize and activate the hydrolytic enzymes. 
7. Sodium acetate, 0.25 mol/l. 34 g of sodium acetate trihydrate was weighed out and 
made up to 1 l with distilled water. 
8. Sodium phosphate buffer, 200 mM, pH 6.6. 31.202 g of sodium phosphate was 
dissolved in 1 l of distilled water.  
2.2 Methods 
2.2.1 Procedures for the RAG and SAG measurements of reference 
standard foods 
All procedures relating to the measurement of the carbohydrate fractions in the 
reference standard foods, with and without the presence of the cinnamon supplements 
(C. cassia, C. zeylanicum), were carried out using Englyst’s technique (Englyst et al., 
2000). One reference standard food (cornflakes) was included in every batch of 
samples. The CV percentages of G20 and G120 (Table 2.1) were calculated. 
 
Table 2.1 The mean, standard deviation and CVs for the reference food used to 
determine the inter-assay variation of RAG and SAG measurements.  
Reference 
food  
Mean (g/100g) SD % CVs inter assay 
G20 G120 G20 G120 G20 G120 
Cornflakes* 81.31 85.43 3.23 4.06 3.97 4.75 
*Englyst food references were ordered from Englyst Carbohydrate Services Ltd., Southampton, UK.  
2.2.1.1 The colorimetric approach  
Fifty mg of guar gum powder was weighed into each of three 50 ml polypropylene 
centrifuge tubes with the addition of five glass balls. Into two of these tubes, 20 ml of 
glucose standard (25 mg/ml) (named as standard) was added, and into the third tube, 
20 ml of acetate buffer (54.4 mg/ml) (named as blank) was added. Additional blanks 
and standards with a cinnamon supplement (a variety of doses, from 32 to160 mg) 
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were also prepared. These tubes were treated exactly the same as the sample after 
adding sodium acetate solution. 
Appropriate amounts of sample (0.8 g of cornflakes) with and without a cinnamon (from 
32 to 160 mg) supplement were weighed into 50 ml polypropylene centrifuge tubes. 
Samples were analysed in duplicate. Ten ml of freshly prepared pepsin-guar gum 
solution was added into each sample tube, and then vortex-mixed before being placed 
in a water-bath at 37 C for 30 min. After incubation, the samples were removed from 
the water-bath and five glass balls were added to each tube along with 10 ml of 0.25 
mol/l sodium acetate. The tubes were shaken gently to disperse the contents. 
The sample tubes, standards and blanks, with and without cinnamon, were placed in 
the water-bath at 37 C to equilibrate for 10 min. After equilibration, the first sample 
was removed from the 37 C water-bath, the cap removed and 5 ml of enzyme mixture 
added. The tube was then capped and the contents mixed gently by inversion. The 
tubes were then secured horizontally in the 37 C shaking water-bath. The shaking 
action of the water-bath was initiated and this time called time zero of the incubation 
period. The shaking action was not interrupted until all of the G120 portions had been 
collected. 
The addition of the enzyme mixture was repeated for the remainder of the sample 
tubes at 1 min intervals, and the tubes then placed in order into the shaking water-
bath. After exactly 20 min of incubation, 0.5 ml of each sample was transferred into 20 
ml of aqueous ethanol (66 %, v/v) and vortex-mixed to stop the hydrolysis reaction; 
this was the G20 portion. The sample tubes were then immediately returned to the 
shaking water-bath. After a further 100 min (total time 120 min), 0.5 ml of each sample 
was transferred from the sample tubes into 20 ml of aqueous ethanol (66 %, v/v) and 
vortex-mixed; this was the G120 portion. Then, the glucose released from the starch in 
the (G20, G120) samples, with or without the presence of cinnamon, was analysed 
colorimetrically, after appropriate treatment, using a spectrophotometer.  
2.2.1.1.1 Spectrophotometric determination of glucose using glucose 
oxidase  
Each of the G20 and G120 samples were centrifuged at 500 g for 5 min before the 
glucose levels were determined. In duplicate, 100 µl of sample (blank, samples and 
standards) was removed and pipetted into separate test tubes containing 2 ml of the 
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glucose oxidase regent, which had been prepared earlier according to manufacturer’s 
instructions. Then, all samples were vortex-mixed and incubated for 20 min at 37 ˚C. 
The absorbance of the standards and samples were measured at 510 nm against a 
reagent blank on a Uvikon 860 spectrophotometer. 
The enzymatic colorimetric analysis was based on the production of glucose derived 
from the exposure of starch to digestive enzymes. The glucose produced was oxidised 
to gluconic acid and hydrogen peroxide by glucose oxidase. The hydrogen peroxide 
then reacts with o-dianisidine in the presence of peroxidase to form a coloured product 
which is proportional to the original glucose concentration. The assay principle is 
demonstrated in the following reactions below: 
Glucose + H2O + O2    Glucose oxidase     Gluconic acid +H2O2 
 
 
 Peroxidase 
H2O2 + Reduced Dianisidine      Oxidized o-dianisidine (colour) 
 
The glucose concentration (gram per 100 g of sample) is given by following equation: 
Glucose (%) = A (t) VC x 100/A(s) W 
A (t) is the absorbance of the test solution; V is the total volume of the test solution1 
(ml), C is the concentration² (mg/ml) of the standard used; A(s) is the absorbance of 
the standard used; W is the weight (mg) of the sample taken for analysis. 
The values for RAG and SAG were calculated from the G20 and G120 values and 
obtained as follows: 
RAG (g) = G20 
SAG (g) = G20-G120  
1 V = 20 ml; 2 C = 25 mg (Englyst’s et al., 2000). 
2.2.2 Preparation of the cinnamon extracts  
Polyphenols can be extracted a number of different ways; proanthocyanidins and the 
procyanidin fraction can be extracted using pure or aqueous methanol, pure or 
aqueous ethanol, or acetone. For the extraction of procyanidins, acetone has been 
shown to possess the highest extraction efficiency followed by ethanol and methanol 
(Lazarus et al., 2001). Therefore, acetone solvent at a concentration of 75 % (v/v) was 
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used. In addition for comparison, deionised water was used to extract the cinnamon 
samples.  
Cinnamon samples were extracted according to Mathew and Abraham (2006) with a 
slight modification in term of duration of stirring and temperature. These extracts were 
used to determine the total polyphenol, tannin and proanthocyanidin content. 
Deionised was added to each cinnamon supplement sample (1.5 g) and continuously 
stirred at 4 C for 7 hours. The extraction process was repeated (three times) until the 
water extract became colorless. This was called cinnamon water extract. The same 
procedure was followed using 75 % acetone (v/v). This was called cinnamon 75 % 
acetone extract. The total solvent volume was 300 ml in each case. 
2.2.3 Measurement of the total phenolic content 
The total phenol content of the extracts was determined using the Folin Ciocalteu 
method described by Lv et al. (2012), with a slight modification. Briefly, 40 µl of each 
cinnamon extract was added to 200 µl of Folin-Ciocalteu reagent. Following a 5 min 
incubation period, 600 μl of sodium carbonate (20 % (w/v)) was added and the samples 
left to stand in darkness for 2 h. The absorbance of the samples was read at 750 nm 
against a blank. The standard curve was determined using gallic acid (0, 50, 100, 200, 
300, 400, 500, 600, and 700 µg/ml) (w/v). The results were expressed as gallic acid 
equivalents.  
2.2.4 Measurement of hydrolysable tannins 
This method is based on the total phenol content present in the cinnamon extracts, 
which were prepared above (section 2.2.3). An insoluble matrix compound, poly-
vinylpolypyrrolidone (PVPP), which binds with cinnamon tannin phenolic compounds, 
enabled measurement of the cinnamon tannins. The tannin content was determined 
according to Makkar et al. (2000). The method is based on the principle that 100 mg 
of PVPP is sufficient to bind 2 mg of total phenols. The method required 1 ml of distilled 
water and 1 ml of each cinnamon extract for each 100 mg of PVPP. The appropriate 
amount of PVPP, which depended on the total phenols of each cinnamon sample, 
distilled water and cinnamon extract were vortex mixed. The mixture was incubated in 
a cool environment (4 C) for 15 minutes. The mixture was vortex-mixed again and 
centrifuged at 3000 g for 10 min. The supernatant was collected to determine the total 
Chapter 2  
  
54 
 
phenolic content after centrifugation (section 2.2.3). The total tannin content was 
calculated by subtracting the value of total phenolic compounds without PVPP from 
the total phenolic compounds with PVPP, equivalent to tannic acid.  
2.2.5 Extraction of the cinnamon samples for HPLC and LC-MS 
The cinnamon samples that were extracted for the HPLC and LC-MS analyser were 
the pure cinnamon samples of C. cassia and C. zeylanicum. The Plant for Human 
Health Institution in North Carolina State University, United States, analysed the C. 
cassia and C. zeylanicum, and HPLC and LC-MS were used to determine the 
polyphenol composition in the cinnamon samples. Moreover, they extracted the 
cinnamon samples (2.2.5.1), and then determined the total polyphenol (2.2.5.2) and 
condensed tannin (proanthocyanidins) (2.2.6) contents. 
2.2.5.1 Extraction of pure cinnamon supplements  
C. cassia and C. zeylanicum powders (0.500 mg) were extracted with 8 ml acetone 75 
% (v/v) by sonication at 55 ºC for 5 min. The mixture was then centrifuged for 20 min 
at 1792 g and the supernatant transferred to 25 ml volumetric flasks. Extraction of the 
pellet was repeated twice more and the combined extracts brought to a final volume of 
25 ml. One ml of the cinnamon extracts was filtered using a 0.2 mm PTFE syringe filter 
and placed in HPLC amber vials (Fisher Scientific, Pittsburg, PA, USA), before 
phytochemical analyses using HPLC and LC-MS. 
2.2.5.2 Measurement of the total phenols 
The total phenol content of the extracts was determined using the Folin Ciocalteu 
method (2.2.3).  
2.2.6 Measurement of the condensed tannins (proanthocyanidins) 
The Plant for Human Health Institution in North Carolina State University, United 
States, determined the total proanthocyanidin (PAC) concentrations. The PAC was 
determined colorimetrically using the DMAC method (2.2.7) in a 96-well plate 
according to Prior et al. (2010). A series of dilutions of standard procyanidin A2 dimer 
were prepared and ranged from 1-100 µg/ml. Blank, standards and diluted samples 
were analysed in triplicate. The plate reader protocol was set to read the absorbance 
at 640 nm for each well in every plate. The concentration of PAC in the solution was 
expressed as mg/l procyanidin A2 equivalents.  
Chapter 2  
  
55 
 
2.2.7 The DMAC method 
DMAC (4-dimethylaminocinnamaldehyde) is a colorimetric method which was used to 
measure the total of proanthocyanidins. The procyanidin A2 dimer (Figure 2.1) was 
used as standard (Prior et al., 2010).  
 
Figure 2.1: Procyanidin A2 dimer (Prior et al., 2010). 
 
2.2.7.1 Procyanidin A2 standard preparation 
Five mg of the standard procyanidin A2 was weighed and quantitatively transferred to 
a 50 ml volumetric flask. Ethanol (91 %, v/v) was added to give a final concentration of 
0.100 mg/ml. Aliquots were placed in 1.5 ml HPLC sample vials and stored at −80 ◦C. 
These standards remained stable for at least 6 months. 
2.2.7.2 Procyanidin A2 control preparation 
A procyanidin A2 control was prepared by transferring 1 ml of the 0.100 mg/ml 
procyanidin A2 solution into a 1.5 ml conical tube. To this, 250 μl of ethanol (91 %, v/v) 
was added and vortexed to give 0.80 mg/ml procyanidin A2 as a quality control sample. 
2.2.7.3  96-Well plate layout 
The absorbance at 640 nm was read for each well in the plate every minute for 30 
minutes. The plate included blanks, standards, controls, and cinnamon extracts at 
serial dilutions of 1-, 2-, 4-, 8-, 16-, and 32-fold. 
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2.2.7.4 Data analysis 
The maximum absorbance readings were used for calculation; this occurred at 20 min. 
PAC concentrations were calculated by using a regression equation:  
Y = a + bX  
Y is procyanidin A2 concentration in μg; a  is the maximum absorbance; b is the blank 
and X is the maximum absorbance minus the blank (X). 
Concentrations of sample extracts were calculated as total: 
PAC = (C × D × V)/(1000 × S) 
PAC values are in mg/g; C is the concentration of PACs in a sample extract in g/l; D is 
the dilution factor; V is the extraction volume in ml and S is the sample size, in g. Data 
were expressed as mg of procyanidin A2 equivalents per g or per 300 ml of sample. 
2.2.8 HPLC analysis  
HPLC analyses were conducted using an Agilent 1200 HPLC with fluorescence 
detection (FLD) and photodiode array detection (PAD). The Wallace and Giusti (2010) 
method was used for separating the different proanthocyanidins. A Develosil Diol 
column was used (250 mm x 4.6 mm (internal diameter) x 5 µm, Phenomenex, 
Torrance, CA, USA). PACs were identified by comparison with the available standards. 
Quantification of the proanthocyanidins was calculated using peak areas and a 
calibration curve for procyanidin A2, and amounts were expressed as procyanidin A2 
equivalents. The mobile phase was 2 % (v/v) acetic acid in distilled water (solvent A) 
and 0.5 % (v/v) acetic acid in 50 % acetonitrile in distilled water (solvent B). The flow 
rate was 1 ml/min with a step gradient of 10 %, 55 %, 100 % and 10 % of solvent B at 
0, 10, 13, 15, 20, 50, 54 and 60 min respectively. Peak areas recorded at 280 nm were 
quantified using a calibration curve obtained using a procyanidin A2 standard (Grace 
et al., 2009, 2013). 
2.2.9 LC-MS analysis 
LC-MS consisted of a LC-MS-IT-TOF instrument (Shimadzu, Tokyo, Japan) and a 
HPLC system (SIL-20A HT auto-sampler, LC-20AD pump system, SDP-M20A photo 
diode array detector). The LC separation was performed using a C18 reverse-phase 
column (Shim-pack XR-ODS column, 50 mm x 3.0 mm i.d. x 2.2 µm particle size, 
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Shimadzu Scientific Inst., Columbia, MD, USA). The mobile phase consisted of 2 % 
(v/v) acetic acid in distilled H2O (solvent A) and 50 % acetonitrile in distilled H2O 
(solvent B). The flow rate was set at 0.35 ml/min with a step gradient of solvent B of 6-
25 % (18 min), 25-60 % (2 min), 60 % (5 min), 60-6 % (2 min), 6 % (3 min). The column 
was re-equilibrated for 5 min at initial conditions (6 %, solvent B). The heat block and 
curved desolvation line (CDL) were maintained at 200 °C. Nitrogen gas was used as a 
nebulizer and drying gas with the flow rate set at 1.5 l/min. The ESI source voltage was 
set at 4.5 kV and the detector was set at 1.5 V. The instrument was calibrated to <5 
ppm error in mass accuracy with an external standard of sodium TFA solution. 
Ionization was performed using a conventional ESI source in negative ionization mode. 
Data was acquired at m/z in the 150-2000 range (Grace et al., 2009, 2013). 
2.2.10 Determination of the antioxidant activity of the cinnamon extracts 
Determination of the antioxidant activity was carried out with pure cinnamon powder 
supplement extracts of cinnamon cassia (C. cassia) and cinnamon zeylanicum (C. 
zeylanicum). 
2.2.10.1  2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity 
The total radical scavenging capacity of cinnamon extracts was determined using an 
adaptation of the method described by Mau et al. (2004). This method was used to 
measure the antioxidant activity of the compounds in the cinnamon extracts. The 
principle of the assay is based on the fact that when antioxidant compounds donate H+ 
to the DPPH molecule, the DPPH is reduced forming a colourless compound (Brand-
Williams et al., 1995; Molyneux, 2004). Thus, the greater the hydrogen donating 
property of a compound, the greater the rate of decolourisation. Trolox and BHT (0.1 
mg/ml) were used as controls. Trolox was dissolved in deionised water whereas DPPH 
was dissolved in aqueous 75 % acetone (v/v). Different concentrations of the cinnamon 
extracts were prepared (0.05, 0.100, 0.150 mg/ml) for all the cinnamon extracts (water-
based C. cassia extract, water-based C. zeylanicum extract, acetone C. cassia extract 
and acetone C. zeylanicum extract). Two ml of the samples or control (Trolox and BHT) 
was added to 0.5 ml of 0.2 mM DPPH. The samples were left to stand in the dark for 
30 min at room temperature and the absorbance was read in the spectrometer at 517 
nm. All analyses were performed in triplicate with the relevant blank for each 
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concentration. The percentage of DPPH radical scavenging activity was calculated 
using the following equation:  
% DPPH= ((control absorbance – test sample)/control absorbance) x 100 
2.2.10.2 Scavenging of hydrogen peroxide (H2O2) 
The hydrogen peroxide scavenging activity of cinnamon sample extracts was 
determined using the method of Gülçin et al. (2007). Different concentrations of 
cinnamon extracts (0.05, 0.100, 0.150 mg/ml) were used. H2O2 (40 mM) was prepared 
in phosphate buffer at pH 7.4 and 0.6 ml added to 1 ml of each of the cinnamon 
extracts. The samples were incubated for 10 min at room temperature, then the 
absorbance of the samples and controls (BHT and trolox (0.1 mg/ml)) were read at 230 
nm. All tests and analyses were performed in triplicate with a relevant blank run for 
each concentration. The percentage inhibition activity was calculated using the 
following equation:  
Inhibition activity (%) = ((control absorbance – test sample)/control absorbance) x 100 
2.2.10.3 Metal chelating activity  
The chelation of ferrous ions by the different cinnamon extracts and standards was 
estimated using a slight modification to the method of Dinis et al. (1994). Different 
concentrations of cinnamon extracts were prepared (0.05, 0.100, 0.150 mg/ml). 0.500 
ml from the samples and 1.5 ml of deionised water were added to 50 µl of 1 mM FeCl2 
and vortexed, then 100 µl of 1 mM ferrozine was added to the mixture, and they were 
incubated for 10 min at room temperature. The absorbance of the solution was 
measured spectrophotometrically at 562 nm. All tests and analyses were performed in 
triplicate with a relevant blank for each concentration. EDTA (0.1 mg/ml) was used as 
control. The percentage of inhibition of ferrozine Fe2+ complex formation was 
calculated using the formula given below:  
% inhibition = ((control absorbance – test sample)/control absorbance) x 100 
2.2.10.4 Reducing power  
The reducing power was determined according to the method of Oyaizu (1986). This 
method is based on determining the ability of the tested samples to reduce Fe3+ (CN)6 
to Fe2+(CN)6, which is a blue-coloured complex. Different cinnamon extract 
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concentrations were prepared (0.05, 0.100, 0.150 mg/ml) for analysis. 2.5 ml of each 
extract was mixed with 2.5 ml of 200 mM phosphate buffer (pH 6.6) and 2.5 ml of 1 % 
potassium ferricyanide (w/v). The mixture was incubated at 50 °C for 20 min in a water 
bath. Then, 2.5 ml of 10 % of trichloroacetic acid was added followed by mixing and 
centrifugation at 1000 g for 10 min. The upper layer (3 ml) was mixed with 3 ml of 
deionised water and 1 ml of 1 % ferric chloride (w/v), and allowed to stand for 10 min 
in room temperature. The absorbance was read spectrophotometrically at 700 nm. A 
higher absorbance denotes a higher reducing power. All tests and analyses were 
performed in triplicate with a relevant blank for each concentration. 
2.2.11 The clinical studies  
Acute and long-term human studies were run in this project; both received ethical 
approval from the University of Surrey Ethics Committee (EC/2011/145/FHMS and 
EC/2013/70/FHMS respectively).  
2.2.11.1 Participant recruitment  
All subjects for the clinical studies were recruited from the University of Surrey staff 
population, as well as around Surrey, by the distribution of both e-mails and posters. 
For the long-term human studies, in addition to distributing the poster by e-mail, the 
recruitment poster for the study was placed in several churches, GP surgeries, 
hospitals and bus stops of Woking, Guildford and Kingston.  
2.2.11.2 Screening   
All participants were screened prior to each study in order to check that they met the 
specific study inclusion criteria. Screening for the acute study required each participant 
to attend the CIU for one morning and fill in the health and lifestyle questionnaire. For 
the long-term study, each participant attended one morning having fasted overnight, 
and the procedures described below were carried out.  
2.2.11.2.1 Health and lifestyle questionnaire  
The questionnaire for acute and long-term human studies included questions regarding 
the participant’s personal details, general health and lifestyle aspects. Participants with 
current or previous medical conditions, for instance, diabetes, were excluded. 
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2.2.11.2.2 Blood glucose testing 
Fasting blood glucose levels were analysed from blood samples obtained using the 
finger prick method for long term study. The blood samples were checked using 
Freestyle Optium. Participants with concentrations outside of the normal range of 
fasting blood glucose (>6 mmol/l) were excluded from the studies. This applied to the 
long-term human studies during screening. 
2.2.11.2.3 Following and monitoring the participants  
Each participant received a reminder, an email and text message, which included 
instructions to follow, one week prior to their visit. A further reminder was sent three 
days prior the study day and a final reminder sent one day prior the visit. 
2.2.11.2.4 Anthropometric measurements  
Height, weight, body mass index (BMI) and blood pressure were taken at the baseline 
for each study. All of these measurements were taken by the same investigator within 
a study in order to reduce inter-operator variation. 
2.2.11.2.4.1 Height  
A standard stadiometer (Seca Ltd., Birmingham, UK) was used to measure the height 
of the participants in centimetres. The participants were asked to remove their shoes, 
and then they stood straight with their feet together and their back against the 
stadiometer. 
2.2.11.2.4.2 Weight and body mass index  
Weight and BMI was determined using Tanita scales (Tanita TBF-300, Tanita UK Ltd., 
Middx, UK) with shoes and socks removed.  
2.2.11.2.4.3 Waist and hip circumference  
Waist and hip circumferences were measured to the nearest 0.1 cm using an Idass 
tape measure (Idass Ltd., Kettering, Northamptonshire).  
2.2.11.2.4.4 pQCT scanner  
A pQCT scanner was used to determine the bone density of the participants. It 
produced radiation less than 1/10 of a normal chest X-ray. The procedure involved the 
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participant sitting on a seat and placing their forearm into the scanning machine. The 
X-ray beam then moved across the forearm (Appendix 1).  
2.2.11.2.4.5 Blood pressure  
Blood pressure was measured three times using an automatic blood pressure cuff 
(Omron MX3 Plus, Omron Healthcare Europe, and UK) with the subjects sitting at rest. 
An average of the three readings was then taken.  
2.2.11.3 Capsule filling procedure  
The filling process followed USA Food and Drug Administration (FDA) rules. Each 
cinnamon (C. cassia) supplement capsule was opened and the cinnamon powder 
collected in a glass container. Then, the manual capsule filling machine CN-400/CN-
400CL was used to produce new cinnamon or placebo dark green capsules, which 
were identical in size and weight. These capsules were used for long term study. 
The base plate, (cap sheet, bottom sheet) was placed on a clean and dry surface. The 
filling tray, (encapsulation sheet) was placed and secured on the top of the base plate. 
The long part of the capsules was poured into the filling tray, and then shaken gently 
to fill all of the holes with capsules. Then the filling tray was removed, and any excess 
long part of the capsules were removed. The filling tray (encapsulation sheet) was 
placed and secured on the top of the upper plate. The short part of the capsules were 
poured into filling tray, which were placed on the upper plate, and shaken gently to fill 
all of the holes with capsules. Any excess short part of the capsules were removed, 
and then the filling tray was removed. The powder keeper was secured on the top of 
the base plate. The cinnamon powder or cornflower was then added to fill the capsules, 
which were on the base plate. The spreader was used to move the cinnamon powder 
back and forth to fill the capsules, and the tamping tool was used to compress the 
fillings, after which the previous procedure was repeated. The middle (joint) plate was 
placed on the top of the upper plate and pushed firmly, to form one unit. This part was 
then turned over and placed on the top of the base plate and pushed gentle, and the 
upper plate was removed. Finally, the middle (joined) plate, which has the joined 
capsules, was removed carefully and the capsules were collected in clean container. 
A specific number of capsules were added to the medical tablet bottles and one bottle 
was handed to each participant on visit 1 and 2 (Appendix 2).  
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The intra CV% of capsules was 3.27 and inter of capsules CV% was 6.28. This shows 
they had good reproducibility between the capsules. 
2.2.11.4 Biochemical analysis 
2.2.11.4.1 Blood sample collection 
Capillary and venous blood sampling methods were applied. In the acute study, 
capillary finger prick blood samples were collected into 300 µl microvette tubes coated 
with fluoride oxalate, and were immediately centrifuged at 2000 g for 10 min at 4 °C. 
The centrifuged plasma was transferred into separate 300 µl plastic plain microvette 
tubes which were then kept in the freezer at -20 °C until analysis (within 3 weeks). 
In the long-term study, the venous blood samples were collected into vacutainer tubes 
containing the following anticoagulants: EDTA for determination CHO, TAG, LDL, HDL, 
NEFA; Fluoride oxalate for determination of the plasma glucose; and Lithium heparin 
for plasma insulin. Serum tubes, which did not contain any additive were used to 
determine cytokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, EGF, IFN-γ, MCP-1, 
TNF-α, VEGF), adhesion molecules (VCAM, ICAM, E-selectin, P-selectin, L-selectin) 
and C reactive protein (CRP). The blood was immediately centrifuged at 2000 g for 10 
min at 4 °C. The serum samples were left for 25 min to clot and then centrifuged at 
2000 g for 10 min at 4 °C. Aliquots of plasma and serum were dispensed into 
appropriately labelled microcentrifuge tubes (1.5 ml) and stored at -80 °C until analysis.  
2.2.11.4.2 Analyses of plasma glucose  
The plasma glucose concentration in the acute study was determined using YSI 2300 
STAT plus analyser, Yellow Springs, UK. The principle for the colorimetric YSI analyser 
method is based on an enzyme for glucose being placed between the membrane 
layers, which are polycarbonate and cellulose acetate. In the present of hydrogen 
peroxide, glucose is oxidised, and the oxidised glucose enters the enzyme layer. The 
hydrogen peroxide produced passes through the cellulose acetate membrane into a 
platinum electrode where the hydrogen peroxide is oxidised. 
D-glucose + O2     Glucose oxidase          D-glucono-o-lactone + H2O2 
                   H2O2           Platinum anode          2 H++ O2+ 2e־               
Chapter 2  
  
63 
 
Twenty-four samples were analysed in each run along with three quality controls. The 
mean and standard deviation of the quality controls were used to determine the intra- 
and inter-assay coefficient of variation (Table 2.2). The results show there were very 
low levels of intra and inter assay variation, suggesting this assay is reproducible and 
the results are representative of the samples. 
Table 2.2 The three quality controls (QCs) that used within automatic analyser 
(YSI2300 STAT).  
QCs Mean 
mmol/l 
SD Intra 
assay 
% CV 
Mean 
mmol/l 
SD Inter 
assay 
% CV 
Low 4.85 0.05 1.16 4.93 0.11 2.17 
Medium 6.84 0.06 0.82 6.73 0.13 1.90 
High 24.35 0.07 0.29 24.60 0.23 0.93 
 
In the long-term study, the ILab 650 method (Instrumentation Laboratory, UK) was 
used to determine the fasting plasma glucose. The ILab 650 method principle is based 
on enzymatic oxidation of glucose in the presence of glucose oxidase (GOD). The 
resultant hydrogen peroxide reacts with phenol and 4-aminophenzone under the 
catalysis of peroxidase (POD) to produce a red–violet quinoneime dye. The 
absorbance of the dye was measured at 510 nm.  
D-glucose + O2 + H2O               GOD                 Gluconic acid + H2O2 
2H2O2 + 4-aminophenzone+ phenol                            POD                     Quinineimine + 4H2O  
Quality controls (QCs) were measured at the beginning and end of each run. 
Intra-assay precision gave CVs of 0.67 % for level 1 (low) QC, 0.49 % for level 2 (high) 
QC. Inter-assay precision gave CVs of 0.77 % and 0.66 % for both level 1 and level 2 
QCs, respectively, which again shows the accuracy and reproducibility of this method. 
2.2.11.4.3 Analyses of plasma cholesterol   
The enzymatic colorimetric method ILab 650 (Instrumentation Laboratory, UK) was 
used to determine total cholesterol. Cholesterol esters were hydrolysed to free 
cholesterol and free fatty acids by pancreatic cholesterol esterase. The liberated 
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cholesterol and any free cholesterol present in the plasma were both oxidized by 
cholesterol oxidase. The assay principle of the reactions is shown below: 
Cholesteryl ester+ H2O    Cholesterol esterase    Cholesterol + Fatty acids    
Cholesterol + O2             Cholesterol oxidase         Cholest-4-en-3-one+H2O2  
2H2O2 + 4-aminophenazone+ phenol   Peroxidase          
                                                    4-(p-benzoquinonemonoimino)-phenazone+ 4H2O 
The absorbance of the quinoneimine pigment was measured at 510 nm. The intra-
assay precision gave CVs for level 1 (low) and level 2 (high) QC of 1.02 % and 1.61 % 
respectively. Inter-assay precision gave CVs for level 1 (low) and level 2 (high) QCs of 
1.90 % and 2.17 % respectively. These results show there was very low inter and intra 
assay variability, meaning the data produced was accurate. 
2.2.11.4.4 Analysis of plasma TAG   
The plasma TAG concentrations were measured using the automated colorimetric 
method (ILab 650 analyser, Instrumentation Laboratory, UK). TAG was hydrolysed to 
glycerol and free fatty acids using lipoprotein lipase, then the glycerol kinase present 
within the assay kit acts upon glycerol and converts it into glycerol-3-phosphate. This 
is oxidised by glycerophosphate oxidase to dihydroxyacetone phosphate, and the 
concentration of the quinoneimine dye generated in the reaction is proportional to the 
concentration of TAG in the sample. The absorbance was measured at 510 nm.  
Triacylglycerides + 3 H2O      Lipoprotein Lipase       Glycerol + Fatty acids  
Glycerol+ ATP   Glycerol Kinase         Glycerol-3-phosphate + ADP 
Gycerol-3-phosphate + O2               GPO     Dihydroxyacetone- phosphate + H2O2  
H2O2 + 4- chlorophenol + 4-aminoantipyrine         POD           Quinoneimine dye+H2O 
Where POD = peroxidase; GPO = glycerol-3-phosphate oxidase; ADP = Adenosine-
5’-diphosphate.  
The within assay precision gave CVs for level 1 (low) and level 2 (high) QC of 1.17 % 
and 1.60 % respectively, while the between assay precision gave CVs of 1.06 % and 
1.74 % for the low and high quality control, respectively. These results shore the 
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variability was Lew for this assay, suggesting there was good reproducibility within the 
standards. 
2.2.11.4.5 Analyses of plasma HDL   
The assay principle is based on the following reactions:  
Cholesterol esters + H2O  Cholesterol esterase   Unesterified cholesterol + fatty acids    
 Unesterified cholesterol + O2         Cholesterol oxidase   Cholestone  + H2O2         
2H2O2 + 5-Aminoantipyrine + N-ethyl-N-(3-methylphenyl)-N’succinylethylene- diamine 
+ H2O + H+ peroxidase Qunoneimine dye + H2O 
When measured at 600 nm, the intensity of the quinoneimine dye product was directly 
proportional to the cholesterol concentration. Within assay precision gave CVs for level 
1 (low) and level 2 (high) QC of 0.98 % and 0.42 %, respectively. The inter-assay 
precision gave CVs of 2.07 % and 0.76 %, respectively.  
VLDL and LDL were calculated from the Friedewald (1972) Formula:  
LDL= T. cholesterol – (HDL-TG)/2.17 (mmol/l) 
2.2.11.4.6 Analyses of plasma NEFA 
Automated colorimetric method (ILab 650 analyser) was used to determine NEFA 
values. The enzymatic reaction of acyl CoA synthetase with NEFA, followed by the 
reaction of acyl CoA with acyl CoA oxidase, produces hydrogen peroxide; the 
hydrogen peroxide reacts with 4-aminoantipyrine which results in formation of a purple 
dye that absorbs at a wavelength of 550 nm. The intensity of the colour is directly 
proportional to the NEFA concentration. 
NEFA + ATP +CoA    synthetase Acyl CoA + AMP + PPi 
Acyl CoA + O2      acyl CoA oxidase              2,3-trans-Enoyl- CoA + H2O2 
2H2O2 + TOOS+ 4-aminoantipyrine   peroxidase    Qunoneimine dye (purple adduct)                                                                                                
+ 4H2O                                                                                                                                                                                                                                 
Where TOOS = N-ethyl-N-(2-hydroxy-3-sulphopropyl) m-toluidine. Two QCs were 
employed and the CVs for the low and high were found to be 3.29 % and 1.74 %, 
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respectively. The between assay precision gave CVs of 3.33 % and 1.33 % for the low 
and high QCs, respectively.  
2.2.11.4.7 Analyses of serum C reactive protein (CRP) 
The automated colorimetric method (ILab 650 analyser) was used to determine the 
CRP levels. The immunoturbidimetric method is based on highly specific binding 
between an antigen and an antibody. Latex particles reacted with an antibody specific 
to human CRP aggregate in the presence of CRP in the sample to produce immune 
complexes, which increased in turbidity. These immune complexes cause an increase 
in light emission which is related to the concentration of CRP in the serum. The 
absorption of light scattering was measured at 570 nm. The CRP concentration was 
determined from a calibration curve developed from CRP standards of known 
concentration. Intra-assay precision gave CVs of 5.39 % for the level 1 (low) QC and 
8.10% for level 2 (high) QC. Inter-assay precision gave CVs of 8.65 % and 7.85 % for 
both level 1 (low) and level 2 (high) QCs, respectively.  
2.2.11.4.8 Analyses of plasma insulin 
Plasma insulin concentrations were determined using a radioimmunoassay. The 
Millipore Human Insulin, which utilized 125I-labeled human insulin and human insulin 
anti-serum to determine the level of insulin in the plasma, was used. This method 
requires two days of setting up; plasma samples were defrosted at room temperature, 
different standard concentrations of insulin were prepared (200, 100, 50, 25, 12.5, 
6.25, 3.125µU/ml), 300 µl of assay buffer was added to non-specific binding (NSB) 
tubes and 200 µl to the reference (BO) tubes and then 100 µl of each standard and 
Quality Control were added. 100 µl of buffer was added to all sample tubes, followed 
by the addition of 100 µl of each plasma sample. 125I-Insulin label was prepared (27 ml 
of ready hydration solution was added to 125I-Insulin, mixed gently and left at room 
temperature for 30 minutes), and 100 µl was added to all the tubes, then 100 µl of 
human insulin antibody was then added to all tubes except the total count and NSB. 
Tubes were vortex mixed, covered and incubated overnight (21 hours) at room 
temperature (23 °C). On the second day, 1 ml of cooled precipitating reagent (4 °C) 
was added to all tubes except total count tubes and vortex mixed. The tubes were 
incubated for 20 min at 4 °C and then all of the tubes were centrifuged, except the total 
count tubes, at 2500 x g for 20 min. The supernatants from all of the tubes were 
Chapter 2  
  
67 
 
aspirated under a vacuum and the pellet containing the antibody bound insulin was 
counted on a gamma counter for 1 minute per sample (Wizard 1470, Wallac 
International, and Finland). Each sample was counted against the standard curve in 
order to ascertain the concentration of insulin in each sample.  
Low and high QC plasma samples were included at the beginning and the end of each 
assay. The intra-assay precision CV% for high and low were 1.20 % and 2.27 %, 
respectively. The inter-assay precision CV% for high and low were 3.50 % and 9.54 
%, respectively.  
2.2.11.4.8.1 Calculation of the homeostasis assessment model (HOMA) 
The Homeostasis Model Assessment (HOMA1) calculator was used to determine the 
beta cell function (%B) and insulin resistance (IR). This calculator was originally 
produced by Mattewa et al. (1985), and was calculated as described by Wallace et al. 
(2004) using the following formula:  
HOMA1 (IR) = (FPI x FPG)/22.5 
HOMA1 (%B) = (20 x FPI)/(FPG - 3.5) 
Levy et al. (1998) updated HOMA1 to HOMA2. In 2004, the HOMA2 calculator in 
computer was released, which is available from www.dtu.ox.ac.uk/homacalculator/. 
This model can be used to determine insulin resistance (IR), insulin sensitivity (%S) 
and β-cell function (%B) (Wallace et al., 2004). This model calculated required fasting 
glucose and insulin value. There is no approximation formula for HOMA-2. The HOMA2 
calculator was used in this study to estimated beta cell function (%B) and insulin 
resistance (IR) and insulin sensitivity (%S). 
2.2.11.4.9 Evidence Investigator 
Biochip array technology in combination with the Evidence Investigator instrument 
(Randox Laboratories Ltd., Crumlin, UK) was used to determine multiple cytokines 
from a single sample in real time. The Investigator system consists of: a Biochip carrier, 
which includes a solid phase of 9 biochip (9 mm2); nine multi-analyte calibration levels; 
handheld barcode scanner to input the details of the calibration and cytokines 
automatically into the system database; three quality controls; a thermo-shaker to 
provide fluid flow and mixing within the wells across the biochip surface; and a charge 
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coupled device (CCD) camera to recorded the light emitted from cytokines which bind 
to the discrete test regions (DTRs). The Evidence assay kit allows up to 54 samples to 
be processed within the Evidence analyser (Appendix 3). 
2.2.11.4.9.1 Principle of biochip array technology 
The protein sandwich immunoassay method was used to detect the serum cytokines 
and adhesion molecules. The protein arrays constructed on the biochip surface allow 
the cytokines and adhesion molecules (ligand, analytes) to bind to their primary 
antibody. Horseradish peroxidase (HRP) labelled secondary antibody, present as a 
conjugate, detected the analytes bound to the biochip surface. The signal reagent 
EV805 produced a light emission (chemiluminescent) reaction on the surface of the 
biochip, and was measured by a super-cooled CCD camera. The CCD camera 
simultaneously recorded the light emission from all of the biochips. The Evidence 
software was used to calculate the cytokine and adhesion molecule concentrations 
from the calibration curves (Appendix 3). 
2.2.11.4.9.2 Determination of high sensitivity cytokines  
The Evidence Investigator (Randox Laboratories Ltd., Crumlin, UK) was used to 
determine the 12 cytokines with high sensitivity (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-
10, VEGF, IFN-γ, MCP-1, TNF-α, and EGF) simultaneously from a single sample. The 
functional sensitivity of cytokines was as follows: IL-1α: 0.19 pg/ml; IL-1β: 0.26 pg/ml; 
IL-2: 2.97 pg/ml; IL-4: 2.12 pg/ml; IL-6: 0.12 pg/ml; IL-8: 0.36 pg/ml; IL-10: 0.37 pg/ml; 
VEGF: 3.24 pg/ml; IFN-γ: 0.44 pg/ml; MCP-1: 3.53 pg/ml; TNF-α: 0.59 pg/ml; EGF: 
1.04 pg/ml (Molloy et al., 2005; FitzGerald et al., 2008; Fabre et al., 2008). 
2.2.11.4.9.2.1 Cytokine high sensitivity approach 
200 µl of assay diluent was added to each biochip well. A total of 100 µl of undiluted 
serum samples, calibration and quality controls were added to the biochip well and 
tapped gently. The samples were incubated in the thermo-shaker for one hour at 37 
°C and 15 g. Then, the biochip samples were incubated for 19 hours at 4 °C. Wash 
buffer was used to wash the biochip well four times, then 300 µl of the conjugate was 
added into each biochip well and taped gently. After this, the samples were incubated 
in the thermo-shaker for one hour at 37 °C and 15 g. 250 µl of signal reagent EV805 
(Luminol and Peroxide, 1:1) was added to each biochip well, then wash buffer was 
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used to wash the biochip wells twice. The Biochip wells were filled with wash buffer 
and then uploaded into the Evidence analyser to take an image for each biochip well. 
Subsequently, the cytokines were quantified automatically using generated calibration 
curves (Evidence Investigator Software) (Molloy et al., 2005; FitzGerald et al., 2008; 
Fabre et al., 2005).  
2.2.11.4.9.3 Determination of the adhesion molecule levels 
VCAM, ICAM, E-selectin, P-selectin, L- selectin were determined using the Evidence 
Investigator (Randox Laboratories Ltd., Crumlin, UK) simultaneously from a single 
serum sample. The functional sensitivity for the adhesion molecules was as follows: 
VCAM: 4.1 ng/ml; ICAM: 1.7 ng/ml; E-selectin: 0.1 ng/ml; P-selectin: 1.9 ng/ml; L-
selectin: 3.2 ng/ml (Molloy et al., 2005; FitzGerald et al., 2008; Fabre et al., 2005). 
2.2.11.4.9.3.1 Determination of the adhesion molecule approach 
Serum samples were diluted (1:10); 25 µl of sample was added to 225 µl of wash buffer 
and mixed thoroughly, then 225 µl of assay diluent was added to each biochip well. 25 
µl of diluted serum samples, calibration and quality controls were added to the biochip 
wells and taped gently. The samples were incubated in the thermo-shaker for one hour 
at 37 °C and 15 g, then 50 µl of conjugate was added into each biochip well and tapped 
gently. After this, the samples were incubated in the thermo-shaker for one hour at 37 
°C and 15 g. 250 µl of signal reagent EV805 (Luminol and Peroxide, 1:1) was added 
to each biochip well, and wash buffer was then used to wash the biochip well four 
times. The Biochip well was filled with wash buffer and then uploaded into the Evidence 
analyser to take an image of each biochip well. Subsequently, adhesion molecules 
were quantified automatically using generated calibration curves (Evidence 
Investigator Software) (Molloy et al., 2005; FitzGerald et al., 2008; Fabre et al., 2005). 
2.2.12 Calculations and statistical analysis  
The details of the statistical analyses are specific to each study and are described in 
each specific chapter. Statistical analysis of the results was performed using either 
GraphPad Prism version 6 for Windows (San Diego, CA, USA) or SPSS statistical 
analyses software (SPSS, version 22 for windows, Chicago, Illinois). All outcomes of 
the human studies were assessed for normality using the Kolmogorov-Smirnov test (K-
S test) and expressed as a mean ± one standard error of the mean (SEM). In the GI 
study the incremental area under the glucose curve (iAUC) for the reference glucose 
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drink was calculated as recommended by WHO (1998). Repeated measures two-way 
ANOVA were used to analyse the difference in the mean of fasting glucose, insulin, 
lipid profiles and inflammatory markers in all visits studies. All data were examined 
using a two-tailed approach with a level of P < 0.05 considered as significant.  
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Chapter Three 
3 Radical scavenging and antioxidant activity of cinnamon supplement 
samples 
3.1 Introduction  
Reactive oxygen species (ROS) are highly damaging reactive molecules that include 
free radicals. A free radical contains an unpaired electron in its structure and an 
example of this is hydroxyl radical (OH•) (Poljsak et al., 2013). ROS, such as the 
superoxide radical (O2-•), H2O2 and the hydroxyl radical (OH•), are produced during 
normal metabolism and play a physiological role in cell signalling, however, the 
concentration of ROS can be increased under environmental stress and radiation, 
which can cause damage to the cell, and in specific circumstances, can lead to disease 
(Valko et al., 2007). When there is an imbalance between ROS production and the 
antioxidant cell defences, this can lead to an excessive amount of free radicals, which 
can cause cellular damage associated with many diseases (Sánchez-Gallego et al., 
2011). Antioxidant compounds are substances that can break the free radical chain 
reaction and inhibit the production of free radicals and act as oxygen scavengers 
(Gülçin et al., 2005; Frankel and German, 2006). In humans, antioxidants are either 
produced in the body (endogenous) or are derived from the diet, which may have a 
direct effect on antioxidant status (Pham-Huy et al., 2008). 
The total antioxidant capacity of food measures the ability of food components to 
scavenge free radicals (Pellegrini et al., 2003). The antioxidant activity can be 
measured by a variety of methods, such as DPPH radical scavenging and reducing 
power (Jimenez and Calixto, 2008; Huang et al., 2005). The most popular synthetic 
antioxidants used in the food industry are butylated hydroxyanisole (BHA) and 
butylated hydroxytoluene (BHT), but there are concerns with these synthetic 
antioxidants as they hepatic toxic effects (Lanigan and Yamarik., 2001). BHA and BHT 
are often used as standards in order to compare the antioxidant capacity of food 
derived substances (Nićiforović et al., 2010; Poljšak and Raspor, 2008). 
Herbs and medicinal plants have been identified as sources of phytochemicals, such 
as polyphenolic and phenolic compounds. Some phytochemicals have powerful 
antioxidant activities, which may play a role in antioxidant defence in plants (Liu, 2003; 
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Dragland et al., 2003; Lichtenstein et al., 2006). Polyphenols are widely distributed in 
plants, and are found in fruits, seeds, and herb barks; and many phenolic compounds 
have been reported to have antioxidant activity (Olchowik et al., 2012). The ability of 
phenols and polyphenols to act as antioxidants comes from their structure, they have 
one or more aromatic rings with one or more hydroxyl groups that can donate a 
hydrogen atom, which then reacts with a free radical and consequently the oxidation 
reaction is stopped (Bondet et al., 1997; Dai and Mumper, 2010). 
Cinnamon contains many polyphenolic compounds, including flavonoids, 
anthocyanins and tannins, which increase the antioxidant activity of the products 
derived from cinnamon that may offer beneficial health properties (Helal et al., 2014). 
Dragland et al. (2003) have determined the total antioxidant activity in several 
medicinal herbs, and C. cassia was shown to have a high total antioxidant activity 
(120.2 mmol/100 g). They determined the antioxidant activity using the ferric reducing 
antioxidant power of plasma (FRAP) assay, which is based on measuring the 
absorption changes that appear with the reduction of ferric (Fe3+) ions to the ferrous 
ion (Fe2+) in the presence of antioxidants (Dragland et al., 2003).  The results showed 
cinnamon herbal medicines have strong antioxidant properties, which may be derived 
from the polyphenolic compounds they contain (Hamidpour et al., 2015). Studies have 
shown there is an inverse relationship between an antioxidant rich diet and human 
disease (Yildirim et al., 2001), however, there is conflicting evidence concerning the 
potential benefit of higher intakes of single antioxidants, for instance, tocopherol 
supplementation did not decrease the risk of CVD (Berger et al., 2012). 
3.2  Study aims 
The aims of this study were:  
1 To prepare water and acetone/water extracts of four commercially available 
cinnamon supplements. 
2 To determine the total polyphenol and tannin content of the four cinnamon 
supplement extracts. 
3 To determine the total condensed tannin (proanthocyanidin) contents in 
Cinnamomum cassia (C. cassia) and Cinnamomum zeylanicum (C. zeylanicum) 
extracts. 
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- To determine the phenolic composition of C. cassia and C. zeylanicum using 
HPLC and LC-MS. 
- To determine the antioxidant properties of water and 75 % acetone C. cassia 
and C. zeylanicum supplement extracts by using three different methods (as follows): 
- The radical scavenging method determined by DPPH and H2O2 scavenging of 
the cinnamon types at different concentrations. 
- Metal chelating activity of the different cinnamon types at a range of 
concentrations. 
- Determining the reducing power for each cinnamon extract at range of 
concentrations. 
3.3 Methods 
3.3.1 Preparation of cinnamon supplement extracts 
This study focused on cinnamon supplements which could be readily purchased from 
health shops and consumed in capsule form. Four cinnamon supplements were used 
in this study. The cinnamon samples were:  
- Cinnamon bark (Bio-Health® Cinnamomum zeylanicum), 350 mg, Bio-Health Limited, 
Rochester, Kent, UK. (C. zeylanicum). 
- Cinnamon bark (Health Aid® Cinnamomum zeylanicum) 850 mg, Health Aid Limited, 
Middlesex, UK. (C. zeylanicum H.). 
- Cinnamon bark (Puritan's Pride's® Cinnamomum cassia) 500 mg, Holbrook, USA. 
(C. cassia). 
- Cinnamon bark (Solgar® Cinnamomum cassia) 500 mg, Solgar Vitamin and Herb, 
USA. (C. cassia S.). 
Each cinnamon sample was extracted with deionised water and 75 % acetone as 
described in Chapter 2 (section 2.2.2).  
3.3.2 Determination of total phenolic content 
The cinnamon extracts were freshly prepared (section 2.2.2, Chapter 2) and triplicate 
analyses were performed to determine total phenolic content (section 2.2.3, Chapter 
2).  
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3.3.2.1 Standards 
A 7 mg/ml gallic acid (GA) standard stock solution was prepared and then diluted with 
deionised water to the following concentrations: 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6 mg/ml 
(w/v). The standard curve was used to calculate the total phenolic content in cinnamon 
samples using the following formula: Y = 0.8859X, R2 = 0.995. 
The standard concentrations were prepared in triplicate.  
3.3.3 Determination of hydrolysable tannin content 
The analysis was performed as described previously (section 2.2.4). 
3.3.3.1 Standards 
A 0.1 mg/ml tannic acid stock standard solution was prepared and diluted with 
deionised water to the following concentrations: 0.025, 0.05, 0.1, 0.2, 0.3, 0.4 mg/ml 
(w/v). A standard curve was used to calculate the hydrolysable tannin content in 
cinnamon samples using the following formula: Y = 0.7381X, R2 = 0.996. 
3.4 Results 
3.4.1 Determination of total phenols 
Standard curves of gallic acid were produced (Figure 3.1) in order to estimate the total 
polyphenolic content in cinnamon extracts. The curve produced had a high R2 value 
showing the points are a good fit. 
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Figure 3.1: Gallic acid standard curve. Standard curve represented as a mean ± SD 
of gallic acid (0-0.600 mg/ml) for a total polyphenolic content determination. R2 = 0.995. 
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3.4.1.1 Total phenolic content of cinnamon samples extracted with 75 % 
acetone  
The total phenolic contents of C. cassia and C. zeylanicum showed some statistically 
significant differences between the samples (Figure 3.2). The total phenolic contents 
of C. cassia and C. zeylanicum H. were similar as they were estimated to be 105.6 mg 
and 101.81 mg, respectively, estimated in terms of gallic acid equivalent/g of dry 
cinnamon. Furthermore, C. cassia S. had a slightly higher content (48.89 mg of GAE/g) 
than C. zeylanicum (39.63 mg estimated of GAE/g), both of which were lower than C. 
cassia (Figure 3.2). These results were confirmed by the analyses at the Plant for 
Human Health Institution in North Carolina State University, United States, which also 
determined the total phenolic contents of C. cassia and C. zeylanicum to be 89.74 
±11.68 and 28.44± 2.91 mg estimated of GAE/g, respectively. Overall these results 
show how the different commercial supplements vary in their phenolic content, which 
may be related to how effective they are as treatments. 
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Figure 3.2: Total phenols in cinnamon samples extracted by 75% acetone. Values are 
mean ± SD (n = 3). Comparisons of means were made using a one-way ANOVA 
followed by Bonferroni test (*** =P<0.0001, * =P<0.05). 
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3.4.1.2 Total phenolic content in cinnamon samples extracted using 
deionised water 
The results for the extraction with deionised water (Figure 3.3) showed that C. cassia 
had the highest total polyphenolic content (30.65 mg GAE/g) among the cinnamon 
samples analysed, which is the same as in the acetone extraction. The total phenolic 
contents of C. cassia, C. zeylanicum, C. cassia S and C. zeylanicum H were: 30.65, 
25.33, 27.89 and 19.63 mg of GAE/g, respectively (Figure 3.3), which are all lower 
than the acetone extraction. Overall these results suggest the 75 % acetone was a 
more effective solvent for extracting total phenols compared with water. The total 
phenolic contents in cinnamon samples extracted by water were almost three times 
lower compared with using 75 % acetone.  
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Figure 3.3: Total phenols in cinnamon samples extracted by deionised water. Values 
are mean ± SD (n = 3). Comparisons of means were made using a one-way ANOVA 
followed by Bonferroni test (*** =P<0.0001, * = P<0.05). 
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3.4.2 Determination of hydrolysable tannin content 
Standard curves for tannic acid were produced (Figure 3.4) and the calculated values 
were subtracted from the total polyphenolic content. Tannin contents are expressed as 
mg/g of tannic acid equivalents (TAE).   
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Figure 3.4: Tannic acid standard curve. Standard curve represented as a mean ± SD 
of tannic acid (0 -0.400mg/ml) for a total tannin content determination. R2 = 0.996. 
 
3.4.2.1 Total (hydrolysable) tannin determined in cinnamon samples 
extracted using 75 % acetone (v/v)  
The hydrolysable tannin content (Figure 3.5) of C. cassia was two times higher (65.69 
mg of TAE/g) than that present in C. zeylanicum (26.79 mg of TAE/g) (p < 0.0001).  
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Figure 3.5: Tannin content in cinnamon samples extracted by acetone 75%. Results 
are mean ± SD (n = 3). Comparisons of means were investigated using unpaired t-test 
(*** =P<0.0001). 
 
3.4.2.2 Total tannin cinnamon samples extracted by deionised water 
The water based extraction (Figure 3.6) showed that C. cassia had a higher level of 
TAE/g (23.01 mg of TAE/g) than that of C. zeylanicum (18.90 mg of TAE/g), which is 
a similar pattern to that observed for the acetone extraction. As with the phenolic 
content, the tannin content was higher in cinnamon samples extracted with 75 % 
acetone compared to those extracted with water, again showing that acetone is more 
efficient at extraction. 
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Figure 3.6: Tannin content in cinnamon samples extracted by deionised water. Results 
are mean ± SD (n = 3). Comparisons of means were investigated using unpaired t-test 
(* =P<0.05). 
 
3.4.3 Determintion of condensed tannin (proanthocyanidin) contents 
The DMAC method was carried out in a 96-well plate to determine the 
proanthocyanidin content (section 2.2.6.3). Furthermore, collaborators from NCSU 
(Plant for Human Health Institution), United States, determined the proanthocyanidin 
content and composition in C. cassia and C. zeylanicum. The results (Figure 3.7) 
showed there was 41.53 ± 2.70 mg of procyanidin A2/g equivalents in C. cassia and 
11.42 ± 1.60 mg of procyanidin A2/g equivalents in C. zeylanicum. 
 
The results showed that the cinnamon extracts were rich in polyphenols, and 
condensed and hydrolysable tannins. Therefore, several methods for measuring 
antioxidant activity were used to determine the antioxidant activity of C. zeylanicum 
and C. cassia preparations. 
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Figure 3.7: Proanthocyanidin content in C. cassia and C. zeylanicum samples. Results 
are mean ± SD (n = 3). Comparisons of means were determined using unpaired t-test 
(*** =P<0.0001). 
 
3.4.4 HPLC and LC-MS analysis 
The cinnamon samples were analysed using HPLC and LC-MS (section 2.2.8 and 
2.2.9) after 75 % acetone was used to extract C. zeylanicum and C. cassia. The results 
suggest that both cinnamon type extracts showed a similar profile.  
Normal phase HPLC with fluorescence detection was able to separate the 
proanthocyanidin components in cinnamon extracts according to their degree of 
polymerisation. The data from the HPLC (Figure 3.8) revealed that both cinnamon 
types (C. cassia and C. zeylanicum) contain flavanol monomers (catechin and 
epicatechin), procyanidin dimers (types A and B), trimers (A-type), tetramers, 
pentamers, hexamers, heptamers, octamers and polymers. The peak intensities for 
the procyanidin A-type trimers reveal a high content in both C. cassia and C. 
zeylanicum, with a higher intensity in the C. cassia trace. Hence, C. cassia and C. 
zeylanicum may primarily contain A-type procyanidin as these are the main peaks in 
the HPLC trace.  
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Figure 3.8: Normal Phase HPLC showing the retention times for C. cassia and C. 
zeylanicum and the procyanidin standards. 
 
The concentration of individual proanthocyanidins was calculated according to their 
degree of polymerisation (DP) by NP-HPLC. The results (Figure 3.9) show high 
concentrations of procyanidin polymers with degrees of polymerisation of 3 and 4 units, 
and polymers with degrees of polymerisation more than 10. It is shown also that 
concentrations of proanthocyanidins are higher in C. cassia in comparison to C. 
zeylanicum. 
 
 
 
C. cassia 
C. zeylanicum 
Chapter 3  
  
83 
 
Catachin (CA), epicatachin (EC), procyanidin dimers type A2 (dimer A2), procyanidin dimers type B2 (dimer 
B2). Procyanidin degree of polymerisation (DP) varies from DP3 to DP10. 
Figure 3.9: Concentrations of individual proanthocyanidins by NP-HPLC as 
procyanidin A2 dimer equivalents. Proanthocyanidin concentrations shown according 
to their degree of polymerization. 
 
The concentrations of procyanidin type A and B dimers, trimers and tetramers, were 
evaluated by extracted ion chromatogram (EIC) analysis (Figure 3.10). Procyanidin A 
and B types were found to be the main content in C. cassia and C. zeylanicum, with 
dimers also being detected strongly in both. This figure reveals the presence of two 
types of procyanidin type B dimers in C. cassia, while C. zeylanicum had only one type. 
Also, two types of procyanidin type A trimers were found in C. cassia, whereas in C. 
zeylanicum only one type A trimer was found, and the presence of two major A type 
tetramers was found at different concentrations in both cinnamon types.  
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Figure 3.10: Extracted ion chromatograms (EIC) of proanthocyanidin dimers, trimers 
and tetramers in C. cassia and C. zeylanicum. 
 
The C. cassia and C. zeylanicum extracts were analysed in the positive and negative 
ion modes using ESI-IT-TOF-MS (Figure 3.11). In the positive ion mode, for both types 
of cinnamon the major procyanidins [M+1]+ were: dimer A-type (m/z 577), dimer B type 
(m/z 579), trimer A-type (m/z 865), tetramer A-type (m/z 1153), and pentamer A-type 
Two major A-type Tertramers in 
C. cassia and C. zeylanicum, but 
differ in concentration of each 
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(m/z 1441). Whereas, in the negative ion mode the major procyanidins [M-1]-  were: 
dimer A-type (m/z 575), dimer B type (m/z 577), trimer A-type (m/z 863), tetramer A-
type (m/z 1151), pentamer A- type (m/z 1439) for both types of cinnamon. 
+ve ion mode -ve ion mode 
  
  
Figure 3.11: ESI-IT-TOF-MSS can spectrum of C. cassia and C. zeylanicum extracts 
in the positive and negative ion modes. 
 
3.4.5 DPPH radical scavenging activity 
The DPPH assay serves as an indirect measurement of the ability of the extracts or 
pure samples to inhibit free radicals. The purple DPPH radical exists as a stable free 
radical and has an absorbance wavelength of 515 nm, and when an antioxidant 
compound donates H• to the DPPH molecule, it is reduced, forming a colourless 
compound. The calculation of the percentage of DPPH radical scavenging (2.2.10.1) 
was converted into the percentage of inhibition caused by both cinnamon types, 
extracted in 75 % acetone and deionised water (Figure 3.12).  
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3.4.5.1 DPPH radical scavenging activity of C. cassia and C. zeylanicum 
extracted by 75 % acetone and deionised water 
The DPPH radical scavenging effect increased with increasing concentrations of both 
cinnamon varieties and solvent (Figure 3.12). The radical scavenging activity of C. 
cassia extracted by 75 % acetone was significantly higher than that of C. zeylanicum. 
The percentage of inhibition caused by C. cassia extracted with 75 % acetone was 
36.07 %, 62.90 % and 71.69 %, respectively, for concentrations of 0.050, 0.100 and 
0.150 mg/ml. However, the scavenging activity found in C. zeylanicum at the same 
concentrations was 10.51 %, 13.99 % and 19.53 % (Figure 3.12). The radical 
scavenging activities of the C. cassia and C. zeylanicum extracted with water were 
quite similar to each other (Figure 3.13), but the values were lower than the acetone 
extracted cinnamon. Furthermore, no significant difference was found between C. 
cassia and C. zeylanicum which had been extracted with water. Overall these results 
follow a similar trend that was seen for the other extraction comparisons, namely that 
the acetone is more efficient at extracting polyphenols, and C. cassia has a higher 
activity due to its higher polyphenol content.  
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Figure 3.12: DPPH radical scavenging activity of cinnamon extracted by 75 % 
acetone. Results are mean ± SD (n = 3). Comparisons of means were detected using 
unpaired t-test (* =P < 0.05). 
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Figure 3.13: DPPH radical scavenging activity of cinnamon extracted by deionised 
water. Results are mean ±SD (n = 3). Comparisons of means were detected using 
unpaired t-test (* =P<0.05). 
 
The radical scavenging activity of cinnamon extracts at 0.1 mg/ml was individually 
compared to that of 0.1 mg/ml of BHT and trolox (Figure 3.14). The DPPH radical 
scavenging capacity of BHT was not significantly different to that of C. cassia extracted 
with 75 % acetone, however, it was significantly different compared with the other 
cinnamon extracts (Figure 3.14). Interestingly, the DPPH radical scavenging activity of 
the C. cassia acetone extract (Figure 3.15) was significantly higher (62.90 %) 
compared with trolox (34.99 %), whereas the radical scavenging activity of trolox was 
significantly higher compared with the 75 % acetone C. zeylanicum extract, and the 
water C. cassia and C. zeylanicum extracts. Overall these results suggest that C. 
cassia extracted by acetone has a higher antioxidant activity than trolox and all the 
other preparations, which correlates with the high polyphenol concentrations observed 
in the previous experiments. 
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Figure 3.14: Comparison between DPPH radical scavenging activity of acetone and 
water C. cassia and C. zeylanicum extracts with BHT at 0.1mg/ml. Values are mean ± 
SD (n = 3). Comparisons of means were made using a one-way ANOVA followed by 
Bonferroni test (*** =P < 0.0001). 
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Figure 3.15: Comparison between DPPH radical scavenging activity of acetone and 
water C. cassia and C. zeylanicum extracts with trolox at 0.1mg/ml. Values are mean 
± SD (n = 3). Comparisons of means were made using a one-way ANOVA followed by 
Bonferroni test (*** =P < 0.0001). 
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3.4.6 Scavenging of hydrogen peroxide  
The capacity of cinnamon extracts to scavenge H2O2 was measured at 230 nm 
(2.2.10.2), as plant polyphenols have the ability to donate an electron to H2O2 and 
convert it to H2O (Nabavi et al., 2008). 
The results showed that the C. cassia and C. zeylanicum 75 % acetone extracts 
(Figure 3.16) strongly inhibited the activity of H2O2 compared with the water based 
extracts (Figure 3.17), and the C. cassia 75 % acetone extracts were significantly (P < 
0.05 for all) more active than the C. zeylanicum 75 % acetone extracts. The percentage 
of inhibition of H2O2 was 95.34 %, 96.06 %, 97.33 % for C. cassia acetone extracts 
(0.050, 0.100, 0.150 mg/ml, respectively). However, the ability of the C. zeylanicum 
acetone extract to scavenge H2O2 at concentrations of 0.050, 0.100, 0.150 mg/ml were 
89.34 %, 92.55 %, 94.12 %, respectively (Figure 3.16). There were no significant 
differences between the water based C. cassia and C. zeylanicum extracts (Figure 
3.17). The difference between the water and acetone extractions is as expected due 
to the lower concentration of polyphenols present in the water extractions. 
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Figure 3.16: H2O2 scavenging activity of cinnamon extracted by 75% acetone. 
Concentrations were 0.05, 0.100 and 0.150 mg/ml. Results are mean ± SD (n = 3). 
Comparisons of means were investigated using unpaired t-test (* =P<0.05). 
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Figure 3.17: H2O2 scavenging activity of cinnamon extracted by deionised water. 
Concentrations were 0.05, 0.100 and 0.150 mg/ml. Results are mean ± SD (n = 3).  
Comparisons of means were investigated using unpaired t-test (* =P < 0.05). 
 
BHT and trolox at 0.1 mg/ml were used as controls to compare with 0.1 mg/ml 
cinnamon extracts. The percentages for the scavenging activities of C. cassia and C. 
zeylanicum acetone extracts were not significantly different when compared with BHT 
(Figure 3.18). However, the C. cassia (96.06 %) and C. zeylanicum (92.55 %) acetone 
extracts scavenged H2O2 radicals to a significantly (P < 0.0001) higher level than trolox 
(48.73 %) (Figure 3.19). Water extracts of both cinnamon types showed significantly 
lower inhibitory activities of H2O2 compared with both BHT and trolox at 0.1 mg/ml. 
Overall this suggests that these concentrations of the acetone cinnamon extracts are 
better scavengers than the controls.  
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Figure 3.18: Comparison between H2O2 scavenging activity of acetone and water 
cinnamon sample extracts with BHT at 0.1mg/ml. Values are mean ± SD (n = 3). 
Comparisons of means were made using a one-way ANOVA followed by Bonferroni 
test (*** =P<0.0001). 
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Figure 3.19: Comparison between H2O2 scavenging activity of acetone and water 
cinnamon sample extracts with trolox at 0.1mg/ml. Values are mean ± SD (n = 3). 
Comparisons of means were made using a one-way ANOVA followed by Bonferroni's 
test (*** =P<0.0001). 
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3.4.7 Metal chelating activity 
The method was described in section (2.2.10.3). During ferrous ion chelation, the Fe2+ 
ferrozine complex formation can be inhibited by the presence of antioxidant 
compounds. A chelating agent that has the ability to inhibit the formation of Fe2+ 
ferrozine complex is considered to be Fe2+ chelating (Ebrahimzadeh et al., 2010). The 
results show the percentages of ferrous chelating activity for each type of cinnamon 
extract (either by 75 % acetone (Figure 3.20) or by water (Figure 3.21) were relatively 
similar for the concentrations investigated. In addition, there was no significant 
difference between the acetone and water based extracts of C. cassia and C. 
zeylanicum. This was due to the low level of chelating that occurs in both types of 
cinnamon.  
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Figure 3.20: Metal chelating activity of cinnamon extracts by 75 % acetone. 
Concentration were 0.05, 0.100 and 0.150 mg/ml. Results are mean ± SD (n = 3). 
Comparisons of means were investigated using unpaired t-test (* =P<0.05). 
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Figure 3.21: Metal chelating activity of cinnamon extracts by deionised water. 
Concentration were 0.05, 0.100 and 0.150 mg/ml. Results are mean ±SD (n = 3). 
Comparisons of means were investigated using unpaired t-test (* =P<0.05). 
 
The ferrous chelating activity of EDTA (Figure 3.22), which was used as control, was 
significantly higher than that of the cinnamon extracts. The ferrous chelating activity of 
EDTA, acetone extracted C. cassia, acetone extracted C. zeylanicum, water extracted 
C. cassia, and water extracted C. zeylanicum extracts were 98.39 %, 8.67 %, 6.61 %, 
4.55 % and 2.80 %, respectively. Overall this shows that the cinnamon extracts had a 
poor chelating activity compared to the control, which suggests chelation is not the 
main method that produces the beneficial effects of cinnamon. 
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Figure 3.22: Comparison between ferrous chelating activity of acetone and water 
cinnamon sample extracts with EDTA at 0.1 mg/ml. Values are mean ± SD (n = 3). 
Comparisons of means were made using a one-way ANOVA followed by Bonferroni 
test (*** =P<0.0001). 
 
3.4.8 Reducing power assay   
Method was described in section (2.210.4). The reducing power of a compound is 
based on its capacity to donate an electron, which is a mechanism of phenolic 
antioxidant action (Hinneburg et al., 2006). The presence of an antioxidant compound 
in an extract leads to the reduction of Fe3+ (ferricyanide complex) to Fe2+ (ferrous) 
through the donation of an electron (Nabavi et al., 2008). The results for the 
investigation of the reducing power of the cinnamon extracts (Figure 3.23 and Figure 
3.24) showed they increased with increased concentration for all extracts, but the 
reducing power of the C. cassia acetone extract was significantly (P < 0.001) higher 
compared with that of C. zeylanicum (Figure 3.23). In addition, the C. cassia water 
extract had higher reducing activity than that of C. zeylanicum, but this was not 
significant (Figure 3.24). These results show that the cinnamon extracts have a 
reducing power, with the acetone extracts having a higher activity than the water 
extracts, which is as expected based on the previous results in this study. The results 
also agree with the other investigations of cinnamon extract activity, as the C. cassia 
has a higher activity than the C. zeylanicum, which fits with the differences observed 
in polyphenol content between the extracts. 
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Figure 3.23: Reducing power of different concentrations from cinnamon samples 
extracted by 75 % acetone. Each value is the mean ± SD of three measurements.  
Comparisons of mean were made using unpaired t-test (** = P<0.001). 
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Figure 3.24: Reducing power of different concentrations from cinnamon samples 
extracted by water. Each value is the mean ± SD of three measurements.  
Comparisons of mean were made using unpaired t-test. 
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3.5 Discussion  
Many previous studies have reported the potential health benefits of procyanidins, for 
example feeding male rats (Zucker Fa/fa) procyanidins extracted from grape seed (345 
mg/kg feed) for 19 weeks, significantly reduced the high levels of CRP, which are linked 
with inflammation (Terra et al., 2009). Andújar et al. (2012) reviewed the potential 
benefits of cocoa polyphenols, and they reported that 58 % of cocoa is consists of 
procyanidin. Grassi et al. (2008) reported from a randomised crossover trial, that 
feeding 19 hypertensive patients flavanol-rich dark chocolate (100 g/day for 15 days) 
significantly decreased their systolic and diastolic blood pressure. Our data identified 
the procyanidins type A and B in cinnamon and other studies have confirmed their 
health benefits. Therefore, this study investigated the antioxidant activity of cinnamon 
samples. 
According to our knowledge, this is the first study compare the antioxidant activities of 
cinnamon extracted with acetone and water, and to compare the antioxidant activities 
of two types of cinnamon supplements (C. cassia and C. zeylanicum). Furthermore, 
the first study determined hydrolysable and condensed tannin in cinnamon. The total 
phenol levels in our study were relatively high compared to the results of the North 
Carolina State University (NCSU), United States, who also analysed the polyphenol 
composition of different cinnamon samples using HPLC and LC-MS. The total phenol 
levels of C. cassia and C. zeylanicum extracted by 75 % acetone in our lab were 105.6 
mg and 39.63 mg, and in NCSU were 89.74 mg and 28.44 mg respectively, of gallic 
acid equivalent/g of dry cinnamon. Both laboratories used the same extraction solvent, 
however, NCSU used a different extraction method. The acetone cinnamon extracts 
were high in total phenols and tannins when compared with the water cinnamon 
extracts. This is due to the solubility of the plant and herb polyphenols being influenced 
by the solvent used for the extraction process; in general, acetone and water mixes 
are more efficient than acetone alone for the extraction of phenolic substances from 
herbal medicines (Meneses et al., 2013). In addition, solvent polarity plays a key role 
in increasing phenolic solubility, which relates to the high total phenolic content and 
antioxidant activity seen in the acetone cinnamon extracts (Naczk and Shahidi, 2006; 
Barchan et al., 2014).  As water has a higher polarity, it is not as efficient at extracting 
phenols because these compounds are often more soluble in organic solvents which 
are less polar than water (Meneses et al., 2013). This observation has been confirmed 
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by Su et al., (2007), who showed that a 50 % acetone solvent produced better 
extractions than another more polar alcoholic solvent (85 % methanol). Nevertheless, 
Tatiya et al. (2011) report that 70 % acetone was efficient for the extraction of tannin. 
Furthermore, for the extraction of procyanidins, acetone has been shown to possess 
the highest extraction efficiency, followed by ethanol and methanol (Lazarus et al., 
2001). Therefore, for this study 75 % acetone was used to extract the phenolic 
compounds, which was more efficient than water. In addition, deionised water was 
used to extract the cinnamon samples in order to have a sample that was similar to 
that experienced by a consumer of cinnamon. 
Su et al. (2007) showed that a 50 % acetone cinnamon extract has 186 mg of gallic 
acid equivalents/g, which was higher than our result (105.6 mg), although both studies 
used acetone. This might be due to their different extraction method, which used 5 g 
ground cinnamon extracted with 50 ml of 50 % acetone for 15 hours, which meant each 
one ml of solvent was used to extract 100 mg of cinnamon. Furthermore, they extracted 
for double the amount of time and therefore, the total phenols in Su et al. (2007) was 
higher compared with our study. In this study, the total polyphenols in C. cassia and 
C. zeylanicum water extracts were 30.65 mg and 25.33 mg of gallic acid equivalents/g 
of dry cinnamon, respectively, which was lower than the findings of Helal et al. (2014), 
who determined the total polyphenols in water C. cassia extract to be 43.8 mg of 
catechin equivalents/g of dry cinnamon. This difference was possibly because they 
used a different method to extract C. cassia. In their methods, 4 g of C. cassia was 
added to 200 ml of boiling water, and was then heated for 5 min below boiling point. In 
addition to this, they used a different standard, which was catechin, which would 
produce a lower result than gallic acid in the assay due to its higher molecular mass. 
These results are also similar to the study by Ranilla et al. (2010) who found that C. 
zeylanicum water extract has 35 mg of gallic acid equivalents/g of dry cinnamon. Again, 
this difference in total phenol content may be due to differences in the extraction 
methods, they added 5 g of cinnamon to 100 ml of distilled water and refluxed the 
mixture at 95 °C for 30 min before cooling. The extract was then centrifuged at 9300 g 
for 30 min, and the final supernatant was re-centrifuged at 1008 g. These studies show 
that the extraction method plays an important role in determining the total phenolic 
content measured in the cinnamon samples. 
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The total phenolic content in the C. cassia acetone extract (105.6 mg GAE/g) found in 
this study was similar to that of Lv et al. (2012) (101.4 mg GAE/g), and this may be due 
to both studies having used acetone at the same percentage, 75 % acetone. In the 
study carried out by Lv et al. (2012), the cinnamon was extracted using an ASE 200 
system stainless steel cell (Dionex, Sunnyvale, CA), which was used for the 
pressurised liquid extraction of the cinnamon, which was then extracted with 75 % 
acetone. Their cinnamon extract was obtained via pressure and high temperature, 
which might have an effect on cinnamon polyphenols. While our method that was used 
to extract cinnamon samples was based on stirring at low temperature, which possibly 
has a lower impurities effect on the cinnamon polyphenols. Sardsaengjun et al. (2010) 
highlighted that increased temperature might increase impurities in the extract that may 
affect total polyphenolic content. Also, higher temperatures may cause the extraction 
of compounds other than polyphenols diversity (Vergara-Salinas et al., 2012). 
In the acetone cinnamon extracts, the total hydrolysable tannin contents of C. cassia 
was much higher than C. zeylanicum, 65.69 mg and 26.79 mg (respectively) of tannic 
acid equivalents (TAE/g), and the water based extract of C. cassia also had a higher 
level of hydrolysable tannins (23.01 mg of TAE/g) than that of C. zeylanicum (18.90 
mg of TAE/g), but the difference was not as large. No previous studies have been 
documented which determined the total hydrolysable and condensed tannin contents 
in cinnamon, which suggests this study is the first study measure the total hydrolysable 
tannin and proanthocyanidin contents of cinnamon, and again shows that acetone was 
a more suitable solvent for the extraction process. 
It is clear from the outcome of this study that C. zeylanicum extracts were lower in total 
phenol and tannin content compared with C. cassia. This might be due to the 
polyphenol compositions obtained from the HPLC and LC-MS analyses (section 
3.4.2.4). Our HPLC results show that C. cassia had higher levels of monomers 
(catechin and epicatachin), which were used as a standard, than C. zeylanicum. This 
was in agreement with Lv et al. (2012) whose HPLC data confirmed that catechin was 
the major phenolic compound in C. cassia. Their study analysed one type of cinnamon, 
whereas our study investigated two types, which provides more details relating to 
cinnamon content. Moreover, our extracted ion chromatogram (EIC) analysis data 
showed that C. cassia has two types of procyanidin type-B dimers, while C. zeylanicum 
has only one type. Also, two types of procyanidin type-A trimers were found in C. 
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cassia, whereas, C. zeylanicum was found to have one type-A trimer. This result 
agrees with the work by Chen et al. (2012) as their HPLC chromatographic profiles 
analysed C. cassia and confirmed that it contained mainly procyanidins of the type-B 
(Chen et al., 2012; Chen et al., 2014). Furthermore, our results were consistent with 
those of Anderson et al. (2004), who found that their HPLC-APCI-MS ion profiling of 
both types of cinnamon extract showed the presence of monomers and trimers of type-
A procyanidins, along with catechin, epicatechin, and procyanidins B1 and B2. Also, 
Anderson et al. (2004) reported that the major procyanidin oligomers in the ethanolic 
and aqueous extracts of cinnamon were doubly linked type-A, which is in contrast to 
the findings of Chen et al. (2012) who reported that C. cassia contained mainly type-B 
procyanidins, which may be due to the extraction process they used. Our study concurs 
with Chen et al. (2012) and Anderson (204). In both varieties cinnamon procyanidins 
type A and B exist and other studies have confirmed their health benefits; therefore, it 
would be useful to test the effects of cinnamon, in which LC-MS and HPLC have 
confirmed the presence of procyanidins, on cytokine levels and blood pressure in vivo.  
In this study, the antioxidant activity of cinnamon extracts increased with concentration, 
which is as expected. The acetone extract of C. cassia had the highest antioxidant 
activity, with DPPH, H2O2 radical scavenging, and reducing power, compared with the 
acetone extract of C. zeylanicum, and both cinnamon water extracts. The acetone C. 
cassia extracts showed a high free radical scavenging capacity compared with BHT 
and trolox at 0.100 ml/ml, suggesting this extract is a strong antioxidant.  In a study by 
Mathew and Abraham (2006), their C. zeylanicum extract showed good scavenging of 
DPPH radicals compared with the BHA positive control, at different concentrations (50-
3125 µg/ml). At a concentration of 125 µg/ml, which was relatively similar to one of the 
concentrations used in this study (100 µg/ml), the scavenging capacity of their C. 
zeylanicum extract was 13 %, and for BHA at the same concentration (125 µg/ml), it 
was 25 %. However, our study found that the scavenging capacity of the acetone C. 
zeylanicum extract was 13.99 %, and for BHT it was 60 %, which shows the similarity 
in the cinnamon results. Although in the study by Mathew and Abraham (2006) the 
cinnamon was extracted with a different solvent (methanol) under stirring, their results 
support and agree with our result in showing that acetone C. zeylanicum extract was 
effective at scavenging DPPH radicals. Furthermore, Dudonné et al. (2009) highlighted 
that a water C. zeylanicum extract inhibited 84.43 % of DPPH radicals. In their study 
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they extracted 125 g of cinnamon with distilled water at 50 °C under agitation and after 
filtration, the water was removed in a Buchi R124 rotary evaporator. However, their 
study did not mention the cinnamon extract concentration used to scavenge DPPH 
radicals, and it was not compared with a positive control making it harder to compare 
the results to our study. In another study, a C. zeylanicum water extract at a 
concentration of 50 mg/ml inhibited 45 % of DPPH radicals (Ranilla et al., 2010). 
Comparing our result with their outcome, our C. zeylanicum water extract at 0.100 
mg/ml inhibited 9.07 % of DPPH radicals, and although the concentrations compared 
are not similar, it is evident that C. zeylanicum water extract at a low concentration 
(0.100 mg/ml) is active in scavenging DPPH radicals. Nevertheless, Yang et al. (2012) 
state that C. cassia extracted with 95 % ethanol scavenged 85 % of DPPH radicals 
when at a concentration of 0.073 mg/ml, which is similar to our result as at a low 
concentration (0.100 mg/ml), the acetone extract of cinnamon performed more 
effectively in scavenging DPPH radicals (62.90 %) than in the study by Yang et al. 
(2012). Also, in their study they did not compare their results with a positive control, 
but overall it seems that acetone is a more efficient extraction solvent than ethanol. 
This has also been confirmed by Lazarus et al. (2001) who emphasised that acetone 
has been shown to possess the highest extraction efficiency of polyphenols, in 
particular procyanidin, followed by ethanol and methanol.  
In a study by Singh et al. (2007), they tested the activity of essential oils and oleoresins 
of the bark of C. zeylanicum in scavenging H2O2 radicals. The highest concentration 
(25 µl/5 ml) of essential oils and oleoresins of the bark of C. zeylanicum showed results 
of 79.6 % and 78.6 %, respectively, and were compared with the synthetic antioxidant 
BHT (83.2 %). These results were not significantly different compared with the positive 
control BHT, but their result corresponds with our H2O2 result, although they used a 
different extraction method and different concentrations. In addition, the chelating 
effects of oleoresins of C. zeylanicum bark at 25 µl/5 ml were 38.5 %, whereas the 
EDTA chelating ability was 90.4 % (Singh et al., 2007), which also agrees with our 
results, which showed that cinnamon extracts could chelate ferrous ions but they were 
not as effective as EDTA.  
In this study, the reducing power of cinnamon extracts increased with concentration as 
expected. This means that cinnamon extracts act as electron donors and can react 
with free radicals to convert them to more stable products. Singh et al. (2007) 
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confirmed our findings that C. zeylanicum extract produced a high reducing power, and 
their results increased with the concentration of oleoresins of bark C. zeylanicum, 
which ranged from 5 -25 µl/5ml. Overall, cinnamon is a natural herb that might donate 
an electron or hydrogen to a DPPH• radical make it a stable molecule. The results for 
C. cassia acetone extract were significantly higher than trolox, but not significantly 
higher than BHT. Therefore, cinnamon could be used as an alternative to synthetic 
antioxidants, and these results show cinnamon has health benefits when used as an 
antioxidant natural herb. The antioxidant activity of the cinnamon extracts may be due 
to the presence of proanthocyanidins, which are potent free radical scavengers and 
contributors to the health benefits of herbs, in particular cinnamon (Prior and Gu., 
2005). 
3.6 Conclusions 
The results of this study have shown that acetone as a solvent was more efficient than 
water in extracting polyphenols and tannins in both cinnamon types, and C. cassia had 
the highest total polyphenol and tannin content. This suggests that acetone as a 
solvent was more efficient than water in increasing the solubility of cinnamon phenolic 
compounds and tannins in C. cassia and C. zeylanicum. Furthermore, the antioxidant 
studies confirm that C. cassia and C. zeylanicum extracts show antioxidant activity. 
The antioxidant activity of 75 % acetone extracted C. cassia was found to be higher 
than acetone extracted C. zeylanicum, and these cinnamon extracts had the ability to 
scavenge free radicals present from DPPH and H2O2. The comparison of cinnamon 
extract antioxidant activities with the common antioxidant compounds BHT and trolox 
showed that C. cassia has a significantly higher activity than trolox and non-
significantly higher than BHT. This activity might be due to the total polyphenol and 
tannin contents that are present in this cinnamon type detected by HPLC and LC-MS 
analysis, which showed that have C. cassia and C. zeylanicum have two types of type 
B procyanidins, C. cassia has two types of procyanidins, type A and B, while C. 
zeylanicum has one type of type A and B. These positive results were shown more 
clearly and strongly in C. cassia compared with C. zeylanicum. These results show 
that cinnamon contains high levels of polyphenols which could affect the digestion and 
absorption of nutrients, therefore the next chapter investigated the effect of cinnamon 
on the RAG and SAG of a starch rich test meal in vitro. 
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Chapter 4 
4 Determination of rapidly available glucose (RAG) and slowly available 
glucose (SAG) values of a starch rich food in the presence of C. cassia and 
C. zeylanicum supplements 
 
4.1 Introduction 
Carbohydrates play a major role in human diets, constituting approximately 50 % of 
the daily food intake (Scientific Advisory Committee on Nutrition (SACN), 2015). 
Carbohydrates are digested by α-amylase, which is secreted by the pancreas and 
salivary glands, and α-glycosidase, which is released from the intestinal epithelia 
(Satoh et al., 2015). Carbohydrates can be classified according to their chemical 
structure, however, this is not a useful approach in terms of their physiological effects; 
therefore Englyst et al. (1999) developed a novel enzymatic method to determine 
carbohydrate digestion in vitro, and linked this with the glycaemic response. This 
method classifies carbohydrates in vitro into rapidly available glucose (RAG), which is 
the rapidly released glucose derived from carbohydrate digestion (within 20 min), and 
slowly available glucose (SAG), which is the glucose released from carbohydrate more 
slowly (between 20 min and 120 min). In 1981 Jenkins and colleagues introduced the 
glycaemic index (GI), which distinguishes carbohydrates according to their 
physiological impact on blood glucose levels. This term ranks foods according to how 
much blood glucose is increased in response to a portion of food containing 50 g of 
available carbohydrate. In addition, the GI has been authorised for use by the 
FAO/WHO (1997), and many researchers and organisations recognise the important 
role of GI in the prevention and treatment of diseases such as obesity, diabetes mellitus 
and cardiovascular disease (Ludwig and Eckel, 2002; Mann et al., 2007; Wang et al., 
2014). Low GI diets have beneficial effects on plasma LDL, and can modulate plasma 
triglycerides and HDL in diabetes, obesity and in healthy people (Liu et al., 2000; 
Toeller et al., 2001; Augustin et al., 2015).  
Studies have shown that the RAG values for a range of carbohydrate rich foods 
correlate strongly with their GI value in vivo (Englyst et al., 1996). Therefore, Englyst 
et al. (1999) suggest that RAG is linked to the rapidly digested carbohydrates, which 
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quickly raise blood glucose levels and insulin responses. However, SAG relates to the 
release of glucose from slowly digested carbohydrates, which results in a slower 
elevation of blood glucose levels and associated insulin responses. This suggests that 
the determination of the RAG value of a specific carbohydrate rich food in vitro could 
be a good indicator of the GI value of the same food in vivo, and this could help 
increase the understanding of how different food types and different food processing 
can impact on blood glucose and insulin levels (Englyst et al. 1999). The Englyst et al. 
(2000) method used to determine RAG and SAG values is based on enzymatic 
procedures which break down the carbohydrate. 
Studies have suggested that foods which are rich in phytochemicals, such as gums 
and polyphenols, show a low glycaemic response and a low RAG value in vitro (Englyst 
and Englyst, 2005). For example, ingesting 150 g of berries, a rich source of 
polyphenols such as proanthocyanidins, with sucrose (35 g), significantly reduced the 
postprandial glycaemic response (Hanhineva et al., 2010).  
Cinnamon is a plant rich in phytochemicals, particularly polyphenols, which is also 
used as a herbal medicine (Jarvill-Taylor et al., 2001; Lu et al., 2011). Research has 
shown that polyphenols derived from berries may be able to inhibit the digestive 
enzymes involved in lipid and carbohydrate breakdown, which may be useful in 
reducing obesity and controlling glucose release from dietary carbohydrate (McDougall 
et al., 2008, 2009). These polyphenols have also been shown to inhibit the digestive 
enzymes α-glucosidase and pancreatic α-amylase (McDougall et al., 2005), and this 
enzyme inhibition may be due to the fact that the berries have high concentrations of 
polyphenols such as proanthocyanidins, which interact with starch digestion by binding 
to one or more sites of digestive proteins. This could change the surface conformation 
needed for an enzyme and so reduce the enzyme activity (Toda et al., 2001; Boath et 
al., 2012). Toda et al. (2001) reported that tannins have the ability to inhibit intestinal 
α-glucosidase activity. Interestingly, the inhibition of carbohydrate digestive enzymes 
is the target of a drug called acarbose, which is used to control blood glucose levels in 
type 2 diabetes patients after meals. Although acarbose is an effective treatment for 
modulating glucose levels in type 2 diabetes patients, it does have side effects 
including the fact that large amounts of undigested starch reach the colon and cause 
fermentation and discomfort (Boath et al., 2012). Therefore, identifying natural herbs 
that contain high levels of polyphenols, such as cinnamon, could be useful in terms of 
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producing potential health benefits, as this might in turn reduce the dose of acarbose 
necessary to treat patients with type 2 diabetes.  
4.2 Study aims 
The aims of this study are: 
- To determine the effect of different doses of C. cassia and C. zeylanicum powder on 
RAG values in a simulated carbohydrate digestion in vitro. 
- To determine the effect of different doses of C. cassia and C. zeylanicum powder on 
SAG values in a simulated carbohydrate digestion in vitro. 
- To extract C. cassia and C. zeylanicum with deionised water (1 g/ml). 
- To determine the effect of C. cassia and C. zeylanicum water extracts on RAG and 
SAG values in vitro. 
- To investigate whether cinnamon extract samples inhibit carbohydrate digestive 
enzyme (α-glycosidase and α-amylase) activity and compare their effect with acarbose 
(1 g/ml). 
4.3 Methods 
4.3.1 Preparation of cinnamon samples  
Two cinnamon supplement samples were selected for the study. They were both 
cinnamon bark supplements: Puritan's Pride's ® Cinnamomum cassia (500 mg, 
Holbrook, USA) and Bio-Health ® Cinnamomum zeylanicum (350 mg, Bio-Health 
Limited, Rochester, Kent, UK). The quantities of cinnamon that were used in the 
method, which were incubated with the hydrolytic mixture of enzymes were 32 mg, 64 
mg, 96 mg, 128 mg, and 160 mg per incubation. The related concentrations of these 
cinnamon additions were 1.28, 2.56, 3.84, 5.12 and 6.4 mg/ml. In addition, four 
reference foods were studied using the RAG and SAG methods; the carbohydrate 
reference sample used with the different cinnamon doses was cornflakes (Englyst 
Carbohydrate Services Ltd, Southampton, UK). The other carbohydrate containing 
foods/samples were potato starch (Sigma Chemical Company Ltd, Poole, UK), white 
wheat flour and biscuits (Englyst Carbohydrate Services Ltd, Southampton, UK). 
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4.3.2 RAG and SAG measurement 
For the measurement of RAG and SAG values, portions of cornflakes (0.8 g) (Englyst 
reference material) were weighed to the nearest ± 1 mg into 50 ml polypropylene 
centrifuge tubes (Corning Inc., USA) in the presence and absence of cinnamon. These 
were incubated for 30 minutes with a freshly prepared pepsin–guar gum solution (as 
described in section 2.1.4). Further procedures and incubations with the hydrolytic 
mixture enzymes were under controlled conditions of temperature (37 °C), pH (pH 5.2) 
and shaking speed, (which are described in section 2.2.1.1). At specific time points (20 
and 120 min) samples (0.5 ml) were collected from the incubation tubes. The samples 
were then analysed for glucose to calculate the RAG and SAG values of cornflakes in 
the presence and absence of cinnamon samples (section 2.2.1.1.1). 
Although four reference foods were tested, cinnamon samples were only added to the 
cornflakes because it is a popular food that is consumed at breakfast. The doses added 
to the starch food (cornflakes) were 32, 64, 96, 128 and 160 mg of both cinnamon 
types. Additional incubation tubes containing cinnamon standards and blanks were 
used to adjust the RAG and SAG values as appropriate. Three further reference foods 
were also analysed, these were cornflakes (Englyst Carbohydrate Services Ltd, 
Southampton, UK), potato starch (Sigma Chemical company Ltd, Poole, UK), biscuits 
(Englyst Carbohydrate Services Ltd, Southampton, UK) and commercial white wheat 
flour, purchased from ASDA. The cornflake reference food (Englyst Carbohydrate 
Services Ltd, Southampton, UK) was included in every batch of samples analysed as 
a quality control. The reference foods purchased were of the same batch number.  
The coefficient of variation (CVs) of G20 and G120 for cornflakes were 3.97 % and 4.75 
%, respectively. The CVs of G20 and G120 for potato starch were 4.71 % and 3.32 %, 
respectively. For white wheat flour the CVs of G20 and G120 were 1.55 % and 3.01 %, 
respectively, and for biscuits they were 3.12 % for G20 and 3.08 % for G120.  
4.3.3 Preparation of acarbose 
Acarbose (˃95 % purity, Sigma Chemical Company Ltd, Poole, UK) was dissolved in 
deionised water at a concentration of 1 g/ml. Acarbose is a drug that inhibits the two 
main enzymes involved in starch digestion, α-amylase and α-glucosidase, and is 
prescribed to control blood glucose levels in type 2 diabetes patients after starch-
containing meals. Acarbose was used in this experiment as a control as it inhibits α-
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amylase and α-glucosidase, which digests starch. Three concentrations were used: 
12.8, 25.6 and 51.2 µg/µl. 
4.3.4 Preparation of water cinnamon extracts  
Cinnamon samples extracted with deionised water at 1 g/ml were used in this 
experiment (section 2.2.2). The same three concentrations were used as that for 
acarbose: 12.8, 25.6 and 51.2 µg/µl. The cinnamon extracts were freshly prepared for 
each experiment. 
4.3.5 Calculation and statistical analyses  
Values for RAG and SAG were calculated from the measured G20 and G120 as the 
following: 
                                     RAG (g) = G20  
                                     SAG (g) = G120- G20 
Results were expressed as the mean ± standard deviation. Differences between the 
RAG and SAG values, in terms of different doses of the same type of cinnamon, were 
examined by one-way analysis of variance (ANOVA) followed by Bonferroni testing 
between different doses and controls, which were the cornflake sample values. Values 
of p ≤ 0.05 were considered significant. 
4.4 Results  
4.4.1 Analysis of the four reference foods (potato starch, wheat flour, 
cornflakes and biscuits) 
The RAG (Figure 4.1) and SAG values (Figure 4.2) for the four reference foods were 
measured using the colorimetric manual method. As expected, cornflakes had the 
highest RAG and the lowest SAG values, among the reference foods, whereas potato 
starch had the lowest RAG value and almost the highest SAG value. White wheat flour 
had the highest SAG value of the reference foods. This shows that the reference foods 
chosen have a range of properties that can be compared to the foods supplemented 
with cinnamon. 
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Figure 4.1: RAG values for the four reference foods obtained from the manual 
colorimetric assays. Values are mean ± SD (n = 3). 
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Figure 4.2: SAG values for the four reference foods obtained from the manual 
colorimetric assays. Values are mean ± SD (n = 3). 
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The results obtained from the reference foods for RAG and SAG values using 
spectrophotometry were significantly different to those in the literature. However, the 
RAG and SAG values of cornflakes were similar to those in the literature (Table 4.1). 
Reference foods were used to make sure that the experiment process worked as 
expected and helped to pinpoint any error in the experiment that could be corrected 
for the next experiment. In addition, it was used to compare with the test food. The 
RAG value for the reference cornflakes was very similar (81.3 vs. 79.0), and also for 
the SAG value (4.1 vs. 2.0). Moreover, the biscuit RAG was similar to that obtained 
from the literature (39.9 vs. 36.1) although the SAG value was lower (16.5 vs. 26.0). 
On the other hand, the RAG value of the potato starch (19.6 vs. 4.0) was significantly 
higher (P = 0.001) than that in the literature (4.0). However, the SAG value was similar 
to that obtained in the literature (23.6 vs. 22.0). 
Table 4.1: The RAG and SAG values for the four reference foods from the manual 
colorimetric assay and literature (Mean ± SD)* Englyst (2000). 
Reference 
Food 
Colorimetric assay Literature* Unpaired t-test 
P value 
RAG SAG RAG SAG RAG SAG 
White wheat 
flour 
46.3 ± 1.8 27.6 ± 2.3 35.0 ± 1 42.0 ± 1 0.001 0.001 
Englyst biscuit 39.9 ± 0.1 16.6 ± 2.7 36.0 ± 1 26.0 ± 1 0.028 0.001 
Potato starch 19.6 ± 2.2 23.6 ± 2.2 4.0 ± 1 22.0 ± 1 0.001 0.119 
Englyst 
cornflakes 
81.3± 3.2 4.1 ± 1.7 79 ± 1 2.0 ± 1 0.289 0.255 
4.4.2 RAG and SAG values of cornflakes (Englyst reference) in the 
presence of different doses of C. cassia  
The C. cassia powder was added to cornflakes in different doses, and the results from 
these incubations were compared with the RAG and SAG values of cornflakes as a 
control. The results (Figure 4.3) showed the RAG value of the cornflakes was reduced 
when the dose of C. cassia was increased. At the doses of 64 mg, 96 mg, 128 mg and 
160 mg of cinnamon the RAG values were reduced significantly (72.1 %, P = 0.0192; 
69.8 %, P = 0.003; 68.6 %, P = 0.0016; 64.4 %, P = 0.0001), compared with the control. 
Whereas, the SAG values (Figure 4.4) were increased when the cinnamon dose 
increased. Moreover, the SAG values of cornflakes with this cinnamon added at doses 
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of 96 mg, 128 mg and 160 mg were increased significantly. The decrease in RAG 
values related to the increase in SAG values.  
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Figure 4.3: RAG value for control and cornflakes with different doses of C. cassia (n 
= 3). Comparisons of means were made using a one-way ANOVA followed by 
Bonferroni test (* =P<0.05, ** =P<0.001, ***=P<0.0001). 
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Figure 4.4: SAG value for control and cornflakes with different doses of C. cassia (n = 
3). Comparisons of means were made using a one-way ANOVA followed by Bonferroni 
test (* =P<0.05, ** =P<0.001, ***=P<0.0001). 
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4.4.3 RAG and SAG values of cornflakes (Englyst reference) in the 
presence of different doses of C. zeylanicum 
Different doses of C. zeylanicum powder were added to cornflakes and compared with 
the RAG and SAG values of cornflakes as a control. The RAG values (Figure 4.5) of 
the cornflakes were significantly reduced by C. zeylanicum at doses of 64 mg, 96 mg, 
128 mg and 160 mg (71.5 %, 70.5 %, 64.7 % and 64.1 %). However, the SAG values 
(Figure 4.6) were only increased slightly in the presence of this cinnamon, and there 
were no significant differences between the cinnamon concentrations. The decrease 
in RAG values related to the slight increase in SAG values caused by C. zeylanicum, 
but this was not significant. 
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Figure 4.5: RAG value for control and cornflakes with different doses of C. zeylanicum 
(n = 3). Comparisons of means were made using a one-way ANOVA followed by 
Bonferroni test (* =P<0.05, ** =P<0.001, ***=P<0.0001).   
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Figure 4.6: SAG value for control and cornflakes with different dose of C. zeylanicum 
(n = 3). Comparisons of means were made using a one-way ANOVA followed by 
Bonferroni test (NS = not significant). 
 
4.4.4 A Comparison of RAG values of cornflakes in the presence of C. 
cassia and C. zeylanicum water-based extracts and acarbose at different 
concentrations  
Water-based extracts were prepared for C. cassia (W.E. cassia), C. zeylanicum (W.E. 
zeylanicum) and acarbose (1 g/ml). These extracts were added at different 
concentrations (12.8, 25.6, 51.2 µg/ ml) to cornflakes to measure their effect on RAG 
and SAG values. The effects of the two varieties of cinnamon were evaluated with 
respect to the cornflakes’ RAG values, and these were determined for each 
concentration and compared with the RAG value of cornflakes (control). The results 
showed that the RAG value of cornflakes was significantly (P < 0.0001) reduced by 
acarbose compared with control cornflakes, at 12.8 µg/ml (26.5 vs. 81.3 %, Figure 4.7), 
25.6 µg/ml (21.0 vs. 81.3 %, Figure 4.8), and 51.2 µg/ml (14.7 vs. 81.3 %, Figure 4.9). 
However, there were no significant effects on the RAG values observed for either 
cinnamon type at any concentration. The concentration of water cinnamon extracts 
were perhaps too low to have an impact on RAG and SAG values. While acarbose 
was pure (˃95 % purity) and had a significant effect on RAG and SAG values.  
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Figure 4.7: RAG values of cornflakes in the presence of water C. cassia, C. 
zeylanicum extracts and acarbose at 12.8 µg/ml (n = 3). Comparisons of means were 
made using one-way ANOVA followed by Bonferroni test (***=p<0.0001). 
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Figure 4.8: RAG values of cornflakes in the presence of water C. cassia, C. 
zeylanicum extracts and acarbose at 25.6 µg/ml (n = 3). Comparisons of means were 
made using one-way ANOVA followed by Bonferroni test (***=p<0.0001). 
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Figure 4.9: RAG values of cornflakes in the presence of water C. cassia, C. 
zeylanicum extracts and acarbose at 51.2 µg/ml (n = 3). Comparisons of means were 
made using one-way ANOVA followed by Bonferroni test (***=p<0.0001). 
 
4.4.5 Comparison of SAG values of cornflakes in the presence of C. cassia 
and C. zeylanicum water-based extracts and acarbose at different 
concentrations  
The effects of the two varieties of cinnamon and acarbose were evaluated with respect 
to the cornflakes SAG values, for each concentration, and were compared with the 
SAG value of the control cornflakes. The SAG value of cornflakes in the presence of 
acarbose was significantly (P < 0.0001) increased compared with the control, at 12.8 
µg/ml (16.42 vs 4.12 %, Figure 4.10) and a smaller significant (P < 0.05) increase was 
observed for 25.6 µg/ml (9.11 vs 4.12 %, Figure 4.11). The SAG values for cornflakes 
in the presence of both cinnamon varieties were slightly increased compared with the 
control cornflakes (Figure 4.10, Figure 4.11 and Figure 4.12), however, these did not 
reach statistical significance. None of the supplements produced a significant 
difference in SAG at a concentration of 51.2 µg/ml. Overall these results show that 
acarbose had a larger effect than cinnamon, but the changes in RAG were not mirrored 
by similar changes in SAG. 
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Figure 4.10: SAG values of cornflakes in the presence of water C. cassia, C. 
zeylanicum extracts and acarbose at 12.8 µg/ml (n = 3). Comparisons of means were 
made using one-way ANOVA followed by Bonferroni test (***=p<0.001). 
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Figure 4.11: SAG values of cornflakes in the presence of water C. cassia, C. 
zeylanicum extracts and acarbose at 25.6 µg/ml (n = 3). Comparisons of means were 
made using one-way ANOVA followed by Bonferroni test (*=p<0.05). 
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Figure 4.12: SAG values of cornflakes in the presence of water C. cassia, C. 
zeylanicum extracts and acarbose at 51.2 µg/ml (n = 3). Comparisons of means were 
made using one-way ANOVA followed by Bonferroni test. 
 
4.5 Discussion  
The objective of this study was to measure the RAG and SAG values of cornflakes in 
the presence of C. cassia and C. zeylanicum at different doses, and to compare this 
with the RAG and SAG values of cornflakes as a control.  
4.5.1 Reference foods (potato starch, wheat flour, cornflakes and biscuit) 
The RAG and SAG values for the reference foods were significantly different compared 
with the literature. The difference occurred in potato, biscuit and wheat flour compared 
with literature were possibly due to differences in the origin, variety and season of 
reference foods used. On the other hand, the RAG and SAG values of cornflakes were 
very similar to literature. Therefore, cornflakes were used as the reference food in the 
presence of the two cinnamon types at different doses.  
4.5.2 RAG and SAG values of Englyst cornflakes in the presence of 
cinnamon samples and acarbose at different concentrations 
When 32 mg (1.28 mg/ml) of C. cassia powder was added to cornflakes in the digestive 
starch model, the RAG value of the cornflakes was slightly reduced. However, when 
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the dose of C. cassia was increased to 64 mg, the RAG value reduced significantly by 
9.1 %. In addition, the doses of 96 mg, 128 mg, and 160 mg continued to decrease the 
RAG value of the cornflakes significantly by 11.51 %, 12.69 % and 16.85 %, 
respectively, whereas the SAG values increased significantly at the doses of 96 mg, 
128 mg and 160 mg of C. cassia by 5.37 %, 7.84 % and 12.7 %, respectively. Similarly, 
C. zeylanicum reduced the RAG value of the cornflakes, with the same pattern for the 
increasing doses of C. zeylanicum. Although there was a trend for an increased SAG 
value of cornflakes in the presence of C. zeylanicum, this did not achieve statistical 
significance. The results show that cinnamon inhibits starch hydrolysis by reducing the 
RAG value of cornflakes, and this effect might by due to cinnamon polyphenols. The 
results suggest that cinnamon polyphenols interfere with the enzymes in the Englyst 
method, which include α-amylase and α-glycosidase, therefore cinnamon polyphenols 
might be able to inhibit the activity of α-amylase and α-glycosidase in vivo. 
Consequently, cinnamon polyphenols might slow glucose release from starch-based 
foods, in this case cornflakes, in the first 20 min (G20, RAG), and so most of it is 
released within 20 to 120 min (G120, SAG).  
In recent years, numerous studies have focussed on the effects of phenolics on starch 
digestion at the in vitro level. Beejmohun et al. (2014) confirm that 25 µg/ml of C. 
zeylanicum alcoholic extract (100 mg/ml) inhibited 50 % of the pancreatic α-amylase 
activity, compared with 18 µg/ml of acarbose. Their study employed a different 
approach as it used 50 % ethanol to extract the cinnamon, whereas our study used 
cinnamon powder and cinnamon water extracts at different concentrations. In our study 
the C. zeylanicum water extracts (1 g/ml) at 12.8, 25.5 and 51.2 µg/ml, which were low 
concentrations compared with cinnamon powder, did not show significant inhibition of 
α-amylase and α-glycosidase activity. This might be due to the fact that water is not 
effective in extracting polyphenols, and the total phenol contents was low (see section, 
3.4.1.2). However, in our study the acarbose significantly inhibited α-amylase and α-
glycosidase activity, as expected. This was shown by the RAG value of the cornflakes 
being significantly reduced by 26.5 %, 21 % and 14.7 % at concentrations of 12.8, 25.5 
and 51.2 ug/ml, respectively. Ranilla et al. (2010) highlighted that water C. zeylanicum 
extract (50 mg/ml) inhibited α-amylase and α-glycosidase activity. The Ranilla et al. 
(2010) method used α-amylase and α-glycosidase assays (described in Worthington 
Biochemical Corp., 1993 a; Worthington Biochemical Corp., 1993 b). In their study with 
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C. zeylanicum extracts at 1.25 mg/ml and 2.5 mg/ml inhibited α-amylase activity by 72 
% and 77 %, respectively. These cinnamon concentrations were similar to the 
concentrations of cinnamon powder that were used in our study, which were of 32 mg 
(1.28 mg/ml) and 64 mg (2.56 mg/ml), which reduced RAG values of the cornflakes to 
be 75.35 % and 71.5 %, respectively. Ranilla et al. (2010) also investigated the effects 
of C. zeylanicum extract on α-glycosidase activity; they found that cinnamon 
concentrations of 12.5 and 25 mg/ml inhibited 95 % and 100 % of α-glycosidase 
activity, respectively. Thus, carbohydrate digestion was reduced by cinnamon and 
could be an approach to maintain and control postprandial blood glucose levels.  
Although, the studies carried out by Ranilla et al. (2010) and Beejmohun et al. (2014) 
used different approaches to extract C. zeylanicum as well as the enzymatic assays 
employed compared with our study, it seems they agree that cinnamon has the 
potential to inhibit the activity of α-amylase and α-glycosidase, which are essential in 
the enzyme mixture of the Englyst method. However, these studies did not use a 
positive control to compare their outcomes, whereas in this study, we used acarbose 
as a positive control at different concentrations (12.8, 25.6 and 51.2 µg/ml), which 
significantly reduced the RAG and SAG values of the cornflakes. This effect of 
acarbose on the RAG values confirmed its ability to inhibit α-amylase and α-
glycosidase activity. Our study is the first study to investigate the effects of two types 
of cinnamon (C. zeylanicum and C. cassia) on starch digestion at different doses, and 
is the first study to investigate the effects of C. cassia on enzymes activity. In a recent 
review on the interactions between phenolic compounds and enzymes, it was 
emphasised that medicinal plants rich in phenolic compounds, such as tannin, 
decrease starch digestion (Zhu, 2015). Studies have suggested that complex tannins, 
such as proanthocyanidins, could bind to the digestive enzymes, thereby inhibiting 
starch hydrolysis (Barrett et al., 2013). This has also been shown by Mkandawire et al. 
(2013) who confirmed that higher molecular weight tannins cause a greater inhibition 
of α-amylase than the lower molecular weight tannins.  
Type-A procyanidins, which are condensed tannins, have been identified in C. cassia, 
and these might be the reason for cinnamon’s ability to work as a potent natural α-
amylase inhibitor (Anderson et al., 2004). This has also been shown by a study which 
confirmed that procyanidins at different doses from cocoa extracts inhibited pancreatic 
α-amylase activity in vitro (Zhu, 2015). 
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The results in chapter 3 demonstrated that C. cassia had higher concentrations of total 
polyphenols (105.6 mg/g equivalent to Gallic acid) than C. zeylanicum (39.6 mg/g 
equivalent to Gallic acid). In addition, C. cassia was richer in proanthocyanidins (41.5 
mg/g equivalent to procyanidin-A2) compared to C. zeylanicum (11.4 mg/g equivalent 
to procyanidin-A2). Furthermore, the LC-MS results for each cinnamon variety showed 
that C. cassia had two types of the B-type dimer, while C. zeylanicum had only one B-
type dimer of the proanthocyanidins, and C. cassia had two types of A-type trimer, 
whereas C. zeylanicum only having one A-type trimer. Two major A-type 
proanthocyanidin tetramers were present in C. Cassia and C. zeylanicum, but at 
different concentrations in each. These results indicate that they could have potentially 
different responses due to their different polyphenol content. However, polyphenols 
might impact upon carbohydrate metabolism at many levels via reducing the glycaemic 
response, and by inhibition of carbohydrate digestion, and glucose absorption 
(Hanhineva et al., 2010). 
Studies have suggested that slowing the starch digestion via phenolic components 
might increase satiety by modulating glucose levels after carbohydrate rich meals 
(Barrett et al., 2013). The effects of polyphenolic foods on postprandial blood glucose 
responses have been investigated in human studies; for instance, strawberry extracts 
and green tea polyphenols have been shown to inhibit α-amylase and reduce 
postprandial hyperglycaemia (Lo Piparo et al., 2008). Furthermore, consuming 6 g of 
cinnamon with rice pudding had the effect of reducing the glycaemic responses 
significantly (P < 0.05) in 14 healthy participants (Hanhineva et al., 2010). A further 
study of the interactions between phenolic compounds and starch-based foods 
highlighted that a combination of black tea polyphenols and starch (maize starch) could 
be used to manipulate postprandial glycaemic responses (Liu et al., 2011; Zhu, 2015). 
Previous studies have shown that RAG values are positively correlated with GI (P = 
0.01), while SAG values are negatively correlated with GI (P = 0.04) (Garsetti et al., 
2005). 
4.6 Conclusions 
Overall, both types of cinnamon powder (C. cassia and C. zeylanicum) appeared to 
have the ability to reduce RAG values and increase SAG values for cornflakes. This 
may be due to the polyphenolic compounds which might inhibit the carbohydrate 
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digestive enzymes. However, C. cassia significantly increased the SAG value 
compared with C. zeylanicum at doses of 96 mg, 128 mg and 160 mg. This may be 
due to the concentration of polyphenolic compounds in C. cassia which were higher 
compared to C. zeylanicum. Acarbose is a drug that inhibits α-glucosidase and α-
amylase activity and is used for treating type 2 diabetes. The RAG and SAG values of 
cornflakes in the presence of acarbose were used as controls to compare with the RAG 
and SAG values of cornflakes in the presence of both cinnamon types at different 
concentrations. These results show that C. cassia acts better than C. zeylanicum to 
reduced RAG value via potentially inhibiting the α-glucosidase and α-amylase activity, 
therefore the next chapter investigated the effect of C. cassia on glucose response in 
vivo. 
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Chapter 5 
5 Assessment of the effect of a Cinnamomum cassia supplement on the 
glycaemic index of a starch rich food 
 
5.1 Introduction 
Cinnamon has a long history of use as an herbal medicine, and it has been suggested 
its health benefits are due to the action of polyphenols (Hamidpour et al., 2015). 
According to the analytical results (Chapter 3), C. cassia had high concentrations of 
phenolic compounds, tannins and in particular proanthocyanidins compared with C. 
zeylanicum. Moreover, C. cassia had a higher antioxidant activity compared with C. 
zeylanicum, which was also evident in water C. cassia extracts.  
 In addition, C. cassia was able to influence carbohydrate hydrolysis in vitro; the 
hydrolysis model showed that it lowered the rapidly available glucose (RAG) value in 
a dose dependent manner (Chapter 4). A low RAG value could be used as an indicator 
of glycaemic index (GI) and therefore cinnamon may be able to reduce glycaemic 
response.  
The GI approach classifies starch rich foods according to their physiological effect on 
the blood glucose level; it is defined as the incremental area under the two-hour blood 
glucose response curve for a test food containing 50 g or 25 g of available 
carbohydrate, expressed as the percentage of the response to the same amount 
carbohydrate from a standard food (white bread or glucose solution) taken by the same 
subject (Wolever et al., 1991; Jenkins et al., 1981; Brouns et al., 2005). Based on the 
GI value, foods can be divided into three groups: low GI foods (GI ≤ 55) are digested 
and absorbed slowly and lead to a lower glycaemic response, high GI foods (GI ≥ 70) 
are quickly digested and absorbed and cause an increased glycaemic response, and 
medium GI foods are those that have a GI of greater than 55 and less than 70 (Foster-
Powell et al., 2002).  
The American Diabetes Association (2015) highlighted the importance and benefits of 
knowing the GI values of foods, as they can play an important role in terms of 
controlling glucose levels in diabetes. Some studies have shown there was a possible 
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health benefit of low GI in CVD and controlling appetite, while in obesity the benefits 
have been debated (Brouns et al., 2005). There is evidence to show that a high GI diet 
stimulates a greater level of insulin secretion than a low GI diet, which leads to 
hyperinsulinaemia, insulin resistance and increased beta cell demand (Jenkins et al., 
1987; Miller, 1994; Ludwig, 2002). The reduction of blood glucose fluctuations 
throughout the day is the main benefit of consuming low GI foods, which is particularly 
useful for diabetic and pre-diabetic people who need to control their glucose levels 
(Jenkins et al., 1992; Ceriello, 1998). 
Studies have shown that the glycaemic response is highly correlated with the glucose 
released from starchy foods when they are digested with pancreatic and brush-border 
enzymes in vitro (Englyst et al., 2003). Therefore, we investigated the glucose released 
from a starch-rich food (cornflakes) in vitro (Chapter 4), and this current chapter 
investigates the effect of C. cassia on the glycaemic response of cornflakes.  
Within plants there are many compounds that can affect their rate of digestion and 
provide medicinal properties, for example the anti-nutrients (Greiner and Konietzny 
2006). These are compounds present in grains, legumes and nuts, and include lectins, 
tannins, polyphenols and phytic acid. All of these compounds can bind to and interfere 
with nutrients affecting their absorption (Greiner and Konietzny, 2006; Alonso et al., 
1999). 
There is evidence to suggest that polyphenols may have the ability to reduce the 
glycaemic response to carbohydrate-rich foods. This effect may be due to the 
polyphenolic compounds inhibiting some of the digestive enzymes in the gut lumen, 
such as amylase, leading to reduced starch digestibility (Alonso et al., 1999; 
Siddhuraju et al., 2005). This has also been shown by the fact that the total phenol 
content in food is negatively correlated with GI in both healthy and diabetic patients 
(Williamson, 2013). The review by Williamson (2013) highlighted the different potential 
mechanisms of how polyphenols reduce GI, such as inhibiting digestive enzymes (α-
amylases and α-glucosidases), or glucose transport. In the standard GI test protocol, 
blood samples are taken at 15, 30, 45, 60, 90 and 120 minutes after the reference, 
either bread or glucose solution, and also after the test food. The glucose blood sample 
results are used to plot the area under the curve, and the results obtained after 
consuming test meals are compared to those obtained after consumption of the 
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reference food (Jenkins et al., 1981). In the presence of compounds such as 
polyphenols, the area under the curve may be decreased and therefore the GI is lower 
(Williamson, 2013). Therefore, this study assessed glycaemic index in the present of 
C. cassia supplements, which are rich in polyphenols. C. cassia was chosen as there 
were clear benefits observed on reducing RAG and increasing SAG in vitro. 
5.2 Study aims 
The aims of this study are:  
-To determine the GI of cornflakes in the presence of 1 g C. cassia supplement. 
-To determine the GI of cornflakes in the presence of a placebo. 
-To evaluate the glycaemic responses of healthy participants after the ingestion of 1 g 
of C. cassia supplement or the placebo. 
-To compare the GI of cornflakes in the presence of 1 g of C. cassia supplement or the 
placebo, with a control (glucose drink). 
5.3 Methods 
5.3.1 Subjects  
A randomised blind crossover design was used with the control glucose drink and the 
cornflakes, combined with either the cinnamon supplement or the placebo, in a random 
order on separate occasions. The study protocol was standardised using the 
FAO/WHO guidelines (FAO/WHO, 1997) for GI testing. The study design received 
ethical approval from the University of Surrey Ethics Committee (EC/2011/145/FHMS) 
(Appendix 4), and ten healthy volunteers were recruited from the postgraduate student 
and staff population at the University of Surrey, after information regarding the study 
was distributed via e-mails and posters. The weight, height and fasting blood glucose 
level of each participant was measured at baseline. Participants were interviewed 
before the study commenced using a screening questionnaire (Appendix 5) to assess 
their suitability for participation. The participants were given a participant information 
sheet (Appendix 6). Participants were deemed able to comply with the study protocol 
and gave their informed consent (Appendix 7).   
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5.3.2 Test food and capsules 
Kellogg’s® cornflakes were used as the test food, the batch number of the cornflakes 
was K115176039 and they were purchased from ASDA. A 30 g portion of Kellogg’s® 
cornflakes, which contained 25 g of available carbohydrate, was accurately weighed 
on a digital balance in the kitchen of the Clinical Investigation Unit (CIU) at the 
University of Surrey. This was prepared in advance the night before the study and was 
stored in an air-tight container.  
The cinnamon bark (Cinnamomum cassia) supplement (500 mg) was supplied by 
NBTY Inc, and was purchased from Puritan’s Pride Ltd. In order to use the cinnamon 
in a capsule form, whereby the participants would not know which capsule was the 
placebo and which contained cinnamon, the cinnamon dose was transferred to new 
brown capsules. These Vcaps® capsules were made from hydroxypropylmethyl 
cellulose and manufactured by Capsugel in Bornem, Belgium. The capsules were 
presented either empty for participants consuming the placebo, or filled with 500 mg 
cinnamon for the cinnamon trial. The filled capsules were prepared at Stickland 
pharmacy in London using their accurate balance and devices to transfer the cinnamon 
powder from the manufactured capsule to the new capsule (Vcaps® capsules). The 
amount of cinnamon in each new capsule was 500 mg (± 10 mg). The solubility of 
Vcaps® capsules was tested (section 5.3.7), and they were found to take 15 minutes 
to dissolve. 
5.3.3 Study design 
The study protocol was standardised using the FAO/WHO guidelines (FAO/WHO, 
1997) and the recommendations of Brouns et al. (2005). To determine GI, each of the 
participants consumed 25 g of available carbohydrate in the form of cornflakes or the 
reference food (25 g of anhydrous glucose dissolved in water) after an overnight fast 
of 12-13 hours. Finger-prick capillary blood samples were taken after the overnight fast 
(-15 minutes), and the participants were then asked to ingest either the cinnamon or 
placebo capsules. Another blood sample was collected 15 minutes later (designated 
time 0 minutes). Further samples were taken at 15, 30, 45, 60, 90 and 120 minutes 
after consumption of the cornflakes. For the control study (response to 25 g glucose in 
250 ml water), blood samples were collected at 0, 15, 30, 45, 60, 90 and 120 minutes. 
Capillary blood samples were collected in 300 µl tubes with fluoride oxalate 
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(Microvette, Sarstedt, Leicester, UK). Unistik 3 Extra (Owen Mumford Ltd., Oxford, UK) 
single use lancets were used to obtain the blood samples. 
On two separate occasions the cinnamon supplement capsules (n = 2, total 1000 mg 
cinnamon) were ingested with 100 ml of water 15 minutes (-15 minutes) prior to the 
test food (cornflakes). Then 15 mins later, a portion of cornflakes containing 25 g of 
available carbohydrate was served to the participants with 150 ml of water (ingesting 
the cornflakes within 10 min). On two other separate and randomised occasions the 
participants ingested the placebo capsules (n = 2) with 100 ml water 15 minutes prior 
to the portion of cornflakes. On three randomised occasions the participants consumed 
the control reference food, which was a glucose drink made from 25 g of glucose in 
250 ml of water (Sigma, Cat. No. G 8270). 
5.3.4 Blood sample collection 
Capillary finger prick blood samples were collected in 300 µl Microvette tubes coated 
with fluoride oxalate, and were immediately centrifuged at 2000 g for 10 minutes, at 4 
°C. The centrifuged plasma was transferred to separate 300 µl plain plastic Microvette 
tubes. The tubes were then kept in the freezer at -20 °C until analysis. 
5.3.5 Glucose measurement  
An automatic analyser (YSI 2300 STAT plus, Yellow Springs, Analytical Technologies, 
YSI Ltd., Fleet, UK) was used for determining plasma glucose concentration. Three 
quality controls were used to determine the intra- and inter-assay coefficients of 
variation (Section 2.2.8.4.2). 
5.3.6 Calculation and statistical analyses  
The incremental areas under the glucose curve (iAUC) for the reference glucose drink, 
cornflakes with cinnamon capsules, and cornflakes with placebo, were calculated 
according to the method recommended by the FAO/WHO (1997). The GI values for 
cornflakes with cinnamon capsules, cinnamon group, and cornflakes with the placebo, 
placebo group, were calculated as follows (source Wolever et al., 1991; Brouns et al., 
2005):  
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The GI values of cornflakes with either the cinnamon capsules or the placebo were 
calculated as an average value obtained from 10 subjects.  
Results were checked for normality using the Kolmogorov-Smirnorv test (K-S test) and 
were expressed as the mean ± one standard error of the mean (SEM). For the human 
study, a two factor (treatment and time) repeated measures analysis of variance 
(ANOVA) was used to analyse the difference in the mean glucose level at each time 
point for the two groups (cinnamon and placebo), and their standard glucose response 
across the time course. In addition, a single factor (treatment) repeated measures 
ANOVA was used to analyse the differences in iAUC for glucose (control) and the test 
food (SPSS 22 for Windows).  
5.3.7 Vcaps® capsules, hydroxypropylmethyl cellulose, solubility 
In order to identify the time taken for the capsules to dissolve, they were added to 
water. To simulate the acidity and temperature of the stomach, the capsules were 
added to 250 ml MilliQ water, with the pH adjusted to 2.1 by the addition of 0.1 M of 
HCL, and heated in a water bath at 37 ºC. The time that each capsule took to dissolve 
was recorded, and the average time taken for the capsules to dissolve was 15 minutes. 
Therefore, the cinnamon capsules were given to the participants 15 minutes prior to 
the portion of cornflakes. 
5.4 Results  
The characteristics of participants (Table 5.1) were investigated at the start of the 
study. They had a mean age of 33 years, were in the overweight category according 
to the average BMI score (26.7 kg/m2), and they had normal fasting blood glucose 
levels. The 10 individuals recruited consisted of 4 females and 6 males, mean age 33.3 
years, age range 21 – 51 year.  
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Table 5.1: The characteristics of the subjects. 
Characteristics  
Age (years)                 33.3 ± 3.5 
Weight (kg)                 79.8 ± 5.9 
Height (m)                                                     1.7 ± 0.02 
BMI (kg/m2)                 26.7 ± 1.2 
Fasting blood glucose (mmol/l)                 5.1 ± 0.05 
Result expressed as Mean ± SEM (n=10 subjects) 
 
The incremental area under the curve (iAUC) for glucose was calculated for the 
reference (glucose drink), cornflakes with cinnamon capsules, and cornflakes with 
placebo (Figure 5.1). The iAUC for the cornflakes with cinnamon supplement and 
placebo were 146 ± 36 and 146 ± 33, respectively (P = 1.00), which meant the GI value 
of the cornflakes with placebo and with cinnamon capsules were not significantly 
different (P = 0.970), as the GI value for the cornflakes ingested with the cinnamon 
supplement was 99 ± 12, while the GI for the cornflakes with placebo was 98.9 ± 9. 
Overall, no significant differences were seen in glucose response for the different 
times, or in the incremental area under the curve between the C. cassia supplement 
and the placebo, but there were differences between the control glucose drink and the 
cornflakes (Figure 5.1). Furthermore, there was no significant difference between the 
fasting plasma glucose (FPG) levels for cinnamon and the placebo (P = 0.84) (Figure 
5.2), which is as expected. 
The peak glucose level (Figure 5.1) for the standard glucose drink occurred at 30 
minutes, whereas the peak glucose level for the cornflakes with cinnamon and the 
placebo occurred at 45 minutes. This shift in the peak glucose level may be due to the 
type of carbohydrate and the other components in the cornflakes, which caused the 
glucose to be released slower than the control solution. At 30 minutes, the peak 
glucose level for the standard glucose drink was higher than the peak glucose levels 
for both cornflake groups. For the cornflakes, with both cinnamon and the placebo, the 
glucose levels declined slowly over the next 45 minutes and then gradually dropped to 
the baseline. On the other hand, the glucose level for the standard glucose drink 
dropped rapidly to below the baseline by 90 minutes, almost a 0.30 mmol/l reduction, 
and the level then increased towards the baseline during the final 30 minutes. This 
Chapter 5  
  
129 
 
shows how the control and the treatments produce different results over time due to 
the composition of the test material. The results (Figure 5.2) also show that 1 g of 
cinnamon supplement produced no effect on fasting glucose. Moreover, the fasting 
glucose levels for the placebo were identical to the cinnamon group.  
 
 
Figure 5.1: Plasma incremental glucose responses during the 2 hours following the 
reference glucose, and cornflakes with cinnamon supplement or placebo (results 
presented as mean (n = 10) ± SEM). 
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Figure 5.2: Fasting plasma glucose levels (results presented as mean (n = 10) ± SEM). 
 
5.5 Discussion  
This human study examined the effects of a C. cassia supplement on the GI of a starch 
rich food (Kellogg’s® cornflakes). This brand of cereal was used in the human study 
because it is high in starch and is commonly consumed at breakfast time in the UK and 
other countries. Cornflakes are also used frequently in GI studies. 
The C. cassia supplement was used in this study due to its effectiveness in terms of 
reducing RAG in vitro. Englyst et al. (1996) confirmed that the RAG values for a range 
of carbohydrate rich foods were found to correlate strongly with their GI values in vivo. 
The GI of cornflakes in the presence of 1 g of cinnamon and a placebo were found to 
be 99 ± 12 and 98.9 ± 9, respectively. This value was slightly higher than the GI value 
of cornflakes in the Harvard list of GI and glycaemic load for over 100 foods (which 
lists the GI of cornflakes as 93), however Wolever and Bolognesi (1996) also showed 
the GI value of cornflakes to be 99, which agrees with our study data. It is evident that 
the GI of cornflakes can vary, for example, Atkinson et al. (2008) published an 
international table listing the GI for 2480 foods. This table referenced five studies that 
determined the GI of Kellogg's® cornflakes, which ranged from 72 ± 16 to 132 ± 33. 
Four of these studies used a glucose drink as a reference and three of them were 
focussed around a health topic. Overall the average GI from these five studies was 95 
± 10, which is similar to the outcome of this study. The variability of GI in the same food 
4
4.2
4.4
4.6
4.8
5
5.2
5.4
5.6
-15 0
P
la
s
m
a
 g
lu
c
o
s
e
 m
m
o
l/
L
Time 
cinnamon (mean)
placebo(mean)
Chapter 5  
  
131 
 
depends on the reference food used, the health state of the subjects, and the 
methodology. Furthermore, some manufacturers produce the same food and brand 
but with differences; for instance, Kellogg’s Special K and All-Bran have different 
formulations in North America, Europe, and Australia (Atkinson et al., 2008). Therefore, 
some variability in the GI value is expected.  
This study showed that ingesting 1 g of cinnamon supplement before a portion of 
cornflakes was not enough to significantly reduce the glucose response when 
compared to a placebo. Some acute studies involving cinnamon support the results of 
this study (Table 5.2) as they have similar results. The first study conducted by 
Hlebowicz et al. (2009) did not observe a change in glucose level after consuming C. 
cassia, which added as either 1 g or 3 g to 300 g of rice pudding. They found that the 
dose of cinnamon had no effect on blood glucose in healthy participants, however, the 
higher dose (3 g) of C. cassia did affect postprandial plasma insulin levels, which 
shows the cinnamon did have some effect. Interestingly, adding a larger dose of 6 g of 
cinnamon to the rice pudding, significantly lowered the postprandial glucose response 
and delayed gastric emptying (Hlebowicz et al., 2007), which suggests a possible 
reason for the lack of effect in our study was due to the small dose used. Importantly, 
neither of these were blinded studies, and the participants were aware that they were 
consuming cinnamon with rice pudding. Also, the cinnamon dose was administered 
together with the rice pudding. However, in our study the participants consumed the 
cinnamon in capsule form 15 minutes prior to the cornflakes, which could have had an 
effect on its activity. Other research supporting the current findings showed that 
ingesting 3 g of C. zeylanicum in capsule form, 1.5 g directly before and 1.5 g after a 
test meal comprising 42 g carbohydrate, 46 g fat and 13 g protein, did not change 
blood glucose concentrations in healthy subjects (Markey et al., 2011). Although they 
used a high fat test meal (a factor which can have an effect on GI value), the ingestion 
of 3 g of C. zeylanicum supplement with this meal did not delay gastric empting or 
effect glucose level (Markey et al., 2011). 
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Table 5.2: Summary of previous acute studies on the effect of cinnamon on glucose control. 
 
Reference / Year Number and 
Condition of 
Subjects 
Cinnamon 
Class / Dose / Duration 
Method of 
Consuming 
Cinnamon 
Effect 
Solomon and 
Blannin (2007) 
7 healthy male 
subjects 
Cinnamomum cassia / 5 g of 
cinnamon was ingested 12 h 
prior OGTT, OR 5 g of 
cinnamon was ingested with 
OGTT 
Cinnamon was 
presented in capsule 
form 
Plasma glucose response decreased 
significantly and insulin sensitivity 
was higher than control. 
 
Hlebowicz et al. 
(2007) 
 
14 healthy 
subjects 
Cinnamomum cassia / 6 g / 
short term duration 
Cinnamon dose was 
added to 300 g of 
cooked rice pudding 
Cinnamon with rice pudding reduced 
postprandial blood glucose and 
delayed gastric emptying. 
Hlebowicz et al. 
(2009) 
15 healthy 
subjects 
Cinnamomum cassia / 1 g 
and 3 g / short term duration 
Cinnamon dose was 
added to 300 g of 
rice pudding 
No significant effect on glucose or 
gastric emptying rate for either dose 
of cinnamon. However, 3 g dose of 
cinnamon reduced serum insulin 
response. 
Markey et al. (2011) 9 healthy subjects Cinnamomum zeylanicum/ 3 
g / short term duration  
Cinnamon was 
presented in capsule 
form 
No effect on glucose concentration, 
postprandial or gastric emptying 
parameters. 
Wickenberg et al. 
(2012) 
 
 
10 subjects with 
impaired glucose 
tolerance 
 
Cinnamomum zeylanicum / 6 
g with OGTT (short term 
duration) 
Cinnamon was 
presented in capsule 
form 
No significant effect on plasma 
glucose or insulin level. 
Magistrelli and 
Chezem (2012) 
30 subjects (15 
normal weight, 15 
obese) 
Cinnamomum cassia / 6 g / 
short term duration/ 
Cinnamon dose was 
added to cooked 
cream of wheat 
instant farina cereal 
Significantly reduced glycaemic 
response. 
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The results in the study by Markey et al. (2011) showed that cinnamon had no effect 
on glucose level, which could be explained as follows; although they used 3 g of 
cinnamon, 1.5 g before the test meal, which consisted of 42 g of carbohydrate, 46 g of 
fat and 13 g of protein, and 1.5 g after the test meal, this was not enough to have an 
effect, possibly because the high fat content of the meal (46 g fat) affected glucose 
absorption from the small intestine (Normand et al., 2001). Furthermore, it might be 
because the dose of cinnamon relative to the carbohydrate in the test meal 
(carbohydrate/cinnamon ratio) was low ratio (14:1) compared to other studies, where 
the carbohydrate/cinnamon ratio was (15:1), which found there was a reduction in 
glucose levels (Solomon and Blannin (2007). In the Solomon and Blannin (2007) study 
the participants ingested 5 g of C. cassia supplement with, or 12 hours prior to, an oral 
glucose tolerance test OGTT (75 g bolus of dextrose in 300 ml water), which resulted 
in a significantly reduced plasma glucose response. The dose of C. cassia was also 
higher than ours (5 g), which might be enough to inhibit glucose transport resulting in 
a reduced glucose response in healthy subjects. They also employed a different 
approach, where the cinnamon supplement was consumed 12 hours prior to the OGTT 
to preload the subjects with a large dose of cinnamon. This approach might allow time 
for the cinnamon polyphenols, such as procyanidin, to be present in the gut, leading to 
an effect on glucose levels and reduce the glucose response. Polyphenols can 
contribute to multiple mechanisms in the gut lumen, which include improving fasting 
glucose, inhibiting glucose transport, inhibiting digestion enzymes and improving 
insulin sensitivity (Williamson, 2013).  
Some studies found that cinnamon had no effect on glucose response, although they 
used high doses of cinnamon, for example Wickenberg et al. (2012) found that 
ingesting 6 g of C. zeylanicum (14 capsules) with an oral glucose dose (75 g) did not 
have a significant effect on the glucose response, insulin level or GI. This ineffective 
result might due to the type of cinnamon used, as C. zeylanicum has been shown to 
have a lower concentration of polyphenols (section 3.4.1.1). In contrast, when 6 g C. 
cassia was ground into 74 g of cream wheat instant farina cereal (containing 50 g 
available carbohydrate), the resulting blood glucose concentration was significantly 
reduced compared to the same meal without C. cassia (Magistrelli and Chezem, 2012). 
This effect could again be due to the cinnamon type, which was C. cassia which is rich 
in polyphenols. Studies show that the polyphenols in cinnamon might inhibit α-amylase 
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due to the hydroxyl group in the polyphenols binding with α-amylase (Xiao et al., 2011), 
and cinnamon may slow the absorption of carbohydrates in the small intestine (Kim et 
al., 2006). Polyphenols were found to increase insulin sensitivity (Weichselbaum and 
Buttriss, 2010). Anderson et al. (2004) isolated the A-type procyanidin oligomers from 
C. cassia, and they found that these polyphenolic polymers enhanced the biological 
activity of insulin in vitro, which may be beneficial in controlling glucose intolerance and 
diabetes. Moreover, Lu et al. (2011) found that C. cassia is rich in B-type procyanidin 
oligomers, which was identical to our findings (Chapter 3), as the LC-MS of the 
polyphenol composition of cinnamon showed that C. cassia has two B-type dimers and 
two B-type trimers, while C. zeylanicum has only one type of each procyanidin, and 
both had two major A-type tetramers.  
It is clear from the in vitro and in vivo studies that the type of cinnamon and size of 
dose play important roles in the level of biological benefits. C. cassia has a positive 
effect compared with C. zeylanicum, although this study used C. cassia, there was no 
effect on glucose level, possibly because the dose (1 g) was low and therefore 
insufficient to affect glucosidase, amylase activity and insulin sensitivity. Furthermore, 
the carbohydrate/cinnamon ratio was (25:1), which was perhaps too low in terms of 
cinnamon dose and thus did not achieve a significant effect on glucose response. In 
addition, the power of the study was possibly not enough to see an effect of cinnamon 
in glycaemic index. The fact that the participants were healthy individuals with a normal 
glucose level may have also made it more difficult to see an effect.    
5.6 Conclusions 
Overall these findings showed that ingesting 1 g of C. cassia supplement prior to 
consuming a high GI food (cornflakes) did not affect the glycaemic response in healthy 
overweight participants, as the GI values of cornflakes with cinnamon, and cornflakes 
with a placebo, were similar. No significant differences were found in glucose response 
for the different time periods, nor in the incremental area under the curve for the C. 
cassia supplement and the placebo. The results suggest that 1 g of cinnamon is 
insufficient to affect the glycaemic response. Further research efforts, particularly long 
term studies, are required to ascertain the health benefits of high doses of C. cassia 
supplement. 
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Chapter 6 
6 An evaluation of serum inflammatory marker levels in overweight women 
consuming a Cinnamomum cassia supplement for eight weeks 
6.1 Introduction 
Diabetes and the associated disorder of metabolic syndrome (MetS) are ever 
increasing worldwide health problems, especially due to the oxidative stress and 
chronic inflammation that are associated with MetS (Gyawali et al., 2015). Another 
world wide health problem is obesity, which can be described as a chronic low-grade 
inflammation, which serves as a major risk factor for hypertension, coronary artery 
disease, dyslipidaemias, and type 2 diabetes (Hotamisligil, 2006; Nehete et al., 2014). 
The inflammation is a result of adipocytes in overweight individuals releasing 
inflammatory markers that may lead to diabetes (Hotamisligil, 2006). There are two 
types of inflammation: acute and chronic; acute inflammatory responses, by definition, 
generally progress over a short period of a few days, whereas chronic inflammatory 
responses continue over a longer time period, from months, to years, to a lifetime 
(Nayak et al., 2013; Fleit, 2014). 
Inflammation is the biological response of the innate immune system, enabling it to 
protect the body against harmful stimuli such as pathogens, damaged tissues and 
irritation (Jungbauer and Medjakovic, 2012; Furie, 2014). In acute inflammation 
leukocytes, and in particular neutrophils, are recruited from the blood to the site of 
inflammation. This movement of leukocytes from the bloodstream to the affected site 
is regulated by adhesion molecules such as ICAM, P-selectin, and chemo-attractants 
such as MCP-1 and IL-8. The neutrophils then release pro-inflammatory cytokines 
such as IL-1, IL-6, tumour necrosis factor (TNF-α) and interferon gamma (IFN-γ) 
(Jungbauer and Medjakovic, 2012; Furie, 2014).  
The level of inflammatory markers are often elevated with increasing age (Prasad et 
al., 2012). Studies have shown that the circulating steroid hormone concentrations are 
decreased with increasing age, and that may contribute to the elevation of pro-
inflammatory markers (Cartiera et al., 2009). Singha et al. (2011) highlighted that 
numerous studies describe an increase in pro-inflammatory cytokine levels after the 
menopause. Moreover, women have a higher percentage of body fat than men (Blaak, 
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2001), and. inflammatory cytokines, such as TNF-α, are secreted 7.5 times higher from 
the adipose tissues (Ratliff et al., 2008). Therefore, women after the menopause have 
an increased chance to have high levels of inflammatory markers, which were chosen 
for this study. 
Early diagnosis of some diseases such as diabetes, hypertension and CVD, is 
relatively straight forward and can help to delay the progression of the disease. Liu et 
al. (2007) identified that high sensitivity C-reactive proteins (hs-CRP), IL-6 and the 
TNF-α receptor can be used as biomarkers for predicting risk of developing diabetes 
in healthy postmenopausal women (Liu et al., 2007). This is supported by studies that 
show elevated levels of cytokines may promote insulin resistance in liver, skeletal and 
vascular endothelia, which might lead to type 2 diabetes and CVD (Wellen and 
Hotamisligil, 2005). 
MetS is a combination of conditions that includes high blood pressure, insulin 
resistance, an excess of body fat around the waist, high cholesterol and high fasting 
glucose concentrations (Vidigal et al., 2015). In MetS there was a linear increase in the 
level of hs-CRP (Gyawali and Richards, 2015), and increased levels of CRP were 
significantly associated with a high BMI (P = 0.012), triglycerides (P = 0.001) systolic 
blood pressure (P = 0.019) (Fredrikson et al., 2004), and also associated with insulin 
resistance and HDL cholesterol (Ford, 2003; Lambert et al., 2004).  
Studies have shown inflammation can be decreased by many approaches including 
diet, exercise, cardiovascular drugs, and insulin sensitizers; a combination therapy 
such as lifestyle modifications and multiple drugs, might be the most effective therapy 
to reduce inflammation (Koh et al., 2005). There is evidence to suggest that in 
overweight and obese individuals, losing weight is an effective way to reduce the risk 
of developing chronic inflammatory disease, diabetes, and CVD, especially if combined 
with exercising and ingesting herbal supplements (Anderson et al., 2003). Non-
steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen are regularly 
used to treat a variety of inflammatory conditions. However, if they are taken over the 
long term, NSAIDs have side effects such as causing liver failure and high blood 
pressure (Gunawarden et al., 2014). Although NSAIDs have been shown to be 
efficacious, looking for alternative natural strategies to treat inflammatory diseases is 
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important such as using food and plant products containing compounds with anti-
inflammatory properties, such as polyphenols (Gunawarden et al., 2014).  
In recent years the use of herbal medicine has increased, and it has attracted the 
attention of researchers all over the world, as medicinal herbs have been reported to 
show antioxidant, antimicrobial and anti-inflammatory properties (Upendra et al., 
2010). Approximately 50 % of approved drugs are derived from plant products, or their 
derivatives (Eisenberg et al., 2011). Indeed, the use of herbal products to treat and 
prevent disease in the USA has increased from 2.5 % in 1990 to 18 % in 2007 
(Eisenberg et al., 2011). This suggests using herbal medicines could be a promising 
area in the treatment, and also the prevention, of some chronic diseases; however, 
more clinical research is needed to observe the effects of these herbal products in 
terms of disease progression, and changes in the modulation of biomarkers that occur 
in humans before wide scale use can be suggested. 
There have been several mechanisms suggested to explain the anti-inflammatory 
action of herbal medicines, including their role in the inhibition cyclooxygenases, nitric 
oxide synthase and cytokines such as TNF-α (Gunawarden et al., 2014). Cinnamon 
(Cinnamomum cassia, family Lauraceae) has been used within many cultures as a 
traditional herbal medicine for the treatment a number of diseases (Ravindran et al., 
2004). Studies, both in vitro and in vivo have reported that cinnamon has anti-
inflammatory, anti-diabetes, anti-microbial, antioxidant, anti-tumour, anti-fungi, anti-
viral, blood pressure lowering, lipid lowering and immunomodulatory effects 
(Gruenwald et al., 2010). For example, studies have shown that C. cassia inhibited the 
growth of Escherichia coli (E. coli), and can therefore be considered as an anti-bacterial 
agent (De et al., 1999; Oussalah et al., 2006).  
Some of the main processes involved in inflammatory and immune diseases are 
oxidative processes and free radical production. Therefore the use of antioxidants in 
pharmacology, such as vitamin C is widely studied (Clark, 2002). There are also many 
studies that have reported that cinnamon has important antioxidant properties, for 
example in vitro, an alcoholic extract of C. cassia showed a greater (96.30 %) inhibition 
of lipid peroxidation in rat liver compared, with α-tocopherol (93.74 %), indicating it is 
a strong antioxidant (Lin et al., 2003). Our study (chapter three) has also confirmed 
that cinnamon has strong antioxidant activity.  
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There are more studies that have shown health benefits of cinnamon, for example in 
vivo C. cassia extract showed antipyretic activity on virus infected mice models, and 
this antipyretic activity was significantly correlated with IL-1 α (Kurokawa et al., 1998). 
There is also evidence that C. cassia extract inhibits the activity of cyclo-oxygenase-2 
(COX-2) and nitric oxide (NO), enzymes that are induced by pro-inflammatory 
cytokines, and growth factors, in mouse macrophage cell line models (Hong et al., 
2002).  
These antioxidant properties might influence the immunomodulatory activity of 
cinnamon, which may affect the anti-inflammatory effect of cinnamon (Gruenwald et 
al., 2010). The main active compounds in C. cassia bark are the high levels of non-
volatile compounds (mainly condensed tannins) which contain 23.2 % 
proanthocyanidins and 3.6 % epi-catechin monomers (Shan et al., 2007). Lee et al. 
(2005) and Kim et al. (2007) found that cinnamonaldehydes isolated from C. cassia 
inhibited COX-2 and NOS in vitro, which may be responsible for the anti-inflammatory 
and anti-oxidant properties of cinnamon.  
The efficacy of cinnamon has been documented as an anti-inflammatory in vitro and 
in animal studies, however, this has not been extensively tested in humans. Therefore, 
this study is going to investigate the effect of consuming C. cassia supplement on 
inflammatory markers.  
6.2 Study aims 
- To investigate the effect of consuming C. cassia supplements (5 g) on cytokine 
and growth factor levels (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, EGF, IFN-γ, MCP-1, 
TNF-α, VEGF) in overweight women aged 45-70 years for eight weeks. 
- To examine the effect of consuming C. cassia supplements (5 g) on high 
sensitive C-reactive proteins (hs-CRP) in overweight women aged 45-70 years for 
eight weeks. 
- To examine the effect of consuming C. cassia supplements (5 g) on adhesion 
molecule levels (VCAM, ICAM, E-selectin, P- selectin, L-selectin).   
-  To examine the effect of C. cassia supplementation (5 g) on blood pressure in 
overweight women aged 45-70 years for eight weeks. 
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-  To examine the effect of consuming C. cassia supplements (5 g) on 
anthropometric measurements in overweight women aged 45-70 years for eight 
weeks. 
6.3 Methods 
6.3.1 Subjects 
The supplementation study was a randomised controlled and single blind trial. This 
study design received ethical approval from the University of Surrey Ethics Committee 
(EC/2013/70/FHMS), (Appendix 8). 
A power calculation estimated for this study was based on data of fasting glucose from 
previous studies, as there were no preceding studies based on the effect of cinnamon 
on inflammatory markers. The primary outcome variable was fasting glucose, which 
was shown by Khan et al. (2003) who observed a 2 mmol/L fall in fasting glucose. 
Based on this data, a common standard deviation (SD) of 1.0 was assumed. The effect 
at 90 % power required 18 individuals for the cinnamon group and 18 for the placebo 
group. An additional twenty-five percent was added to allow for dropout from the study, 
therefore the recruitment target for each group was 23 women. Participants were 
recruited using a poster with details of the study placed at multiple sites around the 
University of Surrey. This information was also emailed to all University staff. Posters 
(Appendix 9) were also placed in local sites relatively close to the University, including 
churches, train stations, bus stops, restaurants, supermarkets, health centres and 
hospitals in Guildford, Woking, Kingston and London. A presentation about the 
cinnamon study to women in a Woking Mosque was also used for recruitment where 
they were able to listen to and ask questions about the study. 
6.3.2 Screening  
Participants were required to fast for a 12 hour period overnight prior to screening, and 
blood glucose levels were tested in the morning at the Clinical Investigation Unit (CIU), 
University of Surrey, using the finger prick method. Furthermore, the participants’ 
weight and height were taken, and they answered a screening questionnaire regarding 
their health and lifestyle (Appendix 10). The participants were given a participant 
information sheet (Appendix 11) and a consent form (Appendix 12), and if they were 
happy to take part they signed the informed consent form. These screening procedures 
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were undertaken to ensure the participants were eligible and healthy so they could be 
enrolled in the study.  
6.3.3 Study participants  
Inclusion criteria were:  
- Female aged 45-70 years 
- Free from medication  
- Free from cinnamon allergy  
- Overweight or obese (BMI ≥ 25) 
- Not taking, or had taken within the last month, any supplements and/or herbal 
supplements  
- Non-smokers 
- Healthy and free from any disease 
- Able and willing to comply with all study procedures 
6.3.4 Study design  
The study was a randomised controlled and single blind design study with subjects 
randomly assigned to either the cinnamon supplementation group or the control 
(placebo) group. The duration of supplementation was eight weeks. The study 
consisted of three visits to the CIU for blood samples and measurements to be taken.  
A cinnamon (C. cassia) supplement which was supplied by NBTY Inc, and purchased 
from Puritan’s Pride, was used in this study. These capsules were emptied and then 
transferred to new opaque coloured capsules (CapsulCN®), which were manually filled 
with cinnamon or corn flour, so both filled capsules appeared identical. CapsulCN® 
capsules were made from bovine gelatine (Halal). The daily dose was 5 g, as either 
cinnamon or placebo, which meant each participant consumed three capsules 
(cinnamon or placebo) after breakfast and three capsules (cinnamon or placebo) after 
their evening meal each day for eight weeks (Figure 6.1).  
On the first study day participants attended the CIU in the early morning having 
consumed a standardised meal (vegetable lasagne, 400 g) with known macronutrient 
composition, the evening before followed by a 12 hour fast. This meal was given before 
each study day to minimise variability. Participants were also told to refrain from 
intense physical exercise and the consumption of alcohol for three days prior to each 
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study day. Volunteers also refrained from consuming caffeine containing drinks 
(tea/coffee/carbonated soft drinks such as Pepsi) for 24 hours before each visit.  
All subjects recorded a diet diary to calculate their food intake for three days prior to 
each study day. Diet plan 6, Forest field software Ltd, was used to calculate the 
macronutrient content of their food intake during these three days, at each visit. 
Fasting blood samples, blood pressure readings and anthropometric measurements 
were taken at each visit. On visit one only, the Peripheral Quantitative Computed 
Tomography (pQCT) was used to scan the wrist bones of the participants. The ionising 
radiation that participants were exposed to from the pQCT was at an extremely low 
level (0.5µ Sv).  
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Figure 6.1. Study design for the investigation of the effect of cinnamon over an 8-week 
study period. 
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6.3.5 Blood sample collection  
Fasting blood samples were taken at week zero, week four and week eight. They were 
analysed for cytokines and growth factors (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, 
EGF, IFN-γ, MCP-1, TNF-α, VEGF), adhesion molecules (VCAM, ICAM, E-selectin, P-
selectin, L-selectin) and CRP. The blood samples were taken by trained phlebotomists 
at the CIU. 10 ml of a fasting blood sample was drawn by vacutainer using a safety 
lock blood collection set and a single use holder, into the vacutainer non additive tubes 
for serum collection (Becton Dickinson (BD) and Company, Oxford, UK). Blood 
samples were left for 25 min to clot, and then centrifuged at 2000 g for 10 min at 4 °C 
to obtain serum. Aliquots of serum were dispensed into appropriately labelled 
microcentrifuge tubes (1.5 ml) and stored   at -80 °C until required for analysis.   
6.3.6 High sensitivity cytokines and growth factor measurement 
Biochip array technology, in combination with the Evidence Investigator (Randox 
Laboratories Ltd., Crumlin, UK) were used to determine multiple cytokine levels (IL-1α, 
IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, EGF, IFN-γ, MCP-1, TNF-α, VEGF) from a single 
sample in real time. The protein sandwich immunoassay method was used to detect 
the cytokines. Cytokine high sensitivity array (EV3623) with three quality controls (QC) 
were used. The inter-assay coefficient of variation of level 1, 2 and 3 QC for each 
marker was determined (Table 6.1). The different controls were as expected and this 
suggested the assay was sensitive enough to detect levels found in vivo. 
6.3.7 Adhesion molecules measurement 
The Evidence Investigator and Biochip array technology (Randox Laboratories Ltd, 
Crumlin, UK) were used to measure soluble VCAM, ICAM, E-selectin, P-selectin and 
L-selectin simultaneously from a single sample. The immunoassay method, which is 
based on protein sandwich, was used to detect the adhesion molecules. Adhesion 
Molecule array (EV3519) with three quality controls were used. The inter-assay 
coefficient of variation CVs % of level 1, 2 and 3 QC for each marker was determined 
(Table 6.1). The different controls were as expected and this suggest the assay was 
sensitive enough to detect levels found in vivo. 
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Table 6.1 The three quality controls (QCs) used to determine the serum markers in the 
Evidence Investigator biochip array. 
 
 
 
 
 
 
 
 
Inflammatory 
Markers 
% CVs inter assay 
Level 1 (low) 
% CVs inter assay 
Level 2 (medium)  
% CVs inter assay 
Level 3 (high) 
IL-1α 3.66 3.28 2.64 
IL-1β 3.45 0.32 3.47 
IL-2 2.54 4.09 6.98 
IL-4 4.53 9.65 7.08 
IL-6  6.84 7.05 10.71 
IL-8 4.40 4.20 3.85 
IL-10 1.97 4.98 7.02 
EGF 8.10 4.29 3.54 
IFN-γ 5.07 8.35 8.10 
MCP-1 2.84 3.53 2.15 
TNF-α 6.41 4.08 6.45 
VEGF 0.04 3.48 16.79 
VCAM 6.01 16.26 5.69 
ICAM 8.93 5.99 0.26 
E-selectin 10.68 7.68 10.57 
P-selectin 3.08 3.78 2.59 
L- selectin 10.80 5.29 0.38 
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6.3.8 CRP 
An enzymatic automated colorimetric method using the ILab 650 analyser 
(Instrumentation Laboratory, UK) was used to measure serum CRP concentrations. A 
High Sensitivity C-reactive protein (hs-CRP) kit (CP3885) along with two quality control 
(QC) samples (Randox Laboratories Ltd., Crumlin, UK) were used. Inter-assay 
precision gave CVs of 8.65 % and 7.85 % for both level 1 (low) and level 2 (high) QCs, 
respectively. The QCs were used to make sure about the efficient use of machines and 
to check the variation during running the samples.  
6.3.9 Statistical analyses 
Statistical analyses were performed using SPSS statistical version 22 (SPSS for 
Windows, Chicago, USA). The data was checked for normality using Kolmogorov-
Smirnov analyses and checked for both the normal and de-trended normal probability 
plots. The outcomes were expressed as a mean ± standard error of the mean (SEM). 
A repeated measures two-way ANOVA was used to study the change in inflammatory 
markers. An unpaired t-test was used to compare the different variables between the 
groups at baseline. In addition, a paired t-test was used to compare the changes at 
weeks four and eight with the baseline. The Pearson correlation coefficient was used 
to examine the relationship between all the variables. All plots presented were plotted 
using GraphPad Prism version 6 for Windows (San Diego, CA, USA). Each plot based 
on the corresponding p-value for cinnamon treatment (T), duration time (D) and 
interaction between treatment and time. Correlation coefficients were used to examine 
the relationship between changes in the different variables. Statistical significant was 
defined as P ˂ 0.05.  
6.4 Results  
6.4.1 Patient recruitment  
The target number of individuals required for each group in the study was not attained. 
Although the investigator used many different ways (section 6.3.1) to advertise the 
study at the University of Surrey, as well as in public areas around Guildford and 
Woking, and London, the number of the participants was lower than hoped for. The 
time of the year, which was during the summer holidays, may have had an effect on 
recruitment. Also, the age criterion was limited to the middle-aged (45-70 years) 
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healthy women. The total number of participants enrolled in the study was 16. 
Moreover, on analysis of the data it was evident that one of the participants as an 
extreme outlier; her BMI was over 40 and this was more than 2 SDs from the mean of 
the rest of the population. Therefore, the number of participants used to run the 
statistical analysis was 15, which was split into eight participants in the cinnamon group 
and seven participants in the placebo group (Table 6.2). 
6.4.2  Baseline characteristics  
The anthropometric and clinical characteristics of subjects at the baseline for both 
groups were measured (Table 6.2). The mean age, height, weight, BMI, waist 
circumference (WC) and hip circumference (HC) of the participants did not differ 
significantly between the cinnamon and placebo groups. In terms of blood pressure, 
there was no significant difference in diastolic blood pressure, however, there was a 
significant difference in systolic blood pressure between the two groups. The systolic 
blood pressure in the cinnamon group was higher (119.88 mm Hg) than control (108 
mm Hg) at the baseline (P = 0.03). In bone trabecular density mg/cm3 
(BTrbDen1mgpercm3) there was no significant different between the groups. The 
BTrbDen1mgpercm3 for both groups was in the normal range according to the 
literature (Grampp et al., 1997). 
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Table 6.2 The characteristics of the study participants at the baseline. *significant 
difference P < 0.05. 
Demographic Cinnamon 
(n = 8) 
Mean ± SEM 
Placebo 
(n = 7) 
Mean ± SEM 
Unpaired 
t-test 
p-value 
Height (m) 1.61 ± 0.01 1.65 ± 0.02 0.13 
Weight (kg) 76.75 ± 2.7 77.29 ± 3.4 0.90 
BMI (kg/m2) 29.46 ± 1.0 28.34 ± 1.3 0.49 
Waist circumference (cm) 94.50 ± 2.2 89.21 ± 2.2 0.11 
Hip circumference (cm) 106.94 ± 2.3 108.00 ± 2.1 0.74 
Systolic Blood Pressure (mm Hg) 119.88 ± 3.1 108.00 ± 3.5 0.03* 
Diastolic Blood Pressure (mm Hg) 83.00 ± 3.2 74.71 ± 3.5 0.10 
Heart Rate (BPM) 67.50 ± 2.2 72.37 ± 3.9 0.28 
Age (Years) 56 ± 1.3 53 ± 2.7 0.22 
Bone Trabecular Density mg/cm3 
(BTrbDen1mgpercm3) 
182.70 ± 14.39 167.42 ± 11.74 0.434 
6.4.3 Changes in anthropometric indices and blood pressure after 
supplements 
There were no significant differences in body weight, height, WC, HC and BMI between 
the two groups at baseline (Table 6.2), however, after four weeks of cinnamon 
supplementation (Table 6.3), there was a significant decrease in body weight for the 
cinnamon group (P < 0.001), and the WC and BMI also significantly decreased (P = 
0.04 and P < 0.001 respectively), however no changes in these parameters occurred 
in the control group, which suggests the difference is due to the cinnamon 
supplementation having an effect.  
After 8 weeks (Table 6.3) there were further significant reductions for the cinnamon 
group; body weight decreased significantly (P = 0.01), BMI, WC and HC also 
decreased (P = 0.01, P = 0.001 and P = 0.01, respectively). The results (Table 6.3) 
show that the daily 5 g supplementation of C. cassia for eight weeks caused an 
average weight reduction almost 2 kg. As with the 4 week results, there were no 
significant changes in the anthropometric measurements observed in the placebo 
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group, which suggests the differences observed were due to the action of the 
cinnamon.  
In terms of blood pressure measurements, both the cinnamon and placebo groups had 
systolic and diastolic blood pressures were in the normal range for the baseline 
measurements. For the cinnamon treatment group, the systolic blood pressure was 
reduced at both weeks four and eight to 114.75 mm Hg and 105.42 mm Hg respectively 
(P = 0.04 and P = 0.01 respectively). The diastolic blood pressure decreased 
significantly at week eight to 73.28 mm Hg compared with the baseline 83.00±3.2 (P = 
0.02). As with the other measurements taken, there was no change observed in the 
control group, suggesting the cinnamon supplement was having an effect on blood 
pressure, either directly or as a result of the changes to the other parameters 
measured. 
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Table 6.3 Changes in anthropometric measurements at week four and week eight compared with the baseline (values are mean 
values± SEM). * signifies a significant change (p values listed). 
 
Demographic 
 
Cinnamon (n = 8) Placebo (n = 7) 
Change at 4 
weeks  
(Mean, SEM) 
Paired     
t-test 
p value 
Change at 8 
weeks 
(Mean, SEM) 
Paired 
t-test 
P value 
Change at 4  
weeks  
(Mean, SEM) 
Paired 
 t-test 
P value 
Change at 8 
weeks  
(Mean, SEM) 
Paired     
t-test 
P value 
Weight (kg) -1.00 ± 0.18 0.001* -1.86 ± 0.55 0.01* - 0.14 ± 0.26 0.60 -0.21 ± 0.40 0.62 
BMI (kg/m2) -0.38 ± 0.06 0.001* -0.71 ± 0.20 0.01* -0.05 ± 0.09 0.62 0.07 ± 0.14 0.64 
Waist 
circumference 
(cm) 
-1.56 ± 0.60 0.04* -3.29 ± 0.73 0.004* 1.21 ± 1.57 0.47 0.14 ± 1.01 0.89 
Hip 
circumference 
(cm) 
-0.65 ± 0.47 0.22 -2.57 ± 0.79 0.01* -0.35 ± 0.17 0.10 -0.64 ± 0.37 0.14 
Systolic Blood 
Pressure  
(mm Hg) 
-5.13 ± 2.14 0.04* -14.00 ± 3.82 0.01* -4.00 ± 1.83 0.10 -1.71 ± 2.94 0.58 
Diastolic Blood 
Pressure  
(mm Hg) 
-3.25 ± 2.01 0.15 -9.14 ± 3.06 0.02* -1.86 ± 1.29 0.20 0.00 ± 1.83 1.00 
Resting Heart 
Rate (BPM) 
-3.38 ± 1.67 0.10 -3.86 ± 1.94 0.09 -0.80 ± 4.10 0.85 -0.51 ± 3.96 0.90 
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6.4.4 Inflammatory marker levels at the baseline  
6.4.4.1 Cytokines and C-reactive protein levels  
The cytokine and CRP levels at baseline (Table 6.4) were within the normal range in 
both groups, and no significant differences between the two groups were evident. 
Furthermore, there was no significant difference in the inflammatory markers observed 
between the two groups, suggesting at baseline the groups are comparable and this is 
a good starting point for investigating any changes due to supplementation. 
Table 6.4 Cytokines and CRP levels of study participants at the baseline. 
Biomarker Cinnamon (n = 8) 
 (Mean ±SEM)  
Placebo (n = 7) 
 (Mean ±SEM) 
Unpaired t-test     
p-value 
IL2 (pg/ml) Insufficient Data* 
IL4 (pg/ml) Insufficient Data* 
IL6 (pg/ml) 1.11 ± 0.24 2.30 ± 0.82 0.17 
IL8 (pg/ml) 4.35 ± 0.63 4.23 ± 0.73 0.90 
IL10 (pg/ml) 0.88 ± 0.09 3.01 ± 1.57 0.17 
VEGF (pg/ml) Insufficient Data* 
IFN γ (pg/ml) Insufficient Data* 
TNFα (pg/ml) 2.96 ± 0.53 5.56 ± 1.95 0.20 
IL1β (pg/ml) Insufficient Data* 
IL1α (pg/ml) 0.28 ± 0.02 0.96 ± 0.53 0.23 
MCP1 (pg/ml) 97.70 ± 11.22 99.72 ± 16.10 0.92 
EGF (pg/ml) Insufficient Data* 
CRP (mg/l) 1.88 ± 0.26 1.56 ± 0.18 0.36 
* The levels were below the level of detection of the high sensitivity cytokines kit used on the 
Evidence Investigator. Values are mean ± SEM, n=3. 
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6.4.5 Changes in cytokine levels after supplementation 
6.4.5.1 IL-1β, IL-2 and IL-4 
The pro-inflammatory cytokines IL-1β, IL-2 and anti-inflammatory IL-4 were measured 
at the baseline and after four and eight weeks of supplementation with either cinnamon 
or the control. Circulating levels were below the level of detection of the high sensitivity 
cytokines kit used on the Evidence Investigator therefore no further analysis was 
possible within this study. The limit of detection (LOD) of IL-1β, IL-2, and IL-4 were 
0.26 pg/ml, 2.97 pg/ml and 2.12 pg/ml, respectively, which suggests the levels in the 
blood of the participants were very low.  
6.4.5.2 VEGF and EGF 
The concentration of VEGF and EGF were lower than the limit of detection of the high 
sensitivity cytokines kit used on the Evidence Investigator at all time points 
investigated, therefore the analysis of these growth factors was not possible. The LOD 
of VEGF and EGF were 3.24 pg/ml and 1.04 pg/ml, respectively, which again suggest 
the participants only expressed a low level in their blood. 
6.4.5.3 IL-6  
The levels of the pro and anti-inflammatory cytokine IL-6 were detectable in all samples 
at all-time points. The fasting serum IL-6 concentrations were within the normal range 
for both groups at baseline (Table 6.4), however the IL-6 concentrations were lower in 
the cinnamon group (1.11 pg/ml) compared with the control group (2.30 pg/ml, P > 
0.05), but the difference was not significant. A repeated measures two-way ANOVA 
(Figure 6.2) revealed that there was no significant effect of the cinnamon treatment on 
IL-6 levels (P = 0.300). However, there was a significant change in IL-6 concentration 
due to time for treatment and control groups together (P = 0.010). Interestingly, the 
level of IL-6 slightly increased at weeks four and eight for the cinnamon group, being 
1.19 pg/ml and 1.59 pg/ml, respectively, however, using t-test this increase was not 
significant compared with baseline (P = 0.356, P = 0.245). For the control group, the 
IL-6 concentration was similar for the baseline, and four and eight weeks. These results 
suggest the IL-6 levels increased over time for the cinnamon groups, but the 
differences were not significant when compared to the control group.  
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Figure 6.2: Fasting IL-6 concentration at baseline, week 4 and 8 for control and 
cinnamon groups. IL-6 levels were determined in each participant (n = 15) at week 0, 
4 and 8. Individual values displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.   
6.4.5.4 IL-8 
These results (Figure 6.3) show there was no effect of treatment on IL-8 levels, when 
compared to the control. The IL-8 concentration, however, changed significantly in the 
cinnamon group and the control group over time (P < 0.001), as cinnamon groups 
showed a significant decrease in concentration after four weeks of treatment when 
compared to the baseline, (P = 0.33, paired t-test) (Table 6.4), and then an increase 
again after eight weeks. However, there were no changes in control. This change was 
in the normal levels and the variability in cytokines levels during time is natural. 
Moreover, there was a significant interaction between treatment and time (P = 0.003, 
paired t-test), which suggests that the time had a greater effect on IL-8 concentration 
at cinnamon and placebo groups.  
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Figure 6.3: Fasting IL-8 concentration at baseline, week 4 and 8 for control and 
cinnamon groups. IL-8 levels were determined in each participant (n = 15) at week 0, 
4 and 8. Individual values displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.     
6.4.5.5 IL-10 
The serum anti-inflammatory cytokine IL-10 concentration in the cinnamon group was 
within the normal range (0.88 pg/ml) at the baseline (Table 6.4), whereas the level in 
the control group was higher than the Randox normal range, however, this level was 
normal according to the literature (Kleiner et al., 2013). The results (Figure 6.4) showed 
there was no significant effect of the treatment on fasting IL-10 concentration. However 
the levels of IL-10 in the cinnamon group slightly increased from 0.88 pg/ml to 0.94 
pg/ml and then to 1.07 pg/ml at weeks four and eight, respectively, whereas in the 
control group, IL-10 levels were very similar to the baseline at all-time points. Overall 
these results suggest there was a small but insignificant effect of the cinnamon on IL-
10 values, which suggests it may have had an effect but this sample size study was 
not enough to observe an effect. 
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Figure 6.4: Fasting IL-10 concentration at baseline, week 4 and 8 for control and 
cinnamon groups. IL-10 levels were determined in each participant (n = 15) at week 0, 
4 and 8. Individual values displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.   
6.4.5.6 TNF-α 
At the baseline level (Table 6.4) both groups were within the normal range, with no 
significant differences between them, even though the control group had values two 
times higher than the cinnamon group. The results (Figure 6.5) showed that overall 
there was no significant effect of the treatment compared to the control (P = 0.644). 
The comparison of the duration for cinnamon and the placebo showed there was a 
significant effect on the TNF-α concentration in both groups (P = 0.002). In addition, 
there was a significant interaction between the effect of time and treatment (P = 0.008). 
The TNF-α concentration in the cinnamon group was decreased slightly at week4 and 
8 (2.82 pg/ml, 2.49 pg/ml, respectively) compared with baseline 2.96. However, the 
concentration of TNF-α in control was slightly increased compared with baseline. 
These results suggest the cinnamon supplementation did have a small effect on the 
TNF-α concentrations, as it caused a reduction, but the effect was too small to be 
significant in this study.  
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Figure 6.5: Fasting TNF-α concentration at baseline, week 4 and 8 for control and 
cinnamon groups. TNF-α levels were determined in each participant (n = 15) at week 
0, 4 and 8. Individual values displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.      
6.4.5.7 IL-1α 
The baseline IL-1α concentrations (Table 6.4) in the cinnamon group were within the 
normal range according to the Randox laboratory range and literature, however, in the 
control group the IL-1α levels (1.07 pg/ml) were high compared to the cinnamon group 
(0.28 pg/ml), however not significantly different (P = 0.23). These values were still 
within the normal range according to literature (Um et al., 2011). The results (Figure 
6.6) suggest there was no significant effect of the cinnamon supplements on the IL-1α 
levels compared to the control. However, there was a significant change due to the 
effect of time on the IL-1α concentration in the control and cinnamon groups (P = 
0.025), and a significant interaction between the effect of time and treatment (P = 
0.044). There was a slight reduction in IL-1α levels in the cinnamon group at week 
eight (0.24 pg/ml) compared with the baseline (0.28 pg/ml), whereas the IL-1α levels 
in the control group increased gradually at weeks four and eight (1.16 pg/ml and 1.37 
pg/ml respectively). Overall these results show there were minor changes in the levels 
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of IL-1α observed over time, but no specific difference was seen between the treatment 
and the control.  
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Figure 6.6: Fasting IL-1α concentration at baseline, week 4 and 8 for control and 
cinnamon groups. IL-1α levels were determined in each participant (n = 15) at week 0, 
4 and 8. Individual values displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.   
6.4.5.8 MCP-1 
The MCP-1 levels in both groups were within the normal range for the baseline (Table 
6.4), with no significant differences between the groups. Even though the MCP-1 levels 
in the placebo group were slightly higher than in the cinnamon group (105.6 pg/ml and 
98.1 pg/ml respectively). The results (Figure 6.7) suggest there was no effect of 
cinnamon supplements on MCP-1 concentration when compared to the control, 
whereas the time factor produced a significant change in MCP-1 concentration in both 
groups (P < 0.001), as the MCP-1 levels were reduced in the cinnamon and control 
groups at week four (86.66 pg/ml and 86.43pg/ml respectively), and then increased 
again slightly at week eight (96.44 pg/ml and 96.21 pg/ml, respectively). This suggests 
there was no specific effect of the cinnamon detected, but there was a variation in the 
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levels expressed over time within the study, in a similar pattern to that observed for IL-
8. 
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Figure 6.7: Fasting MCP-1 concentration at baseline, week 4 and 8 for control and 
cinnamon groups. MCP-1 levels were determined in each participant (n = 15) at week 
0, 4 and 8. Individual values displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.   
6.4.5.7 hs-CRP 
The hs-CRP concentration in the control and cinnamon groups at the baseline were 
within the normal range (Table 6.4), and the baseline hs-CRP concentration in the 
cinnamon group was 1.88 mg/l (Figure 6.8). Consuming cinnamon supplements for 
four weeks reduced significantly the hs-CRP concentration (1.26 mg/l, P= 0.016, paired 
t-test), however, there was no change in control (P = 0.800). The hs-CRP 
concentrations in the control group were almost the same at the baseline and after four 
and eight weeks (1.56 mg/l, 1.53 mg/l and 1.60 mg/l respectively). There were no 
significant differences over time or for the interaction between time and treatment, 
suggesting than cinnamon only had an effect on this marker. There was a positive 
correlation between hs-CRP and bone trabecular density mg per cm3 (BTrbDen 
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mg/cm3) (R = 0. 558, P = 0.031). Increasing bone trabecular density is associated with 
elevated hs-CRP concentration.  
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Figure 6.8: Fasting hsCRP concentration at baseline, week 4 and 8 of control and 
cinnamon groups. hsCRP levels were determined in each participant (n = 15) at week 
0, 4 and 8. Individual values displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.     
6.4.6 Adhesion molecules levels at baseline 
The blood concentrations of adhesion molecules can play a biological role in vascular 
inflammation and atherosclerosis. Therefore the adhesion molecules sVCAM, sICAM, 
sE-selectin (sESEL), sP-selectin (sPSEL) and sL-selectin (sLSEL) were selected for 
measurement.  
There were no significant differences in the levels of the adhesion molecules at the 
baseline (Table 6.5) between the two groups, and the levels of sVCAM, sICAM, sESEL, 
sPSEL were within normal range. The sLSEL concentrations were slightly higher the 
normal range, and there was a positive correlation between age and sPSEL, 
suggesting the increased levels observed at the baseline were due to the age of the 
participants involved in the study.  
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Table 6.5 Adhesion molecule levels of the study participants at the baseline. 
Biomarker Cinnamon (n = 8) 
(Mean ± SEM) 
Placebo (n = 7) 
(Mean ± SEM) 
Unpaired t-test     
p-value 
sVCAM1 (ng/ml) 626 ± 92 621. ± 45 0.965 
sICAM1 (ng/ml) 305 ± 60 263. ± 16 0.535 
sESEL (ng/ml) 20 ± 3.0 17. ± 1.50 0.329 
sPSEL (ng/ml) 126 ± 11 117. ± 8.0 0.517 
sLSEL (ng/ml) 2294 ± 407 1816. ± 158 0.319 
     Values are mean ± SEM, n = 3. 
 
6.4.7 Changes in adhesion molecules levels after supplementation 
6.4.7.1 sVCAM-1 
The fasting soluble sVCAM-1 concentrations were measured at all three time points, 
and there was no significant difference between the normal levels of the groups at 
baseline (Table 6.5). In the cinnamon group (Figure 6.9) the levels of sVCAM-1 
decreased from 626.0 ng/ml at baseline to 557.3 ng/ml and 494.3 ng/ml in weeks four 
and eight respectively, however, this reduction was not statistically significant. In the 
control group there was no change in the sVCAM-1 concentration at either time point 
compared with the baseline. The results (Figure 6.9) show there was no change in 
expression due to time, or interaction effect of time and treatment, which suggests the 
small change observed in the treatment was due to the cinnamon supplementation, 
but the difference was not significant. 
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Figure 6.9: Fasting sVCAM concentration at baseline, week 4 and 8 for control and 
cinnamon groups. sVCAM levels were determined in each participant (n = 15) at week 
0, 4 and 8. Individual values displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.   
6.4.7.2 sICAM-1 
The sVCAM-1 concentration at the baseline (Table 6.5) in both groups was within the 
normal levels, and not significantly different. The fasting sICAM-1 levels for the control 
group (Figure 6.10) at both weeks four and eight were similar to the baseline and in 
the normal range. The sICAM-1 levels in the cinnamon group showed a reduction from 
305.8 ng/ml to 276.1 ng/ml at week four and 232.3 ng/ml at week eight, though the 
difference was not at a significant level. The results showed there was no difference 
over time, or for the interaction between time and treatment. 
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Figure 6.10: Fasting sICAM concentration at baseline, week 4 and 8 for control and 
cinnamon groups. sICAM levels were determined in each participant (n = 15) at week 
0, 4 and 8. Individual values displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.   
6.4.7.3 sESEL 
There were no significant differences between the groups at the baseline (Table 6.5). 
In the cinnamon group (Figure 6.11) the sESEL concentrations at weeks four and eight 
decreased slightly in comparison with the baseline, at the baseline the sESEL levels 
were 20.1 ng/ml, after four weeks they were 18.9 ng/ml and after eight weeks they 
were 16.3 ng/ml, which is a measurable, but insignificant change. This difference may 
have been insignificant due to the spread of values in the cinnamon group, which would 
affect the error bars for each time point. In contrast, in the placebo group (Figure 6.11) 
the levels of sESEL at four (17.21 ng/ml) and eight weeks (16.49 ng/ml) were almost 
the same in the baseline (17.01 ng/ml), which suggest the change observed for the 
cinnamon group was due to the treatment. There was a positive correlation between 
sESEL and systolic blood pressure (R = 0.523, P = 0. 045). Reducing blood pressure 
was associated with decreasing the concentration of sESEL. These suggest that 
reducing sESEL concentration play a role in reducing systolic blood pressure.  
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Figure 6.11: Fasting sESEL concentration at baseline, week 4 and 8 for control and 
cinnamon groups. sESEL levels were determined in each participant (n = 15) at week 
0, 4 and 8. Individual values displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.      
6.4.7.4 sPSEL  
The results (Table 6.5) show that there were no significant differences between the 
groups at baseline, and there was no significant effect of taking cinnamon supplements 
on the sPSEL concentrations (Figure 6.12). However, there was a significant effect of 
time on the sPSEL values in the control and cinnamon groups (P = 0.012). The mean 
sPSEL concentration in the control group after four weeks was slightly increased 
(122.4 ng/ml) compared with the baseline (117.2 ng/ml), however, in the cinnamon 
group the fasting sPSEL levels marginally decreased at weeks four and eight (P = 
0.070, P= 0.261). There was a positive correlation between sPSEL and systolic blood 
pressure, (R = 0.512, P = 0.051), and there was a positive correlation between sPSEL 
and age, (R = 0.513, P = 0.050). Elevated levels of sPSEL was associated with age 
and high blood pressure. Overall these results show that increasing levels of sPSEL 
was associated with age and systolic blood pressure.  
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Figure 6.12: Fasting sPSEL concentration at baseline, week 4 and 8 of control and 
cinnamon groups. sPSEL levels were determined in each participant (n = 15) at week 
0, 4 and 8. Individual value displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.     
6.4.7.5 sLSEL  
The baseline levels of sLSEL (Table 6.5) in the cinnamon group were moderately high 
(2122.5 ng/ml) according to the Randox laboratory range, however, it was normal 
compared to the literature (Schleiffenbaum et al., 1992; Zonneveld et al., 2014). After 
four and eight weeks of ingesting cinnamon supplements (Figure 6.13), the sLSEL 
concentrations slightly decreased to 1830.5 ng/ml and 1647.6 ng/ml, respectively, (P 
= 0.056, P = 0.288), however, this decrease did not reach statistical significance. 
sLSEL levels did not alter significantly within the control group, but there was a small 
increase after four (2029.52 ng/ml) and eight weeks (1881.17 ng/ml) compared to the 
baseline (1816.02 ng/ml). Overall these results show there was no significant effect of 
either treatment or time on sLSEL levels. As with the other markers investigated, these 
small changes may be due to the large variation within the samples affecting the size 
of the error bars and masking any actual change.  
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Figure 6.13: Fasting sLSEL concentration at baseline, week 4 and 8 for control and 
cinnamon groups. sLSEL levels were determined in each participant (n = 15) at week 
0, 4 and 8. Individual value displayed with Mean ± SEM. ANOVA two-way analysis of 
variance treatment effect, D duration effect and D/T treatment and duration interaction 
effect.     
 
Overall, these results show that a daily 5 g dose of cinnamon supplement for eight 
weeks caused a significant reduction in the BMI, and blood pressure, when compared 
to the placebo. This change could not be linked to a significant effect of treatment on 
the cytokines and adhesion molecules investigated, possibly due to the small sample 
size of the study. There was a significant effect of time on some of the cytokines and 
adhesion molecules investigated, including IL-6, IL-8, TNF-α, IL-1 α, MCP-1 and 
sPSEL, which suggests there were general changes in the levels of some the 
inflammatory markers that were investigated. Theses change in cytokines and 
adhesion molecules together indicate the wide variation in cytokine and adhesion 
molecule levels between individuals and within individual over time.  
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6.5 Discussion  
The inflammatory response needs to be tightly regulated as the pro-inflammatory 
cytokines, such as TNF-α, IL-1 and IL-6, produced during the typical inflammation 
response can cause damage to normal tissues. For example, a delay in this regulated 
process, and the associated scavenging reactions, may lead the inflammatory 
response observed in a variety of chronic inflammatory diseases, such as 
atherosclerosis and arthritis (Hong et al., 2012). Some NSAIDs are commonly used to 
treat inflammation, however, they have some undesirable side effects, such as 
increased blood pressure and stomach ulcers (Gunawarden et al., 2014). The side 
effects of these drugs provides the motivation for the development of natural anti-
inflammatory treatments, with potentially fewer side effects, for example some 
preliminary studies have reported that cinnamon has anti-inflammatory properties 
(Kwon et al., 2011). Cinnamon is a traditional medicine that has been used for 
thousands of years in ancient Egypt and China (Lu et al., 2011). In vitro and in vivo 
studies have shown that cinnamon contains biologically active substances that can 
mimic insulin’s properties and can lower the blood sugar in uncontrolled type 2 
diabetics (Khan et al., 2003; Baker et al., 2008). Moreover, many studies have 
investigated the anti-microbial and anti-cancer properties of cinnamon, both in cells 
and in animals (Qin et al., 2010; Ranasinghe et al., 2013). Currently the research into 
the anti-inflammatory properties of cinnamon is limited to that in animals and cells, but 
with positive results, therefore, it is worth determining the health effects of cinnamon 
as an anti-inflammatory in humans. As far as we know, this study is the first research 
investigation into the effect of C. cassia supplements on extensive profiles of cytokines 
and adhesion molecules in overweight healthy subjects.  
There is evidence that cinnamonaldehydes isolated from C. cassia inhibit COX-2 and 
NOS in vitro, which may be responsible for the anti-inflammatory and anti-oxidant 
properties observed for cinnamon (Lee et al., 2005; Kim et al., 2007). Furthermore, 
administering a C. cassia water extract (42.6mg/ml) to mice, which were injected with 
lipopolysaccharide (LPS) (inducer of TNF-α), for 6 days caused a significant reduction 
in serum levels of TNF-α and IL-6, suggesting it had anti-inflammatory properties 
(Hong et al., 2012). 
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The current data with regards to the cytokine profiles of healthy overweight and older 
individuals is limited, but there is evidence that the circulating levels of pro-
Inflammatory cytokines such as TNF-α and IL-6 increase with age, and other factors 
(Cauley et al., 2007; Prasad et al., 2012). Furthermore, elevated CRP levels have been 
found to be associated with developing type 2 diabetes three to four years earlier in 
elderly individuals (Barzilay et al., 2001). Although previous studies have found a 
positive correlation between an increase in cytokine levels and ageing (Franceschi et 
al., 2007; Park et al., 2011), which would mean that older people should have high 
levels of cytokines. Our cytokine and CRP results did not show this increase or 
correlation with age. However, the results for the levels of the adhesion molecule PSLE 
was positively correlated with age (R = 0.513, P = 0.050). This correlation might be 
influenced by environmental factors such lifestyle and smoking, however the 
participants involved in this study were non-smokers (Woodward et al., 2003; Ferrucci 
et al., 2005). Overall the results suggested the levels of cytokines in the participants 
were within the normal range. Furthermore, Singh and Newmana (2011) reported that 
inflammatory cytokine levels increased during the menopause. Although, the 
participants were in the menopause stage, their cytokine levels were within the normal 
range, suggesting the menopause and age did not have a significant effect in this 
group, possibly due to the small sample size. 
Our results showed that some of the inflammatory cytokines investigated reduced 
slightly after consuming cinnamon supplements, whilst others increased. One of these 
markers was IL-6, whose concentration increased significantly in the cinnamon and 
placebo groups due to the effect of time (P = 0.01). The IL-6 levels in the cinnamon 
group increased slightly at weeks four and eight compared with baseline. However, 
this was different in the control group, where the level of IL-6 did not change over time. 
IL-6 is produced by a variety of cells such as vascular endothelial cells, immune cells 
and adipocytes, and has been shown to have anti-inflammatory and pro-inflammatory 
properties (Singh and Newman, 2011). The ability to perform both anti-inflammatory 
and pro-inflammatory functions is based on its interaction with the IL-6 receptor; when 
IL-6 binds to the soluble interleukin-6 receptor (sIL-6R), which is called trans-signalling, 
it activates the pro-inflammatory pathway. However, when IL-6 binds with the 
membrane interleukin-6 receptor (mbIL-6R), which is called classic signalling, it 
activates the anti-inflammatory pathway (Scheller et al., 2011). Thus, it may be that 
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cinnamon activates the anti-inflammatory pathway of IL-6, which would explain why 
our results showed the IL-6 concentrations tended to increase at weeks four and eight 
which corresponded to a reduction in BMI. Studies have shown that CRP levels can 
relate to directly to the IL-6 concentration (Ganesan et al., 2005). The CRP data in this 
study showed no significant change in CRP levels, however, there was a slight 
decrease in the cinnamon group, which could be linked to the changes observed in IL-
6 levels.  
Obesity is also associated with high levels of IL-6, as well as an IL-6 deficiency 
(Wallenius et al., 2002; Pini et al., 2013). Studies have shown that injections of a low 
dose of IL-6 into IL-6 deficient obese mice can lead to a reduction in their weight 
(Wallenius et al., 2002). Therefore it can be speculated that keeping IL-6 levels at the 
high end of the normal range might help in reducing weight. The participants in this 
study who consumed the cinnamon supplement lost almost 2 kg during the 8 week 
duration. This suggest that the slight increase in IL-6 concentrations may therefore play 
a role in helping the cinnamon group individuals to reduce their weight. 
There is some evidence that elevated levels of inflammatory markers such as IL-6 have 
a negative effect on carbohydrate metabolism (Lazar, 2005). Whereas other studies 
show that acute IL-6 treatment increased insulin-stimulated glucose disposal (uptake) 
in humans, and increase fatty acid oxidation in vitro (Carey et al., 2006). These studies 
suggest that IL-6 is involved in a range of biological activities in the body that are not 
solely concerned with inflammation. However, using cytokines for human treatment 
must be undertaken with caution due to their potential side effects (Carey et al., 2006). 
The use of other methods, such as diet and herb supplements, might be a safer 
alternative way to have an effect on cytokines. Although the significant increase in IL-
6 concentrations in this study were due to the effect of time, the mean IL-6 
concentrations in the cinnamon group at weeks four and eight increased, whereas the 
means in the control group did not change. However, this increase in the cinnamon 
group was within the normal range according to the literature (Kim et al., 2011; Martins 
et al., 2011) and the Randox laboratory.  
Another reason for the different concentrations of IL-6 measured at 4 and 8 weeks in 
our study, might be due to the time of the year. This study started in the spring and 
was completed during the summer, which can have an effect on IL-6 levels. To make 
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sure this increase did not have a negative effect on the cinnamon participants, the 
fasting levels of hs-CRP were determined at the baseline and after four and eight 
weeks, for both the cinnamon and control groups. Hs-CRP is an acute phase protein 
produced by the liver in response to an elevation in IL-6, and is regulated in the liver 
by IL-6, IL-1 and TNF-α (Terra et al., 2009). Several studies have shown that IL-6, 
TNF-α, and hs-CRP increased with age in healthy and in overweight or obese 
individuals (Singh and Newman, 2011), but this was not noticeable in our study for the 
participants at the baseline, and during the treatment, although they were older (over 
53 average age), and overweight but healthy. The Pearson correlation that was used 
in our data showed that there was no correlation between the age and cytokines and 
CRP levels, and there was no significant effect of cinnamon supplements on TNF-α 
and hs-CRP, which suggests the increased IL-6 levels did not have a negative effect 
on the participants. In a study by Biancottoet et al. (2013) 27 cytokines levels were 
determined in 144 healthy participants, aged between 21-62 year, at baseline and after 
7 days. Their outcome showed a higher viability between the cytokine levels over time. 
Thus, the variability is expected in the cytokine levels over time in healthy people.   
Some studies have shown that certain inflammatory markers are associated with bone 
loss or osteoporosis, for example IL-6 and hs-CRP have a negative relationship with 
bone mineral density (Gough et al., 1998; Oelzner et al., 1999). However, a study by 
Ganesan et al. (2005) found that the plasma hs-CRP concentration does not correlate 
with bone mineral density, and Kania et al. (1995) highlighted that plasma IL-6 did not 
correlate with bone mineral density either. Our results have shown that the serum 
levels of hs-CRP had a positive correlation with bone trabecular density (BTrbDen 
mg/cm3) (R =0.558, P = 0.031) that mean decreasing BTrbDen was associated with 
reducing CRP levels. However, Rolland et al. (2012) stated that hsCRP levels over 5 
mg/L were associated with lower BTrbDen in men after the age of 72 years. This 
correlation demonstrated by Rolland et al. (2012) were more obvious in the participants 
who had CRP concentrations above the normal range, which is >5 mg/L, and aged 
over 72 years. In addition, the participants in their study were men who may respond 
differently to women.  
In addition, the menopause is correlated with elevated levels of hs-CRP, which has 
also been shown to be significantly associated with CVD in women (Woodward et al., 
2003), and also elevated levels of hs-CRP have been identified as a risk factor in the 
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development of diabetes in women (Freeman et al., 2002). This study has shown that 
the participants’ hs-CRP concentrations were not high and within the normal range. 
These normal levels were possibly due to the participants having passed the 
menopausal period, as the mean age was 53 years in the control group and 56 years 
in the cinnamon group. The mean BTrbDen mg/cm3 values in cinnamon and control 
were 182.70 ± 14.39, 167.42 ± 11.74, respectively. Both groups were in the 
menopausal age range and the density values would tend to be reduced in 
postmenopausal women (Grampp et al., 1997). These values were similar to other 
data on BTrbDen mg/cm3 in postmenopausal women (175 ± 53) (Grampp et al., 1997).    
The outcome of this study illustrated there was a significant reduction in weight for the 
participants that consumed 5 g of cinnamon for 8 weeks. There is evidence of a 
connection between obesity and systemic inflammation, for instance, some human 
studies have shown increased TNF-α expression in adipose tissues in obese 
individuals with a reduction in TNF-α after losing weight (Terra et al., 2009). Studies 
have shown that adipose tissues of obese individuals express increased amounts of 
pro-inflammatory cytokines, such as IL-6, IL-1, TNF-α, IL-8, CRP, sICAM and MCP-1, 
and that the adipose tissue may activate the inflammatory cascades that are 
associated with a chronic low grade systemic inflammation, which can develop in many 
diseases, such as type 2 diabetes (Terra et al., 2009; Leiherer et al., 2013). In addition, 
adipose tissues may play a role in the pathogenesis of hypertension via releasing 
inflammatory cytokines (Ghanem et al., 2007). These studies suggest that there is 
association between cytokine levels and weight reduction. Our study suggests that 5 
g of cinnamon has a slight effect on cytokine concentrations in the cinnamon group, 
such as IL-6, TNF-α and CRP, whereas, there was no change within the control group. 
The anti-inflammatory IL-10 concentration increased slightly during the treatment from 
0.88 pg/ml at the baseline to 1.07 pg/ml at week eight in the cinnamon group, but this 
was not a significant change. IL-10 is a cytokine which suppresses the immune 
response and inhibits the production of pro-inflammatory and systemic inflammatory 
factors such as TNF-α and CRP (Lee et al., 2002). This cytokine is important as a 
balance between the pro-inflammatory and anti-inflammatory factors and leads to the 
recovery of homeostasis, which is very important in the effective inflammatory 
response against pathogens (Marie et al., 1996; Franceschi et al., 2007).  
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Moreover, it is possible that cinnamon contains biological substances that helped the 
cinnamon participants to significantly reduce their weight and keep the balance 
between pro-inflammatory and anti-inflammatory factors. Anderson et al. (2004) 
reported that the active compounds in cinnamon were A-type proanthocyanidins, which 
give cinnamon its antioxidant properties and other health benefits, such as controlling 
glucose levels in humans. Proanthocyanidins are a type of polyphenol (condensed 
tannins) that are oligomers and polymers made up of monomeric       flavan-3-ols, such 
as catechin and epi-catechin (Passos et al., 2007). A-type proanthocyanidins prevent 
bacterial adhesion in bacterial urine infections in vitro, but B-type proanthocyanidins 
do not have this propriety (Howell et al., 2005; Prior et al., 2010). Various studies 
conducted in vivo and using in vitro models have provided evidence that natural 
polyphenols from plant extracts can modulate intestinal inflammation (Andújar et al., 
2012).  
Recent studies have shown that procyanidins have anti-inflammatory properties in rats 
and mice (Terra et al., 2009). The rats were fed procyanidins from grape seeds (345 
mg/kg) for 19 weeks, which significantly reduced the plasma CRP and TNF-α (P < 
0.05). Furthermore, feeding a cinnamon water extract orally at doses of 20 and 100 
mg/kg to mice for 6 days, resulted in a significant reduction in IL-6 and TNF-α levels 
(Hong et al., 2012), showing both treatments produced anti-inflammatory effects. In a 
recent study, Gunawardena et al. (2014) found that cinnamon extract inhibited TNF-α 
production in RAW 264.7 macrophages. They highlighted that the most active 
phytochemical compounds in cinnamon that provided the anti-inflammatory properties 
were E-cinnamaldehyde and o-methoxycinnamaldehyde. Further evidence of the anti-
inflammatory effects comes from a study that showed an aqueous C. cassia extract 
(10 µg/ml) and C. cassia inhibited 82 % of the activity of COX-2 in mouse macrophages 
(RAW 264.7 cells line) (Hong et al., 2002). All these study results show that cinnamon 
is a potential medicinal herb that has a capacity to inhibit the excessive modulation of 
the inflammatory process, such as cyclooxygenases-2 (COX-2) and cytokines, which 
means cinnamon could be used as alternative anti-inflammatory agent. The anti-
inflammatory properties of cinnamon were not detected in this study possibly due to 
the small sample size, which limited the power of the study. 
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6.5.1 Adhesion molecules and blood pressure 
The risk of CVD has been found to be associated with an elevation in some of the 
adhesion molecule levels in circulation, therefore evaluating the biomarker of 
inflammation in circulation, including adhesion molecules, might be a useful tool for 
identifying a patient at high risk of future CVD (Pak et al., 2014). Hypertension is 
defined as a systolic blood pressure greater than 140 mm Hg or diastolic greater than 
90 mm Hg (Medina-Remón et al., 2013). High blood pressure is one of the major risk 
factors for developing CVDs such as coronary disease, stroke and atherosclerosis 
(Kannel, 2000). In the review by Ghanem et al. (2007) they highlighted a potential link 
between inflammation and hypertension. The results of this study confirmed there was 
a positive correlation between sPSEL and systolic blood pressure (R = 0.512, P = 
0.051), and in addition there was a positive correlation between sESEL and systolic 
blood pressure (R = 0.523, P = 0.045), which suggest our results agree with Ghanem 
et al. (2007), that sPSEL and sESEL were positive correlated with hypertension. 
Within our study there were no significant differences between the sVCAM, sICAM, 
sESEL, sPSEL levels at the baseline for the cinnamon and control groups, whereas 
the sLSEL concentrations at the baseline were slightly higher than the normal range 
that are based in the Randox protocol, but they were at a level that was considered 
within the normal range according to the literature (Schleiffenbaum et al., 1992; 
Zonneveld et al., 2014). Studies have shown that consuming alcohol alters adhesion 
molecule metabolism, which leads to increased serum levels of adhesion molecules 
such as sICAM, sESEL and sLSEL (Ponthieux et al., 2004). For this reason, in the 
study protocol, the participants were asked to avoid consuming alcohol for 3 days prior 
to the study day. However, it seems that some of the participants did not follow this 
instruction, which resulted in the baseline readings having a slightly higher levels of 
sLSEL. Moreover, adhesion molecule levels, such as sVCAM, sICAM, and sL-selectin 
increase with age (Nash et al., 1996). Hence, elevated levels of circulating adhesion 
molecules were expected within this age group, and was confirmed for sPSEL as it 
had a positive correlation with age (R = 0.513, P = 0.050). Adhesion molecules such 
as sVCAM, sICAM, sESEL, sPSEL and sLSEL have also been shown to play a role in 
endothelial function; they are involved in the recruitment leukocytes to sites of effected 
tissue (Etzioni., 1996), and they are present on the cell surface of vascular endothelial 
cells. There is evidence that inflammatory cytokines regulate the adhesion and 
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migration of leukocytes across the endothelium, which suggests their levels should 
correlate (Carlos and Harlan, 1994).  
Lifestyle approaches are a widely used effective way to lower blood pressure or 
cardiovascular risk associated with hypertension, this can include smoking cessation, 
physical exercise, weight reduction and increasing plant, fruit and vegetable intake 
(Mancia et al., 2007). In recent years the focus on the management of blood pressure 
has shifted away from pharmacological conventional approaches, towards plant 
therapeutic powers, with or without standard medication (Tabassum and Ahmad, 
2011). Plants, fruit and herbs may contain a specific component that reduces blood 
pressure, and these can work in a variety of ways, for example herbs, seeds, tea and 
vegetables are rich in polyphenol compounds, which provide the antioxidant capacity 
of these foods (Perez-Vizcaino et al., 2009). Flavonoids are one group belonging to 
the polyphenol family, they are important plant metabolites and can be used to control 
high blood pressure (Perez-Vizcaino et al., 2009). For instance, grapes and grape 
seeds contain a high concentration of antioxidant polyphenols such as flavonoids, 
anthocyanins and procyanidins (Packer et al., 1999; Zern and Fernandez., 2005). In a 
study by Barona et al. (2012), the participants with MetS and high risk of developing 
high blood pressure consumed 46 g/d of grape polyphenol supplements for 30 days in 
a double blind crossover design. The results of this study showed that participants who 
used grape capsules had a reduction in the risk factors associated with the metabolic 
conditions. Participants who received the grape polyphenol for 30 days had a 
significant decline in systolic blood pressure to 122 mm Hg, while those who received 
the placebo had a systolic blood pressure of 128 mm Hg. In addition, there was a 
reduction in sICAM-1 concentrations by 10 µg/L, (142 ± 50 µg/L) in grape group 
compared with placebo (151 ± 51 µg/L), whereas the plasma sVCAM-1 levels did not 
differ between the grape (1020 ± 285 µg/L) and placebo groups (1020 ± 240 µg/L). 
Overall the study showed that the changes in sVCAM-1 concentrations were positively 
correlated with changes in systolic blood pressure. Further evidence for the effect of 
polyphenols comes from a review of studies that showed consuming cocoa and dark 
chocolate lowered blood pressure in human beings in short-term studies. Cocoa 
contains high levels of proanthocyanidins (procyanidins), which comprise 58 % of the 
total polyphenol composition, which suggests these are the molecules that are having 
the effect on blood pressure (Andújar et al., 2012; Medina-Remón et al., 2013). Some 
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preliminary studies have reported that cinnamon reduces blood pressure in humans, 
though according to recent meta-analysis, there were only three randomised controlled 
trials that study the effect of cinnamon on blood pressure (Akilen et al., 2013). In our 
randomised controlled trial, 5 g per day of C. cassia supplements given for eight weeks 
reduced systolic and diastolic blood pressure significantly, (P = 0.01, P = 0.02, 
respectively). This suggests that cinnamon, grape and cocoa contain the same active 
compounds which reduce blood pressure, such as the polyphenol and in particular 
procyanidins. Our LC-MS data (chapter three) agrees with this theory as it confirmed 
that C. cassia contains procyanidins. 
Within our study there was no significant difference between the groups at the baseline 
for diastolic blood pressure, however, the systolic blood pressure between the 
cinnamon (119 ± 8 mm Hg) and control groups (108 ± 9.4 mm Hg) was significantly 
different (P = 0.03). The difference between the groups in human experiments can 
occur by chance, possibly due to the lifestyle characteristics of the participants. 
Another reason for the difference could be due to the control group’s age as they were 
somewhat younger than the cinnamon group, and as age increases as blood pressure 
increased. After four weeks of treatment, the systolic and diastolic blood pressures 
were significantly reduced (-5.16 mm Hg and -3.25 mm Hg, respectively) in the 
cinnamon group, whereas there were no reductions in the placebo group. Also after 8 
weeks, cinnamon treatment decreased the systolic and diastolic blood pressures 
significantly (-14 mm Hg and -9.14 mm Hg, respectively), compared to the baseline, 
with no difference in the control. This positive effect of cinnamon on blood pressure 
has been confirmed by two other studies; in the Akilen et al. (2010) study, the cinnamon 
(C. cassia) dose was 2 g/d for 12 weeks (N = 58), which significantly reduced the 
systolic and diastolic blood pressure (P < 0.001) of the cinnamon group. The baseline 
of the systolic and diastolic blood pressure on the cinnamon group was 133 mm Hg 
and 85 mm Hg respectively, which dropped to 129 mm Hg and 81 mm Hg, respectively, 
after treatment. For the placebo group the baseline of the systolic and diastolic was 
135 mm Hg and 86 mm Hg, which changed to 134 mm Hg and 87 mm Hg, respectively 
after treatment. Another study found that ingesting 500 mg of cinnamon extract 
(Cinnulin PF®) daily, which is equivalent to 10 g of cinnamon, for 12 weeks reduced 
systolic blood pressure within the cinnamon group (n = 12) compared with the placebo 
group (n = 10) (Ziegenfuss et al., 2006). On the other hand, Wainstein et al. (2011) 
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only found a marginal effect (P = 0.06) on blood pressure of 1.2 g/d of cinnamon for 12 
weeks (n = 59). This result might be because they only used a low dose of cinnamon, 
and it is likely that the effect of cinnamon on blood pressure is dose dependent. Also, 
in the previous study, the baseline of blood pressure was high, and the higher the blood 
pressure the greater chance it has to decrease, which meant the participants had a 
reduction in their blood pressure. However, in our study the participant’s blood 
pressure was within the normal range, and therefore our results show that 5 g per day 
of cinnamon supplements has a potential benefit for hypertensive individuals. Also, it 
could be considered as an additional dietary supplement option to regulate blood 
pressure levels along with conventional medication, or to prevent high blood pressure.  
There are many possible explanations for the significant reduction in blood pressure 
after being given cinnamon supplements; there is growing evidence from controlled 
trials that dietary flavonoids and polyphenols can improve the endothelial function and 
reduce blood pressure (Hodgson et al., 2006; Barona et al., 2012). Polyphenol 
antioxidants are used to protect endothelial cells against reactive oxygen species 
(ROS), and they can induce the formation of nitric oxide that is responsible for 
relaxation of the blood vessels, which permit easy flow of blood through the vessels, 
thus lowering the blood pressure (Andújar et al., 2012). Damaged endothelial cells, 
due to exposure of oxidative stress, reduces the production of nitric oxide, and as a 
result, endothelial cells of the blood vessels expressed high concentrations of adhesion 
molecules, which might lead to increase blood pressure (Barona et al., 2012; Medina-
Remón et al., 2013). Studies have shown that high levels of ROS increased the 
expression of adhesion molecule such as VCAM (Cook-Mills et al., 2011), therefore 
reducing adhesion molecule levels could increase the antioxidant status. In this study 
the sVCAM, sICAM, sE-selectin, sP-selectin and sL-selectin concentrations were 
slightly (but not significantly) reduced in cinnamon group only. Overall these results 
suggest that the cinnamon contains a biological active compound that helped to 
significantly reduce the blood pressure and decreased the adhesion molecule markers. 
It is possible that cinnamon procyanidins improved the endothelial function and slighter 
reduction in adhesion molecules concentrations. Consequently, this might lead to a 
significant reduction in blood pressure within the cinnamon group after ingesting 5g of 
C. cassia for eight weeks. The study did not see a significant treatment effect in 
sVCAM, sICAM, sESEL, sPSEL and sLSEL possibly because the number of 
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participants was small, which reduced the study power. The effect at 90 % power 
required 18 individuals for the cinnamon group and 18 for the placebo group. Even 
though many methods were employed to recruitment participants, the total number that 
were enrolled, and met the criterion of the study, was only 15 healthy women. 
Moreover, the time of the year, which was during the summer holidays, may have had 
an effect on recruitment, along with the age criterion which was limited to the middle-
aged (45-70 years), healthy women. 
This study also found no correlation between adhesion molecules markers, which 
include sVCAM, sICAM, sESEL, sPSEL and sLSEL, and BMI. This result was 
consistent with the work by Turan et al. (2014) who found there was no correlation 
between ICAM, VCAM and E-selectin levels and BMI. 
Overall, this study showed 5 g of cinnamon supplements taken daily for eight weeks 
significantly lowered blood pressure and significantly reduced the weight. Cinnamon 
had no effect on the concentrations of cytokines and adhesion molecules investigated, 
possibly due to the small sample size. However, some adhesion molecules were 
slightly (but not significantly) reduced sVCAM, sICAM, sESEL, sPSEL and sLSEL, 
which may have led to an improved endothelial function, and that might be responsible 
for the reduction in blood pressure.  
6.6 Conclusions  
The present study showed that ingesting 5 g of C. cassia supplements every day for 
eight weeks displayed important health benefits in healthy overweight woman. During 
the intervention with supplements, the cinnamon participants’ weight was reduced 
significantly, by approximately 2 kg during the eight weeks. Moreover, blood pressure 
was reduced significantly at both weeks four and eight. Cinnamon supplements did not 
have a significant effect on the inflammatory marks such as IL-6, TNF-α, IL-10 and hs-
CRP. Similarly, ingesting 5 g of cinnamon for eight weeks did not change the adhesion 
molecules such as sVCAM, sICAM and sLSEL, significantly. Interestingly, there was a 
slight reduction in some of the markers in the cinnamon group, such as sVCAM, 
sICAM, sESEL, sPSEL, sLSEL, TNFα and hs-CRP concentrations. However, the 
concentrations of most inflammatory markers within the control were not changed, 
possibly due to the small sample size. As a result of the significant effect of C. cassia 
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on weight and blood pressure, further research is required to assessed the effect of C. 
cassia in lipid profiles and glucose levels in humans.  
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Chapter 7 
7 The effect of consuming a Cinnamomum cassia supplement on lipid 
profiles, glucose and insulin levels in healthy overweight participants over 
eight weeks 
7.1 Introduction 
Metabolic syndrome (MetS) is a collection of conditions that includes: high blood 
pressure, insulin resistance, an excess of body fat around the waist, high cholesterol 
and high fasting glucose concentrations (Dai et al., 2015). MetS increases the risk of 
developing CVD and type 2 diabetes, and as such is an important syndrome to treat 
(Grundy., 2008). Studies have shown that increased non-esterified fatty acid (NEFA) 
levels were associated with insulin resistance and high blood pressure (Maison et al., 
2000). Therapeutic agents such as acarbose, and metformin, are used to manage 
hyperglycaemia; an Angiotensin converting enzyme (ACE) inhibitor such as captopril 
can be used to treat high blood pressure, and statins can be used to lower cholesterol 
in the blood. However, all of these therapies are associated with side effects, such as 
abdominal discomfort, diarrhoea and flatulence, therefore being able to use a 
treatment without side effects would be preferable (Phillips et al., 2003; Sönmez et al., 
2005). 
Complementary and alternative medicines, such as herbal medicines, have been used 
as an alternative approach to meet the health needs of patients providing safe, 
effective and low cost remedies for a variety of disorders and diseases (Barnes et al., 
2008). Although plant and herbal products have been used in traditional medicine for 
centuries, the effective attributes of these have only recently been confirmed 
experimentally (Kennedy, 2005; Opara and Chohan, 2014). The use of herbal and 
natural supplements are widespread in the adult population of the USA, which has 
increased from 50.6 million in 2002 to 55.1 million in 2007 (Wu et al., 2007). Of these 
in 2002, there were 38.2 million adults in the United States who used herbal 
supplements to treat a specific condition such as a chest cold, stomach illness, 
diabetes and hypertension (Kennedy, 2005). The National Health Interview Survey 
(NHIS), conducted in the United States in 2007, showed that approximately 18 % of 
adults and 4 % of children used herbal supplements as an alternative medicine, and 
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this was found to be the most common complementary therapy. Moreover, $14.8 billion 
was spent on herbal products in the USA in 2007 (Camiel et al., 2013). More strikingly, 
about 50 % of the population in Australia use herbal medicines on a regular basis 
(Wohlmuth et al., 2002). Furthermore, in Saudi Arabia, about 58.89 % of 518 
participants in survey 2010 used herb medicine (Elolemy et al., 2012). A recent study 
in Saudi Arabia showed that 42.3 % of 292 participants questioned used herbs to treat 
disease (Mohammad et al., 2015). Survey data in 1998 in the UK showed that 28.3 % 
of British population used herbal medicines (Thomas et al., 2001). All of the above 
statistics show that people choose to take herbal medicines as alternatives to 
conventional medicines, due to the supposed low levels of toxicity and their natural 
origins. Although herbal medicines may have several physiological beneficial actions 
on the human body, their underlying mechanisms are largely unclear (Opara and 
Chohan, 2014). There is therefore a need for more research to assess the actions of 
herbal medicines in order to benefit both the current users of herbal products, and to 
contribute to the development of new pharmaceutical products for the prevention and 
management of human diseases such as type 2 diabetes (Fabricant and Farnsworth, 
2001). For instance, metformin, which is a drug that lowers blood glucose by increasing 
the sensitivity of the body’s cells to insulin in type 2 diabetes, is derived from French 
lilac, which is a herbal remedy that was used to treat diabetes in the Middle Ages (Ryan 
et al., 2001). As such further effective treatments may be derived from other plant and 
herb sources. 
Studies have shown that the incidence of type 2 diabetes is increasing rapidly, and this 
to a great extent is due to the obesity epidemic (Lazar 2005). Changes in lifestyle, such 
as an improved diet and an increase in physical activity, can help to control blood 
glucose levels and go some way to preventing the development of type 2 diabetes 
(Buttar et al., 2005; Lichtenstein et al., 2006). Herbs and spices, such as cinnamon, 
cloves, tea, oregano and nutmeg, have been shown to have an insulin-like activity in 
vitro (Broadhurst et al., 2000). Therefore the role of herbs and spices in the treatment 
of diabetes and other diseases is of great interest. 
Cinnamomum cassia (C. cassia) belongs to the Lauraceae family, and has traditionally 
been used in the treatment of disease. C. cassia has been approved as a medicinal 
herb by the German Commission E and the European Scientific Cooperative on 
Phytotherapy (ESCOP) (Blumenthal et al., 1998). The main components in C. cassia 
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bark are the non-volatile compounds (mainly condensed tannins), comprising 23.2 % 
proanthocyanidins, 3.6 % epi-catechins (Shan et al., 2007). Some preliminary studies 
suggest that C. cassia has beneficial effects on glucose uptake, and it contains 
polyphenols, which can stimulate glucose uptake and glycogen synthesis in vitro 
(Solomon and Blannin, 2007). It has also been reported that cinnamon has strong 
antioxidant, antibacterial, anti-inflammatory, and anti-cancer properties, and can be 
used in the treatment of common colds, CVD, and chronic gastrointestinal complaints 
(Verspohl et al., 2005; Kim et al., 2006; Molania et al., 2012; Hong et al., 2012). 
This chapter focuses on the effects of C. cassia supplementation on a variety of 
parameters related to glucose and lipid metabolism, as well as body weight and food 
intake in overweight women over an 8 week period. 
7.2 Study aims 
1. To investigate the effect of C. cassia supplementation (5 g) on fasting blood glucose 
levels in overweight women between the ages of 45-70 years.  
2. To investigate the effect of C. cassia supplementation (5 g) on lipid profiles (CHO, 
HDL, LDL, TAG, NEFA) in overweight women between the ages of 45-70 years.  
3. To investigate the effect of C. cassia supplementation (5 g) on homeostasis model 
assessment (HOMA) in overweight women between the ages of 45-70 years. 
4. To investigate the effect of C. cassia supplementation (5 g) on weight and 
anthropometric measurements in overweight women between the ages of 45-70 years.  
5. To compare the effects of C. cassia supplementation (5 g) on food intake. 
7.3 Methods 
7.3.1 Subjects 
This study took the form of a randomised controlled trial (RCT). Approval for the study 
was granted by the University of Surrey’s Ethics Committee (EC/2013/70/FHMS), 
(Appendix 8). A power calculation for the study was carried out to estimate the numbers 
required; this was based on previous studies which examined fasting glucose levels, 
as this was considered the primary outcome variable of this study. 
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A reduction in fasting glucose of 2 mmol/l was observed by the cinnamon 
supplementation study of Khan et al. (2003), therefore the standard deviation was 
assumed to be 1.0. The power of the study was calculated at 90 %, so 18 participants 
were required for each group; one group would be required to take cinnamon 
supplements and the other group the placebo. In order to allow for participants 
dropping out, a 25 percent margin was added to this; thus 23 participants were required 
for each group.  
The researcher produced a poster (Appendix 9) about the study and placed copies 
around the University site, as well as e-mailing University staff. The locations of the 
posters included train stations and bus stops, restaurants and hotels, supermarkets 
and churches, as well as the hospitals in Kingston, Woking, Guildford and other 
locations. The researcher also presented a talk at Woking Mosque about the study. 
Despite all of these efforts, only 16 women in total volunteered and were found to meet 
the study’s criteria. 
7.3.2 Screening  
A screening process was carried out to ensure the eligibility of the participants.  The 
screening was also used to make sure that the subjects were healthy enough to be 
included in the study. Participants were asked to fast overnight before screening for 
blood glucose levels. This was done in the morning using a finger prick test at the 
Clinical Investigation Unit (CIU) at the University of Surrey. The participants’ weight 
and height were also measured and they were asked to complete a screening 
questionnaire (Appendix 10). This featured questions concerned their health and 
lifestyle. The participants were given a participant information sheet (Appendix 11) and 
a consent form (Appendix 12). 
7.3.3 Study participants  
In order to assess whether or not the participants were suitable for the study, the 
following inclusion criteria were applied: 
1 Female and in the age range of 45 to 70 years old 
2 Not on regular medication 
3 Not allergic to cinnamon 
4 Body Mass Index (BMI) of 25 or more 
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5 Non-smoker 
6 Generally in good health; not suffering from any diseases 
7 Not taking any herbal supplements or other supplements in the last month 
8 Willing and able to comply with the procedures required by the study 
7.3.4 Study design  
The study (Figure 7.1) followed the design of a randomised controlled trial (RCT) and 
included a control group using random number table. A cinnamon (C. cassia) 
supplement which was supplied by NBTY Inc, and purchased from Puritan’s Pride, was 
used in this study. Participants took the supplements for eight weeks, and during that 
time they visited the CIU three times. New dark green capsules (CapsulCN®) were 
filled (2.2.11.3) for cinnamon group with 5 g of cinnamon (C. cassia. The same 
capsules were filled with 5 g of corn flour for the control group. Each participant took 
three capsules after breakfast and three after their evening meal for the eight weeks 
of the trial. As the capsules looked the same, the participants were unaware of whether 
they were consuming cinnamon or the placebo.  
In preparation for each study day, all participants consumed a standardised meal 400 
g of vegetable lasagne with a known macronutrient composition the evening before. 
They were then asked to fast overnight for at least 12 hours. The standardised meal 
was used to reduce the variability between the volunteers. The participants arrived at 
the CIU early in the morning, having not consumed any alcohol or participated in any 
strenuous exercise for the previous three days. They were also asked not to drink any 
liquids which contained caffeine (coffee/tea/soft drinks such as Coca Cola) 24 hours 
prior to each visit. For three days prior to attending the CIU, the participants also kept 
a food diary and recorded their food consumption. The macronutrient content of the 
foods consumed were then calculated using DietPlan version 6 software. Blood 
pressure, fasting blood samples and anthropometric measurements were taken at 
each week.  
At the baseline study day only, Peripheral Quantitative Computed Tomography (pQCT) 
was used in scanning mode of the participants’ wrist bones. Additionally, on the first 
and third visits, the participants were given a drink containing 75 g of glucose, and 
blood samples were taken again after two hours. This was a standard oral glucose 
tolerance test (OGTT). When all of the tests had been completed and all of the 
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necessary information had been collected, the participants were offered breakfast, and 
were provided with a known number of capsules that storage in bottle, either cinnamon 
or placebo, for the following 4 weeks and then a new bottle for remaining weeks.  
Each participant received the capsule bottles at baseline study day. At week 4, the 
participants returned the remaining capsules in the bottle and received a new capsule 
battles. At week 8, the participants returned the remaining capsules in the bottle. Each 
bottle was assessed by counting any remaining capsules in the bottles returned at 4 
and 8 weeks. 
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Figure 7.1 Study design for the investigation of the effect of cinnamon over an 8-week 
study period. 
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7.3.5 Dietary intake  
Food dietary intakes were recorded using information contained in the participants’ 
three-day diet diaries prior study date. The investigator explained the instructions and 
procedures to the participants who needed to complete the food diary. The completed 
food diary was analysed by DietPlan.  
7.3.6 Blood sample collection  
Fasting blood samples were taken at week zero, week four and week eight. They were 
analysed for fasting blood glucose levels, fasting insulin levels, the oral glucose 
tolerant test (0 and 8 week visits) and fasting lipid profiles, which included cholesterol 
(CHO), high density lipoproteins (HDL), triglycerides (TAG), and non-esterified fatty 
acids (NEFA). The blood samples were taken by trained phlebotomists who worked at 
the CIU. 2 ml of a fasting blood sample was drawn by a vacutainer safety lock blood 
collection set and single use holder. Blood was drawn into the vacutainer 
fluoride/oxalate grey tube (Becton Dickinson (BD) and company, Oxford, UK) for the 
determination of the plasma glucose. The same tube was used to determine glucose 
from the oral glucose tolerance test two hours after consuming a 75 g glucose drink. 
An additional 2 ml of a fasting blood sample was taken into lithium heparin vacutainer, 
(Becton Dickinson (BD) and company, Oxford, UK) to determine plasma insulin levels. 
A further 4 ml fasting blood sample was taken into a vacutainer containing dipotassium 
ethylene diamine tetraacetic acid (K2EDTA) (Becton Dickinson (BD) and company, 
Oxford, UK) to determine plasma levels of CHO, HDL, TAG, and NEFA. Blood samples 
were immediately centrifuged at 1750 g for 10 min at 4 °C to obtain the supernatant 
plasma, which was removed by pipette. Aliquots of the plasma were dispensed into 
appropriately labelled micro-centrifuge tubes (1.5 ml) and stored at _ 80 °C until 
required for analysis. 
7.3.7 Statistical analyses 
SPSS software version 22 was utilised for the statistical analyses. A Kolmogorov-
Smirnov analysis was performed to check for the normality of distribution of the data; 
checks were carried out for both normal and de-trended normal probability plots. The 
results of the analysis were represented as a mean ± standard error of the mean 
(SEM). Changes in fasting plasma glucose, insulin, HDL, LDL, CHO and NEFA levels 
were analysed using a repeated measures two-way ANOVA, whilst the baseline 
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variables of the two groups were compared with an unpaired t-test. In weeks four and 
eight, a paired t-test was used to compare the data with the baseline data for some of 
the variables. Relationships between the variables were examined using the Pearson 
correlation coefficient. Graphs were plotted through GraphPad Prism version 6 for 
Windows, with each graph showing the p-values for cinnamon treatment (T) and 
duration (D), and the relationship between them (D/T). Correlation coefficients were 
utilised in order to analyse the relationship between the changes in the different 
variables, where statistical significance was set at P ˂ 0.05.  
7.4 Results  
7.4.1 Patient recruitment  
As mentioned above (section 7.3.1) it was not possible to recruit the target number of 
23 participants for each group; thus only 16 were recruited in total. A possible reason 
for this was that it was the summer holidays and some potential subjects had booked 
in advance for their holidays. Therefore, the study days were not convenient for them. 
In addition, the fact that the participants were required to be in a certain age range, as 
well as healthy, limited the number that could be included in the study. Furthermore, 
one of the participants’ BMI was 40, which did not comply with the inclusion criteria. 
Thus, the number of participants that were used in the statistical analyses was 15. Of 
the 15 participants taking part in the study, seven were randomly assigned to the 
placebo group, and eight to the cinnamon group.  
7.4.2 Baseline characteristics  
 The baseline characteristics and anthropometric data of the participants in both 
groups (Table 7.1), show there were no significant differences in mean weight, height, 
age, BMI, hip circumference (HC) and waist circumference (WC). Significant 
differences were not observed between the fasting glucose and insulin levels of each 
group either. At the beginning of the study, both groups had normal, healthy levels of 
systolic and diastolic blood pressure, with no significant differences in diastolic blood 
pressure between the groups. However, the systolic blood pressure was higher in the 
group who were to receive cinnamon group (119.88 mm Hg) compared to the control 
group (108.00 mm Hg) (P = 0.03), which was perhaps just due to chance.  
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Table 7.1 The characteristics of the study participants at the baseline.  
Demographic Cinnamon 
(n = 8) 
Mean ± SEM 
Placebo 
(n = 7) 
Mean ± SEM 
Unpaired 
 t-test 
p-value 
Height (m) 1.61± 0.01 1.65 ± 0.02 0.13 
Weight (kg) 76.75 ± 2.7 77.29 ± 3.4 0.90 
BMI (kg/m2) 29.46 ± 1.0 28.34 ± 1.3 0.49 
Waist circumference (cm) 94.50 ± 2.2 89.21 ± 2.2 0.11 
Hip circumference (cm) 106.94 ± 2.3 108.00 ± 2.1 0.74 
Systolic blood pressure (mm 
Hg) 
119.88 ± 3.1 108.00 ± 3.5 0.03* 
Diastolic blood pressure (mm 
Hg) 
83.00 ± 3.2 74.71 ± 3.5 0.10 
Heart rate (BPM) 67.50 ± 2.2 72.37 ± 3.9 0.28 
Age (Years) 56.00 ± 1.3 53 00 ± 2.7 0.22 
 
The clinical markers of the subjects at the baseline for both groups (Table 7.2) showed 
there was no significant difference in fasting glucose, fasting insulin, TAG, HDL, LDL 
and NEFA levels at the baseline. Also, in bone trabecular density mg/cm3 
(BTrbDen1mgpercm3) there was no significant different between the groups. In terms 
of cholesterol, there was a significant different at the baseline between the cinnamon 
and control groups (P = 0.016), which was just due to chance. The fasting glucose 
levels of the cinnamon group was 5.80 ± 0.17 mmol/l, and the control groups was 
5.70±0.20 mmol/l, which were marginally higher than the normal range and are 
considered pre-diabetic. Fasting insulin levels, cholesterol and LDL levels in the 
cinnamon group were slightly higher than the normal range, while the control group 
were in the normal range, whereas TAG and NEFA were in the normal range in both 
groups. HDL levels in both groups were desirable. The BTrbDen1mgpercm3 for both 
groups were in the normal range according to the literature (Grampp et al., 1997). 
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Table 7.2 The clinical markers of the participants at the baseline.  
Markers Cinnamon 
(n = 8) 
Mean ± SEM  
Placebo 
(n = 7) 
Mean ± SEM 
Unpaired  
t-test 
p-value 
Fasting glucose mmol/l 5.80 ± 0.17 5.70 ± 0.20 0.638 
Fasting insulin μU/ml 16.57 ± 2.09 11.51 ± 1.83 0.096 
HOMA Beta-Cell Function (B%) 117.78 ± 9.11 97.67 ± 10.88 0.177 
HOMA Sensitivity Insulin (S%) 53.46 ± 9.55 72.21 ± 7.52 0.155 
HOMA Insulin Resistance (IR) 2.20 ± 0.28 1.53 ± 0.24 0.095 
Triglyceride (TAG) mmol/l 0.96 ± 0.14 0.96 ± 0.09 0.984 
Cholesterol (CHO) mmol/l 5.78 ± 0.21 4.84 ± 0.26 0.016* 
HDL mmol/l 1.96 ± 0.20 1.76 ± 0.10 0.427 
Non-esterified fatty acid (NEFA) 
mmol/l 
0.82 ± 0.16 0.83 ± 0.25 0.962 
LDL mmol/l 3.38 ± 0.22 2.63 ± 0.18 0.078 
Bone Trabecular Density 
mg/cm3 (BTrbDen1mgpercm3) 
182.70 ± 
14.39 
167.42 ± 
11.74 
0.434 
 
7.4.3 Changes in anthropometric indices after supplementation 
Four weeks into the study, there were significant reductions in weight (P < 0.001), WC 
(P = 0.04) and BMI (P < 0.001; Figure 7.2) in the cinnamon group, while no such 
reductions were observed in the control group (Figure 7.3). After eight weeks, these 
changes continued; in the cinnamon group, there were significant reductions in the 
participants’ weight (P = 0.01), BMI (P = 0.01), WC (P = 0.001) and HC (P = 0.01), and 
no change for the control group. However, there were small insignificant changes in 
the heart rate of the participants in the cinnamon group during 8 weeks (63.5 BPM) 
compared with baseline (67.50 BPM).  
Overall, the group taking the C. cassia supplement lost about 2 kg in body weight each, 
while no changes were recorded in the placebo group after both four and eight weeks 
(Table 7.3). In terms of blood pressure (Table 7.3), there was a significant reduction in 
systolic blood pressure at weeks four and eight (P = 0.04, P = 0.01) and diastolic blood 
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pressure decreased significantly at week eight (P = 0.02). There was no significant 
change observed in the control group.  
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Figure 7.2: Mean ± SEM of A: Weight, B: waist circumference and C: BMI for study 
participants as a whole at zero (baseline), 4 and 8 weeks of cinnamon 
supplementation. Significant difference from baseline, P<0.01*, P<0.001** 
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Figure 7.3: Mean ± SEM of A: Weight, B: waist circumference and C: BMI for study 
participants as a whole at zero (baseline), 4 and 8 weeks of control. Significant 
difference from baseline, P<0.01*, P<0.001** 
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Table 7.3 Anthropometric measurements at weeks four and eight compared with the 
baseline. Values are means ± SEM. 
Variable 
  
Control Paired 
 t. test 
p-value 
Cinnamon Paired 
 t. test 
p-value 
Weight (kg) Baseline 77.29 ± 3.4  76.75 ± 2.7  
Change at 4 
weeks 
-0.14 ± 0.26 0.60 -1.00 ± 0.18 0.001* 
Change at 8 
weeks 
-0.21 ± 0.40 0.62 -1.86 ± 0.55 0.01* 
BMI (kg/m2) Baseline 28.34 ± 1.3  29.46 ± 1.0  
Change at 4 
weeks 
-0.05 ± 0.09 0.62 0.38 + 0.06 0.001* 
Change at 8 
weeks 
0.07 ± 0.14 0.64 -0.71 ± 0.20 0.01* 
Waist 
circumference 
(cm) 
Baseline 89.21 ± 2.2  94.50 ± 2.2  
Change at 4 
weeks 
1.21 ± 1.57 0.47 -1.56 ± 0.60 0.04* 
Change at 8 
weeks 
0.143 ± 1.01 0.89 -3.29 ± 0.73 0.004* 
Hip 
circumference 
(cm) 
Baseline 108.00 ± 2.1  106.94 ± 2.3  
Change at 4 
weeks 
-0.35± 0.17 0.1 -0.65 ± 0.47 0.22 
Change at 8 
weeks 
-0.64 ± 0.37 0.14 -2.57 ± 0.79 0.01* 
Systolic Blood 
pressure 
 (mm Hg) 
Baseline 108.00 ± 3.5  119.88 ± 3.1  
Change at 4 
weeks 
-4.00 + 1.83 0.1 -5.13 ± 2.14 0.04* 
Change at 8 
weeks 
-1.7 ± 2.94 0.58 -14.00 ± 3.82 0.01* 
Diastolic Blood 
pressure  
(mm Hg) 
Baseline 74.71 ± 3.5  83.00 ± 3.2  
Change at 4 
weeks 
-1.86 ± 1.29 0.2 -3.25 ±2.01 0.15 
Change at 8 
weeks 
0.00 + 1.83 1 -9.14 ± 3.06 0.02* 
Resting Heart 
Rate 
(BPM) 
Baseline 72.37 ± 3.9  67.50 ± 2.2  
Change at 4 
weeks 
-0.80 ± 4.10 0.85 -3.38 ± 1.67 0.1 
Change at 8 
weeks 
0.51 + 3.96 0.9 -3.86 ± 1.94 0.09 
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7.4.4 Changes in plasma glucose concentrations 
A fasting plasma glucose level is used as a marker to diagnose a pre-diabetic state 
and diabetes. Pre-diabetes, obesity and insulin resistance are all considered as risk 
factors for the development of CVD. Studies in vitro and in vivo have shown that herbal 
medicines, such as cinnamon, cloves and tea, may help to maintain normal blood 
glucose levels and delay the development of diabetes (Broadhurst et al., 2000). 
Therefore, this study measured the effect of cinnamon supplementation on fasting 
glucose levels.  
The fasting glucose levels in the cinnamon group and the control group were within the 
normal range at baseline (Table 7.2) and there was no significant difference between 
the groups. There was no significant effect (Figure 7.4) of consuming 5 g of a cinnamon 
supplement on fasting glucose levels after four or eight weeks, and there was no 
change in the control group either.  
In terms of the results from the oral glucose tolerance tests (OGTT), which were 
assessed at the baseline and after eight weeks, in cinnamon and control groups the 
baseline values were 5.5 ± 0.02 and 5.6 ± 0.42 respectively. After 8 weeks, the OGTT 
of cinnamon and control were 5.9 ± 0.04, 5.4 ± 0.6. The results were presented as 
Mean ± SEM. The OGTT levels of both groups were within the normal change at 
baseline and after 8 weeks. There was insufficient data produced for a statistical 
analysis (ANOVA) to be performed. However, based on the results the data shows that 
the OGTT levels were approximately similar at baseline and week 8 in both groups.   
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Figure 7.4: Fasting glucose concentrations at baseline, weeks four and eight of control 
and cinnamon groups. Fasting glucose levels were determined in each participant (n 
= 15) at week 0, 4 and 8. Individual values are displayed with Mean ± SEM. ANOVA 
two-way analysis of variance, T treatment effect, D duration effect and D/T treatment 
and duration interaction effect.     
7.4.5 Changes in plasma fasting insulin levels 
The fasting insulin levels at baseline (Table 7.2) in the cinnamon group were higher 
than normal range (16.43 µU/l), whilst in the control group the levels within the normal 
range (11.10 µU/L), according to the insulin assay protocol (Millipore Insulin kit, HI-
14K) which states the normal range of fasting plasma insulin is 5-15 µU/l. At the 
baseline there were no significant differences in the fasting insulin level between the 
groups. In the cinnamon group (Figure 7.5) the fasting insulin level slightly reduced 
from 16.43 µU/L at the baseline to 14.64 µU/L at week four and to 13.05 µU/L at week 
eight, however this reduction did not achieve statistical significance (P = 0.340, P = 0. 
075, respectively). In the control group the fasting plasma insulin concentration 
increased slightly at weeks four and eight (13.47 µU/L and 12.36 µU/L, versus 
baseline, respectively), but again this was not a statistically significant difference. 
There was a positive correlation between fasting insulin and systolic blood pressure (P 
= 0.030, R = 0.561). Reducing systolic blood pressure was associated with decreasing 
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in fasting insulin levels. Overall these results suggest the cinnamon was having a small 
effect on insulin levels, which could be linked to the weight loss and reducing blood 
pressure observed. These results may have been significant if the sample size was 
larger. 
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Figure 7.5: Fasting insulin concentrations at baseline, weeks four and eight of control 
and cinnamon groups. Fasting insulin levels were determined in each participant (n = 
15) at week 0, 4 and 8. Individual values are displayed with Mean ± SEM. ANOVA two-
way analysis of variance, T treatment effect, D duration effect and D/T treatment and 
duration interaction effect.     
 
 7.4.6 Changes in Homeostasis Model Assessment (HOMA) 
The homeostasis model assessment has been widely used for the estimation of insulin 
resistance (HOMA-IR). The HOMA-IR model was originally produced by Matthews et 
al. (1985) and is calculated by multiplying the fasting plasma insulin (FPI) level by the 
fasting plasma glucose (FPG) level, then dividing that value by 22.5 (Matthews et al., 
1985). Levy et al. (1998) have update HOMA-2. There is an updated version of this 
model, HOMA-2, which uses computer calculations to estimate insulin resistance (IR), 
insulin sensitivity (%S) and β-cell function (%B) (Wallace et al., 2004). In this study the 
HOMA-2 calculator was downloaded from the University of Oxford (Diabetes Trails 
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Unit, 2007) and was used to estimate IR, %B and %S, based on the fasting glucose 
and insulin levels. There is no approximation formula for HOMA-2 and there is also no 
normal range for the measures, as originally 100 % was meant to represent a normal 
person. A higher percentage of %S indicates a greater insulin sensitivity and lower 
ones less sensitivity. Once HOMA-2 insulin resistance (IR) is greater than 1 or %S less 
than 100, this means there is a greater insulin resistance. Insulin sensitivity and beta 
cell function have an inverse relationship.  
7.4.6.1. HOMA insulin resistance index (HOMA-IR)  
There was no significant difference for insulin resistance between the cinnamon and 
control groups at the baseline (P = 0.095). The insulin resistance data for both groups 
at the baseline showed they have a higher insulin resistance 2.20 and 1.53, 
respectively than expected (Table 7.2). In the cinnamon group (Figure 7.6) the insulin 
resistance decreased after four and eight weeks of consuming 5 g of cinnamon (2.01 
and 1.82; P = 0.364, P = 0.080, respectively), though, this reduction was not significant. 
In the control group, the insulin resistance value increased slightly at weeks four and 
eight (1.77 and 1.66, respectively) compared with the baseline (1.53), but again this 
was not significant. These results agree with the fasting insulin levels which also 
showed a slight reduction and could be linked to the weight loss observed. There was 
a significant correlation between insulin resistance and systolic blood pressure (P = 
0.024, R = 0.579) that means reducing blood pressure associated with reduced insulin 
resistance. This could be linked to lower blood pressure observed. These results may 
have been significant if the sample size was larger. 
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Figure 7.6: Insulin resistance at baseline, weeks four and eight of control and 
cinnamon groups. Insulin resistance were calculated in each participant (n = 15) at 
week 0, 4 and 8. Individual values are displayed with Mean ± SEM. ANOVA two-way 
analysis of variance, T treatment effect, D duration effect and D/T treatment and 
duration interaction effect.     
7.4.6.2 HOMA β-cell function (HOMA-B %) 
At the baseline (Table 7.2) there was no significant difference between the cinnamon 
and control groups (P = 0.177). The results (Figure 7.7) show there was no significant 
effect of the cinnamon in terms of the β-cell function index (P = 0.284). The function of 
the β-cells were somewhat higher than normal (Figure 7.7) in the cinnamon group at 
weeks zero, four and eight (117.78 %, 112.20 % and 107.90 %, respectively), and the 
β- cell function was reduced slightly over time so it became closer to the normal 
functional levels. In the control group however, β-cell function was within the normal 
range of function at weeks zero, four and eight (97.67 %, 102.46 % and 101.80 % 
respectively). These results follow the same pattern as the insulin level and the insulin 
resistance, which suggests the treatment is having a small effect in improving the 
health of the participants. 
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Figure 7.7: B cell function at baseline, weeks four and eight of control and cinnamon. 
B cell function was calculated in each participant (n = 15) at week 0, 4 and 8. Individual 
values are displayed with Mean ± SEM. ANOVA two-way analysis of variance 
treatment effect, D duration effect and D/T treatment and duration interaction effect.     
7.4.6.3 HOMA insulin sensitivity (HOMA- S %) 
There was no significant difference in insulin sensitivity at baseline (Table 7.2) between 
the two groups (P = 0.155). There was also no significant change in insulin sensitivity 
(%) after treatment (P = 0.142) (Figure 7.8), but it did increase slightly after consuming 
cinnamon at weeks four and eight (63.87 % and 61.75 %; P= 0.070, P= 0.080, 
respectively) compared with the baseline (53.46 %). In contrast, the insulin sensitivity 
in the control group decreased slightly at weeks four and eight (62.19 % and 62.33 %, 
respectively) compared to the baseline (72.21 %). This small change agrees with the 
small difference seen in β- cell function as the two are linked, and this could be due to 
the weight loss observed in the treatment group. The small sample size may be the 
limiting factor which is stopping these results from being significant. The data in this 
graph are quite disperse due to differences in the participants in this study. This 
variation would possibly be reduced if there were a larger sample size. 
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Figure 7.8: Insulin sensitivity at baseline, weeks four and eight of control and cinnamon 
groups. Insulin sensitivity was calculated in each participant (n = 15) at week 0, 4 and 
8. Individual values are displayed with Mean ± SEM. ANOVA two-way analysis of 
variance, T treatment effect, D duration effect and D/T treatment and duration 
interaction effect.     
7.4.7 Changes in plasma fasting lipid profile levels 
7.4.7.1 Changes in plasma triglyceride TAG 
At baseline (Table 7.2) there was no significant difference in the plasma TAG levels 
between the control and cinnamon groups (P = 0.984). There was no effect of the 
cinnamon treatment (Figure 7.9) on plasma TAG concentrations during the eight 
weeks (P = 0.584). However, there was a significant effect of duration (P = 0.046); the 
plasma TAG concentration increased slightly at week four in the cinnamon and control 
groups (1.12 mmol/l and 1.02 mmol/l, respectively), and then decreased slightly at 
week eight, becoming similar to the baseline levels for both the groups (0.99 mmol/l 
cinnamon, and 0.95 mmol/l control). All the plasma TAG levels in both groups were 
within normal range. This change over time may be as a result the spread of the data 
rather than an actual change in the groups. Overall these results show the variability 
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in TAG levels over time, and these may be linked to changes in the participants' diets 
over the course of the study.  
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Figure 7.9: Triglyceride concentrations at baseline, weeks 4 and 8 of control and 
cinnamon groups. Triglyceride levels were determined in each participant (n = 15) at 
week 0, 4 and 8. Individual values are displayed with Mean ± SEM. ANOVA two-way 
analysis of variance, T treatment effect, D duration effect and D/T treatment and 
duration interaction effect.   
7.4.7.2 Changes in plasma cholesterol (CHO) 
At the baseline (Table 7.2) there was a significant difference in the CHO levels between 
the control and cinnamon groups (P = 0.016). This is possibly because the cinnamon 
group had a slightly higher BMI, waist circumference, and hip circumference, which 
would mean they had a higher % body fat which could affect the CHO concentration. 
The cholesterol concentration (Figure 7.10) in the cinnamon group at weeks zero, four 
and eight were slightly higher (5.78 mmol/l, 5.75 mmol/l, 5.83 mmol/l, respectively) than 
in the control groups (4.84 mmol/l, 4.64 mmol/l, 4.60 mmol/l, respectively). Over time, 
there was no significant effect of the cinnamon treatment on CHO concentrations (P = 
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0.124). Overall this suggests that, despite the associated weight loss, the cinnamon 
treatment did not affect the concentrations of circulating CHO.  
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Figure 7.10: Cholesterol concentrations at baseline, weeks 4 and 8 of control and 
cinnamon groups. Cholesterol levels were determined in each participant (n = 15) at 
week 0, 4 and 8. Individual values are displayed with Mean ± SEM. ANOVA two-way 
analysis of variance, T treatment effect, D duration effect and D/T treatment and 
duration interaction effect.     
7.4.7.3 Changes in plasma high density lipoprotein (HDL) 
There was no significant difference in the HDL concentrations between the groups at 
the baseline (P = 0.427) (Table 7.2), but the cinnamon group was slightly higher. The 
HDL levels decreased slightly in the control group at weeks four and eight (Figure 7.11) 
(1.69 mmol/l and 1.62 mmol/l, respectively) compared with the baseline (1.76 mmol/l). 
In the cinnamon group the HDL concentrations increased slightly by week eight (2.01 
mmol/l) compared to the baseline (1.96 mmol/l), but neither of these changes reached 
statistical significance. Overall these results show that the cinnamon treatment caused 
small but insignificant changes to the HDL levels that could correlate with the weight 
loss observed.  
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Figure 7.11: HDL concentrations at baseline, weeks 4 and 8 of control and cinnamon 
groups. HDL were determined in each participant (n = 15) at week 0, 4 and 8. Individual 
values are displayed with Mean ± SEM. ANOVA two-way analysis of variance, T 
treatment effect, D duration effect and D/T treatment and duration interaction effect.     
7.4.7.4 Changes in plasma low density lipoprotein (LDL) 
The LDL value was calculated using Friedwald et al.’s (1972) formula: 
LDL = Total Cholesterol – (HDL – (TAG/2.2)) mmol/l 
At the baseline (Table 7.2) there was no significant difference in the LDL levels 
between the control and cinnamon groups (P = 0.78). The LDL value in the cinnamon 
group at weeks four and eight (Figure 7.12) were slightly higher than in the control 
group (4.34 mmol/l vs 3.41 mmol/l and 4.26 mmol/l vs 3.41 mmol/l, respectively), but 
the differences were not statistically significant.  In the cinnamon group, the LDL: HDL 
ratio after eight weeks was 1.7, which was similar to the baseline (1.7) and week four 
(1.7). In the control group, the ratio of LDL: HDL at the baseline was 1.5 and 
approximately remained the same after eight weeks (1.6). Overall these results show 
that the cinnamon treatment had no significant effect on the calculated LDL levels.  
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Figure 7.12: LDL concentrations at baseline, weeks 4 and 8 of control and cinnamon 
groups. LDL were calculated in each participant (n = 15) at week 0, 4 and 8. Individual 
values are displayed with Mean ± SEM. ANOVA two-way analysis of variance, T 
treatment effect, D duration effect and D/T treatment and duration interaction effect.     
7.4.7.5 Changes in plasma non-esterified fatty acids (NEFA) 
There were no significant differences in the NEFA levels at the baseline (P = 0.962) 
(Table 7.2). However, there was a significant effect of the treatment (P = 0.017) (Figure 
7.13), which showed consuming 5 g of a cinnamon supplement reduced the NEFA 
concentrations significantly. At the baseline, NEFA levels in the cinnamon and control 
groups were similar (0.82 mmol/l and 0.83 mmol/l, respectively), whereas after four 
and eight weeks, the NEFA concentrations in the cinnamon group decreased 
significantly to 0.48 mmol/l and 0.57 mmol/l, respectively. There was also a slight 
decrease in the NEFA levels for the control at weeks for and eight, but the reduction 
was not as large. This decrease in NEFA shows that the cinnamon treatment is having 
an effect. There was a positive correlation of NEFA with fasting insulin and insulin 
resistance (P = 0.030, R = 0.560; P = 0.028, R = 0.566, respectively). These results 
mean that reducing NEFA levels was associated with a reduction in fasting insulin and 
insulin resistance, which was observed in our data. Overall these results show that the 
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cinnamon treatment has significant effect on NEFA levels which fits with the slight 
reduction that was observed in fasting insulin and insulin resistance values. 
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Figure 7.13: NEFA concentrations at baseline, weeks 4 and 8 of control and cinnamon 
groups. NEFA were determined in each participant (n = 15) at week 0, 4 and 8. 
Individual values are displayed with Mean ± SEM. ANOVA two-way analysis of 
variance treatment effect, D duration effect and D/T treatment and duration interaction 
effect.     
7.4.8 Macronutrient composition calculated from the diet diaries  
Three-day diet diaries were collected from each participant prior to each study day trial. 
The (Table 7.4) macronutrient intake of the participants in both groups at the baseline 
shows there were no significant difference in the total energy intake, or in the intake of 
proteins, carbohydrates, total sugars, total fat, saturated fatty acids and fibre at the 
baseline.   
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Table 7.4 The macronutrient intake data from the three day diaries prior to the study 
day at the baseline. Data displayed as Mean ± SEM for the three days.  
Nutrients 
Control  
(n = 7) 
Mean ± SEM 
Cinnamon 
(n = 8) 
Mean ± SEM 
Unpaired 
t-test 
(p-value) 
Energy (kcal) 1804.86 ± 175.53 1753.12 ± 117.89 0.806 
Protein (g) 70.84 ± 6.63 80.63 ± 4.39 0.229 
Carbohydrate (g) 200.27 ± 18.04 173.73 ± 14.90 0.273 
Total Sugars (g) 79.13 ± 4.56 76.83 ± 7.67 0.809 
Total Fat (g) 76.99 ± 10.42 77.47 ± 8.00 0.970 
Saturated Fatty Acids (g) 27.93 ± 4.02 24.26 ± 2.35 0.431 
Fibre (g) 17.97 ± 3.48 17.31 ± 1.81 0.864 
 
 
7.4.8.1 Changes in macronutrient composition between the groups over eight 
weeks 
There was no significant change regarding the total energy intake, or the intake in 
proteins, carbohydrates, total sugars, total fat, saturated fatty acids and fibre after the 
intervention (Table 7.5 and Table 7.6) compared with the baseline (Table 7.4) in both 
groups. The results show that at week four (Table 7.5) in the cinnamon group there 
was a decrease in carbohydrate (28.36 g), sugar (8.33 g) and energy intake (44.75 
kcal) compared with the baseline, though this was not a statistically significant 
difference. Furthermore, in the control group at week four the carbohydrate and sugar 
intake decreased (14.24 g and 7.59 g, respectively) compared with the baseline. At 
week eight (Table 7.6) there were no significant changes in either group for all 
macronutrients. Overall this suggests that being in the study did not have a significant 
effect on the diet of the participants, at least those that were recorded.   
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Table 7.5 The macronutrient intake changes compared to baseline calculated from the 
three day diaries prior to the study day at week four. 
Macronutrients 
Control 
(n = 7) 
Mean ± SEM 
Paired  
t-test 
(p-value) 
Cinnamon 
(n = 8) 
Mean ± SEM 
Paired 
t-test 
(p-value) 
Energy (kcal) 
28.86 ± 
101.14 
0.785 
-44.75 ± 
241.57 
0.858 
Protein (g) 5.06 ± 5.90 0.424 0.83 ± 6.09 0.896 
Carbohydrate (g) -14.24 ± 17.13 0.438 -28.36 ± 27.32 0.334 
Total Sugars (g) -7.59 ± 6.27 0.272 -8.33 ± 12.69 0.533 
Total Fat (g) 7.57 ± 3.78 0.092 2.75 ± 11.61 0.820 
Saturated Fatty Acids 
(g) 
4.83 ± 2.80 0.135 0.49 ± 3.92 0.905 
Total Dietary Fibre (g) 0.39 ± 2.17 0.865 -2.01 ± 1.60 0.248 
 
Table 7.6 The macronutrient intake changes compared to baseline calculated from the 
three day diaries prior to the study day at week eight. 
Macronutrients 
Control 
(n = 7) 
Mean ± SEM 
Paired 
t-test 
(p-value) 
Cinnamon 
(n = 8) 
Mean ± SEM 
Paired 
t-test 
(p-value) 
Energy (kcal) -31.14 
129.5
0 
0.818 -1.71 
132.3
5 
0.990 
Protein (g) -2.94 5.38 0.604 2.49 4.12 0.569 
Carbohydrate (g) -15.11 13.02 0.290 -6.69 9.13 0.492 
Total Sugars (g) -10.39 8.40 0.263 0.20 9.43 0.984 
Total Fat (g) 3.17 7.42 0.684 -0.87 9.22 0.928 
Saturated Fatty Acids (g) 3.23 3.98 0.448 -2.14 2.50 0.425 
Total Dietary Fibre (g) 1.71 2.28 0.480 -1.47 0.99 0.190 
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7.5 Discussion 
Some studies have suggested that cinnamon has strong antioxidant, antibacterial, anti-
inflammatory, and anti-cancer and anti-viral properties, and therefore can be used in 
the treatment of common colds, CVD, and chronic gastrointestinal complaints 
(Verspohl et al., 2005; Kim et al., 2006; Molania et al., 2012; Hong et al., 2012). This 
study has shown that ingestion of 5 g of a C. cassia supplement for eight weeks 
reduced weight significantly (P = 0.01). Moreover, a significant reduction also occurred 
in the BMI and waist circumference of the participants in the treatment group when 
compared to the control. The total energy intake at the baseline in cinnamon and 
control groups were 1753.13 kcal, 1804.86 kcal, respectively. The total energy intake 
for both groups was lower than recommended dietary allowance (RDA) 
recommendation of energy (1900 kcal) by 7.7 % in cinnamon group and 4.86 % in 
control. The mean total carbohydrate consumed was 200.27 g in cinnamon group, 
which was 70 g the above RDA recommendation of 130 g, whereas the carbohydrate 
consumed in control (173.73 g) was slightly lower but also 43.73 g higher then RDA 
recommendation, which could influence the ability of the participants to lose weight. 
The potential change in weight based on energy intake and energy expenditure in the 
cinnamon and control groups was calculated using the details gathered in this study. 
It was estimated that the cinnamon and control participants had 30 min light exercise 
and 30 min standing and shopping per day. According to their age, weight, height and 
exercise amount, the mean total energy expenditure was 2534 kcal per day 
(http://www.health-calc.com/diet/energy-expenditure-advanced).The estimated weight 
loss in cinnamon group was between –0.78 kg, -0.74 kg per week. Whereas in control 
group the estimated weight loss was between -0.69 kg -0.72 kg per week. Therefore, 
the energy intake in both groups should help them to reduce their weight. However, 
the significant reduction was observed in cinnamon group only. 
There are many mechanisms that may explain the weight loss, for example analysis of 
the food intake for the cinnamon group over four weeks showed a slight reduction in 
the total energy intake (from 1753.13 kcal to 1708.37 kcal), which, as mentioned 
above, is partially responsible for the loss of one kilogram observed after four weeks, 
and the further loss over the following four weeks to give a total loss of about two 
kilograms. It is possible that cinnamon affected the satiety and gastric empting rate, 
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though this study did not determine either of these. Other studies have confirmed that 
adding 6 g of cinnamon to 300 g of rice pudding significantly reduced the postprandial 
blood glucose concentration and delayed gastric empting rate in 14 healthy subjects, 
but these researchers found that the cinnamon did not affect satiety (Hlebowicz et al., 
2007). It may be that the consumption of 5 g of cinnamon in this study delays the gastric 
emptying rate, and thus these participants consumed slightly less in total energy, which 
leads to a reduction in weight. In a different study it was shown that adding 1 or 3 g of 
C. cassia to 300 g of rice pudding did not affect the gastric empting rate, glucose or 
satiety in 15 healthy subjects, whereas 3 g of C. cassia significantly lowered the insulin 
response at 60 min and the area under the curve (AUC) at 120 min (Hlebowicz et al., 
2009). Overall these studies show that the concentration of C. cassia selected can 
have a large effect on the changes observed within the study.   
Controlling the insulin concentration has been shown to play an important role in 
managing an individual’s weight (Woods et al., 1985). Hlebowicz et al. (2009) showed 
that 3 g of cinnamon added to 300 g of rice pudding significantly reduced postprandial 
insulin response in healthy individuals, though this did not change the blood glucose 
concentration in the healthy subjects. The effect of cinnamon in Hlebowicz et al. (2007) 
and Hlebowicz et al. (2009) studies were acute studies and therefore they did not 
examine the long term effect of consuming cinnamon, whereas our study investigated 
the long term effects (eight weeks) and our results showed an insignificant reduction 
in the plasma fasting insulin levels.  
Studies in vitro have shown that cinnamon extract stimulated insulin receptors by 
activating insulin receptor kinase and insulin sensitivity (Imparl-Radosevich et al., 
2000). Further evidence of the effect of cinnamon comes from studies in vivo that 
showed oral administration of a cinnamon extract (30 and 300 mg/kg BW) for three 
weeks enhanced glucose utilization in rats, through stimulating insulin tyrosine 
phosphorylation of the insulin receptor-β and insulin receptor substrate-1 in skeletal 
muscle (Qin et al., 2003). This effect might be due to the fact that the administration 
cinnamon dose was very large (30 and 300 mg/kg BW). While in this study, the dose 
that participants consumed was 5 g per day, which was about 64.93 mg/kg body 
weight. Also, 300 mg of cinnamon per kg of body weight of rats is equivalent to 23 g of 
cinnamon in human. Therefore, in the animal study the large cinnamon dose may be 
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enough to enhance glucose uptake through stimulating insulin to bind with insulin 
receptors, whereas in our study the dose was not large enough to see this effect. 
Our findings showed that consuming 5 g of cinnamon for eight weeks led to a lower 
plasma fasting insulin level, from 16.43 µU/l at baseline to 13.05 µU/l at week eight, 
although this was not statistically significant. These results suggest that cinnamon may 
help reduce the demand for insulin. In addition, insulin resistance in the cinnamon 
group reduced from 2.20 at baseline to 1.82 at week eight, whereas in the control group 
there was a slight increase in this parameter. However, these changes did not reach a 
statistically significance level (P = 0.690), possibly due to the small sample size. In our 
data there was a positive correlation between systolic blood pressure and insulin 
resistance and fasting insulin (P = 0.024, R = 0.579; P = 0.030; R = 0.561). These 
results suggest that cinnamon has a small effect on insulin levels, which could be linked 
to the significant reduction in systolic blood pressure that was observed. In addition, it 
maybe that cinnamon improves the insulin signalling pathway, which would cause a 
reduction in the insulin resistance. This correlation was confirmed also by Baron et al. 
(1993) that hypertension is associated with insulin resistance. 
There is evidence to suggest that elevated plasma NEFA concentrations are 
associated with insulin resistance (Karpe et al., 2011), which correlates with our results 
that showed that taking 5 g of C. cassia for eight weeks significantly reduced NEFA (P 
= 0.017). According to our knowledge this study was the first study looking for the effect 
of cinnamon on NEFA levels. In this study there was a positive correlation of NEFA 
with fasting insulin and insulin resistance (P = 0.030, R = 0.560; P = 0.028, R = 0.566, 
respectively). Our results confirmed that a slight reduction in fasting insulin levels and 
insulin resistance were associated with a significant reduction in NEFA levels due to 
the cinnamon treatment. In addition, elevated plasma NEFA concentrations might be 
a marker for MetS, type 2 diabetes and CVD (Frayn and Williams, 1996). Therefore, 
the use of a 5 g cinnamon supplement that can significantly reduce the NEFA levels 
might improve overall metabolism and reduce the risk in the incidence of type 2 
diabetes and CVD, without any of the side effects associated with the usual 
medications. Furthermore, elevated NEFA concentrations can impair endothelial 
function and raise blood pressure (Steinberg et al., 2000; Florian et al., 2010). This, 
interestingly, is consistent with our findings (Chapter six) where ingesting 5 g of a 
cinnamon supplement slightly improved the expression of some adhesion molecules 
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(sVCAM, sICAM, sESEL, sPSEL, sLSEL) and significantly reduced blood pressure. 
Thus, our data shows that cinnamon significantly reduced NEFA concentrations which 
may be linked to the reduced weight, blood pressure and improved fasting insulin levels 
and improving endothelial function. There was, however, no difference in the ratio of 
LDL: HDL after eight weeks of intervention. 
Cinnamon contains an active biological compounds that might imitate insulin’s 
properties and improve glucose uptake in the body, for example C. cassia is rich in 
type-A procyanidins (Chapter 3). This finding is consistent with previous studies, as in 
vitro studies have highlighted that type-A procyanidin isolated from cinnamon 
enhances insulin receptors and increases insulin sensitivity (Anderson et al., 2004; Lu 
et al., 2011). This is likely to be one of the mechanisms of metformin with which it acts 
to produce satiety and weight loss (Lee and Morley., 1998). Our outcome showed 
consuming 5 g cinnamon for eight weeks caused a slightly reduced fasting insulin, 
however, this change in insulin did not lead to a change in fasting blood glucose. This, 
however, might be due to the low number of study subjects, but it is supported by the 
work of Wickenberg et al. (2012) who found that ingesting 6 g of Ceylon cinnamon did 
not have an effect on glucose levels and insulin response on participants with impaired 
glucose tolerance. The participants in our study were considered to be pre-diabetic 
because their fasting glucose was over 5.6 mmol/m, and in addition, their fasting insulin 
levels were high at the baseline, which indicated there was some insulin resistance.  
Moreover, cinnamon has been used in studies to treat people with type 2 diabetes. 
Khan et al. (2003) showed that ingesting 1, 3 and 6 g of C. cassia powder every day 
for 40 days lowered fasting glucose, TAG, LDL and total cholesterol of patients with 
type 2 diabetes. Nevertheless, consuming 112 mg of aqueous C. cassia extract in 
capsules, which corresponded to 3 g of cinnamon per day, for four months in 
participants with type 2 diabetes, reduced fasting plasma glucose but had no effect on 
CHO, LDL, HDL and TAG levels (Mang et al., 2006). In contrast, Blevins et al. (2007) 
found that ingesting 1 g of C. cassia every day for three months did not improve fasting 
glucose, or lipid and insulin concentrations in people with type 2 diabetes, but it is 
possible that this dose was too small to see an effect. Furthermore, there was no 
improvement seen in fasting plasma glucose levels, insulin levels, TAG, LDL, CHO, 
HDL, or insulin resistance in overweight postmenopausal women with type 2 diabetes 
consuming 1.5 g of C. cassia every day for six weeks (Vanschoonbeek et al., 2006). 
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Further support for a positive effect of consuming low doses of a cinnamon supplement 
comes from a study by Akilen et al. (2010). In their study, 58 poorly controlled type 2 
diabetic participants consumed 2 g of C. cassia supplement every day for 12 weeks. 
Fasting glucose, haemoglobin A1c (HbA1c), systolic and diastolic blood pressures 
were reduced significantly in the cinnamon group compared with the control group. 
Moreover, their BMI and waist circumference decreased, although this was not 
significant. There were also no significant differences in lipid profiles of total 
cholesterol, triglycerides, HDL and LDL cholesterol. The results of Akilen et al. (2010) 
study was consistent with our findings for the lipid profile (total cholesterol, HDL and 
LDL cholesterols), which showed no effect of cinnamon on the lipid profiles. Overall 
our outcomes show that the cinnamon treatment has no significant effect on LDL, CHO 
and HDL levels, which did not fit with the weight loss observed. In our finding there 
was no correlation between weight and LDL, CHO and HDL (P = 0.398, P = 0.268, P 
= 0.195, respectively). In systemic meta-analysis review that found the anti-obesity 
drugs were reduced 3.13 kg compared with placebo, however, this did not significantly 
reduce LDL, CHO and fasting glucose (Zhou et al., 2012). Thus, decreasing LDL, CHO 
and fasting glucose not necessarily associated with losing weight. 
 5 g of C. cassia for eight weeks significantly reduced NEFA (P = 0.017), and according 
to our knowledge this study was the first investigation looking for the effect of cinnamon 
on NEFA. The reduction in the fasting glucose levels in the subjects that were involved 
in the Akilen et al. (2010) study was due to the fact that the subjects had poorly 
controlled glucose levels, whilst our study participants were healthy. Therefore, the 
effects of cinnamon on the normal fasting glucose level, which was 5.8 mmol/l in the 
cinnamon group, may be minimalized, although we used 5 g of cinnamon for eight 
weeks. Ziegenfuss et al. (2006) evaluated the highest cinnamon dose (10 g) on fasting 
plasma glucose levels among pre-diabetics. They used 500 mg of Cinnulin PF® which 
is equivalent to approximately 10 g of whole cinnamon powder (i.e. 20:1 extract) and 
contains at least 1 % doubly-linked polyphenol type-A polymers. The baseline fasting 
plasma glucose was 6.46 mmol/l, and after 12 weeks of consuming 10 g equivalent of 
cinnamon, the fasting glucose and systolic blood pressure were significantly reduced. 
This effect on fasting glucose and systolic blood pressure might be due to their baseline 
levels being higher than normal, and therefore there was more scope for an effect to 
be seen in these subjects. Also, the cinnamon supplement was an extract of cinnamon 
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and not cinnamon powder, which was equivalent to 10 g of cinnamon powder, which 
is a high dose. However, in our study we did not find an effect of using 5 g of cinnamon 
in the fasting glucose results. This could be explained by the fact that our participants 
were healthy and their baseline fasting glucose levels were normal and lower than 
Ziegenfuss et al. (2006) participants.  
It is clear that there are conflicting findings on the effect of cinnamon, which may 
depend on the cinnamon dose, classification of the cinnamon used, the subject’s 
health status and the level of the baseline markers. In Khan et al. (2003) study, the 
participants had poorly controlled glucose levels and they did not receive anti-diabetic 
therapeutic treatments. In their study the positive effect of cinnamon was clear with 
high doses of cinnamon, which were 6 g, whilst it seems there was no effect using a 
low dose of cinnamon for the duration of the study.  
Interestingly, C. cassia has been shown to be more effective than C. zeylanicum in 
vivo studies. For example, Wickenberg et al. (2012) used a high dose of C. zeylanicum 
(6 g), but this treatment did not lead to a change in the fasting glucose, lipid or insulin 
concentrations, which agrees with our findings that the concentrations of polyphenols 
in these two types of cinnamon are different (Chapter 3), which could explain why the 
responses were not the same.  
The main cause of obesity and being overweight is an imbalance between energy 
intake and energy expenditure, therefore weight loss can be achieved through a 
reduction in food intake or increasing energy expenditure (Hursel and Westerterp-
Plantenga., 2010). Stimulation of fat oxidation and thermogenesis in the body is one 
approach in treating obesity and the management of an individual’s weight; the 
sympathetic nervous system (SNS) regulates energy expenditure and it is involved in 
thermogenesis, which can lead to an increase in the use of ATP, or to an increase in 
the rate of mitochondrial oxidation that increases heat production, which expends 
excess energy as heat (Westerterp-Plantenga et al., 2006). The interest in the 
thermogenic effects of natural herbal compounds, which affect the metabolism via 
satiety and increased energy expenditure, such as spices and herbs, has increased, 
especially because these ingredients do not contain any energy themselves (Henry 
and Emery., 1989; Dulloo, 1993; Hursel and Westerterp-Plantenga., 2010).   
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The anti-obesity thermogenic agents have cardiovascular effects such as increased 
hypertension and heart rate (Dulloo, 1999). Therefore, the interest in plants and herbs, 
such as ginger and green tea, that are not accompanied by cardiovascular effects has 
increased; consuming a ginger beverage affects thermogenic and increases satiety 
significantly, which suggests the potential role of ginger in weight management 
(Mansour et al., 2012). Studies have also shown that consuming 525 mg of green tea 
extract in capsular form, containing catechin polyphenol and caffeine, for 6 weeks 
significantly increases energy expenditure (4 %), and carbohydrate and fat oxidation 
in a 24 hour period, but does not increase the heart rate (Dulloo, 1999). Catechins in 
the green tea inhibit the enzyme catechol O-methyltransferase (COMT) that degrades 
catecholic compounds (Hursel and Westerterp-Plantenga., 2010). Catechin is one of 
the polyphenols found in cinnamon that was identified by LC-MS (Shan et al., 2007). 
This suggests that cinnamon catechins may play a similar role to green tea catechin, 
and inhibit catechol O-methyltransferase enzyme. Furthermore, procyanidins are 
metabolised by gut flora and broken down in the gut to catechins (Forester and 
Waterhouse, 2009), which may act in a similar way to green tea catechins. 
The LC-MS and HPLC analysis of cinnamon samples in this thesis confirmed that 
cinnamon is also rich in catechin polyphenols (Chapter 3). Therefore, it might be that 
cinnamon catechin polyphenols increased the energy expenditure and fat oxidation in 
the cinnamon participants, which led to a significant reduction in their weight. However, 
there was no effect on heart rate in the cinnamon group, and in this respect, the 
consumption of cinnamon is distinct from anti-obesity thermogenic agents, which 
increase the heart rate and can have cardiovascular effects. Unfortunately, there have 
been no studies published on cinnamon in relation to energy expenditure and fat 
oxidation. Our data showed that there is an effect of cinnamon on lipid profiles as NEFA 
was reduced significantly after consuming 5 g of cinnamon. This might be confirmation 
that cinnamon has a positive effect on fat metabolism, although the food diary analysis 
showed that there was no significant reduction in energy intake, but the energy intake, 
carbohydrate and fat of the cinnamon participants did decrease slightly during the 
cinnamon treatment.  
Despite the strengths of this RCT study design, there are some limitations to it, the key 
one being the small sample size that was obtained, which reduced the significance of 
the findings of the study. Within this study the counting of the capsules remaining in 
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the supplied bottles at 4 and 8 weeks in both groups, suggests the results are 
representative of the different treatments. One of the limitations of this study was that 
it did not determine energy expenditure, which could help to explain the weight loss. 
Another aspect that would have been useful to include was measuring the urinary 
polyphenols as potential biomarkers of polyphenol intake, as this would help to show 
the different absorption and excretion rates of cinnamon polyphenols in the 
participants, which could correlate with the response of the participants to the 
treatment, and help with assessing compliance. Furthermore, the effects of a high dose 
of cinnamon in the long term needs to be determined in respect of glucose, CHO and 
LDL levels.  
7.6 Conclusions  
Taken together, the findings of the present study demonstrated that consumption of 5 
g of C. cassia had a beneficial effect on certain markers, in particular a significant 
decrease in body weight, BMI, waist circumference, blood pressure, and NEFA. In 
addition, there was a slight reduction in fasting insulin levels, insulin resistance and 
energy intake. Nevertheless, there was no effect of the cinnamon on fasting glucose, 
LDL, HDL and total CHO levels. Fasting insulin was positively correlated with NEFA 
and systolic blood pressure. In addition, insulin resistance correlated with NEFA and 
systolic blood pressure. Overall, cinnamon supplementation (5 g/d for eight weeks) 
displayed important health benefits in this overweight group. Cinnamon may be useful 
as a natural herbal supplement in this setting. Cinnamon might be used as an anti-
diabetic and anti-obesity treatment, as well as potentially being used to reduce the risk 
of diabetes and CVD. The results of this study suggest that future work could further 
investigate the long term effects of taking cinnamon supplementation by measuring 
similar parameters, and also focusing on energy expenditure as well as intake, and 
measuring urinary polyphenols to see if this clarifies the results observed.
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Chapter 8 
8 General Discussion 
The prevalence of obesity and being overweight is increasing rapidly in many countries 
around the world, and both conditions are associated with an increased risk of 
developing type 2 diabetes, hypertension, dyslipidaemia and inflammatory disease 
(Mokdad et al., 2003; Klop et al., 2013). Losing weight reduces the risk that being 
overweight has on individuals in terms of developing diseases such as diabetes, and 
previous studies have shown that changes in lifestyle, such as increasing physical 
activity, improving diet, reduced-energy intake, pharmacotherapy, and surgery, are 
each in their own way effective approaches to preventing and treating obesity (Mokdad 
et al., 2003; Auvichayapat et al., 2008).  
Using natural herbal ingredients as a part of the daily diet has attracted a great deal of 
interest, not only because of their ability in helping to reduce an individual’s weight, but 
especially because these ingredients do not contain any appreciable energy 
themselves (Hursel and Westerterp-Plantenga., 2010). Most of the herbal products 
such as ginger, turmeric, green tea and cinnamon, contain high quantities of several 
polyphenolic compounds, which can produce beneficial effects within the body (Opara 
and Chohan., 2014). Westerterp-Plantenga et al. (2006) reported that the consumption 
of herbal products might produce an effect on metabolic targets such as satiety, 
thermogenesis, and fat oxidation, which might help in preventing obesity. Cinnamon is 
an herbal remedy that has been used for over a century; it is the inner bark of the 
cinnamomum tree, which belongs to the Lauraceae family. The main types of 
cinnamon are C. zeylanicum (also known as C. verum and C. cylone), which is 
produced in Sri Lanka, and C. cassia, which is grown in China (Ravindran et al., 2004; 
Hamidpour et al., 2015). The hypoglycaemic effects of cinnamon have been 
established in preliminary studies, both in vivo and in vitro (Cao et al., 2007).  However 
the effects of consuming C. cassia supplements by overweight individuals at an 
increased risk of developing type 2 diabetes and CVD have not been elucidated. It was 
hypothesised that daily supplementation with C. cassia reduces body weight by 
regulating glucose utilisation, lowering lipid concentrations, suppressing pro-
inflammatory cytokine production, and increasing antioxidant capacity. Therefore, 
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several methods have been used in this project to investigate the potential health 
benefits of cinnamon supplement, firstly in vitro and then subsequently in vivo. 
Herbal supplements have demonstrated they have potential in disease prevention and 
health promotion (Opara and Chohan., 2014). In addition, herbal supplements are 
easily accessible to the general public, compared to prescription pharmaceuticals. 
Scientific research supports the efficacy and safety of herbal therapies (Cheng et al., 
2012), and since 1980, the World Health Organization (WHO) expert committee has 
encouraged the use of medicinal herbs for treatment and prevention of diseases (Lu 
et al., 2010). 
Cinnamon is one of the most common herbs in the world, it is consumed as a flavouring 
spice, as cinnamon tea and as an herbal medicine supplement, and it had been used 
as a traditional medicine for thousands of years (Beejmohun et al., 2014). Many recent 
studies have reported that cinnamon contains biologically active substances that could 
be used to treat and prevent some diseases (Cao et al., 2007). This final chapter will 
review the health properties of cinnamon based on the outcome of a series of studies 
that have been performed in this project and will link them with current knowledge. 
8.1 Anti-oxidant properties of cinnamon supplement samples 
Antioxidants are either produced in the body (endogenous) or they are derived from 
the diet, both of which can directly affect the antioxidant status (Pham-Huy et al., 2008). 
Cinnamon contains phytochemicals which have powerful antioxidant activities 
(Dragland et al., 2003). Indeed, cinnamon was ranked as the fourth antioxidant rich 
food with respect to total antioxidant content, as it contains 17.647 mmol/100 g 
(Halvorsen et al., 2006). In this clinical long term project that studied the effect of 
cinnamon, the participants consumed 5 g of cinnamon, which has been shown 
previously to have a total antioxidant content of 0.882 mmol/g (Halvorsen et al., 2006).   
Polyphenols are amongst the natural dietary antioxidants found in cinnamon, which 
was shown by Helal et al. (2014) who reported that cinnamon contains many phenolic 
compounds including flavonoids, anthocyanins, and tannins, which increased 
antioxidant activity and thus offer beneficial health properties. The first objective of this 
thesis was to determine the polyphenol composition of cinnamon samples and to test 
their antioxidant activity.  
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The results (Chapter three) showed that the total phenolic content in C. cassia extract 
was 105.6 mg and in C. zeylanicum extract was 101.81 mg of Gallic acid equivalents/g 
of dry cinnamon. Furthermore, the condensed tannin (proanthocyanidin) contents in C. 
cassia and C. zeylanicum were 41.53 mg and 11.42 mg of procyanidin A2/g, 
respectively. The results of the HPLC and LC-MS analysis indicated that C. cassia 
contained two types of B-type dimers and two types of A-type trimers, while C. 
zeylanicum has only one type of B-type dimers and one A-type trimer. It is clear that 
the C. cassia extract analysed has a higher total phenolic and proanthocyanidin 
content than C. zeylanicum extract. Furthermore, C. cassia has a greater variety of 
types of procyanidin A and B compared with C. zeylanicum. A-type procyanidin 
contains (+) – catechin and/or (-) epicatechin units that doubly link through carbon 
C2→C7 and C4→C8. B-type procyanidin contains a single link through the C4→C8 
bond (Passos et al., 2007). Kondo et al. (2000) reported that procyanidins have 
antioxidant properties, which is consistent with our findings when the antioxidant 
activity of the cinnamon extracts were tested. The first antioxidant mechanism that was 
tested in this project, was the DPPH radical scavenging. The DPPH radical scavenging 
activity of the C. cassia acetone extract was significantly higher when compared with 
the positive control trolox: 34.99 % and 62.90 % respectively. In addition, C. cassia 
and C. zeylanicum acetone (75: 25) extracts possessed a significant (P ≤ 0.0001) 
scavenging activity of H2O2 compared to trolox (0.1 mg/ml): 96.06 %, 92.55 %, and 
48.73 %, respectively. Interestingly, the scavenging activity of H2O2 for both C. cassia 
and C. zeylanicum extracts were equal to the positive control BHT scavenging activity. 
However, when looking at the metal chelating activity of the cinnamon extracts, it was 
found that cinnamon could chelate ferrous ions, but only at a low level when compared 
to EDTA. This agrees with the results from Mathew and Abraham (2006) who found 
the metal chelating activity of their cinnamon extract (200 µg/ml) was only 3 %. 
Although they used different solvent to extract cinnamon which was methanol, they 
also found that the cinnamon was not as effective at metal chelating as EDTA. In 
addition, Su et al. (2007) determine the Fe2+ chelating activity of cinnamon that was 
0.72 ± 0.08 EDTA equivalents per gram of cinnamon. Also, this study outcome 
confirmed that cinnamon has a lower Fe2+ chelating activity.  
The natural antioxidants such as polyphenols that can be found in the diet can be 
formulated as functional foods, and may help prevent oxidative damage that occurs 
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within the body (Hamidpour et al., 2015). The antioxidants identified in cinnamon were 
polyphenols, such as epicatechin and tannin, and they could potentially replace 
synthetic antioxidants compounds used in food (Hamidpour et al., 2015). Synthetic 
antioxidants, such as BHT, have been added to many food products such as oil rich 
foods and heat- treated foods to protect them from oxidation, and the permitted levels 
allowed within a food stuff is 100 mg/kg (European Food Safety Authority, 2012). 
However, this compound is suspected of being carcinogenic and causing liver damage 
(Barchan et al., 2014), and so there is emphasis within the food industry to reduce its 
use. Therefore, cinnamon could potentially be used as a safe and natural antioxidant 
alternative compound in the food industry.   
Overall, cinnamon extracts showed an excellent free radical scavenging capacity at all 
concentrations compared with BHT and trolox, which were used as controls. Cinnamon 
might donate an electron or hydrogen atom to DPPH radicals and H2O2 to produce 
stable molecules. The acetone extract of C. cassia was significantly more effective at 
scavenging free radicals compared with trolox but not-significantly different to BHT. 
However, cinnamon has a weaker metal chelating activity (8.67 %) compared with 
EDTA (98.39 %) in this study outcome, which was consistent with the results of the 
study by Mathew and Abraham (2006). The antioxidant effect of cinnamon might 
mainly be due to their A-type and B-type procyanidin content, as many studies have 
reported that procyanidins have antioxidant properties (Kondo et al. 2000; Passos et 
al., 2007). In addition, in our study the LC-MS analysis of C. cassia confirmed that it 
contained procyanidins type-B, which agreed with Chen et al. (2012), and Chen et al. 
(2014), and also procyanidin type-A which agreed with Anderson et al. (2004) who 
isolated type-A procyanidins from cinnamon and these displayed antioxidant activities.  
8.2 Anti-glycaemic properties of cinnamon supplements 
Diabetes mellitus (DM) is one of the most prevalent and fastest growing diseases 
around the world, for example, in Saudi Arabia, Al-Rubeaan et al. (2015) highlighted 
that more than 50 % of Saudi population is either diabetic or pre-diabetic in a study 
that was conducted between 2007 and 2009. This is thought to be due to many 
reasons, such as changes in lifestyle and eating patterns. Recently, there is growing 
interest in using herbal medicines for the treatment and prevention of DM, and recent 
in vitro studies have reported that cinnamon contains active substances that mimic 
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insulin properties, and that it has anti-glycaemic effects (Qin et al., 2003; Khan et al., 
2003; Kim et al., 2006). Therefore, the second objective of this series of studies was 
to test the anti-glycaemic properties of cinnamon supplements both in vitro and in vivo, 
and in the short and long term, by using a digestive mechanism and in vivo study 
protocol. In vitro, the effect of cinnamon on the hydrolysis of a starch rich food was 
determined via RAG and SAG measurements. The method measured the glucose 
released from a starchy food after the hydrolysis process at 20 and 120 minutes 
(Englyst et al., 2000). The RAG value of a carbohydrate food correlates strongly with 
the glycaemic index (GI) value in vivo (Englyst et al., 1996). Englyst et al. (1999) has 
suggested that RAG might be linked to rapidly digested carbohydrates, which raise 
blood glucose and insulin response quickly. Conversely, SAG relates to slowly 
digested carbohydrates, which slow the elevation of blood glucose and the insulin 
response. The RAG and SAG methodology is based on enzymatic procedures that 
mimic small intestinal (brush border) digestive enzymes (Englyst et al., 2000; Englyst 
and Englyst, 2005).  
There are a number of factors that have an effect on the glycaemic response in vivo 
and these can be assessed to some extent in terms of the RAG value in vitro. For 
example foods rich in phytochemicals might present a low glycaemic response in vivo 
and a low value of RAG in vitro (Englyst and Englyst, 2005). GI has been shown to be 
negatively correlated with total phenol content in food in both healthy and diabetic 
patients (Williamson, 2013). Cinnamon is rich in phytochemicals, including 
polyphenols, and this study confirmed that both types of cinnamon (C. cassia and C. 
zeylanicum) had 105.6 mg and 101.81mg of Gallic acid equivalents/g of dry cinnamon, 
respectively. It is therefore feasible that cinnamon may have an effect on the GI if 
present in sufficiently high concentrations. 
The hypothesis of the study in vitro was that cinnamon polyphenols would interact with 
the starch hydrolysis process by potentially binding at different sites with digestive 
enzymes, which could inhibit their function and ultimately the levels of glucose 
released. This could be used for predicting the effect of the polyphenols on the GI of 
starchy foods, and it could also help determine the level of cinnamon polyphenols 
needed to produce an effect in vivo. 
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The results (Chapter four) showed that the RAG value of cornflakes was reduced in 
the presence of C. cassia and C. zeylanicum, the SAG values increased when the 
cinnamon doses were increased, and low RAG values were associated with high 
doses of cinnamon, compared with the cornflakes only control. The RAG values in the 
presence of C. cassia and C. zeylanicum, were quite similar at all the doses 
investigated. The addition of 64 mg, 96 mg, 128 mg and 160 mg of C. cassia to the 
cornflakes had a significant reduction on the RAG values (72.1 %, 69.8 %, 68.6 %, 
64.4 %, respectively), compared with the controls (81.3 %). Thus, the cinnamon effect 
is dose dependant; it reduced the RAG value and increased the SAG value. This 
reduction might be due to the cinnamon polyphenols interacting with the digestive 
carbohydrate enzymes, α-amylase and α-glycosidase, and inhibiting their function. 
Ranilla et al. (2010) investigated the effects of C. zeylanicum extract on α-amylase 
activity and they found that cinnamon concentrations of 12.5 and 25 mg/ml inhibited 
72 % and 77 % of α-amylase. C. cassia in this study was richer in proanthocyanidins 
(41.5 mg/g equivalent to procyanidin-A2) compared to C. zeylanicum (11.4 mg/g 
equivalent to procyanidin-A2), so this inhibiting effect might be related to cinnamon 
procyanidin content. A further study that highlighted the ability of procyanidins to inhibit 
α-amylase was conducted by Gu et al. (2011). They showed that cocoa procyanidins 
inhibited α-amylase activity by 17-45.5 % at 100 µM. 
 Acarbose delays the hydrolysis and digestion of complex carbohydrates in the upper 
small bowel via inhibition of pancreatic α-glucosidase and α-amylase activity, which 
hydrolyse complex starches to oligosaccharides in the small intestine. Subsequently 
this slows down the availability of glucose for absorption and helps to control 
hyperglycaemia after the meal, which means it can be used as a treatment for type 2 
diabetes (Standl et al., 2014). As it has a proven effect acarbose was used in this 
method as a control; the RAG and SAG values for cornflakes in the presence of 
acarbose were compared with the RAG and SAG values of cinnamon extract. Water-
based extracts were prepared for C. cassia (W.E. cassia), C. zeylanicum (W.E. 
zeylanicum) and acarbose (stock concentration, 1 g/ml) at different concentrations 
(12.8, 25.6, 51.2 µg/ ml). The acarbose can interfere with the freshly prepared enzymes 
that were added into the cornflakes to digest them. The results showed the effect of 
acarbose was dose dependent; at the concentrations of 12.8, 25.6 and 51.2 µg/ml 
decreased the RAG value by 54.77 %, 60.31 % and 66.62 %, respectively. However, 
Chapter 8 
222 
 
no effect on RAG values was observed for either cinnamon type at any concentration. 
This lack of effect was probably due to the low concentrations of cinnamon used. At 
high concentrations of cinnamon, which were added as powder (6.4 mg/ml), a similar 
effect to acarbose was observed by delaying the release of glucose from starch, 
possibly be inhibiting the digestive enzymes. The compensation between blank and 
standards with and without cinnamon demonstrated that cinnamon didn’t interfere with 
the glucose test. The slow rate of starch digestion could be useful in controlling and 
lowering the postprandial glucose (Hallfrisch and Behall, 2000). Thus, cinnamon may 
help to slow the digestion of the cornflakes, and other similar foods, by reducing the 
RAG value and increasing the SAG value. 
The next objective was to determine the acute effect of C. cassia supplementation on 
the glycaemic response in healthy humans. The GI classifies starch rich foods 
according to their physiological effect on blood glucose (Wolever et al., 1991). The 
results showed that ingesting 1 g of C. cassia supplement 15 minutes prior to 
consuming 25 g of available carbohydrate (cornflakes) did not change the glycaemic 
response. In addition, the incremental area under the curve (iAUC) was similar to that 
demonstrated for the controls. The iAUC results for the glucose drink, cinnamon 
supplement with cornflakes, and placebo with cornflakes were 145 ± 13, 146 ± 25 and 
146 ± 23 respectively. The GI value for the cornflakes when ingested with the cinnamon 
supplement was 99.0 ± 12, while the GI for the cornflakes only (with placebo) was 98.9 
± 9. This value was similar to the GI value for cornflakes that Wolever and Bolognesi 
(1996) obtained, which was 99, and shows there was no effect of the treatment. 
These results suggest that 1 g of C. cassia supplement was not enough to reduce the 
parameters measured that relate to the blood glucose levels. It is possible there was 
no effect because the participants were healthy and young; the mean age was 33 
years. Indeed, there are some acute studies that support the results of this study, for 
example Hlebowicz et al., (2009) showed that the addition of 1 g or 3 g of C. cassia to 
300 g of rice pudding did not have an effect on the blood glucose level of healthy 
participants. This study with rice pudding fed cinnamon at the same time as the starch 
rich food which is in contrast to that in the present study where the cinnamon was given 
before. Nevertheless, no difference was observed. 
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It is possible that a higher dose of cinnamon, such as 5 g or over, would be required 
to have an effect on the glycaemic response. However, this would mean that the 
participants would be consuming about 10 capsules of cinnamon in one go before 
consuming the cornflakes. This number of capsules is perhaps too high for the 
participants since it would require quite a long time for them to swallow them, which 
could also affect the results of the study.  In animal studies the cinnamon doses used 
have been higher, and therefore the effects were more clear, for example, in vivo, oral 
administration of the cinnamon extract (30 and 300 mg/kg BW) for three weeks 
enhanced glucose utilization in rats, through stimulating insulin tyrosine 
phosphorylation of insulin receptor-β and insulin receptor substrate-1 in skeletal 
muscle (Qin et al., 2003). In our study the daily cinnamon dose was 5 g which was 
about 65 mg/kg (BW). Therefore, to see an effect in humans by using the same high 
dose ratio, the dose required about 23 g of cinnamon, which shows that in the acute 
study the 1 g of cinnamon used was perhaps not enough. Although there was no 
significant effect of the cinnamon, the outcome of this study helped the investigator to 
design a study that investigated the effect of consuming cinnamon supplements in the 
long term.  
The long term study investigated the effect of consuming 5 g of C. cassia every day for 
eight weeks on fasting plasma glucose levels, fasting insulin levels and the oral glucose 
tolerance test (OGTT) results. The results for the fasting plasma glucose levels in the 
participants who consumed 5 g of cinnamon for eight weeks showed no significant 
effect on glucose concentrations. However these results are contrary to some other 
studies, for example many in vitro cell culture studies have highlighted that cinnamon 
improves glucose utilisation and mimics the effects of insulin (Mang et al., 2006). 
Furthermore, ingesting 1 g, 3 g and 6 g of C. cassia daily for 40 days decreased fasting 
glucose in people with type 2 diabetes (Khan et al., 2003). However our results do 
agree with a study that found there was no effect of consuming 6 g of C. zeylanicum 
on glucose and insulin response in healthy participants, but this was more to do with 
the type of cinnamon used not the dose selected (Wickenberg et al., 2012). These 
results suggest that cinnamon works well with type 2 diabetics, but does not change 
metabolic parameters in healthy over weight individuals. There may be other reasons 
for the lack of effect observed in our study; the duration might not have been long 
enough for the cinnamon to have an effect on the glucose metabolism, as some of the 
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studies with positive results were longer. Interestingly, the fasting insulin results in the 
cinnamon group showed there was a trend for reduced insulin concentrations, from 
16.43 µU/L at the baseline to 13.05 µU/L at week eight; however, this was not a 
statistically significant change. The results suggest that cinnamon may reduce the 
demand for insulin. In addition, insulin resistance in the cinnamon group was reduced 
from 2.20 at the baseline to 1.82 at week eight, whereas, in control group there was a 
slight increase. However, again these changes did not reach statistical significance (P 
= 0.690). The lack of significance in these results was because the number in each 
group was too small, which meant the power of the study was low. The effect at 90 % 
power required 18 individuals for the cinnamon group and 18 for the placebo group, 
but the number of participants that were involved in the study was small. Anderson et 
al., (2004) confirms that isolated type-A procyanidin from cinnamon enhances insulin 
receptors and increases insulin sensitivity in adipocytes in vitro. Recently, Kraus et al., 
(2009) synthesized type-A procyanidins from benzopyrilium salts and catechin, and 
highlighted the important need for methods to prepare polyphenols derived from 
cinnamon to allow them to be studied in isolation. Therefore, it might useful to test this 
synthesized type-A procyanidins in vitro and in vivo, but the type-A procyanidins may 
not be absorbed in the gut and so the concentrations tested in vitro may not actually 
be reached in the in vivo study, which would need to be taken into consideration when 
designing the study.   
Blevin et al. (2007) found that ingesting 1 g of C. cassia every day for three months did 
not improve fasting glucose, lipid or insulin concentrations in people with type 2 
diabetes. It is possible that the dose was too small to see an effect, and the participants 
were non healthy, as they had type 2 diabetes, which could affect the outcome. In the 
study by Akilen et al. (2010), 58 poorly controlled type 2 diabetic participants consumed 
2 g of C. cassia supplement every day for 12 weeks. Their fasting glucose, HbA1c, and 
systolic and diastolic blood pressures were reduced significantly in the cinnamon group 
compared with the control group. Moreover, their BMI and waist circumference 
decreased, although this was not a significant difference. These effects may have been 
seen because the participants were not able to control their glucose levels, and the 
number of the participants was large, so this would allow any actual effects to be seen. 
Ziegenfuss et al. (2006) evaluated the highest cinnamon dose (10 g), which was 500 
mg of Cinnulin PF® and equivalent to approximately 10 g of whole cinnamon powder 
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(i.e. 20:1 extract), which contained at least 1 % doubly-linked polyphenol type-A 
polymers. They investigated the effect of cinnamon on fasting plasma glucose levels 
among pre-diabetics; who had a baseline fasting plasma glucose of 6.46 mmol/l. After 
12 weeks of consuming 10 g equivalent of cinnamon, the fasting glucose and systolic 
blood pressure were significantly reduced. This effect on fasting glucose and systolic 
blood pressure might be due to their baseline levels being higher and therefore the 
effects could be greater in these subjects, as they could reduce to normal levels. Also, 
the cinnamon supplement was an extract of cinnamon and not cinnamon powder, 
which could have made it more potent, and the dose was equivalent to 10 g of 
cinnamon powder, which is high. However, in our study we did not find an effect of 
using 5 g of cinnamon in the fasting glucose results. This could be explained by the 
fact that our participants were healthy and their baseline fasting glucose levels were 
normal and lower then Ziegenfuss et al.’s (2006) participants, and it is harder to lower 
a parameter that is already in the normal range. Although, consuming 5 g of cinnamon 
for 8 weeks did slightly reduce insulin levels, there were no changes in the glucose 
levels. This might be due to the fact that the participants were healthy and their 
baseline of fasting glucose was within the normal range.   
8.3 Anti- inflammatory properties of C. cassia supplements 
Inflammation plays a key role in the pathogenesis of a number of chronic diseases 
such as obesity and CVD (Umar et al., 2015). NSAIDs such as ibuprofen and aspirin, 
are used to manage inflammatory conditions, however, they have unwanted side 
effects including intestinal ulcers, bleeding and skin reactions (Rainsford, 1999). These 
side effects provide the motivation for looking for natural anti-inflammatory treatments 
with fewer side effects, such as using food and herbal medicines with anti-inflammatory 
properties (Gunawardena et al., 2015). Cinnamon is a traditional Chinese medicine 
which was used by the Chinese and Egyptians to treat pain, fever and backache (Lee 
and Balick, 2005). Some studies report that cinnamon has anti-inflammatory properties 
in vitro (Gruenwald et al., 2010), therefore the objective of this part of the study was to 
measure the anti-inflammatory properties of cinnamon in humans. This was done by 
determining the serum inflammatory marker levels in overweight women after 
consuming 5g of C. cassia supplement for eight weeks. As far as we know, this study 
was the first research to investigate the effect of C. cassia supplementation on the 
extensive profiles of cytokines and adhesion molecules used in overweight healthy 
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subjects. Also, the current data regarding the cytokine profiles in healthy overweight 
and older individuals has been limited, therefore, the data produced in this study might 
be used to apply for further research to study the cytokine profiles in these groups.  
The inflammatory markers measured in this study were IL-6, IL-8, IL-10, MCP-1, TNF-
α, CRP, VCAM, ICAM, E-selectin, P-selectin and L-selectin. The results show that all 
of these markers, before and after treatment, were within the normal range.  
The findings from the data showed that IL-6 levels were significantly increased due to 
the duration effect (P < 0.05), and the baseline level of IL-6 in the cinnamon group was 
in the low normal range. These results may be due to the fact that IL-6 has both anti-
inflammatory and pro-inflammatory functions. Pini et al. (2013) and Wallenius et al. 
(2002) both stated that obesity is associated with high levels of IL-6 and also IL-6 
deficiency. The cinnamon group saw a significant reduction in their weight and this 
may have helped to change the levels of IL-6. Elevated IL-6 concentrations are also 
associated with insulin resistance and high systolic and diastolic blood pressure 
(Bermudez, et al., 2002). Although we found that the IL-6 concentration increased in 
the cinnamon group, the insulin resistance reduced slightly and blood pressure was 
reduced significantly by the treatment. 
The increased levels of IL-6 levels were still in the normal range, so there should be 
no specific concern as to the effects of cinnamon on this marker. Nevertheless, acute 
IL-6 treatment has been shown to increase insulin stimulated glucose disposal 
(uptake), and increase fatty acid oxidation in vitro (Carey et al., 2006). Although the 
significant increase in IL-6 concentration was due to the effect of duration, the mean 
IL-6 concentration in the cinnamon group at weeks four and eight increased, whereas 
the mean IL-6 concentration in the control group did not change. Therefore this 
suggests the increasing IL-6 level was not a risk marker, as this is in the normal range. 
It might be that increasing the IL-6 in the maximum normal range is a good target to 
have, as it may have health benefits such as a reduction in weight. 
The variability in IL-6 over time might suggests there was another reason for the 
increased levels of IL-6. In Biancottoet et al. (2013) study 27 cytokines levels were 
determine in 144 healthy participants, age between 21-62 year, at baseline and after 
7 days. Their outcome showed a higher variability between the cytokines levels over 
time. Furthermore, the circulation of TNF-α and IL-6 levels were determined at the 
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baseline (day 1), 2, 3, 8, 15, 22, 50 and day 78 in 10 patients with heart failure and 10 
healthy subjects. The variation for TNF-α and IL-6 levels increased over time in both 
groups (healthy and heart failure) and there were no significant differences between 
heart failure and control subjects (Dibbs et al., 1999). Thus, the variability is expected 
in the cytokines levels over time in healthy and heart failure patients and this suggests 
any small effect caused by cinnamon would be masked by the natural change.  
Several studies have shown that IL-6, TNF-α and CRP increase with age in healthy 
and in overweight or obese individuals (Singh and Newman, 2011). This was not 
noticeable in our study participants either at the baseline or during the treatment, even 
though they were older, aged over 53, and healthy overweight. There was also no 
significant effect of the cinnamon supplementation on TNF-α and CRP levels, but there 
was a slight reduction in CRP and TNF-α in the cinnamon group, while these did not 
change in the control group. Moreover, the slight reduction in CRP and TNF-α in the 
cinnamon group was associated with a significant reduction in weight. There was 
evidence to suggest that the weight lowering property of fruit and green teas in 
overweight populations is related to their polyphenols, as these might alter the gut 
microflora. In vitro, the metabolism of proanthocyanidins via microflora can derive anti-
inflammatory properties, which reduce the secretion of TNF- α, IL-1b and IL-6, so it is 
possible that this effect is occurring in vivo in the participants in this study (Cardona et 
al., 2013).  
One of the other markers we investigated was IL-10, which is a cytokine that 
suppresses the immune response and inhibits the production of pro-inflammatory and 
systemic inflammatory compounds such as TNF-α and CRP (Lee et al., 2002). 
Interestingly, the anti-inflammatory IL-10 concentration increased slightly during the 
treatment from 0.88 pg/ml at the baseline to 1.07 pg/ml at week eight in the cinnamon 
group; but this was not significant. However, in the control group the IL-10 levels were 
almost the same throughout the experiment. It seems that cinnamon, in addition to the 
effect of time, increased the cytokine’s network and lead to an efficient inflammatory 
response, which can confer high resistance to infectious diseases.  
Animal studies have confirmed that cinnamon has an effect on inflammatory markers. 
The study showed that feeding an aqueous cinnamon extract orally at doses of 20 
mg/kg and 100 mg/kg to mice, which have high serum IL-6 and TNF-α levels, for six 
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days reduced both IL-6 and TNF-α levels significantly (Hong et al., 2012). In a recent 
in vitro study, Gunawardena et al. (2015) emphasised that E-cinnamaldehyde in 
cinnamon extracts has the ability to inhibit TNF-α production in RAW 264.7 
macrophages. This research suggests the cinnamon polyphenols content, such as 
type A and B procyanidins and catechin, and E-cinnamaldehyde, may be the main 
active biological compounds in cinnamon which gives it the anti-inflammation 
properties.  
The investigation of the adhesion molecules in this study showed there was no 
significant effect of cinnamon supplementation on the levels of the markers, which 
included sVCAM, sICAM, sE-selectin, sP-selectin and sL-selectin. Interestingly, there 
was a slight reduction in the levels of sVCAM, sICAM, sE-selectin, sP-selectin and sL-
selectin, which would suggest the cinnamon was having an effect, but the number of 
participants was too low for this to be significant. Adhesion molecules including 
sVCAM, sICAM, sESEL, sPSEL and sLSEL are on the cell surface of vascular 
endothelial cells and are involved in endothelial function (Carlos and Harlan, 1994). It 
seems that cinnamon improves the endothelial function and reduces the sVCAM, 
sICAM, sESEL, sPSEL and sLSEL concentrations slightly. There have been no studies 
in humans using cinnamon supplementation that have investigated the effects on 
adhesion molecule markers to compare with our outcomes. However, there were some 
studies that tested the effect of food polyphenols on some adhesion molecule markers. 
Barona et al. (2012) studied the effect of consuming 46 g/d of grape polyphenol 
supplements for 30 days on 25 participants with metabolic syndrome, who were at high 
risk of developing high blood pressure. The results of this crossover study showed a 
significant decline in sICAM-1 concentrations by 10 µg/L (142 ± 50 µg/L), in the grape 
group compared with placebo (151 ±51 µg/L), whereas, the plasma sVCAM-1 levels 
did not differ between the grape (1020 ± 285 µg/L) and placebo (1020 ± 240 µg/L). In 
our study, there were no significant effects on the adhesion molecule markers. This is 
possibly related to the small number of the participants that were involved in this study. 
8.4 Lipid lowering properties 
According to some previous studies, cinnamon has a positive effect on lipid profiles 
(Khan et al., 2003). Therefore, an objective of this study was to determine the effect of 
ingesting 5 g of C. cassia supplementation on lipid profiles which included CHO, HDL, 
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LDL, TAG and NEFA. Previous studies have examined some of these markers, but 
according to our knowledge this study was the first to look at the effect of cinnamon on 
NEFA levels. The findings (Chapter seven) highlighted that NEFA concentrations 
decreased significantly after ingesting 5 g of C. cassia (P = 0.017). Elevated plasma 
NEFA concentrations are associated with insulin resistance (Karpe et al., 2011). As 
mentioned above, insulin resistance was reduced slightly in the participants consuming 
cinnamon, which might be as a result of the NEFA concentrations being reduced 
significantly. This finding might go some way to reduce the risk of type 2 diabetes and 
CVD, as Frayn and Williams (1996) stated that elevated plasma NEFA concentrations 
might be a marker for metabolic syndrome, type 2 diabetes and CVD. Our data 
demonstrated that reducing NEFA levels was correlated with a reduced fasting insulin 
level and insulin resistance (P = 0.030, R = 0.560; P = 0.028, R = 0.566, respectively). 
Within the literature there was no studies on cinnamon and the effect on the NEFA 
concentration to compare our results with. 
Within our results there was no significant change in CHO, HDL, and LDL levels after 
consuming 5 g of C. cassia. These findings agree with Mang et al. (2006) who found 
that ingesting 3 g of cinnamon capsules for four months did not change CHO, HDL, 
and LDL levels in 79 type 2 diabetes participants. Also in another study, ingestion of 
1.5 g of C. cassia supplements for six weeks did not change CHO, HDL, and LDL 
concentrations in cinnamon group (placebo: 13, cinnamon: 12) (Vanschoonbeek et al., 
2006). Overall from these results it is clear that cinnamon did not change the CHO, 
HDL, and LDL concentrations, though did significantly reduce NEFA levels.  
8.5 Blood pressure lowering properties  
Hypertension is one of the major risk factors for developing CVD, therefore focus on 
the management of blood pressure has shifted from conventional pharmacologic 
approaches, as the therapeutic powers of plants have become more widely recognised 
(Perez-Vizcaino et al., 2009). Plant, fruit and herbs might contain specific components 
that reduce blood pressure, such as polyphenols (Perez-Vizcaino et al., 2009). 
Cinnamon is one of the promising herbal supplements that could be used to help 
reduce blood pressure, but data on its blood pressure lowering potential is limited. 
Therefore, an objective in this study was to look at the effect of 5 g of C. cassia on 
resting blood pressure. 
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The outcome of this cinnamon study on resting blood pressure showed that 5 g per 
day of C. cassia supplementation for eight weeks reduced blood pressure significantly; 
the systolic blood pressure was reduced at both weeks four and eight to 114.75 mm 
Hg and 105.43 mm Hg, respectively (P = 0.04 and P = 0.01 respectively). The diastolic 
blood pressure decreased significantly at week eight to 73.28 mm Hg compared with 
the baseline 83.00 ± 3.2 (P = 0.02), while there were no changes observed in the 
control group for either blood pressure measure. According to a recent meta-analysis 
that was run by Akilen et al. (2013), there were only three randomised controlled trials 
that studied the effect of cinnamon on blood pressure. In the Akilen et al. (2010) study, 
the cinnamon (C. cassia) dose was 2 g/d for 12 weeks, (N = 58). This cinnamon daily 
dose significantly reduced the systolic and diastolic blood pressure (P < 0.001). The 
baseline of the systolic and diastolic blood pressure in the cinnamon group was 133 
mm Hg and 85 mm Hg respectively, while the placebo group was 135 mm Hg and 86 
mm Hg, respectively. After the treatment, the systolic and diastolic blood pressure of 
the cinnamon group was 129 mm Hg and 81 mm Hg respectively, while the placebo 
group was 134 mm Hg and 87 mm Hg, respectively, which is similar to the results of 
our study. Another study found that ingesting 500 mg of daily cinnamon extract 
(Cinnulin PF®), which is equivalent to 10 g of cinnamon, for 12 weeks reduced systolic 
blood pressure significantly within the cinnamon group (n = 12) from 133 ± 14 mm Hg 
[pre] to 128 ± 18 mm Hg compared with the placebo group (n = 10) (Ziegenfuss et al., 
2006). On the other hand, Wainstein et al. (2011) found a marginal effect (P = 0.06) of 
1.2 g/d (n = 59) of cinnamon for 12 weeks on blood pressure, which might be because 
they only used a low dose of cinnamon. Overall these results suggest that the effect of 
cinnamon on blood pressure is dose dependent. Also, in the previous study, the 
baseline of blood pressure was high, and the higher the blood pressure the greater the 
chance it has to decrease, so the participants demonstrated a reduction in their blood 
pressure. However, in our study the participant’s blood pressure was within the normal 
range at baseline. 
Preuss et al. (2006) reported that nutrients and drugs that enhance insulin sensitivity 
or reduce insulin levels, also have the capacity to lower blood pressure in rats 
consuming high levels of sugars. This fits with our data as there was a significant 
reduction in blood pressure associated with a slight decrease in insulin resistance 
(Chapter six). This means that cinnamon components significantly reduced systolic 
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and diastolic blood pressure, which led to slight reduction in fasting insulin. Our 
outcome showed that systolic blood pressure positively correlated with fasting insulin 
and insulin resistance (P = 0.030, R = 0.561; P = 0.024, R = 0.579, respectively). 
Damaged endothelial cells in blood vessels express high concentrations of adhesion 
molecules, which increases the inflammation and might lead to an increased blood 
pressure (Borana et al., 2012). CRP has been found to be strongly associated with an 
increased risk of hypertension in women (Sesso et al., 2007). There is also evidence 
that blood pressure is related to adhesion molecules, such as ICAM, VCAM, sESEL, 
sPSEL and sLSEL and CRP, and thus their concentrations could be used as a risk 
marker of hypertension and CVD. This evidence was confirmed by the Ghanem et al. 
(2007) study which showed that sPSEL and sESEL were positively correlated with 
hypertension (R = 0.512, P = 0.051; R = 0.523, P = 0.045, respectively). Our data 
agree with this correlation that sPSEL correlated with systolic blood pressure (R = 
0.512, P = 0.051), and in addition there was a positive correlation between sESEL and 
systolic blood pressure (R = 0.523, P = 0.045). For this reason, one of our objectives 
(Chapter six) was to determine the inflammatory marker levels, and as previously 
stated our findings showed a small (but not significant) reduction in adhesion molecule 
markers ICAM, VCAM, sESEL, sPSEL and sLSEL and CRP, which might be related 
to the lowered blood pressure observed.  
8.6 Weight reducing properties  
The prevalence of obesity and being overweight is increasing worldwide, and obesity 
increases the risk of chronic diseases such as diabetes mellitus and CVD, including 
hypertension (Auvichayapat et al., 2008). The main cause of obesity and being 
overweight is an imbalance between energy intake and energy expenditure. There are 
many strategies to reduce weight, such as reducing energy intake, increasing exercise 
levels, and increasing the consumption of food rich in polyphenols which leads to 
greater satiety, energy expenditure and fat oxidation (Westerterp-Plantenga et al., 
2006; Rastmanesh et al., 2011).  
The findings from assessing body weight during the eight weeks showed that the group 
taking the C. cassia supplement lost about 2 kg, while no changes were recorded in 
the placebo group after both four and eight weeks. By analysing the food intake data 
of the cinnamon group, the results over the first four weeks showed a slight reduction 
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in the total energy intake (from 1753.13 kcal to 1708.37 kcal), which could be the 
reason why 1 kg was lost after four weeks of consuming cinnamon supplementation. 
By the end of experiment the participants had lost about 2 kg. In addition to the energy 
reduction, it might be that cinnamon components effect satiety and delay the gastric 
empting rate; however, this study did not measure either of these parameters to 
confirm this. A further explanation for the weight loss was that the fasting insulin data 
showed a marginal decrease from 16.43 µU/l at the baseline to 13.05 µU/l at week 
eight; however, this was not a statistically significant difference. In addition, insulin 
resistance in the cinnamon group was reduced slightly from 2.20 at the baseline to 
1.82 at week eight, whereas in the control group there was a slight increase. Also the 
lipid profile outcomes showed that NEFA was reduced significantly after consuming 5 
g of cinnamon (P = 0.017). This might be confirmation that cinnamon has a positive 
effect on fat metabolism, which leads to a reduction in weight. Other studies have 
shown that consuming 525 mg of green tea extract in capsular form, which contained 
catechin polyphenol and caffeine, for 6 weeks significantly increased energy 
expenditure (4 %), and carbohydrate and fat oxidation in a 24-hour period, but did not 
increase the heart rate (Dulloo, 1999). In another green tea study, sixty participants 
(green tea: 30, placebo: 30) consumed 750 mg of green tea or placebo in capsules 
form every day for 12 weeks. The participants’ weight in the green tea group decreased 
significantly, and the total reduction was 3 kg during 12 weeks (Auvichayapat et al., 
2008). It seems that green tea increased energy expenditure, which agrees with our 
results that polyphenol containing plants and herbs can influence weight loss.  
8.7 Concluding remarks 
This thesis has examined the health properties of cinnamon supplementation through 
different approaches both in vitro and in vivo. The in vitro results have shown that 
cinnamon has active components and performs well in terms of antioxidant activities. 
Furthermore, the components of cinnamon might inhibit digestive enzymes and reduce 
their function, which suggests this could thus be used as an alternative to acarbose 
that is used as a treatment for type 2 diabetes. The in vitro data showed that the effect 
of cinnamon was dose dependent as shown by the results for the antioxidant activity 
approaches, and the RAG and SAG values. In the human study, C. cassia 
supplementation (5 g/d for eight weeks) displayed important health benefits in 
overweight individuals that were at risk of developing type 2 diabetes and CVD. The 
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results showed a significant effect in NEFA, weight, blood pressure and IL-6 levels, 
and a slight decrease in some inflammatory markers such as CRP, ICAM and VCAM. 
Overall this study suggests cinnamon may be useful as a natural herbal supplement 
for overweight people trying to control their weight, and cinnamon has the potential be 
used as an anti-diabetic, anti-inflammatory, anti-obesity product and could reduce the 
risk of CVD by reducing the blood pressure.  
8.8 Future work 
- Further studies are needed to confirm the health impact of consuming C. cassia in 
type 2 diabetic and hypertensive participants.  
- Comparison of the GI of different rich starchy foods that are consumed with cinnamon 
(C. cassia and C. zeylanicum).  
- Comparison of the GI of rich starchy foods that are consumed with   C. cassia and at 
high dose, five grams and over.  
- Comparison of the GI of rich starchy foods that are consumed with C. zeylanicum and 
at high dose, five grams and over. 
- Investigate the effect of cinnamon on the digestive enzyme α-amylase in pure form. 
- Determine the effect of cinnamon on energy expenditure.  
All of these studies can follow a similar protocol as described in this thesis, but to make 
the results statistically significant they need to recruit a larger number of participants 
for the treatment and control groups. 
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Appendix 5 
Questionnaire 
Date  ………………………                      Reference number:  ………… 
PERSONAL DETAILS  
Title:  ………………………                      DOB:  ……/……/…… 
Family name: ………………………                      Age:  ……………….. 
Initials: ………………………  (18 – 60) 
Address: ……………………… 
  ………………………   
Telephone: Day ……………… 
  Evening……………... 
Weight (kg): …………… Height (m):   …………..  
GENERAL HEALTH 
Condition/Disorder YES NO 
Psychiatric Disorders   
Drug/Alcohol dependence   
Epilepsy   
Sleep Disorders e.g. Insomnia   
Endocrine Disorders (inc. Diabetes)   
Cardiovascular Disease   
Blood Pressure-Hypertension   
Renal Disease   
Hepatic Disease   
Gastrointestinal Disease   
Cinnamon allergic   
Any food allergies YES/NO 
IF YES: 
Food/s   …………………………………………………………………. 
 
GENERAL QUESTIONS 
Nicotine exposure (please tick the relevant box) Smoker           How many a 
day………… 
Non-smoker  
Do you consume Indian food?      Yes            No  
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Do you drink cinnamon tea?       Yes            No  
Have you ever added cinnamon powder to your drinks?   Yes            No  
Have you ever suffered ill effects after consuming cinnamon rich foods? Yes            No  
 
Average caffeine consumption/day  
How many cups/day:-    Tea……………………….. 
     Decaffeinated tea………… 
     Herbal tea………………… 
     Coffee…………………….. 
     Decaffeinated coffee……… 
     Cola ………………………. 
Average alcohol consumption/week  ……………………. 
 
Pint of beer is 2 units, 125 ml Glass of wine is 1 unit 
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Appendix 6 
PARTICIPANT INFORMATION SHEET:  
PROJECT TITLE: Assessment of the effect of a cinnamon supplement on the 
glycaemic index and insulin index of a starch rich food  
INSTITUTION: Department of Nutrition and Metabolism, Faculty of Health and Medical 
Sciences, University of Surrey  
INVESTIGATORS: Tahany Aldayel, Dr Jonathan Brown, Professor Susan Lanham-New 
 
A: INTRODUCTION 
We would like to invite you to take part in a research project. Before you decide you need to 
understand why the research is being done and what it will involve for you. Please take the 
time to read the following information carefully. Talk to others about the study if you wish. 
B: BACKGROUND 
Many herbal products are now available that claim to have health beneficial properties. 
Cinnamon is an example of this which has been claimed to help lower high blood sugar levels. 
Furthermore cinnamon is a traditional remedy used in some countries in the treatment of 
diabetes. Cinnamon contains some important components that may help the body use sugar 
more appropriately. Sugar in the body comes from foods that contain carbohydrates and the 
ability of the body to use this sugar has an effect of the amount of sugar in the blood. The 
glycaemic index approach is a method used to rank carbohydrate rich foods based on their 
ability to affect blood glucose (blood sugar) levels. This project will involve an investigation into 
the effect of a cinnamon supplement on the glycaemic index (GI) and insulin response of a 
starch rich food and to compare it with the glycaemic index of the same food without the 
cinnamon supplement. The amount of carbohydrate in these foods is known and the responses 
produced will be compared to the same amount of carbohydrate in a reference food (glucose).  
We will ask you to attend seven study legs in total in order to complete the study. The study 
will take place at the Clinical Investigation Unit (17AX00) of the Faculty of Health and Medical 
Sciences. Each leg will last a maximum of 3 hours and be carried out in the morning between 
08.00 hours and 11:00 hours. On two occasions you will consume two capsules (total 1000 
mg) of the cinnamon supplement (Holland and Barrett) 15 minutes prior to the cornflakes; on 
two further days you will consume two placebo tablets 15 minutes prior to the cornflakes. On 
the three other study legs/occasions you will consume the reference food (glucose drink). 
There will be at least two days between study days.  
This study uses a WHO/FAO protocol for assessing the glycaemic index (GI) of the starch rich 
food. The aim of the study is to see whether consuming the cinnamon supplement before the 
starch rich food has an effect on the GI and insulin response.     
   
YOU CAN ONLY TAKE PART IN THIS STUDY IF YOU ARE: 
1. Aged 18-60 years 
2. Free from medication with the exception of minor analgesics e.g. paracetamol  
3. Free from cinnamon allergy  
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YOU CANNOT TAKE PART IN THIS STUDY IF YOU: 
1. Have a familial or personal history of psychiatric disorders, epilepsy, sleep 
      disorders, diabetes, CHD or hypertension, liver disorder or food allergies 
2. Have suffered from infectious hepatitis, jaundice, malaria, tuberculosis and are not HIV 
positive 
3. Have a history of drug or alcohol abuse 
4. Have taken any medication (with the exception of minor analgesics or oral contraceptives) 
within 2 weeks of the start of the study 
5. Have received an experimental drug either clinically or recreationally within the past 3  
        months 
6. Have a phobia of needles/sight of blood 
7. Are or may be pregnant 
8. Have cinnamon allergy 
 
C: PRELIMINARY 
1. SCREENING 
As part of the screening process, you will be asked to answer a screening questionnaire to 
determine your general health status (Appendix 1) and to assess your suitability to participate 
in the study. Depending on the results of your screening evaluation, you may then be eligible 
to participate. All information obtained will be restricted to the investigators only and will be 
kept strictly confidential. All participates must sign a consent form. 
2. PROCEDURES TO BE FOLLOWED 
For 24 hours prior to the study day, you must refrain from consuming alcohol and caffeine-
containing drinks (tea/coffee/carbonated soft drinks such as Pepsi, Coco-cola, Red Bull) and 
avoid strenuous exercise throughout the day before and during the study day. You will not be 
allowed to consume any food or drink, with the exception of water, from 20:00 h prior to the 
study day. 
3. EXPECTED DURATION OF THE STUDY 
You will be asked to attend the Clinical Investigation Unit on seven occasions during the day 
(08:00 hours-11:00 hours). There will be at least two days between each study day. 
4. NUMBER OF SUBJECTS EXPECTED TO PARTICIPATE 
You will be one of approximately 10 subjects who will participate in this study 
D: Protocol 
Study day 1  
You will be required to arrive at the Clinical Investigation Unit (Room 17 AX 00) at 08:00h on 
the day of the study. Blood samples will be collected by finger pricks using preset lancets 8 
samples for each study leg with cinnamon supplement and placebo, whereas reference legs 
required 7 samples. One basal sample will be collected at the start of the study (-15 minutes). 
You will then be asked to consume two capsules (Cinnamon or placebo) +100 ml of water. 
After 15 minutes (0 minutes) a further blood samples will be taken after that you will be asked 
to eat a portion of cornflakes (30 g). Finger prick blood samples (No less than 300 l per 
sample) will be collected at -15, 0, 15, 30, 45, 60, 90 and 120 minutes. Thus, the total blood 
sample is 8 samples. On the three other study legs/occasions you will consume the reference 
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food (glucose drink). One basal sample will be collected at the start of the study (time 0 min). 
Then, finger prick blood samples (No less than 300 l per sample) will be collected at 15, 30, 
45, 60, 90 and 120 minutes after have the reference which is glucose drink. Thus, the total 
blood sample in reference legs is 7 samples. The total volume of blood taken will be less than 
3 ml allowing for wastage.  
You will be required to remain seated throughout the study, except for visits to the toilet. 
A member of the research staff will be present throughout the study. 
Study days 2, 3, 4, 5, 6 and 7 
These will be identical to study leg 1. The order in which the capsules (placebo or cinnamon) 
are given will be randomized.  
E: GENERAL 
All information and data obtained from this study will be restricted to the investigators only and 
will be kept strictly confidential. The data obtained from all participants will be used to establish 
the effect cinnamon on the glycaemic index and insulin response, and once the study is 
complete a summary of the work will available to each participant. It is hoped that the work will 
also be published at a conference. You will be free to withdraw from the study at any time, 
without needing to justify your decision and without prejudice. 
F: ANALYSIS 
Blood samples collected during the study will be analyses for glucose and insulin. All samples 
will be analyses at the Faculty of Health and Medical Sciences, University of Surrey. After 
which they will be disposed of in accordance with the University rules of disposal of biological 
materials. 
G: PAYMENT FOR PARTICIPATION 
A sum of £20 per study occasion (i.e. each study leg) will be paid to you on completion of the 
study as out of pocket expenses if you complete the 7 study occasions. You will be paid less 
if you withdraw from the study early but this is at the discretion of the Principal Investigator. 
H. DISCOMFORT ASSOCIATED WITH STUDY 
There is a possibility that you may experience slight discomfort during finger prick sampling. 
You may have sore or bruised fingers due to multiple finger pricks initially when trying the finger 
prick technique. However previous experience over the last 5 years has shown this to be very 
unlikely. If this was to be the case then you could increase the number of rest days or withdraw 
from the study. The equipment used in this procedure is similar to that used for monitoring 
blood glucose by diabetics. 
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I: CONTACT DETAILS 
If you should have any questions regarding any aspect of this study, please contact: 
 
Tahany Aldayel 
Faculty of Health and Medical Sciences 
University of Surrey 
Guildford 
GU2 7XH 
E-mail: T.Aldayel@surrey.ac.uk 
 
Or Dr Jonathan Brown 
Faculty of Health and Medical Sciences 
University of Surrey 
Guildford 
GU2 7XH 
E-mail: J.E.Brown@surrey.ac.uk 
 
Thank you for taking time to read this Information Sheet  
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Appendix 7 
Consent Form:  
 
 I the undersigned voluntarily agree to take part in the study on Assessment of the effect of 
cinnamon supplement on the glycaemic index and insulin response of a starch rich food. 
 
 I have read and understood the Information Sheet provided.   I have been given a full 
explanation by the investigators of the nature, purpose, location and likely duration of the 
study, and of what I will be expected to do.   I have been advised about any discomfort and 
possible ill-effects on my health and well-being which may result.   I have been given the 
opportunity to ask questions on all aspects of the study and have understood the advice 
and information given as a result. 
 
 I agree to comply with any instruction given to me during the study and to co-operate fully 
with the investigators.   I shall inform them immediately if I suffer any deterioration of any 
kind in my health or well-being, or experience any unexpected or unusual symptoms. 
 
 I consent to my personal data, as outlined in the accompanying information sheet, being 
used for this study and other research.  I understand that all personal data relating to 
volunteers is held and processed in the strictest confidence, and in accordance with the 
Data Protection Act (1998). 
 
 I understand that I am free to withdraw from the study at any time without needing to justify 
my decision and without prejudice. 
 
 I acknowledge that in consideration for completing the study I shall receive the sum of £20 
per leg.  I recognise that the sum would be less, and at the discretion of the Principal 
Investigator, if I withdraw before completion of the study. 
 
 I understand that in the event of my suffering a significant and enduring injury (including 
illness or disease) as a direct result of my participation in the study, compensation will be 
paid to me by the University (or sponsor where a clinical trial is sponsored by a 
pharmaceutical company), subject to certain provisos and limitations.  The amount of 
compensation will be appropriate to the nature, severity and persistence of the injury and 
will, in general terms, be consistent with the amount of damages commonly awarded for 
similar injury by an English court in cases where the liability has been admitted 
 
 I confirm that I have read and understood the above and freely consent to participating in 
this study.  I have been given adequate time to consider my participation and agree to 
comply with the instructions and restrictions of the study. 
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Name of volunteer (BLOCK CAPITALS)                
……….……………………………………………                   
                                                                                          
Signed                        . …................................................................... 
 
Date                                                                  
………………..................................................... 
  
Name of witness (where appropriate) (BLOCK CAPITALS) 
 ........................................................  
 
Signed                         … …. …...........................................................  
 
Date                            …………..….………. ...................................... 
Name of researcher/person taking consent (BLOCK CAPITALS) 
………………………………... .  
 
Signed                            ………….........................................................  
 
Date                                                                                  
………………………………………………… 
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Appendices  
302 
 
Appendix 9 
 
 
“Would you like to take part in a cinnamon study” 
 
“We are looking at the health benefit of consuming cinnamon 
supplement in term of inflammatory markers, lipid profiles, glucose 
tolerance and insulin response” 
We are looking for:  
Healthy Women 
Aged 45-70 
With a BMI >25 
 
If you’re interested please contact Tahany Aldayel e-mail 
T.Aldayel@surrey.ac.uk, mobile number 07450095509 Or 
telephone (01483682599). 
 
This study has received a favourable ethical opinion from the University of 
Surrey Ethics Committee. 
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Appendix 10 
Study screening sheet 
Assessment of the effect of a daily cinnamon supplement on the inflammatory 
markers, lipid profiles, glucose tolerance and insulin response 
 
Participant screening sheet 
 
Date  ………………..                                  Reference number:…………………. 
 
PERSONAL INFORMATION  
 
Name:   …………..……… ……..………………………………………………………………… 
Age:     ……………………………… ……………………………………………………………                                 
Date of birth:                              …………………………………………………………………. 
Address:                   ………………………………………………………………………………. 
                                  ………………………………………………………………………………. 
                                  ...…………………………………………………………………………….. 
                                 ..……………………………………………………………………………… 
 
Contact telephone numbers:   
......................................................................................................... 
                                                    ……………………………………………………………………  
Email address:                          . .…………………………………………………………………  
 
Contact details of someone who could be contacted in an emergency:     
…………………………………………………………………………………………………….. 
……………………………………………………………………………………………………… 
Weight (kg):  ……………………..               Height: ………………….           BMI: …………… 
 
Blood pressure:  R1 ……………    R2 ……………    R3 ……….…     Average:. …………….. 
 
Heart rate:……..   ……….     ………      Average:. …………….. 
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Fasting Glucose level (finger prick): ……………………. 
 
Waist circumference: …………………………              Hip circumference …………………….. 
 
Please tick all/any of the following that apply: 
 
  I am free from any health and medical problems   
  I am not currently taking or have taken any supplements  
  I am not currently taking or have taken any herb or plant supplements  
  I am not currently taking or have taken any steroid drugs  
  I have no prior/present history of kidney disease  
  I have no prior/present history of kidney stone disease  
  I have no prior/present of fracture incidence     
  I have no prior/present history of   Epilepsy   
  I have no prior/present history of Cinnamon allergy 
  I have no prior/present history of Coronary Heart Disease, Angina or Stroke  
  I have no prior/present history of Type 1 or 2 diabetes 
  I have no prior/present history of anaemia  
  I have no prior/present history of hormone disorders 
  I have no prior/present history of gastrointestinal diseases (for example Crohn’s disease, 
Coeliac         
    disease, Irritable Bowel Syndrome)  
  I have no prior/present history of liver disease 
  I have no prior/present history of being treated for depression and/or other psychological  
     disorders 
  I have no prior/present history of eating disorders, including anorexia or bulimia nervosa 
  I have no prior/present history of drug or alcohol abuse within the last 2 years 
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Are you suffering from frequently of infection?                                                            YES/ NO 
If yes, how often and what do you take. 
 
Are you currently on a weight-reducing diet or other dietary restriction?                    YES/ NO 
If yes, please provide details. 
 
Are you taking Non-steroidal anti-inflammatory drugs (NSAIDs) such as Ibuprofen,  YES/ NO                                                                                                
Aspirin, Voltaren, Lodine and Anaprox?                                                                                            
If yes, please provide details. 
 
Are you allergic to any foods?                                                                                      YES/ NO 
If yes, please state what foods you are allergic to.                                             
 
Have you ever suffered ill effects after consuming cinnamon rich foods?                   YES/ NO 
If yes, please provide details. 
 
Have you been involved in a clinical trial in the last 3 months?                                   YES/ NO 
    
Have you taking any regular medication prescribed by my GP in the last 6 months   YES/ NO         
If yes, please state what you are taking. 
 
Have you taking painkiller regularly such as Paracetamol, Panadol and Anadin       YES/ NO  
If yes, how often and at what the dose?        
 
Do you exercise regularly?                                                                                         YES/ NO 
If yes, what type of exercise and how often? 
 
Do you take any dietary supplements such as vitamins, minerals or fish oils?          YES/ NO 
If yes, please state which type and how often. 
 
Do you consume a caffeine drink such as tea, coffee or cola and power drink?         YES/ NO   
If yes, how many cops per day (give details please)  
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Do you smoke?                                                                                                           YES/ NO 
If yes, how many cigarettes per day? 
 
Do your menstrual cycles come regularly every month?                                            YES/ NO 
If no, how often it is come? 
 
Do you drink alcohol?                                                                                                 YES/ NO 
If yes, how many units per week? (See below) 
Alcohol Measure Unit 
Ordinary strength larger (4%)e.g. Carling, Fosters Pint 2.3 
Strong larger (5.2%) e.g. Stella Artois, Kronenburg Pint 3 
Strong large e.g. Stella Artois, Carlsberg Export, Grolsch 440ml can 2.2 
Beer/ordinary strength Ale e.g. John Smith’s, Guinness Pint 2.3 
Red/White Wine Std 175ml 2 
Red/White Wine Lg.250ml 3 
Spirits Std 25ml 1 
Spirits Lg.35ml 1.4 
Alcopop e.g. Smirnoff Ice, Bacardi Breezer, Reef 275ml 1.5 
 
 
 
Signed _________________________________________       Date ____/ ____/______  
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Appendix 11 
PARTICIPANT INFORMATION SHEET:  
 
PROJECT TITLE: Assessment of the effect of a daily cinnamon supplement on the                          
inflammatory markers, lipid profiles, glucose tolerance and insulin response 
INSTITUTION: Department of Nutritional Sciences, Faculty of Health and Medical Sciences, 
University of Surrey 
INVESTIGATORS: Tahany Al-Dayel, Dr Jonathan Brown, Professor Susan Lanham-New 
 
INTRODUCTION 
We would like to invite you to take part in a research project. Before you decide you need to 
understand why the research is being done and what it will involve for you. Please take the 
time to read the following information carefully. Talk to others about the study if you wish.  
BACKGROUND 
Metabolic syndrome is a disorder of a collection of conditions that occur together, including 
high blood pressure, insulin resistance, excess body fat around the waist, high cholesterol and 
high fasting glucose. All these features are risk factors for cardiovascular disease, type 2 
diabetes and kidney disease. The risk of having metabolic syndrome is closely linked to being 
overweight or having obesity. Furthermore, adults with metabolic syndrome show a higher 
inflammatory state, which also increases with age. Inflammation is generally a protective 
mechanism produced in humans to remove injurious or harmful stimuli from body tissue and 
this is part of a healthy immune response. However, although inflammation can occur acutely 
(as above) it can also be produced chronically and it can lead to the development of several 
chronic diseases such as cancer, diabetes, heart disease and Alzheimer’s disease. The level 
of inflammation in the body can be measured by assessing the level of inflammatory markers. 
Thus, high levels of inflammatory markers are associated with most chronic diseases such as 
diabetes. 
Many herbal products are now available that claim to have health beneficial properties. 
Cinnamon (Cinnamomum cassia) is an example of this that has been claimed to improve blood 
glucose, insulin levels and blood lipid profile. There is also some evidence that it can decrease 
inflammation in human studies. Furthermore cinnamon is a traditional medicine used in the 
treatment of dyspepsia, gastritis, blood circulation issues and inflammatory disease. Cinnamon 
has many pharmacological properties such as being an anti-inflammatory agent, an anti-
diabetic agent as well as having anti-tumor activity. The aim of this study is to investigate 
whether consuming 5 g of a cinnamon supplement (Cinnamomum cassia) every day for two 
months will improve inflammatory markers, lipid profiles, glucose tolerance and insulin 
response.  
YOU CAN ONLY TAKE PART IN THIS STUDY IF YOU ARE: 
4. Female aged 45-70 years 
5. Free from medication  
6. Free from cinnamon allergy  
7. Overweight or obese (BMI≥25) 
8. Not taking supplements in last 1 months  
9. Non-smokers 
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10. Healthy and free from any disease 
11. Able and willing to comply with all study procedures 
 
YOU CANNOT TAKE PART IN THIS STUDY IF YOU: 
9. Have a personal history of psychiatric disorders, epilepsy, sleep 
      disorders, diabetes, CHD or hypertension, liver disorder or food allergies 
10. Have suffered from infectious hepatitis, jaundice, malaria, tuberculosis and are not HIV 
positive 
11. Have a history of drug or alcohol abuse 
12. Have taken any medication (e.g. either a prescription medicine (e.g. antibiotics) or an over 
the counter medicine other than vitamin supplements 
13. Have any medical problems 
14. Have received an experimental drug either clinically or recreationally within the past 1 
months 
15. Have a phobia of needles/sight of blood 
16. Have a cinnamon allergy 
17. Already taking cinnamon or other herbal supplement 
18. Participated in a clinical trial within the last 1 months 
19.  Have an addiction to caffeine products (more than 3 cups of caffeinated products per day) 
 
STUDY PROCEDURE 
Once you have shown an interest to be involved in this study, you will then be asked to answer 
a screening questionnaire regarding your current health and lifestyle. To make sure you are 
suitable to enroll in this study we will check your blood pressure and fasting blood glucose by 
finger prick test. You will be offered an appointment to attend the Clinical Investigation Unit 
(CIU) 17AX00 at the Faculty of Health and Medical Sciences after an overnight fasting which 
means you should not consume anything except water from 20:00 h prior to the screening 
days. Refreshments thought will be offered after the screening day. 
The screening days will help us decide whether you are eligible and healthy to take part in the 
study. It also helps us make sure that it is safe for you to be involved in the study (e.g. some 
health conditions will mean you cannot take part). If you are eligible for the study then you will 
be offered an appointment to attend the Clinical Investigation Unit (CIU) 17AX00 at the Faculty 
of Health and Medical Sciences, for your first visit session. All information obtained from the 
study will be restricted to the investigators only and will be kept strictly confidential. 
 
This study has received a favourable ethical opinion from the University of Surrey Ethics 
Committee. All participates must sign a consent form before they participate in the study. 
 
In this study you will receive capsules to consume every day for 8 weeks. These capsules may 
contain cinnamon or not contain cinnamon (placebo). You will consume 5 g of the cinnamon 
(that has been purchased from Puritan’s Pride) or placebo as a capsule. Three capsules (the 
total will be 2.5 g) after your breakfast meal and three capsules (the total will be 2.5g in the 
evening) after your evening meal.  
Please do not squeeze or open the capsules. 
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STUDY VISITS  
You will be asked to be involved in the study for a period of 8 weeks. During this time, you will 
be required to visit the CIU on three separate occasions over the 8 weeks. 
Visits will take place at Week 0, Week 4 and Week 8. 
All three visits will follow a very similar order of activities. Each visit will last approximately 3 
hours and all visits will take place in the morning (8 am to 11 am). For the purposes of obtaining 
an appropriate blood sample (required as part of the study), you will be requested to attend 
the CIU after an overnight fast, which means you should not consume anything except water 
from 20:00 h (8 pm) prior to each of the study days. However, once you have completed all of 
the assessments on each study visit day you will be offered refreshments. 
 
The study activities for each visit will be as follows:  
Visit 1 (Week 0)  
- A blood sample (approximately 25 ml) will be taken in the fasted state. 
- You will then be asked to drink a glucose drink (75 g of glucose), and then after 2 hours, 
another blood sample (approximately 5 ml) will be taken for the oral glucose tolerance 
test (OGTT). 
- Your anthropometric measurements including height, weight, body composition, 
(measured by bioelectrical impedance analysis), waist and hip circumference, heart 
rate and blood pressure will be determined. 
- A scan of your wrist bones by a technique called Peripheral Quantitative Computed 
Tomography (PQCT) will be completed. 
- Diet Diary before your first visit; you will have been asked to record all your food intake 
for three days prior the study date. This information form will be collected from you at 
your visit.  
- Refreshments (e.g. coffee, tea, juice) and standard breakfast will be offered and you 
will then be supplied with cinnamon or placebo capsules that you have been randomly 
assigned to consume for the study. 
Visit 2 (Week 4)  
- This visit will be identical to study visit 1 except the oral glucose tolerance test (OGTT) 
and the scanning by PQCT, will be not be required. 
- Blood samples (approximately 25 ml), anthropometric measurements and blood 
pressure will be repeated as described for Visit 1. 
- Diet Diary before your second visit; you will have been asked to record all your food 
intake for three days prior the study visit date. This information form will be collected 
from you at your visit. 
- Time available for you to talk with us about the study and how you have found the 
supplement.  
- Refreshments (coffee, tea) and standard breakfast will be offered (as per study visit 1). 
 
Visit 3 (Week 8)  
- This visit will be identical to visit 1 except the scanning by PQCT will not be required. 
- A blood sample (approximately 25 ml) will be taken in the fasting state. 
- You will be asked to drink a glucose drink (75 g of glucose), and then after 2 hours, 
another blood sample (approximately 5 ml) will be taken for the oral glucose tolerance 
test (OGTT). 
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- Your anthropometric measurements (including height, weight, body composition 
(measured by bioelectrical impedance analysis), waist and hip circumference, heart 
rate and blood pressure will be determined. 
- Diet Diary before your third visit; you will have been asked to record all your food intake 
for three days prior the study date. This information form will be collected from you at 
your visit.  
- Refreshments (coffee, tea, juice) and standard breakfast will be offered and you will be 
asked to return the remaining supplements. You will now have completed the study.  
 
PROCEDURES TO BE FOLLOWED BEFORE THE STUDY VISIT  
For 3 days prior to each study day, you must refrain from intense physical exercise and refrain 
from consuming alcohol. Moreover, you must refrain from consuming caffeine-containing 
drinks (tea/coffee/carbonated soft drinks such as Pepsi, Coco-cola, Red Bull) for 24 hours 
before each visit. Drinking caffeine products might affect the blood glucose levels which are 
an important part of the study so we want you to try to avoid these drinks 24 hours before each 
study visit day. Dietary food intake records will be completed by you to provide information on 
your dietary intake for 3 days before each study day (you will need to write down all that you 
have consumed (food and drink) over a 3 day period before each study visit in as much detail 
as possible). These will be used to standardize dietary intake before the oral glucose tolerance 
test OGTT trials, which will be a part of the study test measurements. In addition, all 
participants will be fed the same standardized meal (which will be a vegetable lasagna (400 g) 
the evening before each of the study days. You will not be allowed to consume any food or 
drink, with the exception of water, from 20:00 h prior to each of the study days. 
NUMBER OF PARTICIPANTS EXPECTED TO PARTICIPATE 
You will be one of approximately 46 subjects who will participate in this study 
GENERAL 
All information and data obtained from this study will be restricted to the investigators only and 
will be kept strictly confidential. The data obtained from all participants will be used to establish 
the effect of cinnamon on inflammatory markers, lipid profiles, glucose tolerance and insulin 
response. Once the study is completed a summary of the work will available to each participant 
on request. It is hoped that the work, which will be anonymised, will also be published at a 
conference. You will be free to withdraw from the study at any time, without needing to justify 
your decision and without prejudice. 
ANALYSIS 
Blood samples collected during the study will be analysed for inflammatory markers, lipid 
profiles, glucose and insulin response. All samples will be analysed at the appropriate 
laboratory. There is no DNA analysis in this study and the remaining blood samples will be 
destroyed at the end of the study according to the University rules for the disposal of biological 
materials. 
PAYMENT FOR PARTICIPATION 
We will pay the public transportation costs associated with your travel to the University on 
screening and visit days or the cost of car parking. You will also receive £100 for completing 
the study. These payments will be made at the end of study.  
DISCOMFORT AND RISKS ASSOCIATED WITH STUDY 
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The risk of side effects is likely to be minimal. However, you may experience slight discomfort 
when swallowing the capsules every day for 8 weeks. You will have a chance to speak to us 
at visits 2 and 3 to discuss any issues you may be having, and contact us via telephone or 
email throughout the study if your enquiry needs to be answered more quickly. 
Blood samples will be taken by a fully trained phlebotomist/nurse at each trial visit. To minimize 
infection they will wash their hands thoroughly and use disinfectant rubs before taking blood 
from each participant. Taking the blood sample may cause some slight bruising and this may 
take some time to go away. If the bruising continues we will advise you to go to your GP. 
Occasionally some people may feel faint when they have their blood taken and so to help us 
reduce the risk of this, please let us know if you have any phobia of needles/sight of blood. 
Nevertheless, the staff in the CIU are fully trained to deal with such situations. It is the 
participant’s responsibility to inform the investigators if you feel dizzy, ill or have other 
symptoms before and during blood donation. Your blood sample will be taken in a reclined 
chair by qualified phlebotomist/nurse.  
Caffeine withdrawal symptoms may occur when a person misses their daily dose of caffeine 
(such as tea, coffee or cola). The common symptoms are headache and lack of concentration. 
In these cases, we advise you to be aware of these symptoms. 
Peripheral Quantitative Computed Tomography (PQCT) scan involves an extremely low level 
of ionising radiation which you will be exposed to once during the course of the study. The 
amount of radiation absorbed from the scan is 0.5μ Sv which is equivalent to two hours of 
natural background radiation found in the UK which is 2.2 Sv per year. 
Ionising Radiation Medical Exposure Regulations (IRMER) 
A peripheral Quantitative Computed Tomography (PQCT) scan of the forearm will be 
performed at the University of Surrey. The procedure is painless and dose not involve going 
through a tunnel of any kind. The radiation dose is considered negligible and is equivalent to 
around 2 hours natural background radiation that we are exposed to throughout our lives: less 
than 1/10 of a normal chest X- ray. You will be asked to sit on a seat where a scan of your 
forearm will be performed. The procedure involves placing your forearm into the scanning 
machine where an X-ray beam moves across it. The scans together take approximately 20 
minutes to complete and must be removed for the arm scan. 
CONTACT DETAILS 
If you should have any questions regarding any aspect of this study, please contact: Tahany 
Aldayel (e-mail: T.Aldayel@surrey.ac.uk ) or Dr Jonathan Brown (e-mail: 
J.E.Brown@surrey.ac.uk).  
Any complaint about any aspect of this study you can contact Dr Jonathan Brown (e-mail: 
J.E.Brown@surrey.ac.uk).  
Thank you for taking time to read this Information Sheet  
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Appendix 12 
 
Consent Form:  
 
 I the undersigned voluntarily agree to take part in the study on Assessment of the effect of 
a daily cinnamon supplement on the inflammatory markers, lipid profiles, glucose tolerance 
and insulin response 
 I have read and understood the Information Sheet provided. I have been given a full 
explanation by the investigators of the nature, purpose, location and likely duration of the 
study, and of what I will be expected to do.   I have been advised about any discomfort and 
possible ill-effects on my health and well-being which may result.   I have been given the 
opportunity to ask questions on all aspects of the study and have understood the advice 
and information given as a result. 
 
 I agree to follow all the instruction that given to me during the study and to co-operate fully 
with the investigators.   I shall inform them immediately if I suffer any deterioration of any 
kind in my health or well-being, or experience any unexpected or unusual symptoms. 
 
 I consent to my personal data, as outlined in the accompanying information sheet, being 
used for this study and other research.  I understand that all personal data relating to 
volunteers is held and processed in the strictest confidence, and in accordance with the 
Data Protection Act (1998). 
 
 I am healthy and have disclosed any known medical problems and I am not taking 
medicines and supplements. 
 
 I understand that I am free to withdraw from the study at any time without needing to justify 
my decision and without prejudice. 
 
 I acknowledge that in consideration for completing the study I shall receive the cost of 
public transportation or car parking.  
 I understand that in the event of my suffering a significant and enduring injury (including 
illness or disease) as a direct result of my participation in the study, compensation will be 
paid to me by the University (or sponsor where a clinical trial is sponsored by a 
pharmaceutical company), subject to certain provisos and limitations.  The amount of 
compensation will be appropriate to the nature, severity and persistence of the injury and 
will, in general terms, be consistent with the amount of damages commonly awarded for 
similar injury by an English court in cases where the liability has been admitted 
 
 I confirm that I have read and understood the above and freely consent to participating in 
this study.  I have been given adequate time to consider my participation and agree to 
comply with the instructions and restrictions of the study. 
 
 I acknowledge that in consideration for completing the study I shall receive £100. I 
recognise that the sum would be less, and at the discretion of the Principal Investigator, if 
I withdraw before completion of the study. 
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Name of volunteer (BLOCK CAPITALS)  ........................................................ 
 
Signed                                                                                           
….....................................................                     
Date                                                                             ……………………………………                
       
  
 
Name of witness (where appropriate) (BLOCK CAPITALS) 
……………………………………….      
 
Signed            ………………………………………….                                                                                     
Date                                                                                 
…………………………………………….. 
   
Name of researcher/person taking consent (BLOCK 
CAPITALS)………………………………….   .  
 
Signed                                                                                               
.........................................................                                                                       
 
     Date                                                                          
.............……………………………………         
  
 
 
 
 
 
 
 
 
 
 
Appendices  
314 
 
Appendix 13 
Conference and publications 
1. T. Aldayel, S.M. Hampton, S.A. Lanham-New and J.E. Brown. (2013). Acute effects of 
cinnamon on glucose response in vivo to a standard carbohydrate-rich food. 
Proceedings of the Nutrition Society, 72 (OCE4), E203. 
2. T. Aldayel, S.M. Hampton, S.A. Lanham-New and J.E. Brown. (2014). Assessment of 
the effect of cinnamon supplement on the glycaemic index of a starch rich food, In 7th 
Saudi Students Conference,2014, Edinburgh United Kingdom. (Published). 
3. Tahany Aldayel, S.M. Hampton, S.A. Lanham-New, P. Williams and J.E. Brown. An 
Evaluation of serum cytokine levels in overweight women consuming a cinnamon 
supplement for 8 weeks. (2014). Immunology, 143, supplement 2, 177-186. 
4. T. Aldayel, S.A. Lanham-New, J.E. Brown. (2014). Antioxidant activities of water and 
acetone extracts of Cinnamomum cassia, In 5th PhD Experience conference, University 
of Hull. (Unpublished). 
5. T.  Aldayel, S.M. Hampton, S.A. Lanham-New, F. Robertson, P. Williams & J.E. Brown. 
(2015). The effect of cinnamon supplementation on serum cytokine and C. Reactive 
protein (CRP) levels in overweight Women, In University of Surrey Postgraduate 
Research Conference. (Unpublished). 
6. Tahany. S. Aldayel, S.M. Hampton, S.A. Lanham-New, F. Robertson, P. Williams and 
J.E. Brown. (2015). Attenuation of cell adhesion molecules and C-reactive protein in 
overweight women consuming cinnamon for 8 weeks, In World Immune Regulation 
Meeting IX conference, 2015, Davos, Switzerland. (Unpublished). 
7. Tahany Aldayel, S.M. Hampton, S.A. Lanham-New, P. Williams and J.E. Brown. 
(2015). The health benefit of consuming a cinnamon supplement for 8 weeks in 
overweight women, In the 6th International Conference on Fixed Combination in 
Treatment of Hypertension, Dyslipidaemia and Diabetes Mellitus conference, 2015, 
Berlin, Germany. (Unpublished). 
8. T. Aldayel, S. Hampton, S. Lanham-New, P. Williams & J. Brown. (2015). The effect of 
cinnamon supplementation on glucose, lipid profiles and C. Reactive protein (CRP) 
levels in overweight women, In H3 Symposium - Physiology, pathophysiology and 
future treatment options for diabetic complications conference,2015, London, United 
Kingdom. (Unpublished). 
9. Tahany. S. Aldayel, S.M. Hampton, S.A. Lanham-New, P. Williams and J.E. Brown. 
(2016). The 9th   Saudi Students Conference, 2016, Birmingham, United Kingdom. 
(Published). 
 
